Modulation of p53 signalling and response to MDM2-p53 binding antagonists by Esfandiari, Arman
  
Modulation of p53 signalling and response to 
MDM2-p53 binding antagonists 
 
Thesis submitted in partial fulfilment of the requirements of the degree 
of Doctor of Philosophy 
 
 
 
Arman Esfandiari 
 
University of Newcastle upon Tyne 
Faculty of Medical Sciences 
Molecular Oncology Research Group 
Northern Institute for Cancer Research 
09/2015
 I 
 
Abstract 
Mutational inactivation of the p53 tumour suppressor protein, encoded by the TP53 
gene, occurs in ≈50% of malignancies overall. Non-genotoxic activation of p53 
signalling in the remaining TP53 wild-type malignancies is a promising therapeutic 
strategy. MDM2 inhibitors, such as Nutlin-3 and RG7388, can activate p53 in a non-
genotoxic manner, mobilising p53-dependent signalling; however, sensitivity to these 
compounds varies widely among TP53 wild-type cell lines. In this study p53 signalling 
network components involved in the response to DNA damage and p53 homeostasis are 
investigated for their role as determinants of cellular sensitivity to MDM2 inhibitors. 
Deciphering determinants of sensitivity to this group of compounds will enable 
optimisation of their therapeutic potential. 
Chemical inhibition of kinases, ATM and DNA-PKcs, which are critical for DNA 
double strand break repair and activation of p53 signalling in response to DNA damage, 
did not affect the cellular sensitivity to Nutlin-3 in the absence of DNA damage. 
However, inhibition of these kinases enhanced the cellular sensitivity of TP53 wild-type 
cells to the combined effect of Nutlin-3 and DNA damage induced by ionising 
radiation, in a cell type dependent manner. In a neuroblastoma derived TP53 wild-type 
and mutant, otherwise isogenic, cell line pair, ionising radiation increased the growth 
inhibitory effect of Nutlin-3 in a p53-dependent manner and this was enhanced 
significantly in the presence of the DNA-PKcs inhibitor NU7441. In contrast, in the 
osteosarcoma derived TP53 wild-type and mutant, otherwise isogenic, cell line pair, 
exposure to ionising radiation decreased the growth inhibitory effect of Nutlin-3 in a 
p53-dependent manner and DNA-PKcs inhibition did not influence this protective 
effect. 
Given that ATM and DNA-PKcs activate p53 through phosphorylation of key residues, 
inhibition of the WIP1 phosphatase (encoded by the PPM1D gene) that 
dephosphorylates one such residue, was tested for the effect on cellular sensitivity to 
MDM2 inhibitors. Cellular growth/proliferation was assessed in TP53 wild-type and 
matched mutant/null cell line pairs, differing in their PPM1D genetic status, when 
treated with MDM2 inhibitors Nutlin-3/RG7388 + a highly selective WIP1 inhibitor 
GSK2830371 or transient siRNA knockdown of WIP1 expression. The effects of 
GSK2830371 and transient WIP1 siRNA knockdown on MDM2 inhibitor induced 
p53Ser15 phosphorylation, p53-mediated global transcriptional activity and apoptosis 
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were also investigated.  
WIP1 transient siRNA knockdown increased p53Ser15 phosphorylation and sensitivity to 
MDM2 inhibitors in TP53 wild-type parental cell lines.  TP53 wild-type and mutant cell 
line pairs were relatively insensitive to single agent GSK2830371 regardless of their 
PPM1D status. However, a non-growth inhibitory dose of GSK2830371 markedly 
potentiated the response to MDM2 inhibitors in TP53 wild-type cell lines, most notably 
in those harbouring PPM1D activating mutations or copy number gain (up to 5.8-fold 
decrease in GI50). Potentiation also concurred with significant increase in MDM2 
inhibitor induced cell death endpoints which were preceded by a marked increase in 
phosphorylated p53Ser15, a WIP1 negatively regulated substrate, and known to increase 
p53 transcriptional activity. Microarray-based gene expression profiling showed that the 
combination treatment increases the subset of early RG7388 induced p53-transcriptional 
target genes involved in growth inhibition and apoptosis.  
Increased mRNA and protein expression of WIP1 has been associated with poor clinical 
outcome in various malignancies in which MDM2 inhibitors are being considered as a 
potential therapeutic strategy. For neuroblastoma mining the Amsterdam microarray 
databank showed WIP1 mRNA expression to correlate with worse survival. Therefore, 
WIP1 protein expression was assessed by immunohistochemical (IHC) staining of 
neuroblastoma tissue microarrays.  A wide range of WIP1 IHC staining was found, 
however there was no significant association between high WIP1 staining and clinical 
outcome. 
Overall these findings show that manipulating p53 post-translational modification 
following its activation by MDM2 inhibitors or DNA damaging agents can increase 
cellular sensitivity to this class of compounds. Furthermore, these observations provide 
evidence to support the inhibition of WIP1 phosphatase activity as a strategy for 
enhancing the efficacy of MDM2 inhibitors, particularly in TP53 wild-type, PPM1D 
overexpressing/overactive malignancies. 
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Chapter 1 Introduction
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1.2 Genomic integrity  
The genomic integrity of cells is constantly threatened by exogenous and endogenous 
factors that can directly or indirectly result in DNA damage. However, cells have 
evolved a series of mechanisms that prevent the propagation of deleterious genetic 
alterations to their daughters. There is extensive crosstalk between the signalling 
networks involved in detection of DNA damage and those which orchestrate normal cell 
cycle progression, growth, differentiation, senescence and programmed cell death (e.g. 
apoptosis). DNA damage response (DDR) biochemical signalling pathways are 
triggered by cytotoxic DNA lesions, which then either promote arrest at specific cell 
cycle checkpoints to provide sufficient time for repair mechanisms to rectify the 
damage, or alternatively signal the initiation of programmed cell death to effector 
molecules if the damage incurred is irreparable. Defects or overwhelming of such 
safeguard mechanisms can lead to positive selection of non-lethal genetic alterations 
which favour autonomous cellular proliferation, disturbance of tissue homeostasis and 
the ultimate emergence of malignant cancer cells that are unfavourable for the survival 
of the organism (Fearon and Vogelstein 1990, Hanahan and Weinberg 2000, Hanahan 
and Weinberg 2011). A pivotal component of the mechanisms evolved to protect 
genomic integrity of the germline and somatic tissue is the TP53 gene, encoding the 
tumour suppressor p53 protein, which has been aptly dubbed “guardian of the genome” 
(Lane 1992, Belyi, Ak et al. 2010). This chapter aims to introduce p53 signalling and 
discuss its potential utility in cancer therapy. 
1.3 Cancer 
Cancers are defined as a group of more than 100 distinct diseases that are characterised 
by autonomous cellular growth and their malignant invasion of other anatomical 
locations (metastasis), which can potentially result in the death of the organism. The 
aetiologies of human cancers are considered mostly environmental with only 5-10% of 
cancers considered to be associated with identifiable germline mutation which increase 
predisposition to development of particular cancers (Garber and Offit 2005). The 
correlation of cancer incidence with age and its stepwise pathological progression from 
premalignant (benign) to malignant tissue observed throughout tumourigenesis suggests 
that cancer development is a multistep process (Hanahan and Weinberg 2000). A clonal 
model of cancer development, first put forward in 1976 by Peter Nowell, postulates that 
stepwise acquisition of stochastic genetic changes in a progenitor somatic cell 
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ultimately, through Darwinian adaptive evolution, results in transformation from normal 
to malignant pathology (Nowell 1976). This model has consistently been supported by 
more advanced genetic and molecular examination of cancer development (Greaves and 
Maley 2012). The traits associated with these groups of stepwise and sequential genetic 
changes have been categorised into distinct groups and proposed to represent 
“Hallmarks of cancer” (Hanahan and Weinberg 2000, Hanahan and Weinberg 2011). 
1.4 Hallmarks of cancer 
In a seminal publication by Douglas Hanahan and Robert A. Weinberg (2000) it was 
proposed that the prerequisite genetic changes for malignant growth manifest 
themselves in six distinct traits depicted in Figure 1-1. The authors also emphasised the 
potential importance of “heterotypic signalling”, or the interaction of transformed cells 
with the tumour microenvironment, in studying disease progression and pursuing new 
treatment strategies (Hanahan and Weinberg 2000). This conceptual framework was 
built upon with the addition of new traits in a more recent publication (Hanahan and 
Weinberg 2011) (Figure 1-2).  
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Figure 1-1 Diagram outlines the six “hallmarks of cancer” as first described by 
Hanahan and Weinberg in 2000 (Hanahan and Weinberg 2000). 
 
Figure 1-2 Diagram obtained from “Hallmarks of Cancer: Next generation” 
depicts the four additional proposed archetypal tumour traits and outlines 
examples of targeted therapeutic agents, at different stages of pre-clinical and 
clinical development, designed to combat these ten traits (Hanahan and Weinberg 
2011). 
  
 5 
 
1.4.1 Proto-oncogenes 
Proto-oncogenes are a group of genes which when overexpressed or overactive have 
been shown to promote malignant transformation. The discovery of proto-oncogenes 
was initially through the study of acutely transforming RNA retroviruses (Pierotti MA, 
Sozzi G et al. 2003). These viruses reverse transcribed their own genome into DNA, 
which is then incorporated into the host’s genomic DNA, promoting tumour formation 
(Varmus 1988). It was shown that these viruses carry hyperactive mutant versions 
(gain-of-function) of genes present within the host cell. These host genes were termed 
proto-oncogenes as it was shown that their gain-of-function mutation or increased 
expression could result in transformation and tumourigenesis in animal models and 
human cancer patients (Pierotti MA, Sozzi G et al. 2003). Changes in expression of 
proto-oncogenes can be due to changes in chromosomal structure such as 
amplification/copy number gain or juxtaposition of enhancer elements upstream, 
increasing their expression. Inhibition of activated or overexpressed proto-oncogenes 
(i.e. oncogenes) by small molecular weight compounds has been a successful strategy 
for targeted cancer therapy, which is consistent with the proposed addiction of cancer 
cells to oncogenic drivers (Vivanco 2014). This thesis explores the function of MDM2 
and PPM1D proto-oncogenes and their small molecular weight inhibitors in regulation 
of p53 signalling. 
1.4.2 Tumour suppressor genes 
Tumour suppressor genes (TSGs) are a group of genes the loss of which results in 
tumour formation. These genes were discovered through investigation of somatic hybrid 
cells by Henry Harris et al., (1969) who showed that hybridisation of transformed cells 
with normal cells resulted in reversal of their ability to form tumours in compatible 
murine hosts (Harris, Miller et al. 1969). This suggested that genetic material from the 
normal cell was suppressing tumour formation by the transformed cells. The molecular 
identification of individual TSG’s was achieved through different routes of 
investigation some of which are introduced in the context of the TP53 tumour 
suppressor gene. 
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1.5 A brief history of p53 
1.5.1 Discovery 
The human tumour suppressor gene TP53, was discovered early on to be one of the 
most frequently mutated genes in cancers (Hollstein, Sidransky et al. 1991, Caron De 
Fromentel and Soussi 1992, Lane 1992, Levine 1997) and remains so to date (mutated 
in >50% cancers overall) (Olivier, Hollstein et al. 2010). Transformation related protein 
53 (Trp53/p53), the product of the Trp53 gene (murine homologue of TP53), was first 
identified by immunoprecipitation (IP) experiments as a 54kDa protein bound to simian 
virus 40 (SV40) large T-antigen in SV40-transformed rodent fibroblasts (Chang, 
Simmons et al. 1979, Kress, May et al. 1979, Lane and Crawford 1979, Linzer and 
Levine 1979, Melero, Stitt et al. 1979). When Levin and Linzer showed that p53 was 
also overexpressed in SV40-uninfected embryonal carcinoma cell lines F9 and PCC-
4aza-1, it was established that p53 was encoded by the host’s genome and was not a 
viral protein (Linzer and Levine 1979). Antibody mediated responses towards p53 were 
also detected both in the serum of animal models with chemically/virally induced 
tumours and in human cancers (De Leo, Jay et al. 1979, Kress, May et al. 1979, Melero, 
Stitt et al. 1979, Rotter, Witte et al. 1980, Crawford, Pim et al. 1982). These findings 
brought to light the importance of p53 in the regulation of tissue homeostasis and 
ultimately cancer development. 
1.5.2 Oncogenic tendencies 
Early data on p53 behaviour suggested that this protein plays an oncogenic role in cell 
cycle regulation. When non-transformed murine 3T3 cells were serum deprived and 
serum was reintroduced, p53 mRNA and protein levels elevated immediately before the 
initiation of DNA synthesis commenced (Reich and Levine 1984). Another group 
showed that mitogenic stimulation of non-dividing murine T-lymphocytes, using 
concanavalin A, leads to increased expression of p53 right before the cells undergo 
DNA synthesis and mitotic division (Milner and McCormick 1980). Around the same 
time it was also shown that microinjection of quiescent Trp53 wild-type (Wt) murine 
NIH3T3 cells with antibodies raised against p53; abolishes serum induced growth 
stimulation (Mercer, Nelson et al. 1982, Mercer, Avignolo et al. 1984). The case for 
oncogenic activity of p53 became stronger when it was shown, in independent studies, 
that ectopic co-expression of p53 with activated ras oncogene (encoded by C-Ha-Ras 
oncogene) could immortalise and transform cells as implied by loss of contact inhibition 
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measured by foci formation efficiency in culture (Eliyahu, Raz et al. 1984, Jenkins, 
Rudge et al. 1984, Parada, Land et al. 1984, Jenkins, Rudge et al. 1985). Because of the 
sub-cellular localisation of p53 and its short half-life (~6 min in splenocytes) it was 
suspected that p53 plays an important role in cell cycle progression (Reich, Oren et al. 
1983, Rogel, Popliker et al. 1985). In the former study specific p53 cDNA was used in 
northern blots to measure p53 mRNA levels and then a pulse chase method was used to 
measure p53 protein half-life in four different cell lines in addition to a cell line 
transformed by SV40 (Reich, Oren et al. 1983). The authors showed that p53 turnover 
has biphasic kinetics, that p53 has a short half-life and that its half-life varies between 
cell lines of different origin (Reich, Oren et al. 1983). Importantly, unbeknown to the 
authors they had demonstrated that Wt p53 levels are regulated at the protein level 
rather than mRNA level because they were misled by the increase in F9 p53 mRNA 
levels, which expressed mutant p53 (explained later). Full-length p53 antisense RNA 
mediated downregulation of p53 protein was also shown to prevent DNA synthesis, as 
measured by tritiated thymidine incorporation, and cell cycle progression in transformed 
and non-transformed 3T3 fibroblasts (Shohat, Greenberg et al. 1987). In addition 
immunocytochemical (ICC) and immunohistochemical (IHC) evidence showed 
accumulation of p53 and until 1990 it was thought that this was accumulation of Wt p53 
(Soussi 1994).  
1.5.3 A classic tumour suppressor  
The evidence for the tumour suppressor activity of p53 emerged from studying 
immunocompetent mice infected with the Friend leukaemia virus, which is a complex 
of two different viruses: a replication-defective spleen focus-forming virus (SFFV) and 
a replication-competent Friend murine leukaemia virus (F-MuLV) (Mowat, Cheng et al. 
1985). These mice develop erythroleukaemia and foci of transformed cells in their 
spleen. Cell lines were established from the transformed cells and showed 40% of the 
infected mice had given rise to cell lines that either did not express p53 or expressed a 
truncated form. Genomic rearrangements resulting in aberrations of both alleles of 
Trp53 were detected using cDNA clones corresponding to Trp53 in southern blotting 
experiments (Mowat, Cheng et al. 1985). The regions of p53 that were removed were 
evolutionarily conserved and their absence, which was likely to be associated with loss 
of function, seemed to result in growth advantage implying strongly that p53 had a role 
in growth suppression. Most importantly it was shown that the transformation activity in 
combination with activated ras oncogene differed among p53 cDNA clones from 
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alternative sources (Finlay, Hinds et al. 1988). For example cDNA clone that was 
derived from the F9 embryonal carcinoma cells was incapable of transforming cells 
when co-expressed with activated ras oncogene (Finlay, Hinds et al. 1988). However by 
inserting certain mutations in F9 derived p53 cDNA it gained the ability to transform 
primary embryo fibroblast cells when co-expressed with ras oncogene (Finlay, Hinds et 
al. 1988). It was concluded in this paper that it was likely that the F9 cDNA encodes the 
Wt allele of p53 as its sequence was identical to pcD35 clone derived from the 
concanavalin A stimulated T cells (Milner and McCormick 1980, Finlay, Hinds et al. 
1988). Sequence comparison of p53 between various species indicated that these 
deviations from the F9 sequence were not likely to be polymorphisms due to their 
frequent occurrence in highly conserved regions (I-V) of the p53 open reading frame 
(Figure 1-3) (Soussi, Defromentel et al. 1987, Soussi and May 1996). This brought 
forward the notion that the p53 cDNA sequences used in the previous experiments, 
wherein the co-expression of p53 with ras had led to transformation of fibroblasts, 
harboured inactivating mutations (Soussi, Defromentel et al. 1987, Soussi and May 
1996). The role of p53 as a tumour suppressor was further validated when the ectopic 
co-expression of Wt Trp53 and activated ras oncogene did not lead to transformation of 
murine fibroblasts. Importantly, the plasmid encoding Wt Trp53 was also capable of 
preventing the transforming properties of other oncogene co-expressions such as E1A 
and ras which further supported the notion that Wt p53 is a universal tumour suppressor 
protein (Finlay, Hinds et al. 1989). Along with the animal data being consistent with 
tumour suppressor activity of p53, human data were also emerging which showed 
aberrant p53 in many different tumour types. In a key publication where the authors had 
mapped chromosome deletions in 172 colorectal cancer specimens, chromosome 17p 
loss (which includes the locus for TP53; 17p13) occurred in 75% of colorectal 
carcinomas cases (Vogelstein, Fearon et al. 1988). Recurrent loss of heterozygosity 
(LOH) at a given locus in tumour specimens was hypothesised to be associated with the 
location of a tumour suppressor gene; based on the loss of 13q corresponding to the loss 
of Retinoblastoma protein (RB1 gene) and 11p13 Wilms’ Tumour (WTAP Gene) (for 
Knudson’s two hit hypothesis refer to (Knudson 1971)) (Ponder 1988) (Call, Glaser et 
al. 1990). Baker et al., 1989 subsequently showed by direct sequencing that where 17p 
is lost the remaining TP53 allele is also mutated in colorectal cancer specimens (Baker, 
Fearon et al. 1989). In lung cancer cell lines LOH of 17p was also coupled with TP53 
mutation (Takahashi, Nau et al. 1989). Since these key early publications the evidence 
for the role of p53 in tumour suppression has accumulated and many of the upstream 
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and downstream signalling mechanisms leading to its activation and tumour suppression 
have been deciphered in detail and will be introduced in more in the following sections 
of this chapter (Meek 2015). 
 
Figure 1-3 Cross species alignment of the p53 amino acid sequence showing the 
most conserved regions of p53 amino acid sequence (I-V). Image taken from Soussi 
and May 1996 (Soussi and May 1996).
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1.5.4 Trp53 knockout transgenic mice 
Further evidence validating the role of p53 as a tumour suppressor was the increased 
incidence of tumour formation in Trp53-/- transgenic mice (Donehower, Harvey et al. 
1992). The birth rate of Trp53 null mice was not affected and these mice appeared 
otherwise developmentally normal, however by the age of six months 74% had 
developed tumours and by ten months all of the mice had died. Trp53+/- transgenic mice 
were also more susceptible to tumour development in comparison to Trp53+/+ mice, as 
by the age of 15 months 27% of them had developed tumours (For review see 
(Donehower and Bradley 1993)). Furthermore transgenic mice expressing the Friend 
erythroleukaemia mutant version of p53 (46kDa protein described earlier) showed an 
increased incidence of lung adenocarcinomas, osteosarcomas and lymphomas. It was 
later shown that the female Trp53-/- mice had neural tube malformations resulting in 
craniofacial abnormalities and reduced frequency of females at birth (Sah, Attardi et al. 
1995) (For further information of the developmental abnormalities of Trp53-/- mice refer 
to (Armstrong, Kaufman et al. 1995)) (Rotter, Schwartz et al. 1993).  
The role of p53 as the “guardian of the genome” was strongly supported by the 
protective effect of p53 against the formation of abnormal offspring after exposure to 
known teratogenic agents such as IR or Benzo[a]pyrene (Nicol, Harrison et al. 1995, 
Norimura, Nomoto et al. 1996). Trp53-/- embryos showed much higher rates of 
malformation : embryonic lethality ratio (10:1) after IR exposure than their Wt counter-
parts (1:3) (Norimura, Nomoto et al. 1996). This was attributed to p53 mediated 
apoptosis of p53 Wt murine embryos, in response to IR induced DNA damage, thus 
protecting the integrity of the genome (Norimura, Nomoto et al. 1996). In other studies 
whole body exposure of adult mice to gamma radiation resulted in tissue specific 
accumulation of p53 (Midgley, Owens et al. 1995). Mouse splenocytes, thymocytes and 
osteocytes showed accumulation of p53 whereas no accumulation was observed in 
hepatocytes. This difference may be reflective of tissue proliferation and turnover. This 
meant that in vivo upstream signals resulting in accumulation of p53 after DNA damage 
work in a tissue specific manner (Midgley, Owens et al. 1995). Among tissues that 
showed p53 accumulation, osteocytes did not undergo apoptosis, which suggests that 
the consequences of p53 accumulation and its downstream signalling are also regulated 
in a tissue specific manner. Another study demonstrated that the tissue specific 
regulation of p53 in response to DNA damage observed in adult mice is not the same in 
murine embryos (MacCallum, Hupp et al. 1996). Using previously developed transgenic 
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mice in which there is a p53 dependent lacZ reporter, they showed that DNA damage 
induced accumulation of p53 is homogeneous (not tissue specific) in murine embryos in 
contrast to adult mice (MacCallum, Hupp et al. 1996). This may be because embryonic 
tissue are rapidly proliferating and undergoing differentiation. 
1.5.5 Human germline mutations in TP53  
The autosomal dominantly inherited Li-Fraumeni syndrome is characterised by high 
incidence of a group of diverse but well defined cancers particularly sarcomas (Malkin, 
Li et al. 1990). Other familial cancer predispositions had been associated with loss of a 
tumour suppressor gene, as it was discovered to be the case in Retinoblastoma (RB) and 
Wilms Tumour (Knudson 1971, Ponder 1988, Call, Glaser et al. 1990). The tumour 
suppressor role of p53 and the fact that p53 null/mutant transgenic mice also showed a 
high incidence of sarcomas was a strong indication that it may be involved in the Li-
Fraumeni syndrome. Subsequently it was found that mutant TP53 allele transmission 
was strongly correlated with cancer incident in Li-Fraumeni families (Malkin, Li et al. 
1990, Srivastava, Zou et al. 1990). Non-cancerous skin fibroblasts from a Li-Fraumeni 
family with an inherited TP53 germ-line mutation were found to be radio-resistant 
(Srivastava, Zou et al. 1990). Genomic DNA obtained from two generations of this 
family carried the same mutation of their p53 (D245G) (Srivastava, Zou et al. 1990). 
This data further validated the role of p53 in tumour development and DNA damage 
induced cell death. 
1.5.6 TP53 gene and its isoforms 
TP53 is located on the minus strand of the short arm of chromosome 17 (17p13.1) with 
the genomic co-ordinates chr17:7571720-7590863 (UCSC genome browser). The p53 
protein is encoded by 11 exons which can give rise to multiple isoforms and variants 
due to alternative splicing and multiple transcription start sites (Khoury and Bourdon 
2010). TP53 gene family also has two structurally related members TP63 and TP73 that 
encode for p63 and p73 respectively. They both share transcriptional targets with p53 
and play distinct roles from p53 in murine development (Murray-Zmijewski, Lane et al. 
2006). Details about single nucleotide polymorphisms (SNPs), variants and isoforms 
can be found on the International Agency for Research on Cancer (IARC) database and 
UCSC genome browser, which is regularly updated and curated.  
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1.5.7 TP53 mutations: Gain-of-function or dominant-negative? 
Within the last decade however, evidence has emerged that certain TP53 mutations may 
incur a gain-of-function phenotype promoting tumourigenesis. This has been reviewed 
in detail by Muller and Vousden (2014) (Muller and Vousden 2014). The first 
publication suggesting p53 gain-of-function mutation relied on evidence from mutant 
p53 ectopic overexpression in p53 null cells which resulted in much higher expression 
of mutant p53 than is observed in physiological or pathophysiological settings (Dittmer, 
Pati et al. 1993). Since then many studies have shown that stable transfection or 
endogenous levels of gain-of-function mutant p53 in cell lines results in phenotypes 
conferred by well-characterised oncogenes such as increased migration, invasion, 
anchorage independent growth, colony formation, xenograft growth etc. (Listed in 
Muller and Vousden table 1). The most compelling data for p53 gain-of-function 
mutations comes from studies in knock-in transgenic mice. Knock-in mice harbouring 
heterozygous Trp53R172H (Equivalent of human R175H) were shown to have more 
aggressive tumours, as measured by metastasis and survival, than the heterozygous 
wild-type mice missing the other copy of Trp53 (Doyle, Morton et al. 2010, Morton, 
Timpson et al. 2010). It is worth mentioning that in both studies these mice also 
expressed a well-known oncogenic driver mutation such as KRasG12D. Interestingly, in 
the Li Fraumeni mouse models harbouring Trp53R172H/+ only 3/13 tumours had p53 
LOH strongly suggesting that the loss of the wild-type copy of Trp53 is not necessary 
for the aggressive phenotype observed these mice (Lang, Iwakuma et al. 2004). Similar 
observations were made in another independent study of Trp53R172H/+ and Trp53R270H/+ 
(Equivalent of human R273H) (Olive, Tuveson et al. 2004). This suggests that certain 
p53 mutations may confer a selective advantage for tumour progression independent of 
the genetic status of the other Trp53 allele. The human data for TP53 gain-of-function 
mutations are also consistent with the transgenic mouse data. A proportion of Li 
Fraumeni patients (≈70%, figures vary), a condition typified by predisposition to early 
tumour development (diverse but well characterised tumours), have been associated 
with heterozygous TP53 mutations passed through the germline (Li and Fraumeni 1969, 
Li and Fraumeni 1969, Li, Fraumeni et al. 1988). Recent studies have compared Li 
Fraumeni patients with heterozygous TP53 mutations that result in either loss of 
function or no expression of p53 from one allele. The data showed that the age of onset 
of tumours was significantly earlier (by approximately a decade) in patients with TP53 
missense heterozygous mutation compared to those with mutations that resulted in no 
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p53 expression from one allele (Bougeard, Sesboüé et al. 2008, Zerdoumi, Aury-Landas 
et al. 2013). Crucially, the second copy of TP53 is frequently lost in malignancies with 
p53 mutations (described earlier to be due to chromosome 17p deletion). Although, the 
authors did not investigate whether loss of the second copy of TP53 was necessary for 
tumourigenesis or not in these Li Fraumeni patients, the fact still remains that the age of 
onset of tumours was earlier in cases with TP53 gain-of-function mutations. This 
suggests that certain TP53 mutations may be playing a role accelerating tumour 
development. However, the homo-tetramerisation of p53, which is required for 
consensus sequence binding, is unaffected by these proposed gain-of-function 
mutations. This has been shown to result in p53 Wt and DNA binding defective mutant 
hetero-tetramer formation which results in the loss of p53 tetramer consensus sequence 
binding (Reviewed by (Sabapathy 2015)). This may mean that a gain-of-function 
phenotype observed may simply be due to a dominant-negative effect on the tumour 
suppressor function of the wild-type TP53 allele. Although, other data support the gain-
of-function hypothesis. Two main mechanisms have been proposed to explain the gain-
of-function activity conferred by certain TP53 mutations (Reviewed by Weisz et al., 
(2007)) (Weisz, Oren et al. 2007). First model is based on the observation that gain-of-
function mutant p53 protein were shown to inhibit the transcriptional activity of other 
p53 family members, p63 and p73, thereby inhibiting their tumour suppressor function. 
The second model arises from the observations that the transactivation domain of gain-
of-function mutant p53 is necessary for the expression of certain oncogenes and that 
mutant p53 retains some degree of specific DNA binding. Others more recent 
publications have reported mutants to activate well known oncogenic signalling 
pathways through transcription dependent and independent mechanisms (Muller and 
Vousden 2014). 
Overall the main body of evidence suggests that most of the proposed gain-of-function 
mutations of TP53 primarily result in the loss of DNA binding to p53 consensus 
sequence and thereby loss of p53 transcriptional regulation from promoters of genes 
important in tumour suppressor mechanisms. Therefore, it must be clearly stated here 
that TP53 is still widely accepted as a clear tumour suppressor. However, other data 
also suggest that a given mutation can both inactivate the tumour suppressor function of 
a protein while resulting in its gain of oncogenic function. 
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1.6 p53 structure and function 
The nuclear phosphoprotein p53 encoded by the TP53 gene, is 393 amino acids long 
and has a theoretical non-post-translationally modified mass of 43653Da (GeneCards, 
Weizmann Institute). The name p53 was assigned to this protein because it migrates at 
approximately 53kDa in SDS-polyacrylamide gel electrophoresis. Interspecies 
comparison of p53 sequence show five domains in p53 that are strongly conserved and 
encode residues 13-23, 117-142, 171-181, 234-250 and 270-286 (Figure 1-3)  (Soussi 
and May 1996, May and May 1999).  These conserved regions correspond to functional 
domains of p53 as a transcription factor (Fields and Jang 1990, Farmer, Bargonetti et al. 
1992, Cho, Gorina et al. 1994, May and May 1999).  
1.6.1 Transactivation domain 
The N-terminal domain contains an acidic region which behaves as a transcriptional 
transactivator (Fields and Jang 1990, Raycroft, Wu et al. 1990). This was demonstrated 
by using the yeast and mammalian two hybrid system utilising the fusion of the N-
terminal fragment suspected of transactivation activity with GAL4 DNA binding 
domain (DBD) (Fields and Jang 1990). Residues 1-73 on the amino terminus of p53 
form a very effective transactivation domain (TA) likened to the strongest known TA 
domain found on herpes virus protein VP16 (May and May 1999). It was later 
established that only residues 1-42 are essential for transactivation activity (Unger, 
Mietz et al. 1993). Using reporter gene analysis to study the structure function 
relationship of p53 in a TP53 null background, the authors showed that the truncated 
forms of p53 and mutants commonly found in cancers differed in their transactivation 
efficiency (Unger, Mietz et al. 1993). This transactivation activity of p53 was found to 
be coupled to the nonspecific binding to the DNA and also 15 tumour derived murine 
transforming p53 mutations altered this non-specific binding ability (Steinmeyer and 
Deppert 1988, Kern, Kinzler et al. 1991). Immuno-precipitation of 32P end-labelled 
random fragments (300-1000bp) of the human genome and cosmid and plasmid 
libraries with p53 showed that p53 binds to a specific DNA sequence. By further 
mutational analysis and assessing whether sub-fragments can be precipitated with p53 
the authors characterised a 33-mer sequence that was precipitated with p53 which was 
also affected by cytosine methylation and particular base substitutions (Kern, Kinzler et 
al. 1991). These findings paved the way for identifying the consensus p53 DNA binding 
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site which consists of two repeats of the 10bp symmetrical motif 5'-
PuPuPuC(A/T)(T/A)GPyPyPy-3' separated by 0-13 nucleotides where Pu and Py stand 
for purines (Adenine/Guanine) and pyrimidines (Thymine/Cytosine),  respectively 
(Eldeiry, Kern et al. 1992). It was interestingly shown that mutations in the hotspots of 
p53 found most commonly in cancers (discussed later) abolished p53 binding to this 
consensus sequence (Eldeiry, Kern et al. 1992). It was also found that p53 must form a 
homo-tetramer in order to bind to the consensus p53 binding sequence, indicating that 
p53 must have an oligomerisation domain (Kraiss, Quaiser et al. 1988, Clore, 
Omichinski et al. 1994). The p53 homotetramer requires one Zinc ion per subunit 
(Bargonetti, Friedman et al. 1991, Rahman-Roblick, Johannes Roblick et al. 2007). 
Further identifications of an expanded version of this consensus sequence and 
alternative versions revealed new p53 transcriptional targets (for details see (Bargonetti, 
Friedman et al. 1991, Funk, Pak et al. 1992, Bourdon, DeguinChambon et al. 1997)). 
The consensus sequence was thought to be in the promoter/intronic regions of target 
genes and allows the p53 TA domain to interact with the basal transcription machinery 
such as TATA box binding factors, replication protein A (RPA) and p62 subunits of the 
TFIIH holoenzyme (Wagner, Ma et al. 2005). Using reporter gene analysis it was found 
that p53 can also downregulate transcription from other important promoter sequences 
such as those associated with c-fos, c-myc, c-jun, β-actin, hsc-70 and IL-6 (Ginsberg, 
Mechta et al. 1991, Lechner, Mack et al. 1992, Ko and Prives 1996). The interaction of 
p53 with TATA binding protein (TBP) which is also a subunit of the TFIID 
transcriptional machinery was discovered to be responsible for p53 mediated 
transrepression and that DNA binding was not required for this function of p53 (Seto, 
Usheva et al. 1992, Ragimov, Krauskopf et al. 1993, Truant, Xiao et al. 1993). More 
recent findings have shown that the N-terminus of p53 is subject to complex post-
translational modification which fine tunes its transactivation/transrepression function 
in response to the type of stimulus and the genetic and epigenetic background of the 
cell. This will be introduced further in the following sections of the introduction and 
then in the context of the results in the following chapters. 
The functional significance of specific residues in p53 transcriptional transactivation has 
been investigated using site-directed-mutagenesis both in vivo and ex vivo. Brady CA et 
al., (2011) generated Cre-Lox conditional p53 knock-in mice homozygous for Trp53L25Q 
& W26S and/or Trp53F53Q & F54S which only expressed these mutant p53 alleles when Cre 
was expressed (Brady, Jiang et al. 2011). Microarray gene expression analysis was 
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carried out on MEFs derived from these mice after they were transfected with Cre 
expressing vector. It was shown that Trp53L25Q & W26S and trp53L25Q & W26S, F53Q & F54S 
homozygous knock-in MEFs cannot induce some of the well-established p53 
transcriptional pro-arrest and pro-apoptotic target genes (e.g. p21Waf1, Noxa and Puma) 
whereas the induction of others (e.g. Bax) were unaffected by these mutations. MEFs 
derived from p53F53Q & F54S homozygous knock-in mice induced p53 targets as 
efficiently as p53wt homozygous cells suggesting that these residues are dispensable for 
induction of p53 downstream target. Chromatin immunoprecipitation assays 
investigating the binding of p53L25Q & W26S showed that these residues are dispensable 
for binding to p53 response elements. Mutation in p53L25Q & W26S also resulted in the loss 
of p53 apoptotic response in radiosensitive tissue (e.g. thymus and intestinal) 6 hours 
following 5Gy ionising radiation as measured by terminal deoxynucleotidyl transferase 
dUTP nick end labelling (TUNEL). However, 6 hours may be too early to observe p53 
dependent apoptotic effects and the FACT that TUNEL staining has diminished at 6 
hours may be related to the impact of these mutations on p53 dependent DNA double 
strand break repair processes. The authors generated mice that also had a Cre dependent 
conditional KrasG12D mutant knock-in mice with the p53 variant alleles explained 
above. In these mice intranasal Ad-Cre instillation results in non-small cell lung cancer 
like tumours if p53 is null. The tumour suppressor activity of p53 remained the same in 
each of the Trp53L25Q & W26S or Trp53F53Q & F54S homozygous mutant mice expressing 
KrasG12D, whereas the compound mutation resulted in a dramatic loss of p53-dependent 
tumour suppression albeit to a lesser extent than what was observed in a p53 null 
background. Other subsequent studies have confirmed that only a small subset of p53 
transcriptional target genes such as Bax and the more recently described Phlda3, Abhd4, 
and Sidt2 are likely to have crucial involvement in p53 mediated tumour suppression in 
mice (Johnson, Hammond et al. 2005, Jiang, Brady et al. 2011). This is because the rest 
of the transcriptional targets have been shown to be dispensable in p53 mediated 
suppression of most if not all malignancies.  
1.6.2 Proline rich region 
The N-terminus of p53 also possesses a proline rich region (PRR) that bears a striking 
peptide sequence similarity to the Src homology 3 (SH3) domain, containing 6 repeats 
of the PXXP motif (Walker and Levine 1996, Sakamuro, Sabbatini et al. 1997). When 
mutant p53 (p53ΔPP) missing residues 77-89 (in the proline rich region) in the N-
terminus was transfected into p53 null SAOS-2 cells, p53 still retained its 
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transcriptional transactivation activity (Sakamuro, Sabbatini et al. 1997). The authors 
then queried whether this region is important for the induction of apoptosis by using an 
established system namely a BRK cell line which has been transformed by the action of 
adenovirus E1A and a temperature sensitive mutant p53V135(Sakamuro, Sabbatini et al. 
1997).  At 38ºC the non-permissive temperature the p53V135 can oligomerise but cannot 
bind DNA and therefore the cells have a transformed phenotype. However, in the non-
permissive temperature (32ºC) the cells undergo cell cycle arrest followed by apoptosis. 
The additional shuttling of p53ΔPP cDNA to this system abolishes the p53-induced 
apoptosis following the shift into the permissive temperature, (32ºC) but not the 
transcriptional transactivation and cell cycle arrest (Sakamuro, Sabbatini et al. 1997). 
PRR was found to promote apoptosis by promoting transcriptional transrepression of 
certain genes and inducing TP53 inducible protein 3 (TP53I3/PIG3) gene which 
encodes an oxidoreductase (Venot, Maratrat et al. 1998). Loss of PRR was shown to not 
affect the induction of key p53 transcriptional target genes however, it contributed to 
loss of transrepression activity (Venot, Maratrat et al. 1998). It is also known that the 
PRR is important for suppression of tumour growth and it is one of the two binding sites 
of p53 with the high risk human papilloma virus E6 (HPV-E6) protein which leads to 
p53 degradation (Li and Coffino 1996, Walker and Levine 1996). Interestingly, codon 
72 in p53 is polymorphic (P72R) and individuals carrying two copies of the R72 allele 
are reportedly more susceptible to tumour development caused by HPV-E6 infection in 
some populations (Rosenthal, Ryan et al. 1998, Storey, Thomas et al. 1998). However, 
epidemiological studies regarding this polymorphism are controversial due to 
contradiction. In the light of these data, investigating the genes that are repressed by p53 
which lead to apoptosis may prove useful in understanding apoptotic fate of the cell 
after non-genotoxic p53 activation (Venot, Maratrat et al. 1998).   
1.6.3 DNA binding domain 
80-90% of p53 mutations occur in the previously mentioned DBD, residues 102-292, 
which also encompasses the last four highly conserved regions of p53 (Regions II-V see 
Figure 1-3) (Eldeiry, Kern et al. 1992). The DNA binding domain of p53 was 
characterised by assessing the binding of a p53 thermolysin digested proteolytic 
fragment to the consensus p53 binding DNA sequence (Bargonetti, Manfredi et al. 
1993). A thermolysin resistant fragment of p53 migrating at roughly 27kDa was 
detected to bind strongly with the p53 binding site murine muscle creatine kinase 
promoter (MCK) (known to bind strongly to p53) as determined by electrophoretic 
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mobility shift assay (EMSA) (Bargonetti, Manfredi et al. 1993). The specific DNA 
binding ability of this fragment increased as more thermolysin was used which 
corresponded to a reduction in larger fragments that may have diminished the DNA 
binding ability of this region (Bargonetti, Manfredi et al. 1993). It was also 
demonstrated that proteolytic digestion of common mutant p53 fragments showed no 
DNA binding activity (corresponding to DBD) (Bargonetti, Manfredi et al. 1993). This 
region was also resistant to proteolysis by subtilisin and zinc ion was found to be 
required for DNA binding activity (Pavletich, Chambers et al. 1993). It is noteworthy 
that this core domain is the region essential for the interaction of SV40 large T-antigen 
and tumour protein p53 binding protein 1 & 2 (53BP1 and 53BP2) (Jenkins, Chumakov 
et al. 1988, Ruppert and Stillman 1993, Iwabuchi, Bartel et al. 1994, Gorina and 
Pavletich 1996). 53BP1 & 2 are involved in p53 response to DNA damage and they 
reportedly increase the transcriptional transactivation activity of p53 (Iwabuchi, Li et al. 
1998).  
When the x-ray crystallography structure of p53 in a complex bound to its putative 
consensus DNA target was solved, it showed two β-sheets that provide structural 
support for two large loops and a loop sheet helix (LSH) motif which can accommodate 
a tetrahedrally coordinated zinc atom (Cho, Gorina et al. 1994). The loops and the LSH 
motifs in the structure were found to correspond to previously known conserved regions 
(Figure 1-4)  (Cho, Gorina et al. 1994). Arginine 248 located in loop 3 sits within the 
minor groove whereas loop 1 (LSH) binds to the major grove. Loops 2 and 3 are held 
together by a tetrahedrally co-ordinated zinc atom. This zinc atom is essential for 
consensus specific DNA binding (Hainaut and Milner 1993, Hainaut and Milner 1993).  
Most mutations in other tumour suppressor genes result in complete absence or loss of 
function however >90% of TP53 mutations found in cancers are point missense, 
resulting in intact protein expression (Soussi and Beroud 2001). This suggests that TP53 
mutations that lead to intact mutant protein formation may confer a selective advantage 
to transformed cells as discussed earlier (section 1.5.7) (Michalovitz, Halevy et al. 
1991). TP53 mutations generally affect the DNA binding domain of this protein with 
functional consequences dependent on location and the properties of the altered amino 
acid residue (Rainwater, Parks et al. 1995). The 6 most frequently affected mutational 
hotspots in p53 are R248 (9.6%), R273 (8.8%), R175 (6.1%), G245 (6.0%), R249 
(5.6%), R282 (4%) (Figure 1-5) (Cho, Gorina et al. 1994). Two of the most frequently 
mutated arginine residues  are R248 and R273, which directly contact the DNA 
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molecules (Cho, Gorina et al. 1994). Some p53 mutations can result in the formation of 
inactive hetero-tetramers of p53 wild-type and mutant p53, resulting in loss of p53 
activity (Gannon, Greaves et al. 1990). These p53 hetero-tetramers have a unique 
epitope that can be detected with PAb240 antibody (Gannon, Greaves et al. 1990, 
Sabapathy 2015). These mutations are considered to be dominant-negative p53 
mutations, as despite the Wt copy of TP53 the mutant allele is capable of abolishing p53 
activity in these cell lines (Gannon, Greaves et al. 1990, Sabapathy 2015). Although in 
cancers, TP53 loss of function is often associated with loss of heterozygosity due to 17q 
deletion (Baker, Fearon et al. 1989, Nigro, Baker et al. 1989), which is evidence in 
contradiction to dominant-negative p53 mutations. 
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Figure 1-4 Topological diagram of the core domain of p53 shows the loops and the 
LSH motif and the coordinated zinc atom within the secondary structure. The 
conserved regions are colour coded, Yellow; region II, Blue; Region II, Red; 
Region IV, and Purple; region V. The diagram was taken from Cho et al., 1994 
(Cho, Gorina et al. 1994) 
 
Figure 1-5 The five conserved regions of TP53 with relation to its mutational 
hotspots detected in tumours. The bars show the approximate position and relative 
frequency of these mutations in human cancers. Figure from Cho et al., 1994 (Cho, 
Gorina et al. 1994) 
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1.6.4 C-terminus 
It was discovered that truncated versions of p53 missing the C-terminal region were not 
capable of forming tetramers which implied that the oligomerisation domain of p53 may 
be located in this region (Milner and McCormick 1980, Kern, Pietenpol et al. 1992). In 
1992 Shaulian and colleagues defined this hydrophobic oligomerisation domain of p53 
to be at the C-terminal, and demonstrated that this region is important in explaining 
dominant-negative p53 mutations (Shaulian, Zauberman et al. 1992). Various truncated 
p53 mini-proteins representing the C-terminal hydrophobic regions of p53 which 
carried no mutations were nevertheless capable of transforming cells (Shaulian, 
Zauberman et al. 1992). Both X-ray crystallography and nuclear magnetic resonance 
(NMR) methods have shown the structure of the tetramerisation domain spanning from 
residues 323-356 (Jeffrey, Gorina et al. 1995) (Clore, Omichinski et al. 1994). The N-
terminal of the oligomerisation domain monomer forms a beta-sheet which can interact 
with a beta sheet from a second monomer in an antiparallel fashion forming a dimer. 
The hydrophobic central and C-terminal residues of the oligomerisation domains form 
an alpha helical structure through which p53 dimers can form a homo-tetramer (Figure 
1-6) (Clore, Omichinski et al. 1994). The transformation ability of dominant-negative 
p53 mutants is abolished when the oligomerisation domain is truncated. This suggested 
that if the tetramerisation domain is intact but the other critical domains such as 
transactivation domain/DBD are mutated, chimeric tetramers will form in spite of the 
presence of a wt copy of p53, giving rise to an array of complex phenotypes. Three 
nuclear localisation signals (NLS) are also located at the C-terminal region of p53, 
residues 316-325 (NLS1), 369-375 (NLS2), and 379-384 (NLS3). NLS1 mutation 
excludes p53 from the nucleus whereas mutations in NLS2 &3 result in loss of 
signalling dependent localisation (Dang and Lee 1989, Shaulsky, Goldfinger et al. 
1990). The basic region (BR) comprised of residues 363-393 is thought to also be 
involved in transcriptional regulation, DNA damage recognition and apoptosis (Reed, 
Woelker et al. 1995, Wang, Vermeulen et al. 1996). It was found that microinjection of 
a small modified peptide or an antibody which masks the BR in the C-terminus of p53 
could lead to sequence specific binding in the absence of radiation induced DNA 
damage which meant that the BR was a negative regulator of p53 sequence specific 
binding (Hupp, Sparks et al. 1995, Abarzua, LoSardo et al. 1996). It was put forward 
that the C-terminal of p53 may be able to allosterically inhibit p53 tetramer’s ability of 
sequence specific DNA binding (Halazonetis and Kandil 1993) (Hupp and Lane 1994, 
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Hupp, Sparks et al. 1995). 
The C-terminal undergoes multiple forms of modification in response to different 
modes of p53 activation (Ko and Prives 1996, Shaw, Freeman et al. 1996, Sakaguchi, 
Herrera et al. 1998). Sakaguchi and colleagues showed that in response to DNA damage 
(by UV light or IR) histone acetyl transferases (HAT) p300 and PCAF are responsible 
for the acetylation of p53 K382 and K320 respectively (Sakaguchi, Herrera et al. 1998). 
Ser-33 and Ser-37 were also shown to be phosphorylated in response to these stressors 
using phosphorylation specific antibodies (Sakaguchi, Herrera et al. 1998). Small 
phosphopeptides corresponding to S33/S37 could inhibit the p300 and PCAF dependent 
acetylation of p53 on C-terminal residues in intact cells. The authors suggested that S33 
and S37 phosphorylation events enhance the interaction of p300 and PCAF and promote 
the acetylation of the C-terminus of p53 by p300 and PCAF positively regulating p53 
transcriptional activity (Sakaguchi, Herrera et al. 1998). The p53 tetramer was later 
found to be allosterically regulated by acetylation and phosphorylation events that 
modulate its interaction with transcriptional co-activators like p300/CBP and PCAF 
(Lill, Grossman et al. 1997, Scolnick, Chehab et al. 1997, Wadgaonkar and Collins 
1999). There is also evidence of glycosylation-dependent proteolytic cleavage of the C-
terminus in response to p53 activation (Shaw, Freeman et al. 1996, Okorokov, Ponchel 
et al. 1997). Okorokov and colleagues showed in 1997 that both p53 N-terminus and C-
terminus undergo proteolytic cleavage after DNA damage and that this C-terminal 
cleavage is also induced by free ssDNA (Okorokov, Ponchel et al. 1997). It was shown 
that primary fibroblasts obtained from DNA repair deficient patients with Xeroderma 
pigmentosum (XP) were not sensitive to apoptosis induced by microinjection of Wt 
TP53 expression vector (Wang, Vermeulen et al. 1996). Fibroblasts from these patients 
lacked Wt XPD/ERCC2 or XPB/ERCC3 helicase activity and are therefore defective in 
base excision repair (BER). The XP defective fibroblasts undergo apoptosis in response 
to other stimuli such as microinjection of human apoptosis inducing gene (Ich-1L) or 
mammalian Ced-3 homologue (ICE gene). The authors showed that this lack of 
sensitivity can be reversed by microinjection of Wt ERCC2 or ERCC3 which encode 
helicases incorporated in the TFIIH complex, that also physically interact with the C-
terminal region of p53 (Wang, Yeh et al. 1995, Wang, Vermeulen et al. 1996). A 
helicase ERCC6/CSB from the TFIIH complex involved in excision repair also interacts 
with p53 C-terminal domain in vitro (Wang, Yeh et al. 1995). Post-translational 
modifications of p53 C-terminus (particularly acetylation events) have also been shown 
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to impact the regulation of p53 stability which will be discussed in the context of p53 
MDM2 interaction (Meek 2015). 
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Figure 1-6 Ribbon drawing of the p53 oligomerisation domain and important 
amino acid residues involved in its function. Figure taken from Clore et al., 1994 
(Clore, Omichinski et al. 1994). 
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1.7 Cell cycle checkpoints  
Although the growth and proliferation of eukaryotic cells is a continuous process, 
phases have been characterised, that mark the beginning and completion of significant 
discontinuous events such as DNA synthesis (Hartwell and Weinert 1989). Eukaryotic 
cells appear to follow a cycle with respect to these discontinuous processes, and the 
initiation of each subsequent discontinuous phase in this cycle, is contingent on the 
accurate completion of the prior phase (Murray 1994). Cell cycle checkpoints safeguard 
that cell cycle events occur accurately and sequentially. Also in the face of errors or 
damage, checkpoints arrest progression to the next phase to provide sufficient time for 
repair or allow the initiation of programmed cell death. Defects in cell cycle checkpoints 
can lead to accumulation and propagation of changes conducive to the development of 
malignancies (Nyberg, Michelson et al. 2002). 
1.7.1 Regulation of cell cycle progression 
Four phases have been categorised for the life cycle of all eukaryotic cells namely Gap 
1 (G1), DNA Synthesis (S), Gap 2 (G2) and Mitosis (M) with a quiescent stage G0 
when the cells leave this cycle (Vermeulen, Van Bockstaele et al. 2003) (Figure 1-7). 
Cyclin-dependent kinases (CDKs) are a family of serine/threonine protein kinases 
involved in cell cycle progression and their activity is regulated by another family of 
proteins termed cyclins. CDK levels remain constant throughout the cell cycle however 
periodic expression of distinct cyclins at each stage of the cell cycle regulates cell cycle 
progression by activating specific kinases at each stage of the cell cycle. Cyclin 
expression is dependent on many intracellular and extracellular factors such as DNA 
integrity and availability of growth factors (mitogens). Different cyclin-CDK complexes 
phosphorylate and regulate specific target proteins that are critical for cell cycle 
progression at each stage. Unlike the periodic expression of other cyclins, D-type 
cyclins (Cyclins D1, D2 and D3) are expressed as long as mitogen signal is present. D 
cyclins couple with and activates CDK4/6 during G1 phase which phosphorylate 
downstream targets that promote progression into S-phase. A key phosphorylation 
substrate of Cyclin D-CDK4/6 complex is the product of the retinoblastoma tumour 
suppressor gene (RB). Hypophosphorylated RB negatively regulates E2F-1 and DP-1 
transcription factors that are involved in the transcription of key genes for G1 to S-
phase progression (Vermeulen, Van Bockstaele et al. 2003). Phosphorylation of RB 
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results in activation of E2F-1 and DP-1 which initiate cell cycle progression into S-
phase by induction of Cyclin A, Cyclin E and CDC25. Cyclin E-CDK2 maintains RB 
phosphorylates throughout the cell cycle and is essential for G1 to S transition. Cyclin 
A-CDK2 complex is important throughout S-phase and Cyclin A-CDK1 promotes G2 
to Mitosis transition. Cyclin B-CDK1 complex is also known to regulate mitosis by 
promoting chromosome condensation nuclear lamina resolution and mitotic spindle 
assembly (Vermeulen, Van Bockstaele et al. 2003).  
1.7.1.1 CDK inhibitors 
In response to a variety of stimuli such as cellular stress (e.g. DNA damage) or absence 
of mitogenic signal CDK activity can be inhibited by members of two distinct families 
of CDK inhibitor proteins INK4 and CIP/KIP (Sherr and Roberts 1995) (Figure 1-7). 
Members of the INK4 family include CDK inhibitor 2A (CDKN2A/INK4a/p16)), CDK 
inhibitor 2B (CDKN2B/INK4b/p15), CDK inhibitor 2C (CDKN2C/INK4c/p18) and 
CDK inhibitor 2D (CDKN2D/INK4d/p19) which bind to CDK4/6 and prevent the 
interaction of D cyclins with these CDKs in G1 (Vermeulen, Van Bockstaele et al. 
2003). CIP/KIP family of CDK inhibitors comprise of CDK inhibitor 1A 
(CDKN1A/WAF1/CIP1/p21), CDK inhibitor 3 (CDKN3/CIP2/p27) and CDK inhibitor 
1C(CDKN1C//KIP2/p57) which are involved in inhibition of G1 cyclin-CDK 
complexes and to a lesser degree cyclin B-CDK1 (Vermeulen, Van Bockstaele et al. 
2003). Inhibition of CDKs in this manner prevents cell cycle progression until either the 
stress is resolved or the cell undergoes programmed cell death. 
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Figure 1-7 The cell cycle, and the regulation of its progression by different cyclin-
CDK complexes and CDK inhibitors. Adapted from Vermeulen et al., (2003). 
1.8 Cell cycle checkpoints and the role of p53 
Checkpoints and DNA repair mechanisms are very much intertwined, as the detection 
of DNA damage by surveillance mechanisms often leads to mobilisation of DNA repair 
proteins and signalling networks which are themselves involved in cell cycle regulation 
(For a comprehensive review refer to (Sancar, Lindsey-Boltz et al. 2004)). The 
inhibition of transition between these stages of the cell cycle, such as G1 to S, due to 
cellular stress is what is referred to as cell cycle checkpoints (Sancar, Lindsey-Boltz et 
al. 2004). The checkpoint before DNA replication is termed the G1/S checkpoint (a.k.a. 
restriction point) which regulates entry into/commencement of DNA synthesis and 
replication phase of the cell cycle. Cellular stressors or detection of DNA damage by the 
components of stress response machinery, lead to modulation of effector molecules that 
can inhibit critical downstream regulators of cell cycle progression. A critical 
transcription factor activated in response to cellular stress is the nuclear transcription 
factor transformation protein 53 (TP53/p53) encoded by the aforementioned TP53 gene 
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(Meek 2004). Post-translational modifications of p53, and other molecules involved in 
its regulation, following stress and DNA damage can lead to its activation and 
subsequent transcriptional induction of its downstream target genes, the products of 
which are involved in cell cycle arrest and/or senescence (e.g. p21WAF1, 14-3-3σ, 
GADD45) (Figure 1-7) or apoptosis (e.g. BAX, NOXA, DR5 and PUMA). For example 
activation of ataxia telangiectasia mutated (ATM) or ATM and Rad3 related (ATR) 
protein kinases, in response to DNA damage, can directly and indirectly, phosphorylate 
p53 residue Ser15 which is considered a “nucleation event” for other activating post-
translational modifications such as Thr18 and/or Ser20 phosphorylation or acetylation 
of p53 c-terminus (Saito, Yamaguchi et al. 2003, Meek 2004). These post-translational 
modifications culminate to free p53 from its negative regulatory binding partner 
MDM2, which leads to p53 stabilisation and activity (explained in more detail later). 
The most studied transcriptional target of p53 is CDKN1A which encodes the CDK 
inhibitor p21CIP1/WAF1 described earlier.  In addition to inhibition of cell cycle 
progression at G1 and G2/M as described earlier, p21WAF1 also inhibits proliferating cell 
nuclear antigen (PCNA) which is critical for DNA synthesis hence causing S-phase 
arrest (Sherr and Roberts 1995, Waga, Li et al. 1997, Bartek and Lukas 2001). Cell 
cycle regulatory transcriptional target of p53, 14-3-3σ/YWHAS, encodes a scaffold 
protein 14-3-3σ which removes cyclin B-CDK1 complex from the nucleus thus 
inhibiting G2/M progression (Hermeking, Lengauer et al. 1997). Another mechanism 
through which p53 negatively regulates G2/M progression is through direct induction of 
GADD45 which inhibits cyclin B-CDK1 interaction (Zhan, Antinore et al. 1999). 
Induction of cell cycle arrest by p53 in response to DNA damage may at face value be 
considered a mechanism that protects genomic integrity by allowing sufficient time for 
DNA repair thus preventing propagation of genetic changes detrimental to the survival 
of the organism or the fitness of its offspring. However, because DNA repair 
mechanisms are error prone, it can also be postulated that p53-mediated reversible cell 
cycle arrest may allow the accumulation of oncogenic genetic alterations in successive 
generations of cells resulting in stepwise transformation of somatic tissue. This is 
indeed consistent with the observation that p53 is a relatively late mutational event in 
colorectal cancer development (Vogelstein, Fearon et al. 1988). This is also consistent 
with IR induced lymphomas being significantly delayed in Cdkn1a null mice , which 
develop normally but are deficient in G1 checkpoint, suggesting that p53 mediated G1 
arrest may accelerate the selection of tumourigenic changes in certain contexts (Deng, 
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Zhang et al. 1995, Martín-Caballero, Flores et al. 2001). Furthermore, even though 
Cdkn1a null mice develop spontaneous tumours earlier than their wild-type 
counterparts, these tumours are observed later (after 7 months) than those in Trp53 
(murine homologue of TP53) null mice (74% of mice had tumours before 7 months). It 
may be that the reported roles of p53 mediated senescence and apoptosis are more 
important for tumour suppressor function of p53 (Symonds, Krall et al. 1994, Cosme‐
Blanco, Shen et al. 2007, Xue, Zender et al. 2007). In the following sections the role of 
p53 in induction of senescence and apoptosis in tumour suppression are introduced and 
discussed in more detail. Recently, transgenic mouse studies have shown that the role of 
p53 in regulation of cellular metabolism may also play an important role in tumour 
suppression (Explained in more detail later) (Jiang, Brady et al. 2011, Li, Kon et al. 
2012, Valente, Gray et al. 2013). Due to such observations and the fact that the tumour 
suppressor function of p53 is the most frequent negatively selected process during 
tumourigenesis of somatic tissue reinstating the function of p53 is widely considered an 
effective cancer therapeutic strategy (Khoo, Verma et al. 2014).  
1.9 Cellular senescence and the role of p53 
Cells are considered senescent when they have exited the cell cycle and no longer divide 
in the presence of growth factors or mitogens. The role of p53 in senescence has been 
reviewed in detail by Rufini et al., (2013) therefore it will only be discussed briefly 
here. Senescent cells have an enlarged flat morphology and they express distinct 
biochemical markers as increased expression of β-galactosidase, p53, p21WAF1 and other 
CDK inhibitors along with senescence associated heterochromatic foci (Rufini, Tucci et 
al. 2013). There are three main proposed underlying causes for senescence: 1) 
shortening of telomeres referred to as replicative senescence, 2) sustained oncogenic 
drive and 3) Oxidative damage caused by reactive oxygen species (ROS). These stimuli 
activate stress response effector molecules that crosstalk with and modulate the role of 
p53 in inducing or inhibiting senescence. 
Mouse embryonic fibroblasts (MEFs) derived from transgenic knock-in mice 
homozygous for Trp53R172P, do not undergo senescence in response to ectopic 
expression of TRF2 (Telomere repeat binding factor 2) compared to their Trp53 wild-
type counterparts (Cosme‐Blanco, Shen et al. 2007). Given that telomere dysfunction 
results in DNA damage (Double strand breaks at telomeres), it has been proposed that 
the activation of p53 in response to telomere dysfunction is through the activity of DNA 
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damage response kinases of the phosphatidyl inositol 3-kinase like serine/threonine 
kinase (PI3KK) family such as ATM (Artandi and Attardi 2005, Rufini, Tucci et al. 
2013). This suggests that post-translational modifications of p53 by stress response 
effector molecules may be important in inducing p53-dependent senescence following 
telomere shortening. Furthermore, sustained oncogenic drive from Ras in human 
fibroblasts results in the activation of DNA double strand break repair mechanisms 
followed by activation of p53 and oncogene induced senescence. Stable knockdown of 
p53 or DNA damage response protein ATM resulted in reversal of oncogene induced 
senescence suggesting that oncogene induced senescence is dependent on the ATM-p53 
signalling pathway (Di Micco, Fumagalli et al. 2006). The role of p53 in response to 
ROS however is considered as a double edged sword. Although p53 activation is 
followed by induction of its anti-oxidant downstream transcriptional targets such as 
superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPX1) and sestrin 1 and 2 
(SESN1 & SESN2), ectopic p53 expression has been reported to induce an early 
increase in ROS in cells that undergo apoptosis in that context (Rufini, Tucci et al. 
2013). 
Other reports suggest that p53 may play an anti-senescent role in certain contexts. 
Senescence has classically been considered as an irreversible state. However, relatively 
recent evidence suggests that activation of p53 through the nutrient sensor mammalian 
target of rapamycin (mTOR) may play an anti-senescent role (Demidenko, Korotchkina 
et al. 2010). The authors initially showed that induction of p21WAF1 from an IPTG 
inducible promoter results in cellular senescence in culture. They then showed that non-
genotoxic activation of p53 by an MDM2 inhibitor Nutlin-3 (discussed later), which 
also leads to induction of p21WAF1, resulted in reversible cell cycle arrest (a.k.a 
quiescence). The phosphorylation of a substrate of mTOR and a surrogate marker of its 
activity (S6 ribosomal protein) was inhibited in response to Nutlin-3 or ectopic 
expression of p53 as compared to when p21WAF1 was induced by IPTG suggesting that 
p53 activation inhibits mTOR pro-senescent activity. Interestingly, transgenic knock-in 
mice homozygous for mutant p53 serine 18 to non-phosphorylable alanine (p53S18A 
equivalent of p53S15A in human), show reduced induction of some p53 transcriptional 
targets (e.g. Puma), premature aging consistent with the anti-senescent role of p53. 
Homozygous Trp53S18A knock-in mice are more likely to develop late-onset tumours 
compared to their homozygous wild-type or heterozygous littermates. Furthermore, B 
cells derived from p53S18A/S18A mice show defects in DNA damage induced apoptosis 
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suggesting that modification of single residues on p53 in response to a particular 
stressor may be the determinant of the decision between cell cycle arrest senescence and 
cell death. Importantly, S18 is a key substrate for activity of stress response kinases 
such as ATM. Conversely, studying other hypermorphic mutant p53 knock-in mouse 
models (hyperactive p44 and p53T21D & S23D) have indicated that increased p53 
transcriptional activity can also promote premature ageing (Liu, Ou et al. 2010). These 
observations suggest that p53-mediated senescence is highly stimuli/context-dependent 
and the precise mechanism through which p53 transcriptional activity regulate cellular 
commitment to senescence is yet to be determined. Overall, post-translational 
modifications appear to play an important role in fate determination following p53 
activity. The next section will introduce the role of p53 in programmed cell death or 
apoptosis.  
1.10 Apoptosis and the role of p53 
Apoptosis was first described in 1972 as an active cell death mechanism with distinct, 
active and controlled morphological steps which was in contrast to cell lysis or necrosis 
observed in response to noxious stimuli (Kerr, Wyllie et al. 1972). Apoptosis occurs in 
various physiological (e.g. during ontogenesis) or pathophysiological (e.g. in untreated 
malignant neoplasms) contexts and is considered both a mechanism of healthy tissue 
renewal and tumour suppression. During apoptosis chromatin is condensed and then the 
membrane forms apoptotic bodies (known as membrane budding) which are then 
phagocytosed by the surrounding cells. This is different in necrosis during which 
plasma membrane swells and ruptures releasing the contents of the cell in the 
surrounding tissue often leading to inflammation.  
Apoptosis signalling can be generally perceived as extrinsic or intrinsic in that the 
mechanism initiating this process can be initiated by external or internal cellular 
signalling events (Reviewed in detail by (Reed 2000)). Extrinsic apoptosis is stimulated 
by ligand binding to a family of death receptors and their stimulation which is followed 
by recruitment of adaptor molecules that can activate an initiator member of the 
cysteine-aspartate protease (caspase) family. Initiator caspases then activate executioner 
caspases (caspase-3, -6 & -7) which then results in global proteolysis and cell death by 
apoptosis. The intrinsic apoptotic pathway on the other hand is initiated by stressors 
from within the cell and mediated through the release of apoptogenic molecules (e.g. 
cytochrome c) from mitochondria resulting in caspase-dependent and/or -independent 
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cell death (Dashzeveg and Yoshida 2015). It has been suggested that p53 exerts its pro-
apoptotic effect primarily through the transcription of pro-apoptotic targets that promote 
the intrinsic apoptotic pathway (e.g. pro-apoptotic members of the BCL-2 family) and 
that other p53 transcriptional targets which are components of the extrinsic apoptotic 
pathway (e.g. Death receptor family) augment the intrinsic apoptotic signal (Fridman 
and Lowe 2003). Over 100 pro-apoptotic genes have been reported as p53 
transcriptional target genes, based on chromatin immunoprecipitation, reporter gene 
analysis and/or analysis of global differential gene expression profiles after p53 
activation (Mirza, Wu et al. 2003, Yu and Zhang 2005). Roles of a few key p53 
transcriptional targets important in the extrinsic and the intrinsic pathway will be 
described here.  
Key transcriptional targets of p53 that promote the extrinsic apoptotic pathway include 
tumour necrosis factor receptor superfamily, member 6 (TNFRSF6/FAS), 10A 
(TNFRSF10A/DR4) and 10B (TNFRSF10B/DR5) (Yu and Zhang 2005). These cell 
surface receptors contain intracellular death domains and are activated by ligands such 
as Fas ligand (TNFSF6), tumour necrosis factor-related apoptosis inducing ligand 
(TNFSF10/TRAIL) or tumour necrosis factor (TNF) (Duprez, Wirawan et al. 2009). For 
example TNFSF6 or TRAIL binding to their respective receptors result in the formation 
of an intracellular death inducing signalling complex (DISC) which can recruit and 
activate initiator caspase-8 and/or -10 through Fas-associated death domain (FADD). 
Caspase-8 and -10 can then activate executioner caspases downstream. For more 
detailed description regarding the interaction of other ligands that promote extrinsic 
apoptosis and their internal complexes the reader is directed to reviews by Duprez et al., 
(2009) and Siddiqui et al., (2015) (Siddiqui, Ahad et al. 2015). 
The main pro-apoptotic mechanisms through which p53 induces intrinsic apoptosis are 
through altering mitochondrial outer membrane permeability (MOMP) and 
mitochondrial permeability transition pore (PTP). These mechanisms have been 
reviewed in detail by Dashzeveg and Yoshida (2015) and will therefore only be briefly 
introduced here (Dashzeveg and Yoshida 2015). Anti-apoptotic BCL-2 is thought to 
sequester pro-apoptotic BCL-2 family members such as BCL2-Antagonist/Killer 1 
(BAK1), BCL2-Associated X Protein (BAX). Transcriptional induction of BAK and 
BAX by p53 overwhelms BCL-2 while p53 pro-apoptotic transcriptional targets such as 
p53-upregulated mediator of apoptosis (PUMA), Phorbol-12-Myristate-13-Acetate-
Induced Protein 1 (NOXA) and Tumour protein p53-regulated apoptosis inducing 
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protein 1 (p53AIP1) are known to interact and inhibit the anti-apoptotic BCL-2 family 
members. It has also been reported that p53 can promote apoptosis through a 
transcription-independent mechanism by physically interacting and inhibiting the 
function of anti-apoptotic members of the BCL-2 family, BCL-XL and BCL-2, at the 
mitochondrial membrane. These overall enable BAK and BAX forming complexes that 
traverse the outer membrane of mitochondria and form pores its outer membrane 
allowing apoptogenic molecules such as cytochrome c to be released into the cytoplasm 
(Dashzeveg and Yoshida 2015). Cytochrome c then activates apoptotic peptidase 
activating factor 1 (APAF-1) which can then recruit and activate initiator caspase-9 as 
part of the apoptosome. Caspase-9 cleaves pro-caspase-3 and the activation of 
executioner caspase-3 leads to global proteolysis (Siddiqui, Ahad et al. 2015).  
The importance of the role of p53 in induction of apoptosis was first brought to light 
when it was shown that thymocytes and intestinal stem cells derived from Trp53 
knockout mice are resistant to ionising radiation induced apoptosis while MEFs from 
the same mice were also shown to be resistant to oncogene or chemotherapy induced 
apoptosis compared to their wild-type counterparts (Clarke, Purdie et al. 1993, Lowe, 
Ruley et al. 1993, Lowe, Schmitt et al. 1993). Study of whole body radiation in Trp53 
null mice showed that DNA damage induced pro-apoptotic role of p53 is tissue-type 
dependent as gamma radiation induced apoptosis was notably deficient in radiosensitive 
tissue (e.g. thymus and spleen) of the Trp53 null mice compared to the wild-type 
littermates; whereas there was no difference in apoptosis in other radio-resistant tissue 
types (e.g. osteocytes or hepatocytes) (Midgley, Owens et al. 1995). Transient ectopic 
expression of mutant variant of Trp53L25Q, W26S, which is incapable MDM2 binding and 
of transactivation of p53 induced target genes, resulted in contradictory findings when 
investigated in different contexts, until it was shown that MEFs and embryonic stem 
cells derived from homozygous Trp53L25Q, W26S knock-in mice were deficient in 
apoptosis induced by DNA damage compared to their wild-type counterparts (Chao, 
Saito et al. 2000, Jimenez, Nister et al. 2000). Also as mentioned earlier homozygous 
Trp53S18A knock-in mice have defects in induction of p53 regulated apoptotic 
transcriptional target genes and DNA damage induced apoptosis (Chao, Hergenhahn et 
al. 2003, Chao, Herr et al. 2006, Armata, Garlick et al. 2007). These reports overall 
strongly suggested that p53 induced transactivation of pro-apoptotic genes is essential 
for apoptosis in these contexts.  
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1.11 MDM2 regulates p53 stability and function 
In an unstressed cell, p53 remains mostly bound by mouse double minute 2 
(MDM2/HDM2 in humans), an E3 ubiquitin ligase, which targets p53 for proteasome 
mediated degradation through the 26S proteasome complex (Böttger, Böttger et al. 
1997, Kubbutat, Jones et al. 1997). MDM2 also regulates p53 function by inhibiting its 
transcriptional transactivation domain and localising p53 to the cytoplasmic 
compartment of the cell (Li, Brooks et al. 2003). However, in response to cellular stress, 
such as DNA damage, unbound p53 and MDM2 both undergo post-translational 
modifications which prevent their dimerization (Meek and Anderson 2009, Meek and 
Hupp 2010, Meek 2015). This leads to the stabilisation and accumulation of p53 in the 
nucleus where it can exert its effects as a transcription factor by binding a consensus 
sequence adjacent to its target genes and promoting their transcription (Dumaz and 
Meek 1999). The canonical transcriptional target genes up-regulated by p53 include 
CDKN1A, BAX, PUMA and growth arrest and DNA-damage-inducible (GADD45), all 
of which play a either growth inhibitory or pro-apoptotic role (Levine, Momand et al. 
1991, Harper, Adami et al. 1993, Levine 1997). The MDM2 gene is also 
transcriptionally up-regulated by p53, resulting in an autoregulatory feedback loop (Wu, 
Bayle et al. 1993).  
1.11.1 Indirect regulation of p53 stability and function from the CDKN2A locus 
Another important indirect regulator of p53 activity is encoded by the cyclin-dependent 
kinase inhibitor 2A (CDKN2/INK4a/MTS1) locus (Quelle, Zindy et al. 1995). Mice 
lacking this gene are embryonically viable but are prone to early spontaneous 
tumourigenesis and hypersensitive to genotoxic agents (Serrano, Lee et al. 1996). This 
locus is a tumour suppressor lost or silenced by methylation in many types of cancers 
and it encodes multiple transcripts one of which is p16INK4a a cyclin D-dependent kinase 
CDK4 and CDK6 inhibitor preventing their phosphorylation of RB protein and hence 
cell cycle progression from G1 to S-phase. However, interestingly the same locus 
encodes another protein from an alternate reading frame (ARF), p14ARF (p19ARF in 
mice), which is also involved in the regulation of G1/S transition. Figure 1-8 depicts 
how p14ARF is reportedly transcribed from the alternative reading frame of CDKN2A 
locus. There is strong evidence that the oncogenic induced activation of p53 happens 
through p14ARF/p19ARF mediated negative regulation of MDM2/Mdm-2 activity (Bates, 
Phillips et al. 1998, de Stanchina, McCurrach et al. 1998, Palmero, Pantoja et al. 1998, 
Zindy, Eischen et al. 1998). This p19ARF/MDM2/p53 pathway is also activated in 
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response to oncogenic stress through the p38(Akt) mitogen activated kinase (MAPK) 
pathway and inhibits the interaction of p53 and MDM2 (Bulavin, Phillips et al. 2004). A 
diagram describing p53 activation by DNA damage response or oncogenic stress is 
shown in Figure 1-9. 
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Figure 1-8 Alternate reading frame of the CDKN2A locus giving rise to p14ARF. 
Exons 1α and 3 are reportedly excluded during transcription to allow the p14ARF 
mRNA. 
 
Figure 1-9 MDM2 is the most important regulator of p53. Transcriptional activity 
stability and nuclear localisation of p53 are all regulated primarily by MDM2. 
Cellular stress can result in disruption of this molecular interaction and lead to 
p53 stability MDM2 is also a direct downstream transcriptional target of p53 and 
hence these two molecules form an auto-regulatory feedback loop. Figure obtained 
and modified from (Tweddle, Pearson et al. 2003). 
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1.12 An overview of MDM2 
1.12.1 MDM2 gene and protein 
MDM2/HDM2 is located on chromosome 12q15 with the genomic co-ordinates 
chr12:69,201,971-69,239,320 (UCSC genome browser). This gene comprises 11 exons, 
with more than 40 splice variants reported, in both normal and tumour tissue (Bartel, 
Taubert et al. 2002) (GeneCards, Weizmann Institute) some of which retain 
transforming ability despite loss of N-terminal p53-binding domain exons (Sigalas, 
Calvert et al. 1996). MDM2 encodes a 491 amino acids long 55233Da protein which 
migrates at 90kDa and is known to behave as an E3 ubiquitin ligase most likely due to 
post-translational modifications. Characterised MDM2 functional domains include: p53 
binding domain (residues 19–102), acidic domain (residues 223–274), a central zinc-
finger (residues 305–332) and a RING-finger at its C-terminal end (residues 438–478) 
(Chen, Marechal et al. 1993, Boddy, Freemont et al. 1994). 
1.12.2 MDM2: Inhibitor of p53 transactivation  
The Mdm2 (Murine homologue of MDM2) gene is a potent oncogene which was 
originally found in a spontaneously transformed murine 3T3 cell line that had double 
minute chromosomes (Double minutes are cytogenetically identified paired acentric 
chromatin bodies harbouring amplified genes) (Cahilly-Snyder, Yang-Feng et al. 1987 
). The overexpression of Mdm2 was shown to increase the tumourigenicity of murine 
cell lines (Fakharzadeh, Trusko et al. 1991). The earliest evidence of p53-Mdm2 
interaction was reported in 1992 when Momand and colleagues demonstrated a protein 
migrating at 90kDa which immuneprecipitated with both mutant and Wt p53. The 
authors then demonstrated with a reporter gene assay that MDM2 inhibited 
transcriptional activity induced by p53 (Momand, Zambetti et al. 1992). MDM2-
amplificaiton was detected in one third of human sarcomas and the association between 
this event and loss of p53-dependent cell cycle regulation was made (Oliner, Kinzler et 
al. 1992). Others have confirmed the prevalence of MDM2-amplification or 
overexpression (e.g. due to SNP309 (Bond and Levine 2007)) in sarcomas and other 
cancers (Buesoramos, Yang et al. 1993, Ladanyi, Cha et al. 1993, Leach, Tokino et al. 
1993, Cordoncardo, Latres et al. 1994). During the mid-1990s multiple groups showed 
that the physical interaction of the Mdm2 N-terminus and the N-terminal acidic TA 
domain of p53 was necessary for inhibition of p53 transactivation activity (Chen, 
Marechal et al. 1993, Oliner, Pietenpol et al. 1993, Haines, Landers et al. 1994, Lin, 
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Chen et al. 1994). This physical interaction between p53 and Mdm2 was later confirmed 
and detailed insight into the binding mode gained by determination of the X-ray crystal 
structure of the p53 and MDM2 N-terminal complex (See (Kussie, Gorina et al. 1996)). 
Chen and colleagues showed that p53 mediated G1 arrest and apoptosis is inhibited by 
Mdm2-dependent mechanisms (Chen, Wu et al. 1996). Two independent studies 
developed Mdm2 knockout transgenic mice and showed that these mice underwent 
early embryonic lethality, which was only rescued by concomitant deletion of Trp53 
(Jones, Roe et al. 1995, Luna, Wagner et al. 1995). This suggested that the most 
important role of Mdm2 in early development is negative regulation of the pro-
apoptotic and cell cycle regulatory effects of p53.  
After it was established that MDM2 interacts with the N-terminus of p53 (Picksley, 
Vojtesek et al. 1994), site specific mutagenesis of the key amino acids involved in 
transactivation function of p53, namely L22 and W23, were identified to interact with 
Mdm2 (Lin, Chen et al. 1994). L14 and F19 were also shown to be needed for the 
binding of p53 to MDM2 (Lin, Chen et al. 1994). As expected, none of these mutations 
affected p53 sequence specific DNA binding  (Lin, Chen et al. 1994). To map the 
MDM2 binding site for p53 Böttger, A., et al., (1997) used pre-defined short peptides 
from a phage library to inhibit the interaction between MDM2 and p53 and assessed 
which peptide had the lowest inhibitory concentration 50 (IC50) in vitro as measured by 
an enzyme-linked immunosorbent assay (ELISA) (Böttger, Böttger et al. 1997). This 
study also confirmed the earlier findings that the N-terminal domain of p53, especially 
F19, W23 and L26, were critical residues for the p53-MDM2 interaction (Böttger, 
Böttger et al. 1997). This was subsequently demonstrated by the X-Ray diffraction 
determined atomic resolution crystal structure of the MDM2-p53 dimer, which showed 
that p53 forms an N-terminal amphipathic alpha-helix with three critical side chains 
projecting from F19, W23 and L26 all of which sit in a small N-terminal hydrophobic 
binding pocket formed by MDM2 (Kussie, Gorina et al. 1996). Importantly MDM2-p53 
association was identified to cause a steric hindrance to p53 interaction with TAFII40, 
TAFII60 and TAFII31 which thus inhibits transcriptional transactivation (Lu and 
Levine 1995, Thut, Chen et al. 1995). Bottger and colleagues also used electrophoretic 
mobility shift assays to assess whether the MDM2-p53 interaction inhibits p53 sequence 
specific DNA binding and observed that the p53-DNA complex was supershifted by 
MDM2 indicating that MDM2 does not inhibit the p53-DNA interaction (Böttger, 
Böttger et al. 1997). Despite the important role of MDM2 in p53 regulation it is also 
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known that MDM2 can directly interacts with DNA, RNA, L5 ribosomal 
protein(Marechal, Elenbaas et al. 1994), RB(Xiao, Chen et al. 1995), E2F (Martin, 
Trouche et al. 1995) and NBS1(Carrillo, Hicks et al. 2015). More recent findings 
suggest that p53 is active and ready for transcriptional induction at the promoter sites of 
some target genes and is only inhibited by MDM2 and another closely related protein 
MDMX. This is termed the “anti-repression model” which is consistent with p53 
transcriptional activity observed after non-genotoxic decoupling of MDM2 and p53 by 
small molecular weight inhibitors or peptides (Kruse and Gu 2009). 
1.12.3 MDM2 a transcriptional target of p53 
It was shown that UV light-induced DNA damage promotes the expression of MDM2 in 
a p53-dependent manner and that this expression is delayed at higher doses of UV light 
in spite of the sharp rise in p53 (Perry, Piette et al. 1993). MDM2 has three promoter 
sequences in the MDM2 gene however only the second one is responsive to p53 
(Saucedo, Myers et al. 1999, Liang and Lunec 2005). The first promoter (P1) is located 
upstream of exon 1 and is regulated by the tumour suppressor phosphatase and tensin 
homologue (PTEN) (Chang, Freeman et al. 2004). The second promoter (P2) is 
regulated by p53 pertaining to four p53 response elements (p53RE) in intron 1 (Barak, 
Juven et al. 1993, Zauberman, Flusberg et al. 1995).  The third promoter (P3) is in 
intron 3 and contains a p53 consensus DNA binding sequence, which in contrast to the 
P2 promoter acts as a repressor, negatively regulating MDM2 transcription at higher 
levels of p53 (Liang and Lunec 2005). The transcripts from P1 and P2 have the same 
transcriptional start site (exon 3) and they both possess two alternative translational start 
sites. This can give rise to two different size proteins, p90, is translated from the ATG in 
exon 3 and p76 is translated from ATG in exon 4 (Olson, Marechal et al. 1993, 
Iwakuma and Lozano 2003). The shorter alternate protein, p76, is thought to be 
involved in negative regulation of p90 as it is missing parts of the p53 binding domain. 
The transcripts from P1 and P2 are known to differ in their 5’-untranslated regions 
resulting in different translation efficiency (Jin, Turcott et al. 2003). The Ras-driven 
Raf/MEK/MAP kinase pathway also positively regulates MDM2 at the P2 promoter. 
Activated Raf in response to fibroblast growth factor (FGF), insulin like growth factor 1 
(IGF-1) and platelet-derived growth factor (PDGF) upregulates MDM2 mRNA and 
protein (Ries, Biederer et al. 2000). In the absence of p19ARF (a physiological Mdm2 
inhibitor protein) this Mdm2 upregulation leads to Mdm2 mediated degradation of p53 
(Ries, Biederer et al. 2000). MDM2 has also been reported to be a downstream 
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transcriptional target of MYCN (Slack, Chen et al. 2005), although this requires further 
validation.  
1.12.4 MDM2 ubiquitinates p53  
The levels of p53 increase in response to DNA damage or oncogenic stress due to post-
transcriptional events. This is due to an increase in p53 post-translational stabilisation of 
p53 while p53 mRNA remains more or less constant (Reich, Oren et al. 1983, Prives 
and Hall 1999). In 1997 Haupt and colleagues showed that Mdm2 is responsible for 
rapid degradation of p53 (Haupt, Maya et al. 1997). A construct encoding a truncated 
form of Mdm2 (ΔX), defective in binding to p53, was used to show that p53 
degradation is dependent on interaction with Mdm2. A wild-type p53 construct was co-
transfected with Wt mdm2 or ΔX mdm2 into a p53 null background (H1299 cells) and 
p53 protein levels were measured after 24 hours by immunoblotting. The p53 level was 
markedly reduced when Wt p53 and Wt mdm2 were co-transfected into H1299 cells in 
comparison to co-transfection of ΔX Mdm2 and Wt p53(Haupt, Maya et al. 1997). 
Mutated p53, deficient in Mdm2 binding, was refractory to Mdm2 mediated degradation 
indicating that Mdm2-p53 binding is critical for p53 degradation (Haupt, Maya et al. 
1997). Fusion of the first 42 N-terminal residues of p53 to a Gal4 DBD also resulted in 
rapid degradation of the fusion protein. Most importantly the Mdm2 dependent 
downregulation of p53 was shown to be independent of mRNA levels (Haupt, Maya et 
al. 1997).  
Transactivation repression of p53 was only dependent on the N-terminus of Mdm2 
leaving room for speculation as to what the rest of this protein does (Chen, Wu et al. 
1996, Kubbutat, Jones et al. 1997). Previous knowledge of interaction of HPV E6 and 
its ability to target p53 for ubiquitin mediated degradation was also suggestive that p53 
degradation was proteasomal (Scheffner, Werness et al. 1990). Using specific 
proteasome inhibitors it was shown that p53 ubiquitin mediated degradation is 
dependent on the 26S proteasome and subsequently that MDM2 is the E3 ubiquitin 
ligase primarily responsible for p53 ubiquitination (Maki, Huibregtse et al. 1996, 
Honda, Tanaka et al. 1997). Lactacystin (another proteasome inhibitor) was also able to 
abolish Mdm2 mediated degradation of p53, which supported degradation by a  
proteasomal dependent system (Kubbutat, Jones et al. 1997). It is important to note that 
both non-treated cells and cells pre-treated with IR  accumulate ubiquitinated p53 when 
proteosomal degradation is inhibited, indicating that ubiquitination is involved in basal 
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p53 turnover (Maki, Huibregtse et al. 1996).  The ubiquitination reaction is carried out 
in a three step biochemical reaction, starting from ubiquitin activating enzyme (E1), 
followed by ubiquitin conjugating enzyme (E2), and finally ubiquitin ligase (E3) 
(Honda, Tanaka et al. 1997). E1 attaches ubiquitin  to a 76 residues long protein, E2 
accepts this activated ubiquitin and passes it on to E3 ubiquitin ligase which catalyses 
the covalent attachment of ubiquitin to the target substrate (Iwakuma and Lozano 2003). 
MDM2 was found to carry out the final step with respect to p53 in vitro and also its 
amino acid sequence showed sequence similarity to other ubiquitin ligase enzymes 
(Honda, Tanaka et al. 1997). Multiple target lysine residues, namely K370, K372, 
K373, K381,K382 and K386, at the C-terminus of p53 were found to be ubiquitinated 
by MDM2 and site directed substitution mutations of these residues were found to 
interfere with ubiquitination (Nakamura, Roth et al. 2000, Rodriguez, Desterro et al. 
2000). Although, later in vivo mouse knock-in data emerged showing that the 
equivalent of these residues are dispensable MDM2 mediated p53 degradation (see 
section 8.4) (Feng, Lin et al. 2005, Krummel, Lee et al. 2005). The ubiquitylating 
activity of MDM2 was reported to be dependent on its RING finger domain, which is 
also responsible for its self-ubiquitination (Fang, Jensen et al. 2000, Honda and Yasuda 
2000). This autoubiquitination was shown to only require E1 and E2 enzymes in vitro 
(Fang, Jensen et al. 2000). When Zn was chelated using N,N,N′,N′-tetrakis(2-
pyridylmethyl)-ethylenediamine (TPEN) or MDM2 residues involved in coordination of 
Zn were mutated, the ubiquitination did not occur, indicating that MDM2-dependent 
ubiquitination and autoubiquitination require a Zn atom, consistent with the 
involvement of the RING finger domain. Interestingly when the RING domain of 
MDM2 was replaced with that of another E3 enzyme (Praja1), MDM2 failed to 
ubiquitinate p53 suggesting that the RING domain on MDM2 targets p53 in a substrate 
specific manner (Fang, Jensen et al. 2000). The Herpes virus-associated ubiquitin-
specific protease (HAUSP; a deubiquitinase) and death domain associated protein 
(DAXX) are also involved in p53 turnover through MDM2. In unstressed conditions 
DAXX stabilises MDM2 and HAUSP complex also increases MDM2 stability and 
intrinsic enzymatic activity, thereby promoting degradation of p53 by MDM2 (Tang, 
Qu et al. 2006). 
1.12.5 Nuclear Shuttling of MDM2 
It was known that when MDM2 is transiently expressed it localises to the nucleus due to 
it possessing a nuclear localisation signal (Chen, Lin et al. 1995). Heterokaryon assay 
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was used to show the shuttling of ectopically expressed MDM2 between the nucleus 
and cytoplasm. Point mutations, G58A, D68A and V75A, which affected the interaction 
of p53 and MDM2 did not result in the abolition of MDM2 shuttling. This indicated that 
MDM2 nuclear export is independent of the interaction with p53. Sequence similarity 
between the nuclear export signal of lentiviruses and a domain on MDM2 highlighted 
the potential of a nuclear shuttling sequence on MDM2 (Roth, Dobbelstein et al. 1998). 
Loss of the nuclear export sequence meant nuclear localisation of MDM2.  
1.12.6 MDMX 
Another protein involved in the stability and negative regulation of p53 function is the 
closely related MDM2 paralogue, mouse double minute 4 (MDM4/MDMX), but unlike 
MDM2 it is not a transcriptional target of p53 (Finch, Donoviel et al. 2002, Wade and 
Wahl 2009). Despite very close sequence and structural similarities between MDMX 
and MDM2 these two proteins cannot compensate for one another in vivo in early 
development (Wade and Wahl 2009). Absence of MDM2 or MDMX results in 
embryonic lethality in mice, and in both cases the murine embryos can be rescued by 
concomitant loss of Trp53 (de Oca Luna, Wagner et al. 1995, Jones, Roe et al. 1995, de 
Rozieres, Maya et al. 2000, Wade and Wahl 2009)  (de Oca Luna, Wagner et al. 1995, 
Jones, Roe et al. 1995, de Rozieres, Maya et al. 2000, Wade and Wahl 2009). Temporal 
and tissue specific expression of both proteins may account for their lack of ability to 
compensate for one another in early development (Wade and Wahl 2009, Pant, Xiong et 
al. 2011). MDMX physically interacts with the RING domain on MDM2 and the 
transactivation domain of p53, preventing its transactivation activity (Tanimura, 
Ohtsuka et al. 1999, Popowicz, Czarna et al. 2007). Although MDM2/MDMX 
heterodimerisation regulates p53-MDM2 interaction and stability, this dimer is thought 
to be dispensable in later development and it is thought to not target p53 for degradation 
(Tanimura, Ohtsuka et al. 1999, Badciong and Haas 2002, Popowicz, Czarna et al. 
2007). Increased expression of MDMX has been reported to reduce sensitivity to 
Nutlin-3 (an MDM2-p53 binding antagonist) which is known not to inhibit MDMX 
binding to p53 (Hu, Gilkes et al. 2006). MDMX-amplification or overexpression may be 
a causative reason for p53 pathway inactivation in retinoblastoma and other cancers, 
consistent with an oncogenic role for MDMX (Laurie, Donovan et al. 2006). Therefore 
considering the role of MDMX amplification as a determinant of response to MDM2 
antagonists may be needed in cell lines that show reduced sensitivity.  
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1.13 DNA strand break repair mechanisms 
The multitude of sources of DNA damage induce distinct yet diverse DNA damage 
lesions however DNA double strand breaks (DSB’s) or single strand breaks (SSB’s) 
that can lead to DSBs at the replication fork are considered the most lethal (Polo and 
Jackson 2011). Therefore in this section repair mechanisms of DNA DSB’s are briefly 
introduced and their crosstalk with p53 signalling is discussed. 
1.13.1 Homologous recombination repair 
In homologous recombination DNA repair (HRR) DNA DSB’s are detected by the 
MRN protein complex, comprised of MRE11, Rad50 and NBS1, which then directly 
stimulates ataxia telangiectasia mutated (ATM) enzymatic activity to target its 
downstream effectors including: histone H2AXS139, CHEK2T68, MDM2S407, S419, S425, S429 
& S395, MDMXS403, Cdc25C (through CHEK2) and p53S15, S46 (Lee and Paull 2004, Meek 
2009, Meek 2015). Phosphorylated H2AX (termed γH2AX) results in nucleosome 
remodelling and increases DNA accessibility to other repair proteins such as breast and 
ovarian cancer susceptibility protein 1 (BRCA1) and 53BP1 (Celeste, Fernandez-
Capetillo et al. 2003). CHEK2 however further modifies downstream targets including 
p53, MDM2 and MDMX (Meek 2009). Transgenic mice with Mdm2S394A or 
MdmxS342A, S367A & S403A homozygous substitutions are radio-resistant and MEFs derived 
from Mdm2S394A mice do not undergo apoptosis in response to ionising radiation (Maya, 
Balass et al. 2001, Gannon, Woda et al. 2012). Interestingly, responses to Nutlin-3 are 
unaffected in Mdm2S394A mice suggesting that this residue is not pertinent in 
determining the response to MDM2 inhibitors. Although the affinity of Nutlin-3 to 
murine Mdm2 may not the same as human MDM2. Another protein involved in HRR is 
poly (ADP-ribose) polymerase 1 (PARP-1). PARP-1 inactivation was discovered to 
have a synthetic lethal effect in BRCA1 and BRCA2 homozygously mutated cancer 
cells found in sporadic and familial types of breast and ovarian cancers (McCabe, 
Turner et al. 2006). PARP-1 is responsible for detecting DNA strand breaks and 
catalyses the poly ADP-ribosylation of proteins associated with chromatin structure, 
allowing chromatin remodelling and access of repair proteins to the sight of damage 
(Shall and de Murcia 2000, Hochegger, Dejsuphong et al. 2006). SSBs as defined by 
discontinuities in one strand of the double stranded DNA molecule, are more prevalent 
than DSBs, and are cytotoxic to the cell if not repaired efficiently. SSBs can occur as a 
result of oxidative damage caused by endogenous ROS, aberrant topoisomerase 1 
activity (or Topo 1 inhibitors), base excision repair (BER) of damaged bases/abasic sites 
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or direct disintegration of oxidised sugar (Caldecott 2008). Replication protein A (RPA) 
binds to and stabilizes SSBs present as part of the normal DNA replication process in 
between Okazaki fragments on the lagging DNA strand. RPA coated DNA can also 
recruit ATR-interacting protein (ATRIP) complex to the site of damage (Cortez, 
Guntuku et al. 2001, Caldecott 2008). ATM- and Rad3-related (ATR) is then activated 
and phosphorylates downstream proteins like CHEK1, p53 and MDM2 (Cortez, 
Guntuku et al. 2001). ATR is thought to mainly respond to replication stress and strand 
crosslinking, however the overlap between the role of ATR and ATM are not 
completely defined yet (Cortez, Guntuku et al. 2001). In contrast to Atm and Trp53, Atr 
null mice and human somatic cells are not viable (Brown and Baltimore 2000, Cortez, 
Guntuku et al. 2001). Interestingly loss of CHEK1, the well-established substrate of 
ATR, is also embryonically lethal in mice (Liu, Guntuku et al. 2000). ATR 
autophosphorylation and phosphorylation of CHEK1 are essential for the G2/M cell 
cycle checkpoint response to DNA damage (Liu, Guntuku et al. 2000).  
1.13.2 Non-homologous end joining  
Non-homologous end joining (NHEJ) DNA repair begins by sequence independent 
recognition of DSB’s (both blunt ended and 3’- or 5’-overhang) through a heterodimer 
protein called Ku which is composed of Ku80 and Ku70 (Yannone, Khan et al. 2008, 
Mahaney, Meek et al. 2009). Ku subsequently holds the two broken ends of DSBs 
together by self-association and then recruits other proteins involved in NHEJ such as 
DNA dependent protein kinase catalytic subunit (DNA-PKcs), XRCC4-Ligase IV 
complex, XLF, DNA polymerases μ and λ (Cary, Peterson et al. 1997, Mahaney, Meek 
et al. 2009). Recruitment of DNA-PKcs to either sides of the DNA DSB by Ku enables 
“synaptic complex” formation and allows both the catalytic subunits to trans-
phosphorylate and thus activate one another (DeFazio, Stansel et al. 2002 ). Non-
ligateable DNA ends are then processed to 5’-phosphate and 3’-hydroxyl ends so that 
they can be ligated in a sequence non-specific manner (Yannone, Khan et al. 2008, 
Serrano, Li et al. 2012).  
1.14 Strand break repair machinery and p53 crosstalk 
Integral to the function of the repair processes described above, are three members of 
the aforementioned PI3KK family of protein kinases; ATM, ATR and DNA-PKcs. 
Germline defects in genes encoding these kinases have been shown to cause syndromes 
typified by acute sensitivity to DNA damaging agents and predisposition to various 
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cancers, as well as immunodeficiency disorders (Savitsky, Bar-Shira et al. 1995, 
O'Driscoll, Ruiz-Perez et al. 2003, van der Burg, Ijspeert et al. 2009). Somatic 
mutations of these genes are also found in many different tumour types (Lempiaeinen 
and Halazonetis 2009). As described above, recruitment and activation of each kinase to 
specific DNA damage lesions requires a complex of sensor proteins which first 
recognise the lesion and then provide a docking site for the specific kinases. In NHEJ 
DNA DSBs are first bound by Ku70/Ku80 heterodimer which then recruit and activate 
DNA-PKcs to the site of damage allowing for initiation of this process (Gottlieb and 
Jackson 1993). In HRR DNA DSBs are first bound by the MRN sensor complex 
(MRE11–RAD50–NBS1) which then recruits and activates ATM (Polo and Jackson 
2011). Single strand breaks in the DNA are sensed by replication protein A (RPA) 
which recruits ATR to the site of the damage with the help of ATR interacting partner 
(ATRIP) (Polo and Jackson 2011). These three PI3KKs are then activated to directly 
and indirectly phosphorylate p53 on different and overlapping residues resulting in its 
dissociation from MDM2 and stabilisation (See Figure 1-9) (Meek 2009, Meek and 
Anderson 2009). Once p53 is stabilised it can induce the transcription of its pro-arrest 
transcriptional targets, to allow time for repair of the damage, or promotes cell suicide 
through a PCD mechanism (e.g. apoptosis) if the damage is irreparable, or the 
consequences of missrepair are unfavourable for the survival of the cell. ATM, ATR 
and DNA-PKcs can thus induce p53 tumour suppressor activity in response to different 
types and severities of DNA strand breaks (Meek and Anderson 2009). 
1.14.1 WIP1 phosphatase and homeostasis of p53 in response to stress and DNA 
damage 
Reversible p53 induced cell cycle arrest in the event of sub-lethal damage is made 
possible through multiple p53 negative autoregulatory mechanisms (Harris and Levine 
2005). As described earlier, the p53-MDM2 negative autoregulatory feedback loop 
plays the most crucial role in homeostatic regulation of p53 stability and function. 
However, there are many more subtle feedback mechanisms to help keep the p53 
growth inhibitory and lethal function at bay. One such mechanism involves p53 
mediated induction of protein phosphatase, Mg2+/Mn2+ dependent, 1D 
(PPM1D/WIP1). Henceforth, PPM1D (Ppm1d in mice) will be used to denote the gene 
and WIP1 (Wip1 for the mouse homologue) to denote the protein.  WIP1 directly 
dephosphorylates phospho-p53Ser15, which is the product of PI3KKs, and indirectly 
affects the phosphorylation of other residues (Thr18 & Ser20) that are important for 
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dissociation of p53 from MDM2. Furthermore, WIP1 reportedly dampens down DNA 
damage response and stress signalling to p53 by dephosphorylation-mediated 
deactivation  of ATMSer1981, CHEK1Ser345 & CHEK2Thr68 , γH2AX, p38αThr180 (MAPK-
pathway), nuclear factor kappa B Ser536 (NF-κBSer536), UNG2Thr6, XPCSer196 and 
XPASer892. WIP1 also reportedly dephosphorylates MDM2Ser395 and MDMXSer403 
increasing their stability resulting in negative regulation of p53. The diagram highlights 
some of the mechanisms through which WIP1 dampens stress signalling to p53 as 
reviewed extensively by (Figure 1-10) (Lu, Nguyen et al. 2008, Lowe, Cha et al. 2012). 
In the chapters 4 and 5 of this thesis the role of WIP1 transient knockdown and 
chemical inhibition in regulation of p53 signalling will be explored and discussed in 
more detail.   
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Figure 1-10 Some of the mechanisms through which WIP1/PPM1D has been 
reported to directly and indirectly regulate the p53 network in response to 
oncogenic stress and DNA damage. Image adapted and modified from Lu et al., 
2008 (Lu, Nguyen et al. 2008) 
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1.15 An overview of PPM1D/WIP1 
1.15.1 PPM1D/WIP1 gene and proteins 
PPM1D is located on the positive strand of the long arm of chromosome 17 (17q23.2) 
with the genomic co-ordinates chr17: 60590183-60676280 (UCSC genome browser). 
Alternative splicing of the mRNA of this gene results in two transcripts producing two 
different sized proteins both of which retain their phosphatase activities (Chuman, 
Kurihashi et al. 2009). The short transcript produces a 605 amino acid long WIP1 
protein (PPM1D605) whereas the longer transcript due to exon inclusion, and a 
premature stop codon within that exon, results in a 430 amino acid long WIP1 protein 
(PPM1D430) (Figure 1-11). While PPM1D605 is ubiquitous across human tissue types, 
WIP1430 is exclusive to testes and leucocytes. 
 
Figure 1-11 A) Figure obtained from Chuman et al., (2009) shows the alternative 
splicing and inclusion of exon 5’ between PPM1D exons 5 and 6. B) Sequence 
corresponding to intron exon boundaries of exon 5’ in addition to the 10 amino 
acids and the stop codon encoded by the PPM1D430 transcript. C) The diagram 
shows the location of the stop codon in PPM1D430 with respect to the WIP1 
catalytic site.  
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1.15.2 PPM1D/WIP1 C-terminal truncating mutations and other variants 
Similar to the truncated WIP1 isoform there have been reports of PPM1D mutations in 
human cancer cell lines and primary tissue that confer a C-terminus truncated protein 
with gain-of-function phenotype. Kleiblova et al., (2013) were the first to report the 
PPM1D gain-of-function mutations in a colorectal cancer cell line, HCT116, and an 
osteosarcoma cell line, U2OS (Kleiblova, Shaltiel et al. 2013). The authors then went on 
to show that the truncated WIP1 was enzymatically more active in vitro and more stable 
than the full-length wild-type WIP1. Mutation of Asp314Ala abolishes the phosphatase 
activity of WIP1 (Takekawa, Adachi et al. 2000) hence it was used as a negative control 
in their in vitro phosphatase assay (Kleiblova, Shaltiel et al. 2013). The authors also 
showed that both these cell lines had impaired IR induced G1 arrest and that silencing 
of WIP1 by RNA interference (RNAi) resulted in G1 arrest in response to IR. 
Importantly it was shown that this G1 arrest was p53-dependent as co-silencing of 
WIP1 and p53 prevented these cell lines to undergo G1 arrest in response to IR. 
Germline mosaic mutation in the same region of PPM1D were reported to predispose 
individuals to breast and ovarian cancers (Ruark, Snape et al. 2013). Also interestingly 
PPM1D truncating gain-of-function activating mutations and TP53 mutations were 
reported to be mutually exclusive in brainstem gliomas (Zhang, Chen et al. 2014).  
Single nucleotide polymorphisms of WIP1 (A82S, L120F, P322Q and I496V) reported 
on the National Institute for Biotechnology Information have also been investigated to 
assess their potential impact on WIP1 function (Dudgeon, Shreeram et al. 2013). The 
phosphatase activity of these variants against Phospho-ATMSer1981 was investigated in 
vitro showing that L120F and P223Q variants of WIP1 had lost their WIP1 phosphatase 
activity while A82S did not change WIP1 activity. It is noteworthy that in these 
experiments only truncated WIP1 was used as full-length WIP1 is poorly soluble. This 
meant that the impact of the I496V was not investigated in vitro. However when 
expressed in cell lines I496V was shown to reduce WIP1 phosphatase activity. When 
the authors investigated WIP1 mutations reported in cbioportal.org they found that two 
thirds of WIP1 mutations occur in the C-terminus. Interestingly, a unique WIP1 C-
terminal truncating mutation, R552X, was found to not impact WIP1 stability or 
function in contrast to all other C-terminal truncating mutations of WIP1 which have 
been reported to increase WIP1 stability and phosphatase function (Dudgeon, Shreeram 
et al. 2013). 
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1.15.3 PPM1D transcriptional regulation 
The PPM1D transcript was first discovered to be induced in response to ionising 
radiation (IR) in a p53-dependnet manner (Fiscella, Zhang et al. 1997). It was 
discovered in subsequent studies that the PPM1D promoter region also contains 
response elements for cyclic AMP response element binding protein (CREB), NF-κB, 
oestrogen receptor α (ERα), c-jun and E2F1 (Reviewed extensively in (Lowe, Cha et al. 
2012)). Basal levels of WIP1 protein were reported to be regulated from the CREB 
response element (CRE) 283 bases upstream pf the PPM1D translational start site. 
However, the p53 response element was discovered to be 168 bases to the upstream of 
the PPM1D translational start (Rossi, Demidov et al. 2008). This was consistent with 
the abundance of a transcript with a shorter 5’-untranslated region (UTR) in response to 
IR or UV light in TP53 wild-type cells, suggesting that in response to DNA damage 
PPM1D transcription is regulated from the further downstream p53 response element 
rather than the CRE. It was reported that the longer PPM1D transcript has a very 
complex 5’-UTR structure which may make its export from the nucleus more difficult. 
Furthermore, it has been shown that the 3’-UTR region of the PPM1D transcript is also 
important in determining its stability and WIP1 protein expression following DNA 
damage by the radiation mimicking agent neocarzinostatin (NCS) (Zhang, Wan et al. 
2010). MicroRNA-16 (miR-16), which undergoes processing and maturation in a p53 
dependent manner, was found to be complementary to the 3’-UTR region of the 
PPM1D transcript. Antagonising miR-16 with oligonucleotides increased PPM1D 
mRNA stability and the rate and intensity of WIP1 protein induction suggesting that 
miR-16 negatively regulates WIP1 expression at an early time-point after DNA damage 
by binding to its 3’-UTR. Interestingly, the authors also showed that miR-16 inhibits the 
proliferation of mammary tumour stem cells from MMTV-ErbB2 mice 
1.15.4 WIP1 degradation  
Investigations into the mechanism of degradation of WIP1 began by investigating the 
levels of WIP1 protein throughout the cell cycle (Macurek, Benada et al. 2013). A 
double thymidine block was used to synchronise the HeLa cells at the point of G1/S 
transition and then the medium was changed to one containing the anti-microtubule 
agent, nocodazol, to arrest cells in mitosis. It was shown that WIP1 protein expression 
was markedly diminished specifically at mitosis. The same was reported about U2OS 
cells however, the data were not shown. This could possibly be because the authors 
could not explain the faster migrating WIP1 band detected in U2OS cells. Interestingly 
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the levels of WIP1 mRNA were reported to remain constant throughout the double 
thymidine block and release experiment which suggested that WIP1 degradation during 
mitosis is at the protein level. Fluorescent, ubiquitination-based cell cycle indicator 
(FUCCI) was used on synchronous cells to assess whether the thymidine block 
influenced the cell cycle dependent degradation of WIP1. In this technique the cell cycle 
stage of each cell within an asynchronous population can be determined using 
fluorescent markers that are expressed and degraded at different stages of the cell cycle. 
Using FUCCI the authors confirmed that WIP1 is degraded during mitosis. The authors 
then showed that proteasome inhibitor MG132 inhibits WIP1 degradation during 
mitosis showing that WIP1 degradation relies on the function of the proteasome. It was 
then showed that ubiquitination of WIP1 relies on the E3 ubiquitin ligase activity of the 
anaphase promoting complex APC/CCDC20. Depletion of APC/C activator CDC20 by 
siRNA resulted in stabilisation of WIP1 during mitosis. Furthermore, mass 
spectrometry of WIP1 in nocodazol arrested cells showed that 7 residues on the 
catalytic subunit of WIP1 (Thr34, Ser40, Ser44, Ser46, Ser54, Ser85 and Ser97) are 
heavily phosphorylated during mitosis. Site directed mutagenesis was used to show that 
the phosphorylation of these residues are important for WIP1 phosphatase activity 
following DNA damage. Interestingly the C-terminus of WIP1 was also shown to be 
phosphorylated during mitosis, however the impact of these phosphorylation events was 
not investigated further (Macurek, Benada et al. 2013).  
1.15.5 WIP1 substrates  
In a quest to develop a peptide inhibitor for WIP1 Yamaguchi et al., (2006) were the 
first to define, in detail, the ideal substrate motifs for dephosphorylation by WIP1. The 
one letter code of amino acids are used here to define these motifs. The two optimal 
motifs dephosphorylated by WIP1 are X−1pTX+1pYX+3 where X-1 can be any amino 
acid, X+1 is an aliphatic amino acid and X+3 is any amino acid but proline (Yamaguchi, 
Durell et al. 2006) and (D/E)(D/E)X−1p(S/T)QX+4
 where X+4 is any amino acid but 
proline or basic amino acids. The former is found on p38α MAPK and UNG2, and the 
latter on the phosphorylation targets of PI3KK’s which are involved in the DNA 
damage response and p53 signalling (Yamaguchi, Durell et al. 2007). The 
dephosphorylation of these motifs on proteins of the DNA damage response may result 
in homeostasis of DNA damage response in cases of reversible damage.   
1.15.6 Ppm1d knockout transgenic mice models 
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Ppm1d null transgenic mice are viable however they present with sporadic male runting, 
male reproductive organ atrophy, reduced male fertility, reduced male longevity and 
immune defects (Choi, Nannenga et al. 2002). MEF’s from Ppm1d knockout embryos 
do not grow well in culture and are resistant to transformation by combination 
overexpression of the following oncogenes E1A + Hras1, Hras + Myc or Hras + ErbB2 
in mouse xenografts experiments (Bulavin, Phillips et al. 2004). Interestingly, although 
xenografts of Ppm1d null MEF’s overexpressing Hras, Myc or Erbb2 did not result in 
the formation of tumours in mice, simultaneous loss of Trp53 in these MEF’s resulted in 
tumour formation, which implies that Ppm1d is important for holding back the tumour 
suppressor effect of p53. Importantly this protection against transformation was 
proposed to be due to p38 MAPK mediated activation of p16Ink4a and p19ARF expression 
in the absence of Ppm1d. Inhibition of p38 (by SB203580) in Ppm1d null MEFS 
overexpressing two oncogenes  resulted in tumour formation in xenograft studies in 
mice.   
1.16 MDM2 inhibitors  
1.16.1 Oligonucleotides and peptides 
Early findings that disruption of the MDM2 inhibitory activity on p53 can promote p53 
stability and increase sensitivity to damage induced by IR came about in the late 1990s. 
Chen and colleagues screened nine 20-mer antisense oligonucleotides and identified 
one, namely HDMAS5, which could inhibit MDM2 expression in MDM2-amplified 
SJSA-1 (osteosatrcoma) and JAR (Choriocarcinoma) cell line (Chen, Agrawal et al. 
1998). They subsequently showed that antisense inhibition of MDM2 expression using 
this complementary phosphorothioate oligodeoxynucleotide can lead to stabilisation of 
p53, induction of its downstream transcriptional targets and increase sensitivity of the 
cell lines to Topo I inhibitor induced DNA damage in a synergistic manner (Chen, 
Agrawal et al. 1998). Following these findings it was demonstrated that inhibition of the 
MDM2-p53 interaction using a small peptide (IP3), homologous to the MDM2 
interaction domain of p53, can result in p53 stabilisation transcriptional transactivation 
reduced colony formation, cell cycle arrest and cell death (Wasylyk, Salvi et al. 1999). 
The authors also demonstrated p53-dependent reduced E2F 1/DP1 activity in the 
presence of the IP3 peptide. A similar study in the following year assessed the ability of 
a synthetic peptide to inhibit the MDM2-p53 interaction, resulting in non-genotoxic 
activation of p53 as determined by the relative absence of p53Ser15 phosphorylation 
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(Chene, Fuchs et al. 2000). The phosphorylation of p53Ser15 induced by the peptide was 
very modest (at 24 hours ) in comparison to that observed by cisplatin in the same cell 
line (Chene, Fuchs et al. 2000). Tortora and colleagues (Tortora, Caputo et al. 2000) 
showed that antisense inhibition of MDM2 expression using an oligonucleotide can also 
potentiate the effect of cytotoxic drugs such as topoisomerase inhibitors, taxanes and 
platinum-derived drugs as measured by colony formation assay in vitro. In this study 
nude mice were also injected with the GEO human colorectal carcinoma cell line and 
tumours were challenged by the MDM2 antisense molecule in combination with 
different cytotoxic regiments (Tortora, Caputo et al. 2000). Relative increase in 
apoptosis was shown to be enhanced by combination of MDM2 antisense with 
topotecan, taxotere and cisplatin in vitro. Apoptosis was determined by quantification of 
cytosolic DNA bound histone fragments by ELISA (Tortora, Caputo et al. 2000). 
Intraperitoneal injection of the same antisense molecule in combination with cytotoxic 
drugs resulted in reduced tumour growth as measured by tumour volume and improved 
percentage survival (Tortora, Caputo et al. 2000). For a review of MDM2 antisense 
oligonucleotides refer to (Zhang and Wang 2003).  
1.16.2 Small molecule MDM2 inhibitors 
By high throughput screening of a library of synthetic chemicals Vassilev and 
colleagues were the first to identify a group of cis-imidazoline compounds (nicknamed 
Nutlins) which bound and masked the p53 binding pocket on MDM2 (Vassilev, Vu et 
al. 2004). Nutlins could inhibit the MDM2-p53 interaction in cell-free assays with IC50 
values of 100-300nM. Both enantiomers of a Nutlin-3 racemic mixture were isolated 
using a chiral column and the isomers were named Nutlin-3a and Nutlin-3b. It was 
shown that Nutlin-3a is a 150-fold more potent at inhibition of the MDM2-p53 
interaction in vitro than the inactive enantiomer (Nutlin-3a IC50=0.09μM and Nutlin-3b 
IC50= 13.6μM). The atomic resolution X-Ray diffraction crystal structure of Nutlin-2 
(another cis-imidazoline analogue) bound to MDM2 was derived, which verified that 
Nutlins mimic the three main amino acid residues on p53 involved in its interaction 
with MDM2 (Figure 1-12).  
Nutlin treatment of various cell lines resulted in a dose dependent increase in p53 
downstream transcriptional targets such as p21 and MDM2 contingent on a wild-type 
TP53 status. This resulted in cell cycle arrest, apoptosis and growth inhibition of SJSA-
1 osteosarcoma cell lines ex vivo. SJSA-1 tumour xenografts in nude mice treated with 
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200 mg/kg twice daily over a 20-day period showed inhibition of tumour growth with 
no apparent systemic toxicity to the mice. Inhibition of MDM2-p53 interaction was 
therefore shown to mirror earlier findings with antisense oligonucleotides and synthetic 
peptides. This was proof of concept that selective small-molecule inhibitors of the 
MDM2-p53 interaction could provide non-genotoxic therapeutic options for activating 
p53. The cellular inhibitory activity of MDM2 inhibitors and their biochemical effect on 
p53 signalling has since been extensively investigated with Nutlin-3 and other novel 
MDM2 inhibitors; reviewed in (Zhao, Aguilar et al. 2015). These studies have 
consistently shown that TP53 wild-type cell lines respond by growth inhibition 
following treatment with MDM2 inhibitors and canonical p53 transcriptional targets are 
induced in a class independent manner. 
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Figure 1-12 This shows how Nutlins (Nutlin-2: carbon atoms drawn as white 
spheres, nitrogen in blue, oxygen in red, and bromine in brown) can mimic 
important p53 residues (F19, W23 & L26 carbon atoms drawn as green spheres) 
and therefore interfere with the interaction of p53 and MDM2. One bromophenyl 
moiety sits in the W pocket and the other in the L pocket. The ethyl ether moiety 
sits in the F pocket.  The imidazoline ring plays the role of the peptide backbone of 
p53. 
1.16.3 Further developments 
Since the discovery of Nutlins, multiple chemical classes of MDM2 antagonists, and 
indeed more potent compounds developed from Nutlins, have been identified and 
progressed through preclinical and early phase clinical studies (Zhao, Aguilar et al. 
2015). Presently at least seven compounds have reached phase I clinical trials, namely 
RG7112/RO5045337, RG7388/RO5503781, MI77301/SAR405838, AMG232, 
CGM097, DS-3032b and MK8242. Nutlin-3a derived, RG7112 (IC50 = 18nM), was the 
first MDM2 antagonist to reach phase 1 clinical trials (Ray-Coquard, Blay et al. 2012). 
This compound was orally administered to patients with advanced well-
differentiated/poorly differentiated liposarcomas and haematological malignancies. 
Patients were administered three cycles of 20-1920mg/m2/day over a 10 day period with 
18 days rest between each cycle. RG7112 was overall well-tolerated with the most 
prominent adverse effects being neutropenia and thrombocytopenia, which is in keeping 
with the mechanism of action of MDM2 antagonists and is considered an on-target 
effect, although this has not been unequivocally established. Immunohistochemistry and 
analysis by quantitative real time polymerase chain reaction (qRT-PCR) of tumour 
samples obtained from patients after 8 days of treatment indicated signs of activation of 
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p53 downstream targets (e.g. p21 and MDM2) and inhibition of proliferation (as 
measured by proliferative marker Ki67). However macrophage inhibitory cytokine-1 
(MIC-1), which is a direct transcriptional target of p53, was the only marker of p53 
activity that was shown to correlate with the area under the curve of (AUC) 
measurements of RG7112 in plasma. Thus the authors suggested that MIC-1 plasma 
levels could play the role of a surrogate pharmacodynamics marker for RG7112 
activation of p53 (Ray-Coquard, Blay et al. 2012). Overall 14/20 patients showed stable 
disease for the duration of the treatment and one had confirmed partial response which 
is promising however it was concluded that in future trials the potential for 
haematological toxicities has to be considered carefully. In late 2011 RG7338 (IC50 = 
6nM), which was designed based on the structure of RG7112 and MI-219 (an mdm2 
inhibitor of the spiro-oxindole family) entered into phase I clinical trials in solid tumour 
patients. In addition to mimicking structure of the three key amino acids at the N 
terminus of p53 (F19, W23 and L26) the 2-Chlorophenyl group also makes π-π 
interactions with p53 H96 (Figure 1-13) (Zhao, Aguilar et al. 2015). Maximum tolerated 
doses of RG7388 were dependent on scheduling and this compound had similar dose 
limiting haematological toxicities as observed in RG7112 (Siu, Italiano et al. 2014). 
This compound is being taken forward to phase II trials with the recommended dose of 
500mg/m2 with daily, 5 day scheduling. Clinical data for other classes of MDM2 
inhibitors were not available at the time of drafting of this thesis however an extensive 
review of the list of reported MDM2 inhibitors at different stages of development has 
been carried out by Zhao et al., (2015). This includes Newcastle University’s in-house 
Isoindolinone derived series which are at an advanced stage of pre-clinical 
development. 
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Figure 1-13 A) Co-crystal structure of MDM2 and the pharmacophore used for the 
derivation of RG7388 shows the π-π interaction of the 2-chlorophenyl moiety with 
H96 in the eMDM2 hydrophobic binding pocket. B) Chemical structure of 
RG7388. The additional fluorine atoms on the chlorophenyl moieties and the m-
methoxybenzoic acid (blue) increased MDM2 binding affinity, cellular potency, 
microsomal stability and PK properties of the pharmacophore. Images were 
obtained from (Zhao, Aguilar et al. 2015). 
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1.16.4 Combination of MDM2-antagonists with DNA damaging agents  
Since the discovery of MDM2 inhibitors their interaction with various DNA damaging 
agents have been assessed in a preclinical setting and early clinical combination trials 
have begun with more potent cis-imidazoline analogues (RO5045337/RG7112). 
Although the clinical results are still not published, the preclinical data are so far 
suggestive of potential benefits of combining MDM2 antagonists with DNA damaging 
agents. As discussed earlier, the antisense inhibition of the MDM2-p53 interaction had 
been shown to synergise and potentiate response to various DNA damaging agents 
using both ex vivo and in vivo models (Chen, Agrawal et al. 1998, Tortora, Caputo et al. 
2000, Grunbaum, Meye et al. 2001).  Since the discovery of Nutlins they have been 
shown to be radio-sensitisers of lung cancer cell lines and augment both cell cycle arrest 
and apoptosis ex vivo (Cao, Shinohara et al. 2006). Conradt and colleagues also showed 
recently with cell lines derived from murine KrasG12D-driven pancreatic ductal 
adenocarcinoma models that Topo II inhibitors and the MDM2 antagonist Nutlin-3a 
synergise (Conradt, Henrich et al. 2013). They also showed that MDM2 interacts with 
the MRN DNA repair complex and that it slows the rate of homologous recombination 
repair by comparing the γH2AX staining 3 hours after the co-administration of 
etoposide (5μg/ml) + Nutlin-3a (5μM) (Conradt, Henrich et al. 2013). This increase in 
γH2AX at an early time point was also observed with another MDM2 antagonist 
namely PXN822 (Priaxon AG) in combination with etoposide (Conradt, Henrich et al. 
2013). Although genotoxicity data on this drug was not available, its mechanism of 
action mirrored that of the cis-imidazoline compounds (Conradt, Henrich et al. 2013). 
An earlier study had also shown an increase in γH2AX staining in response to MDM2 
antagonists Nutlin-3a and Caylin-1 (Nutlin-3 analogue) in combination with etoposide 
(Verma, Rigatti et al. 2010). Nutlin-3 treatment (at 10μM) of cancer cell lines was 
shown to induce activating phosphorylations of DNA damage response proteins 
including ATM and CHEK1 and increased γH2AX staining in a p53-independent 
manner (Valentine, Kumar et al. 2011). The high doses of MDM2 antagonist used and 
the time points in the last two studies mentioned may have resulted in off-target effects 
or may have been a consequence of later apoptotic related events due to MDM2 
antagonist treatment. This is in contrast to the study by Conradt et al., 2013 where, 
much lower doses of MDM2 antagonists were used in combination with etoposide. In 
the light of these data inhibition of DSB repair pathways may augment/synergise with 
the response to MDM2 antagonists in the presence of DNA damage. 
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1.16.5 Range of sensitivity to MDM2 inhibitors  
The pharmacological inhibition of the MDM2-p53 interaction with small molecular 
weight MDM2 inhibitors has been a very successful approach of non-genotoxic 
activation of p53 in preclinical and clinical settings with encouraging anti-tumour 
activity (Vassilev, Vu et al. 2004, Ray-Coquard, Blay et al. 2012, Ding, Zhang et al. 
2013, Zhao, Liu et al. 2013, Zhao, Aguilar et al. 2015) (For a comprehensive review of 
compounds see (Zhao, Aguilar et al. 2015)). Drug sensitivity data generated by the 
Sanger Institute using cell viability assays on a large panel of cancer cell lines, with 
known genetic status of cancer related genes, suggest that the strongest determinant of 
response to the MDM2 inhibitor, Nutlin-3a, is the genetic status of TP53 (P-value = 
1.26e-54; Figure 1-14) (Barretina, Caponigro et al. 2012, Garnett, Edelman et al. 2012). 
However, within the group of TP53 wild-type cell lines there is nevertheless a range of 
sensitivity to the MDM2 inhibitor, Nutlin-3a, as measured by GI50/IC50 (50% growth 
inhibitory concentration) (Figure 1-15). It has been suggested that this approximate 
3500-fold range in sensitivity to MDM2 inhibitors may be an exaggeration due to 
misclassification of cell lines with respect to their TP53 genetic status. However, 
Amgen have also recently reported a wide range of sensitivity to their MDM2 inhibitor 
AMGMDS3 among their carefully curated panel of TP53 wild-type and functional cell 
lines (500-fold IC50 difference from the least to the most sensitive cell lines) (Saiki, 
Caenepeel et al. 2015). Interestingly, other cancer causing genetic events highlighted on 
the Sanger database to correlate with increased MDM2 inhibitor sensitivity have been 
independently verified. Examples of findings that are consistent with the overall Sanger 
Database predictions include MYCN-amplification which has been reported to increase 
sensitivity to MDM2 inhibitors (Gamble, Kees et al. 2012). Contradictory evidence also 
exists in the literature for example with regards to the CDKN2A (p14ARF) the transient 
knockdown of which has been reported to decrease sensitivity to MDM2 inhibitors 
(Van Maerken, Rihani et al. 2011), whereas mutations in this gene are predicted to 
increase sensitivity to MDM2 inhibitors on the Sanger database. A more detailed 
approach for identifying such genetic variables was recently taken by Zhong et al., 
(2015) (Roche pharmaceuticals), who compared RNASeq-derived transcript levels of 
287 human cancer cell lines to their in vitro sensitivity to the MDM2 inhibitor RG7112 
currently in clinical trials (Zhong, Chen et al. 2015). This showed that combined 
increase in basal mRNA expression of MDM2, XPC and BBC3 and reduction in 
expression of CDKN2A were predictors of sensitivity to RG7112. Signature scores 
 60 
 
(GMDM2 + GXPC + GBBC3 -GCDKN2A at baseline) obtained from pre-treated acute 
lymphoblastic leukaemia (ALL) patients corresponded with better clinical outcome in 
response to RG7112 and RG7388 (Zhong, Chen et al. 2015). Importantly, the signature 
score remained significant when adjusted for TP53 genetic status which meant that 
changes in expression of other genes can also be predictors of MDM2 inhibitor 
sensitivity between TP53 wild-type cell lines (Zhong, Chen et al. 2015). These data 
highlight the gap in knowledge of the underlying mechanistic determinants of MDM2 
inhibitor sensitivity in TP53 wild-type cells.
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Figure 1-14 Volcano plot shows that although TP53 is the strongest determinant of response to Nutlin-3a, there are many other genes, which if 
altered, can influence sensitivity to Nutlin-3a. Y-axis: The p-value from multivariate ANOVA of drug gene interaction on an inverted log10 
scale. X-axis: Magnitude of the effect that genetic events have on the GI50 of the drug in cell lines. The size of the circle indicates the number 
of genetic events corresponding to the analysis for a given gene or a drug. Figure obtained from (http://www.cancerrxgene.org/).
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Figure 1-15 Range of Nutlin-3a IC50/GI50 in TP53 mutant and wild-type panel of 
cell lines from the Wellcome Trust Sanger Institute drug sensitivity database. 
1.16.6 Determinants of cell fate after activation of wild-type p53 by MDM2 
inhibitors 
Expectedly, the wide range in sensitivity of TP53 wild-type cell lines translate into the 
clinic as it is implied by the interpatient variability in response to MDM2 inhibitors 
among patients with TP53 wild-type tumours (Ray-Coquard, Blay et al. 2012). It has 
been suggested that the extent of sensitivity to MDM2 inhibitors in TP53 wild-type cell 
lines is contingent on cell fate following p53 activation (Tovar, Rosinski et al. 2006, 
París, Henry et al. 2008, Sullivan, Padilla-Just et al. 2012). This can range from 
continual growth and division, reversible cell cycle arrest, senescence or programmed 
cell death. These alternative outcomes may be dependent on the type, duration and 
intensity of p53 activating stimuli, genetic and epigenetic background of the cell, and 
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cell growth stage at the time of p53 activation (Espinosa 2008, Murray-Zmijewski, Slee 
et al. 2008). Given the large numbers of variables that need to be considered large scale 
genetic knockdown or chemical inhibition screens have been carried out to identify 
optimal combination strategies. Alternatively single candidate targets based on our 
current knowledge of p53 signalling have also been investigated within the literature. 
An example of chemical inhibition screen (Saiki, Caenepeel et al. 2014) and single 
candidate gene investigation (Marine, Dyer et al. 2007) will be discussed in this chapter 
and an example of the shRNA library screen combined with Nutlin-3 will be described 
in the introduction of chapter 3 of this thesis (Sullivan, Padilla-Just et al. 2012). The 
tumour suppressor role of p53 relies heavily on its modular ability to regulate the 
transcription of different sets of genes in response to a diverse set of stimuli which are 
involved in cell fate decision making. Therefore understanding the underlying 
mechanisms that modulate p53 transcriptional function in favour of reversible arrest as 
opposed to irreversible arrest or apoptosis is important in understanding the 
determinants of cell fate after p53 activation.  
The key concepts pertaining cell fate decision making following p53 activation has been 
reviewed in detail by Carvajal and Manfredi (2013) they will only be briefly introduced 
in this section (Carvajal and Manfredi 2013). One school of thought about cell fate 
decision after p53 activation (e.g. dissociation from MDM2) proposes that total level of 
active p53 is the main determinant of whether a cell undergoes cell cycle arrest 
senescence or apoptosis (Chen, Ko et al. 1996). In this model it is proposed that pro-
arrest p53 transcriptional target genes have higher affinity p53 response elements 
compared to p53 pro-apoptotic transcriptional target genes, hence the likelihood of 
induction of apoptosis is proportional to the concentration of active p53. Consistent with 
this promoter affinity model; it has been shown that p53 pro-arrest target genes are 
induced at an earlier time-point than pro-apoptotic target genes (Zhao, Gish et al. 2000). 
However, in vitro binding assays comparing promoters for different p53 target genes 
have shown that that although the majority of p53 pro-arrest target gene promoters have 
a higher affinity p53 response elements; there are still some key p53 pro-apoptotic 
targets such as BBC3/PUMA, TP53AIP1 and NOXA which also have equally high 
affinity p53 response elements (Weinberg, Veprintsev et al. 2005). This suggests that 
there are other layers of regulation for p53 promoter binding and transcription than 
promoter affinity alone. One other factor proposed to influence the observed differences 
in the kinetics of p53 target induction is the variation in RNA Polymerase II occupancy 
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in the core promoters of p53 target genes in unstressed conditions (Espinosa, Verdun et 
al. 2003, Morachis, Murawsky et al. 2010). Using chromatin immunoprecipitation it had 
been shown that RNA polymerase II binding to endogenous CDKN1A (p21WAF1, pro-
arrest p53 transcriptional target) promoter was significantly greater than binding to the 
FAS/APO1 (Pro-apoptotic p53 transcriptional target) promoters in unstressed cells 
(Espinosa, Verdun et al. 2003). To further investigate the role of core promoter 
structures in determining the kinetics of induction of these two p53 targets; Morachis et 
al., 2010 assessed the speed and frequency preinitiation complex formation on each 
promoter during in vitro transcription. The authors showed that CDKN1A core 
promoters support quicker TATA box-dependent assembly of RNA Polymerase II pre 
initiation complex relative to that of the FAS core promoter. However, the FAS core 
promoter was shown to support more rounds of preinitiation complex formation better 
suited for sustained induction of this gene (Morachis, Murawsky et al. 2010). This is 
consistent with in sillico predictions suggesting that transient pulses of p53 activation 
promote pro-arrest gene expression and sustained pulses of p53 in the same context 
promote pro-senescent or pro-apoptotic gene expression (Zhang, Liu et al. 2009, Purvis, 
Karhohs et al. 2012). 
Central to the data which will be presented in this thesis post-translational modifications 
of p53 have also been shown to influence p53 promoter selectivity following its 
activation. The complex set of p53 post-translational modifications and their potential 
roles in regulation of p53 function, stability and cell fate determination has been 
reviewed extensively to date (Murray-Zmijewski, Slee et al. 2008, Meek and Anderson 
2009, Meek 2015). The complexity and heterogeneity of the set of post-translational 
modifications p53, which happen in a highly context dependent manner, make 
investigating roles of individual post-translational modifications in cell fate 
determination challenging. For example there are contradictory findings when it comes 
to the role of p53Ser15 phosphorylation in stability, transcriptional activity and cell fate 
determination (Fiscella, Ullrich et al. 1993, Huang, Clarkin et al. 1996, Rathmell, 
Kaufmann et al. 1997, Shieh, Ikeda et al. 1997, Banin, Moyal et al. 1998, Canman, Lim 
et al. 1998, Lambert, Kashanchi et al. 1998, Dumaz and Meek 1999). In spite of this 
challenging complexity more recent efforts by studies carried out in cell line models and 
knock-in transgenic mice have implicated this phosphorylation event in regulation of 
p53 transcriptional activity and tumour suppressor function (Introduced earlier and will 
be discussed in more detail in results and general discussion chapters) (Saito, 
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Yamaguchi et al. 2003, Armata, Garlick et al. 2007, Teufel, Bycroft et al. 2009, 
Loughery, Cox et al. 2014). Another N-terminal post-translational modification of p53 
has also been implicated in promoter selectivity and induction of p53 pro-apoptotic 
target TP53AIP1 which has been shown to localise to the mitochondria and promote the 
release of cytochrome c from the mitochondria (Oda, Arakawa et al. 2000). Consistent 
with this observation phosphorylation of p53Ser46 by p38 MAPK in response to UV has 
been reported to play a role in induction of apoptosis in response to UV mediated DNA 
damage (Bulavin, Saito et al. 1999). Embryonic stem cells, MEFs and thymocytes 
derived from homozygous p53HupKIS46A Knock-in mice expressing a chimeric p53 
including human p53 exons 4-6, with the mutated S46A, were partially defective in 
DNA damage and oncogene induced apoptosis (Feng, Hollstein et al. 2006). UV 
mediated induction of p53 pro-apoptotic targets Noxa and Perp was significantly 
reduced in the homozygous p53HupKIS46A Knock-in mice. These observations are 
consistent with the previously reported role of this p53S46 in promoting the induction of 
p53 pro-apoptotic transcriptional targets and cell fate determination.  
Cell fate determination after activation of p53 may also depend on the function of other 
proteins that can function as co-factors in p53-mediated transcription. The Apoptosis-
Stimulating of p53 Protein (ASPP) family of proteins for example include ASPP1 & 2 
(pro-apoptotic) and inhibitor of ASPP (iASPP, anti-apoptotic) which can interact with 
p53 to either promote or inhibit the transcription of its apoptotic target genes (Samuels-
Lev, O'Connor et al. 2001, Bergamaschi, Samuels et al. 2006). The interaction of iASPP 
with the PRR of p53 has been shown to inhibit transcription from the p53 regulated 
BAX promoter. This is also consistent with earlier observations regarding the 
importance of the PRR in inducting apoptosis. Interestingly, it has also been shown that 
a propyl isomerase Pin1 binds to phosphorylated p53Ser46 and prevents iASPP binding 
therefore promoting apoptosis (Zheng, You et al. 2002). Other cofactors such as 
Haematopoietic Zinc Finger (Hzf) which is itself a p53 transcriptional target has been 
shown to promote cell cycle arrest after p53 activation promoting selective transcription 
of p53 pro-arrest target genes (Das, Raj et al. 2007). In contrast to Hzf+/+ MEFs, those 
MEFs derived from Hzf-/- transgenic mice undergo p53 mediated apoptosis instead of 
cell cycle arrest following ionising radiation.  
Mechanisms described above can potentially be targeted genetically and 
pharmacologically to assess how they would impact cell fate determination following 
treatment with MDM2 inhibitors. This thesis focuses on the role of WIP1 phosphatase 
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(described earlier) as a potential determinant of response to MDM2 inhibitors.  
1.16.6.1 Screening for synergy with MDM2 inhibitors  
Other pharmacological agents can also be used to screen for targets that synergise with 
MDM2 inhibitors. This is provided that the compounds used have little or no off-target 
effects at the doses used in the screen. Amgen and their academic partners recently 
screened a combination of 1169 compounds with MDM2 inhibitors in 10 cell lines 
(seven TP53 wild-type and three mutant) (Saiki, Caenepeel et al. 2014). The screen 
identified thirteen targets the inhibition of which synergised with their MDM2 
inhibitors. Three of the thirteen synergistic compounds targeted the MEK and PI3K 
pathways. Loewe’s additivity model was used to measure synergy which requires dose 
effect curves for each individual drug including the dose effect slope together with the 
minima and maxima. Synergy was further validated in a panel of 40 cell lines (thirty-six 
TP53 wild-type and four mutant) with MTT assay. Apoptotic endpoints Sub-G1 events 
and Caspase 3/7 activity were shown to be enhanced in a selected group of TP53 wild-
type cell lines. Multiple selective targeted agents such as the MEK inhibitor Trametinib, 
BRAF inhibitor Vemurafinib, PI3K inhibitor GDC-0941 and an mTOR kinase inhibitor 
AZD8055 were then used for inhibiting different nodes within the two pathways, which 
all resulted in synergy in combination with MDM2 inhibitors (Saiki, Caenepeel et al. 
2014). Furthermore, these results are consistent with other independent reports in the 
literature using different classes of MDM2 inhibitors in combination with inhibition of 
these pathways (Lunghi, Mazzera et al. 2007, Zhang, Konopleva et al. 2007, Ji, Kumar 
et al. 2013, Wang, Zubrowski et al. 2014). However these combinations would likely be 
efficacious in a context-dependent manner such as TP53 wild-type tumours that rely on 
MEK and PI3K signalling (i.e. TP53 wild-type cases of melanoma) and not all 
malignancies. Therefore identifying other oncogenic pathways the inhibition of which 
synergise with MDM2 inhibitors remain a strategy to be explored. 
1.16.6.2 Candidate target investigation 
An alternative strategy for identification of determinants of cell fate following non-
genotoxic activation of p53 by MDM2 inhibitors is a candidate target approach. 
Individual candidate targets can be selected based on their well established and 
validated present mechanistic understanding of their roles in the p53 network or cell 
survival in general. This allows for the identification of novel targets and can take into 
consideration the druggablity of the targets, potential tissue tumour type stratification 
strategies and a more robust validation of mechanistic combinatorial effects. 
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The role of the MDM2 homologue, MDMX, in regulation of p53 transcriptional 
transactivation is well established (Marine, Dyer et al. 2007). Although mice null for 
MDM2 or MDMX are both embryonic lethal in a p53-dependent manner, ablation of 
MDMX ex-vivo does not result in the same extent of p53 activation as MDM2 
inhibition (Jones, Roe et al. 1995, Parant, Chavez-Reyes et al. 2001, Hu, Gilkes et al. 
2006). Conditional inactivation of Mdmx with a LoxP-Cre system in cardiomyocytes, 
smooth muscle cells and the gastrointestinal tract in mice also results in only modest 
defective phenotypes in those tissues (Boesten, Zadelaar et al. 2006, Grier, Xiong et al. 
2006). This has been put down to compensation by the p53-MDM2 autoregulatory 
feedback mechanism (Barak, Juven et al. 1993, Wu, Bayle et al. 1993, Marine, Dyer et 
al. 2007). However, overexpression of MDMX at physiologically relevant levels by 
stable transfection has been reported to result in a decrease in MDM2 inhibitor 
sensitivity (Hu, Gilkes et al. 2006). MDMX knockdown was also reported to result in 
increased apoptosis in response to Nutlin-3 as measured by flow cytometry (Sub-G1 
events) and MTT cell viability assay (Hu, Gilkes et al. 2006). Importantly MDMX is 
amplified or overexpressed in mostly TP53 wild-type malignancies which would benefit 
from the dual inhibition of these two targets (Oliner, Kinzler et al. 1992, Shvarts, 
Steegenga et al. 1996, Gembarska, Luciani et al. 2012). Hence, MDMX inhibitors 
and/or MDM2-MDMX co-inhibitors are also being investigated pre-clinically (Pazgier, 
Liu et al. 2009, Bernal, Wade et al. 2010, Reed, Shen et al. 2010, Graves, Thompson et 
al. 2012). 
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Aims 
The primary mechanism of action of MDM2 inhibitors is through no-genotoxic 
activation of p53 signalling. However, there is a wide range of sensitivity to MDM2 
inhibitors among TP53 wild-type cell lines and tumours. This suggests that there are 
other determinants of sensitivity to MDM2 inhibitors, and that combination regimens or 
tumour stratification strategies are necessary to harness the full potential of MDM2-p53 
binding antagonists in the clinic.  
There is extensive crosstalk between DNA repair and p53 signalling. This is mostly 
through post-translational modifications of components of p53 signalling by the 
machinery that sense and repair DNA damage. Therefore manipulating the activity of 
the components of DNA damage response which regulate post-translational 
modification of p53 may influence cellular sensitivity to MDM2-p53 binding 
antagonists.  
 Investigate the role of DNA repair machinery and its crosstalk with p53 in 
determining the sensitivity to MDM2-p53 binding antagonists in the presence and 
absence of DNA damage. 
 Determine whether the transient knockdown or chemical inhibition of WIP1 
influences cellular sensitivity to MDM2 inhibitors. 
 Determine the role of WIP1 phosphatase activity in regulation of p53 signalling 
following MDM2 inhibitors.
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Chapter 2 Materials and methods
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2.1 Tissue culture practice and cell line authentication 
Tissue culture work on all cell lines listed in was carried out in the sterile environment 
of a class II biological safety cabinet (Biomat, Medair Technologies, MA, USA) at all 
times. Good cell culture practice was observed at all times to minimise the risk of cross 
contamination of cultures (For more details see Nims et al) (Nims, Sykes et al. 2010). 
All cell lines were authenticated using short tandem repeat (STR) DNA profiling (LGC 
Standards) and early post-authentication passages were cryogenically preserved in 
liquid nitrogen until the working stock reached post-authentication passage 30, after-
which a lower passage number  reserve batch was revived and used in subsequent 
experiments.  STR DNA profiling uses hypervariable DNA microsatellite regions, 
which are 1-6bp long repeated DNA motifs, to assign unique molecular fingerprints to 
cell lines of interest which can then be monitored for potential cross contamination 
and/or genomic instability before and during experimental use of the cell lines (Reid 
and Storts 2013 ). 
2.1.1 Cell line growth conditions and husbandry 
All cell lines were grown in RPMI-1640 supplemented with L-glutamine (2mM) and 
sodium bicarbonate (Sigma Aldrich #R8758), 1% Pen/Strep (Sigma # P4333) and 10% 
heat-inactivated FBS (Gibco #10082147) in a humidified 37˚C incubator containing 5% 
CO2 in air unless otherwise specified (Table 2-1). When cells reached 70-90% 
confluence, growth media was removed, the monolayer of cells was washed with 
phosphate buffer saline (PBS, devoid of divalent cations and pH 7.2) and then the cells 
were incubated with 1 × trypsin EDTA (Sigma) for 1-5 mins to allow them to detach 
from the surface of the plate/flask. Ethylenediaminetetraacetic acid (EDTA) forms 
chelates with divalent cations which would otherwise inhibit the peptidase activity of 
trypsin. Following trypsinisations the cells were observed under the microscope to 
ensure that they had all detached then re-suspended in fresh media and split 1:10 or 1:20 
into 25cm2, 75cm2 or 175cm2 flasks (Corning, Amsterdam, Netherlands). Cell lines 
were tested every 3-6 months for mycoplasma infection through PCR based method 
(Work carried out by Mrs. Liz Matheson).  
2.1.1.1 Monitoring cell morphology using a phase contrast microscope 
Cell morphology was examined regularly with phase contrast microscopy to check for 
signs of infections, the integrity of cell membranes and cellular compartments. When 
light traverses through a specimen with a different refractive index (e.g. plasma 
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membrane) the velocities of light wave is reduced resulting in a phase shift with respect 
to the background light. A phase contrast microscope dims the background light by 
passing it through a grey filter then shifts the phase by passing it though a phase shift 
ring which causes destructive interference thus reducing its amplitude. This results in an 
overall higher amplitude of the light that has passed through the specimen which leads 
to a halo effect around intact cell membranes (Lab 2011).  
2.1.2 MDM2 inhibitor resistant TP53 mutant sub-clones 
TP53 wild-type, MDM2-amplified SJSA-1osteosarcoma cell line and TP53 wild-type 
MYCN- and MDM2-amplified NGP neuroblastoma cell line, along with their Nutlin-3 
resistant TP53 mutant daughter clones S_N40R2 and N_N20R1 respectively were used 
to investigate MDM2 inhibitor mediated p53-dependent biochemical and cellular 
endpoints (Table 2-1). From this point onward in this thesis the underscore will be 
removed from these clone names (i.e. S_N40R2 will be referred to as SN40R2). MDM2 
inhibitor resistant daughter cell lines were derived by continually growing the parental 
cell lines in escalating concentrations of Nutlin-3 and isolating the resistant clones and 
expanding them. Sanger sequencing later determined that these cell lines harbour TP53 
mutations and show loss of p53 transcriptional function. Derivation of these clones 
along with more detailed TP53 genetic and functional characterisation along with 
fluorescent in situ hybridisation (FISH) were carried out by Dr Junfeng Liu, Dr 
Xiaohong Lu and Dr Catherine J. Drummond prior to the start of this project and a 
manuscript of this work is in progress for submission with additional data supplied by 
the author of this thesis (Figure 2-1). FISH data showed that SN40R2 cells have TP53 
loss of heterozygosity (17q loss) whereas N20R1 cells retained both copies of TP53 
with a possible mutation on each. STR DNA profiling described earlier was not able to 
differentiate parental TP53 wild-type from their MDM2 inhibitor resistant daughter cell 
lines. These data lead to the assumption that in spite of their TP53 mutations, the 
daughter cell lines are otherwise isogenic or very closely related to their parental cell 
lines. Furthermore the isogenic cell line pairs have been used routinely in preclinical 
development of MDM2 inhibitors by the Northern Institute for Cancer Research Drug 
Discovery team and other groups within the institute (Chen, Rousseau et al. 2015).  
2.1.3 U2OS cell line pairs 
U2OS cell line pair were grown in McCoy’s 5A modified medium supplemented with 
1% Pen/Strep and 10% heat-inactivated FCS and split as above.  
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Cell lines 
Tumour of 
origin 
TP53 
Status 
MDM2 
status 
MDMX 
status 
PPM1D 
Status 
SJSA-1 Osteosarcoma Wt 
Amp. Wt Wt 
SN40R2 Osteosarcoma Mut 
NGP Nuroblastoma Wt 
Amp. OE OE 
N20R1 Neuroblastoma Mut 
HCT116+/+ 
Colorectal 
carcinoma 
Wt 
Wt Wt 
c.1344delT/Wt 
(L450X) Gain-
of-function 
(Kleiblova, 
Shaltiel et al. 
2013) 
HCT116-/- 
Colorectal 
carcinoma 
Null 
U2OS Osteosarcoma Wt 
Wt Wt 
c.1372C>T/Wt 
(R458X) Gain-
of-function 
(Kleiblova, 
Shaltiel et al. 
2013) 
U2OS-DN 
Osteosarcoma 
Mut 
MCF-7 
Breast 
adenocarcinoma 
Wt Wt OE Amp. 
Table 2-1 TP53 Wild-type (Wt) and mutant (Mt)/Null cell line pairs from different 
tumour origins and their MDM2, MDMX and PPM1D genetic status. Amp.: 
Amplified; OE: Overexpressing.
  
 
7
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Figure 2-1 A & B) Schematic diagrams describing the derivation of MDM2 inhibitor resistant sub-clones including segments of the 
chromatograms generated by Sanger sequencing which show the sites of mutations in these clones. C) Fluorescent in situ hybridisation of the 
chromosome 17 centromer (Red foci) and 17p loci  (Green foci) in parental and resistant cell lines. D) Mutant specific PCR amplification 
showing that the mutations could not be detected in the parental population.
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1.1.1 Culturing of glioblastoma cell lines stably transfected with Firefly and 
Renilla Luciferase enzymes 
DBTRG (TP53 Wild-type) and T98G (TP53 mutant) glioblastoma cell lines stably 
transfected with a reporter genes encoding Firefly (Photinus pyralis) and in internal 
control Renilla (Renilla reniformis) luciferase enzymes regulated by a p53-driven 
promoter and a minimal transactivation promoter respectively were provided to us by 
Sienna Biotech (Figure 2-2). DBTRG derived Dp53/R-DD7 cells were cultured in 
RPMI-1640 as above and T98G derived Tp53/R-DR4 cells grown in Eagle’s Minimum 
Essential Medium (EMEM) with the same supplements as above. Both cell lines were 
kept under positive selection by Hygromycin B and Puromycin with doses outlined in 
Table 2-2 and sub-cultured as described above. 
Cell line name  Hygromycin B (µg/ml 
of media) 
Puromycin  (ng/ml 
of media) 
TP53 status 
Dp53/R-DD7 30 250 Wt 
Tp53/R-DR4 175 400 Mut 
Table 2-2 Selection conditions for glioblastoma cell lines stably transfected with a 
reporter and an internal control vector 
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Figure 2-2 Cartoon of the process involved in generation of glioblastoma clones 
with stably transfected p53 response element (RE) driven Firefly reporter and 
minimal transactivating promoter (mTA) driven Renilla luciferase internal 
control. TA: Transactivation; bp: base pairs; R: Resistance; Wt: Wild-type; Mut: 
Mutant. 
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2.1.4 Cell count  
Cell densities were estimated using either a Neubauer haemocytometer (Hawksley, 
Sussex, UK) or a Coulter counter (Beckman Coulter) depending on the number of 
samples that had to be counted in an experiment. The same technique was always used 
between repeats of an experiment. 
2.1.4.1 Haemocytometer 
The haemocytometer was prepared as per the manufacturer’s instructions before 10µl of 
cell suspension or a 1:2 dilution of the suspension in 0.4% trypan blue dye (Biorad, 
#145-0021) were added to each  side of the cover-slip. Each grid has a volume of 
0.1mm3 and therefore counts/grid represent 1×104 cells/ml. A minimum of two grids on 
each side of the haemocytometer were counted and the average cell count/grid was then 
either multiplied by 104, or 2 × 104 if the suspension had been diluted with the 0.4% 
trypan blue prior to loading. Dead/dying cells, with compromised membrane integrity, 
will be stained blue upon exposure to trypan blue while viable cells with intact plasma 
membrane will remain clear. Therefore absolute or % viability can be calculated 
however this count must be carried out within 5 min following the addition of the dye 
mixture otherwise viable cells will also be stained blue.  
2.1.4.2 Coulter counter 
The cell suspension was syringed with a 21G needle in order to remove any 
agglomerates of cells then 0.5ml of the cell suspension was diluted in 0.5ml Carnoy’s 
fixative before being further diluted in 1:10 in BD FACSFlow™ Sheath Fluid 
(#342003). This diluted suspension was then run through a particle counter (Coulter) 
where in cells/particles are suspended in a conductive fluid such as FACSFlow will be 
sucked through a small hole to another compartment with conductive fluid disrupting 
the electrical current across the hole. Because the impedence caused by the cell/particle 
is proportional to its volume, parameters on the counter can be set so that only particles 
of a volume corresponding to an average mammalian cell (8-24 microns in diameter) 
will be counted. Coulter counter will count the number of particles per 0.5ml therefore 
the final average count of three was multiplied by 40 to obtain the number of cells/ml of 
the original cell suspension. 
2.1.5 Cryogenic preservation and revival of cells 
Exponentially growing cells were trypsinised and re-suspended in freezing media so 
that they are >106 cells/ml. Freezing media consisted of each cell line’s appropriate 
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growth media plus an additional 10% FBS (v/v) and Dimethyl sulfoxide anhydrous 
(DMSO) at 10% (v/v) (Sigma #276855). This cell suspension was then divided into 1ml 
aliquots in cryogenic vials (NUNCTM, Rochester, NY, USA) and stored in -80˚C freezer 
before being transferred to liquid nitrogen cryostore (Biosystem, Cryostor). Passage 
number and the date of harvest were recorded on the cryovials. When needed the vials 
were removed from liquid nitrogen and thawed rapidly in a water bath at 37˚C before 
being diluted 1:10 in 37˚ growth media. This cell suspension was then centrifuged at 
1000rcf, the supernatant was disposed and fresh media devoid of any DMSO was added 
to the pellet. The cells were then transferred to a tissue culture flask and placed in the 
incubator described above.  
2.2 Sulforhodamine B assay 
The use of Sulforhodamine B (SRB) in estimating cell numbers in multi-well plates for 
drug screening was developed by Skehan et al (Skehan, Storeng et al. 1990). SRB is an 
anionic protein dye, the sulphonic group of which electrostatically binds basic amino 
acids of proteins in cells under mild acidic conditions. Optical density of this dye is 
measured at 564 nm and it shows linearity with cell number. SRB has a signal to noise 
ratio of 1.5 with 1000 cells/well at this wavelength (Skehan, Storeng et al. 1990).  
2.2.1 SRB staining protocol 
Cells in 96-well plates were fixed with Carnoy’s fixative at appropriate time-points and 
stored in 4˚C up to 2 weeks. They were then washed 5 times with distilled H2O (dH2O) 
and allowed to dry overnight before staining with 0.4% SRB dissolved in 1% acetic acid 
(w/v) for 30 min. Unbound stain in wells was then washed off by washing the plate 5 
times in 1% acetic acid. A fresh batch of 1% acetic acid was used for each plate as re-
using the same batch between plates increases background SRB signal. Bound SRB was 
then solubilised in 100µl/well of 10mM Tris-HCL (pH10.5) and optical density at 
564nm was quantified using a multi-well spectrophotometer, BioRad (Model 680). 
2.3 Growth curves 
Cells were seeded in 96-well plates (Corning, UK) at different densities in 6 inter-
experimental repeats. The same plate was replicated 7 times to monitor the growth of 
cells over a week. Each plate was then fixed every 24 hours with Carnoy’s fixative (3 
parts methanol in 1 part acetic acid) and kept at 4 ºC until SRB stain can be used as a 
surrogate for cell density in each well (See 2.2.1). Doubling time for each cell line was 
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then calculated by fitting the SRB growth curve data for the most rapidly growing 
densityto an exponential function, Y = Y0*exp (k*X) where Y0 = y value when X time 
is 0, k = the rate constant, and doubling time was calculated as ln(2)/k (See Prism user 
guide for more detail). 
2.3.1 Growth inhibition assay and calculation of 50% growth inhibitory 
concentration (GI50) 
Cells were seeded in 96-well plates at the densities stated in Table 2-3 and treated as 
detailed in specific materials and methods section of the relevant chapters. After 
treatment the cells were fixed and stained with SRB as described above. Mean, standard 
deviation (Std. Dev.) and standard error of mean (SEM) of optical density for each data 
point was calculated using the optical densities for 3-5 intra-experimental repeats. Mean 
optical densities were either expressed as a percentage of 1% DMSO treated control 
unless otherwise stated in specific materials and methods in each chapter. Concentration 
was Log10 transformed and a non-linear regression curve was fitted to the data 
(Lowess/spline fit, Chapters 5 and 6) using Graph Pad Prism 6 software and 50% 
growth inhibitory concentration (GI50) of a given drug in individual experiment was 
interpolated from the curve. Data from >3 independent experiments were compiled in 
order to generate overall GI50 values ± Standard Error of Mean (SEM).  
2.3.2 Measuring Potentiation, Synergy, additivity or antagonism 
Potentiation, synergy, additivity or antagonism in this thesis were measured using data 
from SRB growth inhibition experiments. A drug was considered to potentiation the 
growth inhibition of another only when its administration at a non-growth inhibitory 
dose resulted in enhancement of the growth inhibitory effect of another drug. 
Combination index (CI) values calculated based on median dose-effect analysis by 
CalcuSyn V2 (Biosoft, Cambridge, UK) were taken as a measure of synergy, additivity 
or antagonism as described by Chou and Talalay (Chou and Talalay 1984, Chou 2010). 
CI<1 was considered synergistic, CI=1 additive and CI>1 antagonistic. Interpretation of 
combination index values are discussed more within the chapters where relevant. 
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Figure 2-3 SRB growth curve experiments were carried out in order to determine 
the doubling time and the optimal cell density (cells/well) for growth inhibition 
assay experiments 
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Cell line name Density seeded for 
growth inhibition 
(Cells/well) 
Population doubling time 
(approximate Hrs) 
SJSA-1 4 × 103 33-46 
SN40R2 4 × 103 33-49 
NGP 1.2 × 104 43 
N20R1  1.2 × 104 49 
HCT116TP53+/+ 4 × 103 24 
HCT116TP53-/- 4 × 103 24 
U2OS 1.25 × 103 40 
U2OS-DN 1.25 × 103 38 
DD7 2.5 × 103 80 
DR4 2.5 × 103 61 
MCF-7 4 × 103 35 
Table 2-3 Seeding densities used for growth inhibition assays along with the 
approximate doubling time of each cell line during exponential growth. 
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2.4 Clonogenic assay 
Clonogenic assays were carried out to assess whether any of the treatment regimens 
resulted in reduced of colony formation ability of cells which is thought to be a superior 
measure of the cytotoxicity. Concentration which resulted in 50% loss of clonogenic 
survival (LC50) was determined by fitting a Lowess/Spline curve to the data-points and 
interpolating the X-coordinate from Y at 50% on the curve. 
2.4.1 Conventional method 
Exponentially growing cells were seeded at 6 × 105 cells/well of a 6-well plate (corning) 
and allowed to adhere for 24 hours before being treated with solvent or drug of interest 
for 48 hours. In the case of siRNA mediated knockdown and Nutlin-3 combination 
treatment, the drug treatment was delayed by a further 24 hours to allow efficient 
knockdown. Following treatment the adhered cells were trypsinised and pooled with 
floating cells from the same well, and counted using a coulter counter as described 
above. The cells were then re-seeded, at empirically determined densities for each dose, 
in triplicates into 100mm dishes (Corning, USA) containing their growth medium and 
placed back in the incubator 10-14 days (cell-type dependent) to form colonies. Media 
was then aspirated and the colonies fixed with Carnoy’s fixative. Subsequently they 
were stained with 0.4% (w/v) crystal violet dissolved in dH2O for 5 min, washed with 
slow running cold water and allowed to dry over-night. Visible colonies (>50 cells) 
were counted and cloning efficiency in control samples (i.e. DMSO treated) was 
calculated using the following formula: (Counted colonies/colonies seeded) × 100. 
Percentage survival at each data-point was derived by normalising the colony 
counts/dish to the estimated expected number of surviving colonies based on the 
cloning efficiency of that cell line. An assumption was made that cloning efficiency 
remains constant across different seeding densities. These data were plotted against dose 
and fitted to a Fit spline/Lowess curve in GraphPad prism 6 software. The dose of drug 
which lead to 50% loss of colony efficiency or lethal dose 50 (LD50) was calculated by 
interpolating the x-coordinate based on the clonogenic survival curve.  
2.4.2 Modified method  
Empirically determined cell densities were seeded in triplicates in each well of a 6-well 
plate 24 hours before drug treatment. Following 48 hours of drug exposure media 
containing solvent/drug was replaced by normal growth media and the plates were left 
in the incubator to form colonies for 10-14 days. Colonies were fixed and stained as 
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described above and the same data processing was carried out. 
2.4.3 Clonogenic survival in response to ionising radiation 
Cells were seeded at empirically determined densities in 100mm dishes and allowed to 
adhere for 24 hours prior to being treated with increasing doses of ionising radiation (0-
10Gy). The cells were then allowed to form colonies for 10-14 days. Fixing, staining 
and data processing was carried out as described in 2.4.1. 
2.5 Drugs and specificities 
2.5.1 MDM2 inhibitors 
Racemic mixture of Nutlin-3 (C30H30Cl2N4O4), an MDM2 antagonist with the molecular 
weight (MW) of 581.5 g/mol was purchased from NewChem Technologies Limited 
(#548472-68-0) in solid form. The powder was solubilised in DMSO (Sigma #276855) 
to a final concentration of 10mM, and then smaller aliquot were stored at -20 ºC from 
which more dilute stocks were prepared each time when it was required. (+/-) Nutlin-3 
racemic mixture is a combination of Nutlin-3a, the active enantiomer, and Nutlin-3b, 
the inactive enantiomer. (+/-) Nutlin-3 (Referred to as Nutlin-3 henceforth) inhibits 
MDM2-p53 interaction with cell free assay IC50 value of 0.09μM in vitro.  
Idasanutlin; also known as (a.k.a.) RG7388 or RO5503781 (C31H29Cl2F2N3O4, MW = 
615.15) is the most potent MDM2 inhibitor (Cell free assay IC50 = 6nM) by Roche 
currently in clinical trials. This compound was synthesised in-house by Newcastle 
University’s medicinal chemistry group and prepared in 1mM stocks and stored as 
described above. 
2.5.2 PPM1D/WIP1 inhibitor 
After a comprehensive review of the literature for commercially available WIP1 
inhibitors, the most selective and potent WIP1 inhibitor GSK2830371 (C23H29ClN4O2S, 
MW = 461.02) was purchased from Tocris (#5140) and prepared as explained above in 
10mM stocks dissolved in DMSO. This WIP1 inhibitor binds to the unique flap-
subdomain of WIP1, inhibits its catalytic activity and reduces WIP1 protein stability 
from this allosteric site which is proximal to a known WIP1 ubiquitination site (K238). 
Cell free assay IC50 values of GSK2830371 for WIP1 and 21 other phosphatases were 
published to highlight the selectivity of this tool compound (Gilmartin, Faitg et al. 
2014) (Table 2-4 & Table 2-5). This can be compared to SPI-001 and CCT007093 
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selectivities (Rayter, Elliott et al. 2007, Yagi, Chuman et al. 2012).  
2.5.3 Kinase inhibitors 
NU7441 a.k.a. KU57788 (C25H19NO3S, MW = 413.49) is a DNA-PKcs inhibitor with 
an IC50 of 14nM in vitro and was provided to us by Professor Herbie Newell 
(Newcastle University). The drug was already dissolved in 100% DMSO to a final 
concentration of 2mM, then smaller aliquots were stored in -20˚C from which less 
concentrated stocks were prepared each time for use. 
KU55933 (C21H17NO3S2, Mr = 395.49) is an ATM inhibitor is with an IC50 of 13nM in 
vitro and was purchased from Tocris Bioscience in solid form. The powder was 
solubilised, stored, and used as explained above for Nutlin-3. A comparison of the cell 
free assay IC50 values of NU7441 and KU55933 between different members of the 
PI3KK family can be made to assess the selectivity and specificity of these kinase 
inhibitors in vitro (Table 2-6). 
Wortmannin (C23H24O8, MW = 428.43) is fungal metabolite which is a potent but not 
specific PI3-K inhibitor with inhibitory function against members of the PI3KKs (Table 
2-6). 
Ralimetinib/LY2228820 (C24H29FN6, MW = 420.52) is an ATP analogue selective 
MAPK p38α and p38β inhibitor with in vitro IC50 of 5.3nM and 3.2nM respectively 
(Campbell, Anderson et al. 2014). 
WIP1 inhibitor  IC50 (nM) Cellular activity in PPM1D-
amplified cells 
GSK2830371* 6 & 13 MCF-7 clonogenic sensitivity 
(IC50 = 0.5µM) 
SPI-001  480 ± 40 N/A 
CCT007093 8400 MCF-7 cellular IC50 = 1.35µM** 
Table 2-4 Cellular and Cell free assay 50% inhibitory concentrations (IC50) values 
for the top three WIP1 inhibitors commercially available along with data on 
cellular activity in MCF-7 cells. *IC50 values in two different cell free assays with 
different substrates; **: Data obtained from the Sanger institute drug sensitivity 
database; N/A: Not analysed 
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GSK2830371 
PPM1D/WIP1 and closely related 
Phosphatases 
Cell free assay IC50 
PPM1D 6 & 13 
CD45 >30’000 
DUSP22 >30’000 
HePTP >30’000 
LMPTP-A >30’000 
LMPTP-B >30’000 
MKP5 >30’000 
PP1α >30’000 
PP2A >30’000 
PP5 >30’000 
PTP MEG1 >30’000 
PTP MEG2 >30’000 
PTP-1B >30’000 
PTPN22 >30’000 
PTPß >30’000 
RPTPµ >30’000 
SHP-1 >30’000 
SHP-2 >30’000 
TCPTP >30’000 
TMDP >30’000 
VHR >30’000 
YopH* >30’000 
SPI-001 
PPM1D  480 
PPM1A (68% at 40 μM)** 
PP2A (11% at 40 μM)** 
Table 2-5 Published cell free assay IC50 values for GSK2830371 and SPI-001. * 
Yeast phosphatase; ** % Inhibition and 40µM. Table derived from data published 
in (Gilmartin, Faitg et al. 2014) & (Yagi, Chuman et al. 2012). 
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Closely related 
kinases  
Cell free assay IC50  
In vitro IC50 with 
NU7441 (nM)  
In vitro IC50 with 
KU55933 (nM)  
In vitro IC50 
with 
Wortmannin 
(nM) 
DNA-PK  14 2500nM  16 
ATM  >100000 13nM  150 
ATR  >100000 >100000nM  1800 
mTOR  1700 9300nM  200 
PI3-K  5000 16600nM  2 
Table 2-6 In-vitro IC50 values with respect to other kinases within the kinome are 
provided above to give a scope of the selectivity of these two kinase inhibitors. 
Final column data were obtained from (Sarkaria, Tibbetts et al. 1998). 
 
Kinase enzyme 
IC50(nmol/l) ± 
SEM 
p38α MAPK 5.3 ± 1.6 
p38β MAPK 3.2 ± 0.3 
p38δ MAPK >20,000 
p38γ MAPK >20,000 
ERK1 >20,000 
ERK2 >20,000 
JNK1 894 ± 43 
JNK2 80 ± 11 
JNK3 158 ± 21 
Table 2-7 In-vitro IC50 values for LY2228820 with respect to other kinases 
obtained from (Campbell, Anderson et al. 2014). 
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2.6 Analysis of cell cycle distribution via fluorescence-activated cell sorting (FACS) 
As described in the introduction a population of dividing cells fall into three distinct 
phases of the cell cycle based on their DNA content. In G1/G0 phases cells harbour one 
copy of the genome (n=2) and in G2/M the DNA content has been doubled (n=4) 
following an intermediate DNA synthesis phase (S-phase) (2>n<4). Distribution of a 
population of cells into each phase of the cell cycle can be estimated by quantifying the 
DNA content of individual cells within a large sample derived from that population and 
plotting a frequency distribution histogram. Importantly, changes to cell cycle 
distribution in response to treatment can provide clues as to the underlying mechanism 
of drug action.  
2.6.1 Sample preparation and FACS protocol 
Cells were seeded at 3 × 105 cells/well (double this in transient knockdown) of a 6-well 
plate (Corning) and treated as outlined in specific materials and methods of the relevant 
chapters. After treatment floating and adherent cells in each well were harvested and 
pooled before being syringed 3 times to remove any clumps of cells. An aggregate of 
two G1/G0 cells (each n=2) can be counted as a G2/M (n=4) which will confound the 
results therefore syringing the cell suspension is critical. The cells were then washed 
and re-suspended in PBS before being diluted 1:1 in a propidium iodide (PI) solution 
(Table 2-8) and incubated at RT for 20 min before FACS. PI is a fluorescent nucleotide 
dye that intercalates between the bases in double stranded DNA and RNA. DNase free 
Ribonuclease A (RNase A) cleaves the P-O5’ bond in cellular RNA molecules that 
would otherwise be stained by PI and confound the results. When bound to DNA, PI has 
excitation/emission maxima of 535/617nm and the fluorescence intensity is proportional 
to the DNA concentration. After PI staining, the cell suspension was put through the 
FACSCalibur (Becton Dickinson, BD Biosciences) where a vacuum is used to suck the 
cells through a narrow sample injection tube that hydrodynamically focused a stream of 
fluid of single cells past a 488-nm argon ion laser beam. The cell and its PI stained 
nucleus intercepts the light which causes transmission and scattering of the light. The 
light that transmits through the cell is detected by a forward scatter (FSC) diode and the 
scatter by a side scatted (SSC) diode which provide measures of cell volume and 
granularity respectively. Also the fluorescence collection lens focuses the beams of 
scattered light toward dichroic mirrors positioned at a 90˚ angle to the laser and they 
specifically reflect the fluorescent light emitted from PI towards the FL-2 585/42 
detector while transmitting other wavelengths of light through them for other detectors 
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to pick up (Omerod 2000). Detectors are photomultiplier tubes that can amplify signals 
from single photons so that they can be quantified and recorded electronically.  
2.6.2 FACSCalibur instrument setting and gating 
In order to record and analyse events attributed to cells rather than unrelated particles 
intercepting the light, instrument settings have to be optimised to detect objects with 
size and complexity characteristic of mammalian cells. Therefore CellQuest software 
(Beckton Dickinson), which enables simultaneous modification of instrument settings 
and data acquisition from FACSCalibur was used to optimise instrument settings based 
on FSC and SSC dot plots of untreated samples of each cell line. Also events attributed 
to aggregates of cells were identified and gated-out using FL2-A vs. FL2-W plots as 
shown in (Figure 2-4). FL2-A was set so that G1 peak frequency distribution histogram 
of control samples falls above 200 signal intensity so that events that have an FL2-A 
intensity just below n=2 DNA (Namely Sub-G1 events) can be detected. Data 
acquisition was capped at 10000 events/sample.  
2.6.3 FACS data analysis 
FCS files acquired were analysed using CellQuest software to generate representative 
2D and 3D histograms of control and treated sample cell cycle distribution. In order to 
analyse the percentage (%) of events attributed to each stage of the cell cycle, Cyflogic 
v 1.2.1 software was used to manually gate-out sub-G1 events on the FL2-A histogram 
plots calculating the percentage of events in each of the peaks corresponding to G1/G0 
and G2/M plus events in S-phase. Percentages were then plotted on grouped bar charts 
using GraphPad Prism 6 software. Sub-G1 events were also calculated as a percentage 
of total events in the same manner and expressed as bar charts. G1:S and G2:S ratios 
were calculated as measures of G1 and G2 arrest respectively in response to various 
treatment conditions and SubG-1 events were attributed to cell death. 
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Constituent  Mass or volume/ 
volume of PBS 
Final concentration 
Propidium iodide (Sigma) 1g/l 0.15mM 
DNase free RNase A (Sigma) 2g/l 3.88mM 
Triton-X 100 (Sigma) 3ml/l 0.3% (v/v) 
Table 2-8 Recipe for PI solution used for live cell FACS 
 
Figure 2-4 Manual gating of events based on FL2-A v FL2-W plots and FL2-A 
frequency distribution histogram. 
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2.7  Targeted silencing of gene expression using RNA interference (RNAi) 
Napoli, et al., reported in 1990 that ectopic overexpression of the chalcone synthase  
gene in petunia can somehow co-suppress the expression of the endogenous gene 
(Napoli, Lemieux et al. 1990). Multiple other findings during the early 1990’s showed 
that viral RNA replicons homologous to endogenous genes can also suppress the 
expression of specific genes (Hannon 2002). However, targeted post-transcriptional 
silencing of  specific genes with antisense double stranded RNA termed RNA 
interference (RNAi) was first reported in 1998 when Fire, et al., (Fire, Xu et al. 1998) 
showed that double stranded RNA (dsRNA) was more efficient at knocking down gene 
expression in Caenorhabditis elegans compared to sense or antisense strands alone and 
that there was likely an underlying enzymatic reaction involved. It is now well-
understood that this process is dependent on machinery that are conserved in many 
eukaryotic species both as a part of endogenous processing of endogenous non-coding 
RNA molecules into microRNA and as a mechanisms of protection against pathogenic 
and parasitic nucleic acids  (Hannon 2002, Sen and Blau 2006, Rana 2007).  
Entry of long RNA molecules into mammalian cells is followed by their enzymatic 
cleavage by Dicer, a member of the RNase III family, into 20-25 small interfering RNA 
(siRNA) molecules.  These double stranded siRNA molecules then form a complex with 
RNA-induced silencing complex (RISC) which recognises and cleaves target RNA 
molecules through the catalytic activity of ribonucleases Argonaut and Dicer (Elbashir, 
Martinez et al. 2001). RNAi mediated knockdown using synthetic siRNA molecules 
delivered either by electroporation or transfection reagents is now routine for 
knockdown of specific genes in mammalian cell lines in culture.  
2.7.1 Design of synthetic siRNA molecules 
Targeted WIP1 siRNA molecule along with a universal control siRNA was selected 
from a comprehensive comparison of siRNA mediated knockdown reported in the 
literature selecting the construct that resulted in the most efficient WIP1 protein 
knockdown (Fujimoto, Onishi et al. 2005). These were modified and synthesised by 
Eurofins MWG Operon based on previously published methods with symmetrical 2-
nucleotide 3’ TT overhang which leads to approximately equal ratio of sense and 
antisense siRNA molecules in the formation of small interfering ribonucleoprotein 
complexes (siRNPs) and it does not influence the silencing of the target (Elbashir, 
Harborth et al. 2001, Elbashir, Martinez et al. 2001). Additional WIP1 targeting siRNA 
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molecules were also designed and synthesised by Eurogentec (SR-NP001-004). See for 
siRNA construct identifiers and their respective sequence. 
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siRNA Sequence (5’-3’) RNA [TT] DNA 
WIP1.1 Sense: GUGCCAUAGUAAUCUGCAU 
Antisense: AUGCAGAUUACUAUGGCAC 
WIP1.2 Sense: GGUGUAGUCAUACCCUCAA 
Antisense: UUGAGGGUAUGACUACACC 
WIP1.3 Sense: GCCCUUCCUAUAAUAGUCA 
Antisense: UGACUAUUAUAGGAAGGGC 
WIP1.4 (Fujimoto, Onishi 
et al. 2005) 
Sense: UUGGCCUUGUGCCUACUAA 
Antisense: UUAGUAGGCACAAGGCCAA 
Universal control Sense: GCGCGCUUUGUAGGAUUCG 
Antisense: CGAAUCCUACAAAGCGCGC 
Table 2-9 siRNA constructs and their respective sequence. 
2.7.2 Transfection protocol 
Cells were seeded at 6 ×105 cells/well of a 6-well plate and allowed to adhere for 24 
hours before transfection. Constructs of siRNA were stored as 20µM stocks and a fixed 
ratio of 1:1.25 (v:v) siRNA stock and Lipofectamine 2000 (Invitrogen) were mixed in 
order to allow the formation of optimal complexes for siRNA delivery (Method 
optimised by Dr Laura Gamble). Lipofectamine 2000 is composed of a propriety 
formula of cationic and neutral lipids that have undergone microfluidisation resulting in 
unilamellar liposomal structures with a positive surface which can form complexes with 
negatively charged siRNA molecules. These complexes cannot penetrate through the 
negatively charged surface of the phospholipid bilayer but they are taken up by 
endocytosis and are released in the cell. Lipofectamine and siRNA were added to 
separate vessels containing 400µl of OptiMEM-glutamax (Optimem) serum free media 
(Invitrogen) so that their mixture would observe the 1:1.25 (v:v) ratio and incubated at 
room temperature for 10 min before being mixed and allowed to form complexes for an 
additional 30-45min. Meanwhile growth media was aspirated from each well and 
replaced with 1.6ml of Optimem before the 800µl of additional Optimem containing 
siRNA-Lipofectamine complexes prepared earlier was added to appropriate wells in a 
dropwise manner. Cells were then left in a tissue culture incubator overnight before 
each well was supplemented with 10% FBS for collection or treatment at a later time-
point.  
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2.8 Caspase-3/7 activity 
The Caspase-Glo® 3/7 Assay (Promega, Southampton, UK) uses a pro-luminescent 
substrate which contains the substrate motif of executioner caspase-3 and -7 a DEVD. 
Presence of active caspase-3/7 results in cleavage and luminescence of this substrate. A 
Luminometer can then be used to measure luminescence as a surrogate for caspase-3/7 
activity. Cells were seeded at 2×104 cells/well in white-well 96-well plates 24 hours 
before drug treatment then the Caspase-3/7 reagent was prepared as per manufacturer’s 
protocol and added at a 1:1 ratio to the media containing cells. After 1 hour of 
incubation luminescence was measured using Fluostar Omega Plate Reader (BMG 
LABTECH). 
2.9 Western blotting 
2.9.1 Principles of western blotting 
“Western blotting” was a term first coined by Neil Burnette in 1981 after he had 
optimised on a previously described technique by Towbin et al., (1979) which allowed 
the electrophoretic transfer of proteins from a sodium dodecyl sulfate (SDS) 
polyacrylamide gel onto a nitrocellulose membrane (Towbin, Staehelin et al. 1979, 
Burnette 1981) This technique allowed the detection and semi-quantitative analysis of 
specific proteins and their post-translational modifications in a complex mixture of 
proteins by using specific antibodies. Proteins in a mixture are initially separated based 
on their mass (kDa) through SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
are then transferred onto a nitrocellulose membrane across an electric field where they 
are adsorbed and immobilised most likely through electrostatic and hydrophobic 
interactions (Low, Shaimi et al. 2013). Specific antibodies conjugated to horseradish 
peroxidase (HRP) can then be used to detect proteins of interest and visualise them 
through detection of chemiluminescence.  
2.9.2 Lysate (Cellular protein mixture) preparation 
Cells were seeded at 6 × 105 cells/well of a 6-well plate 24 hours before being treated as 
described in specified materials and methods in each chapter. At the end of each 
treatment the cells were washed with 4ºC PBS and 40µl of lysis buffer (0.0625M Tris-
HCl pH 6.8, 2% w/v SDS (Sigma), 10% v/v Glycerol (Sigma)) was added to each well 
before cells were then scraped and the lysate was transferred into microfuge tubes 
(Eppendorfs). The lysates were kept on ice from this point onwards unless otherwise 
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stated. Lysates were heated at 95˚C for 10 min before being sonicated at 23KHZ using 
Soniprep 150 plus (MSE) for 10 sec (Amplitude set at 6.0). Lysates were then 
centrifuged at 16000rpm at 4˚C (Eppendorf Centrifuge 5417R) and the supernatant was 
preserved for measuring total protein and SDS-PAGE. 
2.9.3 Measuring total protein 
For measuring total protein concentration in lysates Pierce BCA Protein Assay Kit 
(Thermo Scientific; Prod. No: 23227) was used. This kit contains a detergent 
compatible formulation based on biocinchoninic acid (BCA) for the colourimetric 
detection and quantitation of total protein. This assay combines the reduction of Cu2+ 
to Cu1+ by protein in an alkaline medium with the colourimetric detection of Cu1+. 
Firstly the Cu1+ is chelated to peptides >3 amino acids long (Biuret reaction) to form a 
coloured complex. Subsequently BCA can interact with the already chelated Cu+1 ion 
(2:1 ratio) to form a purple water soluble complex that has a linear absorbance at 
570nm. The assay was carried out in a 96-well plate as per the manufacturer’s protocol. 
Standard curves (0.2-2.0mg/ml) were obtained from 2mg/ml bovine serum albumin 
(BSA) stock each time and were quantified in parallel to lysates. The standard curve 
was then used to interpolate the lysate concentration estimate (Figure 2-5).  
 
Figure 2-5 An example of a standard curve for used for protein estimation.  
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2.9.4 SDS-PAGE and transfer stages 
20-30µg of each lysate was diluted in SDS-loading (Table 2-10) buffer and made up to 
a volume of 15µl before being incubated at 100˚C on a heating block for 10 min. For 
analysis of low molecular weight proteins (<100kDa) the samples were loaded into 
wells of a Mini-protean TGX 4-20% gradient pre-cast gel (Bio-Rad) set up in the tank 
with running buffer (Table 2-11) along with SeeBlue Pre-stained molecular weight 
protein standard 1× (Life Technologies, #LC5625). The proteins were then transferred 
onto 0.45 micron nitrocellulose membrane (Hybond-C Ammersham, #RPN203C) 
(100V for 30 min). Transfer buffer constituents are listed in table (Table 2-12). Once 
transferred, the membrane was then blocked in 5% milk dissolved in 1 × TBS, 0.1% 
Tween-20 (Fisher BioReagents) pH 7.6 (TBS/T) (Table 2-13) at room temperature for 
an hour. In case of specified manufacturer guidelines or probing for phospho-epitopes 
the membrane was blocked in 5% bovine serum albumin (BSA) (Sigma) dissolved in 
TBS/T. The membrane was then cut and strips were probed with the appropriate 1º 
antibodies in blocking reagent of previously stated composition. Antibody 
specifications and incubation times are stated below (Table 2-14). The membranes were 
then washed briefly with TBS/T and exposed to the appropriate HRP-conjugated 2º for 
an hour in the stated blocking reagent. 
For high molecular weight proteins (> 100 kDa), the same processes were carried out 
however a different gel and running buffer were used to get better separation. 3-8% 
Criterion XT Pre-cast gels (Bio-rad, #345-0129) and the 20× XT Tricine running buffer 
(Bio-Rad, #161-0790) diluted to 1× in dH2O were used at the polyacrylamide gel 
electrophoresis stage. 
2.9.5 Protein visualisation using enhanced chemiluminescence 
After the incubation with the 2º antibody and the membranes were washed 7 × 4 min in 
TBST before being incubated for a 1 min at room temperature with enhanced 
chemiluminescent (ECL) substrate mixture. This mixture provides the 
chrmiluminescent substrate and an oxidising agent (e.g. H2O2). HRP conjugated to the 
2º antibody then converts the substrate to triplet carbonyl and its decay to singlet 
carbonyl results in emission of light. An X-ray film (Kodak) was then used to detect the 
emission from the product decay and autoradiographs were generated showing the 
relative amounts of proteins detected by the antibodies. The autoradiographs were then 
scanned and analysed.  
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Amount of constituent  Final Molarity 
in solution 
2.5ml of 0.5M Tris/HCl pH 6.8 62.5mM 
0.4g SDS 69.4mM 
1ml β-mercaptoethanol (stock of 14.3M) 715.0mM 
2ml Glycerol (density1.261g/cm3, Mr = 92.09) 2.7mM 
1ml 0.1% bromophenol blue (density 2.2g/ml, Mr = 
669.96g/mol) 
0.2μM 
Note: make up to a final volume of 20ml in distilled water 
Table 2-10 SDS-loading buffer constituents and final concentration are stated 
above. 
 
Amount of constituent  Final molarity 
in solution 
144g Glycine (Sigma G8898) 1.9M 
30g Tris base (Fisher 10667243) 247.6mM 
10g SDS (Sigma L3771) 34.7mM 
Note: dissolve and make up to a liter with distilled water 
Table 2-11 10 × Running buffer was prepared as stated above and diluted 1:10 for 
each use. 
 
Amount of constituent  Final molarity 
in solution 
70.7 Glycine (Sigma G8898) 188.4mM 
15.15 Tris base 25.0mM 
1L 99.9% methanol (Fisher BioReagents) 
Note: dissolve and make up to a 5 liters with distilled water 
Table 2-12 Transfer buffer was prepared as stated above. 
 
Amount of constituent  Final molarity 
in solution 
80.0g NaCl (Sigma S7653) 1.4M 
24.2 Tris base (Fisher 10667243) 199.8mM 
Note: dissolve and make up to a 1 liters with distilled water 
Table 2-13 TBS 0.1% Tween-20 was prepared as stated above and the pH was 
adjusted to 7.6. 
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Antibody 
name/clone 
 Migrates 
at ≈ kDa 
Cat No. 
(Company) 
Raised 
in  
Dilution  Blocked/ 
Incubation in 
Cleaved caspase-
3 
17, 19 9661S 
(Cell signaling) 
Rabbit 1:1000 5% Milk 12-
18Hrs 
p21 18 OP64 
(Calbiochem) 
Mouse 1:100 5% Milk 1Hr 
PUMA 21 PC686 
(Calbiochem) 
Rabbit 1:500 5% Milk 12-
18Hrs 
BAX 21 2772 
(Cell signalling) 
Rabbit 1;1000 5% BSA12-
18Hrs 
Actin  42 A4700 
(Sigma)  
Mouse 1:3000 5% Milk 1Hr 
p53 (DO-7) 53 NCL-L-p53-DO7 
(Novocastra) 
Mouse  1:500 5% Milk 1Hr 
pp53Ser15 53 9284 
(Cell signalling) 
Rabbit 1:1000 5% BSA12-
18Hrs 
WIP1 (H-300) 85 & 67 sc-20712 
(Santa Cruz) 
Rabbit  1:200 5% Milk 12-
18Hrs 
WIP1 (F-10) 85 & 67 sc-376257 
(Santa Cruz) 
Mouse 1:200 5% Milk 12-
18Hrs 
MDMX 72 A300287A-2 
(Bethyl 
laboratories) 
Rabbit  1:1000 5% Milk 1Hr 
MDM2 90 OP40 
(Calbiochem) 
Mouse 1:300 5% Milk 1Hr  
ATM 350 Ab78 
(Abcam)  
Mouse  1:500 5% milk + 
5% BSA 12-
18Hrs 
P-ATMSer1981 350 AF1655 
(R & D Systems) 
Rabbit 1:1000 5% milk + 
5% BSA 12-
18Hrs 
DNA-PK (H163) 460 sc-9051 
(Santa Cruz)  
Rabbit 1:1000 5% milk + 
5% BSA 12-
18Hrs 
P-DNA-PKSer2056 460 Ab18192 
(Abcam) 
Rabbit 1:500 5% milk + 
5% BSA  
PARP-1 (C2-10) 114 (85 for 
apoptosis) 
4338-MC-50 
(Trevigen) 
Mouse 1:1000 5% Milk 12-
18Hrs 
2º goat anti 
mouse HRP  
N/A PO447 
(Dako) 
Goat 1:1000 Same as in 1º 
2º goat anti 
rabbit  
HRP 
N/A PO448 
(Dako) 
Goat  1:1000 Same as in 1º 
Note: All the solutions in the last column on the right were made up in TBS, 0.1% 
Tween 20 (pH 7.6) and if the incubation time was 12-18Hrs it was carried out at 4 ºC. 
Table 2-14 Information on antibodies and incubation times are been stated above. 
HRP: Horseradish peroxidase, Hr: Hour.  
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2.10 Primer-directed polymerase chain reaction (PCR) 
Primer-directed polymerase chain reaction (PCR) is an in vitro biochemical procedure 
whereby low copies of specific sequences of nucleic acids can be amplified rapidly and 
accurately. The development and optimisation of this procedure spans over decades 
since the discovery of the structure of DNA in 1953 (Watson and Crick 1953). 
However, PCR was finally optimised in its present form by Saiki et al., in 1988 (Saiki, 
Gelfand et al. 1988). Small complementary oligonucleotides (~20mer primers) are 
designed to flank the region of interest on the target DNA molecule from which point 
they will prime the in vitro DNA polymerisation reaction carried out by thermostable 
DNA polymerase (From Thermus aquaticus or Pyrococcus furiosus) that can synthesise 
the remainder of the sequence in the presence of deoxyribonucleic acids (dNTPs) dATP, 
dTTP, dCTP and dGTP and appropriate co-factor. Thermal cycling allows template 
denaturation (95°C) and primer annealing (~62°C) which before an elongation step 
during which the polymerase synthesises the new strand (5’-3’ direction). Because the 
molarity of reaction constituents are in excess of the target DNA molecule the number 
of copies of the DNA molecule of interest is increases exponentially. 
2.10.1 Quantitative real-time PCR  
Quantitative real-time PCR (qRT-PCR) is a technique used for amplification and 
simultaneous quantification of nucleic acids. Total messenger RNA was converted to 
cDNA using the Promega Reverse Transcription System (A3500, Promega) as 
described by the manufacturer. To assess quantity of transcripts of interest primers are 
designed to flank regions of a given gene’s mRNA transcript including all known splice 
variants for that gene (Table 2-15). qRT-PCR was carried out using SYBR® green RT-
PCR master mix (Life technologies) as per the manufacturer’s guidelines. SYBR green 
is a double stranded DNA (dsDNA) binding (and intercalating) fluorescent dye with an 
excitation wavelength of ~ 485nm and an emission wavelength of ~ 524nm. Fluorescent 
signal from SYBR green directly correlates with dsDNA quantity and therefore PCR 
dsDNA products can be quantified after every elongation step in real time. 50ng/µl of 
the cDNA samples per 10µl final reaction volume, with the standard cycling parameters 
(Stage 1: 50˚C for 2min, Stage 2: 95˚C for 10min then 40 cycles of 95˚C for 15 Sec and 
60˚C for 1 min), were set and carried out on an ABI 7900HT sequence detection 
system. Data were presented as mean ± standard error of mean (SEM) relative quantities 
(RQ) of four independent repeats where GAPDH was used as endogenous control and 
DMSO used as the calibrator for each independent repeat with the formula 2-ΔΔCT. 
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Analysis was carried out using SDS 2.2 software (Applied Biosystems).  
Target Gene Primer sequence 5’-3’ 
AEN F-CTTCCAGGCGCTCAAGTATGT 
R-GGGCCAGGTCCTTTAGAGAGA 
BTG2 F-CCTGTGGGTGGACCCCTAT  
R-GGCCTCCTCGTACAAGACG 
CDKN1A F-TGTCCGTCAGAACCCATGC 
R-AAAGTCGAAGTTCCATCGCTC 
GAPDH F-CAATGACCCCTTCATTGACC 
R-GATCTCGCTCCTGGAAGAT 
MDM2 F-CAGTAGCAGTGAATCTACAGGGA 
R-CTGATCCAACCAATCACCTGAAT 
PHLDA3 F-GCCTCTGCCAGATGCCTCC 
R-GGCACATCCCGCGAGCTGCC 
TNFSRF10B 
 
F-ATGGAACAACGGGGACAGAAC 
R-CTGCTGGGGAGCTAGGTCT 
TP53INP1 F-TCTTGAGTGCTTGGCTGATACA 
R-GGTGGGGTGATAAACCAGCTC 
XPC F-CATCGTGGGAGCCATCGTAAG 
R-CTCACCATCGCTGCACATTTT 
Table 2-15 Primer sequences used in qRT-PCR. F: Forward; R: Reverse. 
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2.11 Bacterial culture 
Aseptic techniques were observed throughout working with bacterial cultures. Bacterial 
cells were grown in nutrient rich lysogeny broth (LB) medium (Bertani 1951) or on LB 
agar plates (1.5% agar w/v) containing 100µg/ml ampicillin (Sigma, # A0166) for 
selection of bacteria carrying vector of interest that harboured a copy of the β-lactamase 
TEM-1(blaTEM-1) gene which confers resistant to β-lactam antibiotics (i.e. ampicillin) 
by hydrolysing the β-lactam ring in their structure (Bush 1988).   
2.11.1 Bacterial transformation  
Bacterial transformation is a naturally occurring process whereby bacteria in certain 
environmental conditions become competent to acquire external naked DNA molecules 
(i.e. accessory DNA such as plasmids) which contributes to horizontal gene transfer 
(Lorenz and Wackernagel 1994). Bacterial cells (i.e. Escherichia coli (E.coli )) can also 
be made competent in the laboratory through their incubation with CaCl2 (50mM) 
which affects the porosity of their membranes, allowing the uptake of hydrophilic 
molecules, such as DNA, during a heat shock procedure (Mandel and Higa 1970). 
Concentrated plasmid stocks (50-250ng/µl) were diluted 1:20 (v/v) in a 50µl aliquot of 
commercially available NEB 5-α transformation competent E. coli (Transforming 
efficiency: 1 - 3 x 109 cfu/μg pUC19 DNA) cells (New England Biolabs Inc., C2987H) 
and incubated on ice for 30min, placed on a heating block at 42˚C for 30sec (heat 
shock) and then put back on ice for a further 5min. The cells were then transferred to 
0.5ml of SOC Outgrowth Media (New England Biolabs Inc., B9020S), incubated at 
37˚C while being shaken for 45min-1Hr. An aliquot of the cell suspension (50µl) was 
streaked on LB Agar plates containing Ampicillin (Sigma) at 100µg/ml final 
concentration and incubated overnight at 37˚C in order to positively select for clonal 
populations of E. Coli carrying a plasmid with a selectable marker. Individual colonies 
were then picked using sterile pipette tips, inoculated in 5ml of LB broth containing 
Ampicillin (100µg/ml), and placed on a shaker in a 37˚C incubator to grow overnight 
(12-16Hrs) at which point the culture would be in the transition between the logarithmic 
to stationary phase. Cell suspension was then centrifuged at 3000rpm, supernatant was 
disposed of and the pellet was used to extract the plasmid as described below. 
2.11.2 Plasmid DNA Extraction  
Plasmid DNA was extracted using a QIAGEN Plasmid Mini Kit (QIAGEN, 12123) 
which employs modified alkaline cell lysis method followed by the use of columns with 
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silica-gel stationary phase and high salt concentration mobile phase to allow adsorption 
of plasmid DNA. Ribonuclease A (RNase A) is present during the lysis process to 
degrade RNA and unbound molecules are removed and disposed of in wash steps before 
the plasmid DNA is eluted in low salt concentration (Please refer to QIAprep® 
Miniprep Handbook 05/2004).  
Larger amounts of Plasmid DNA were extracted using QIAGEN Plasmid Maxi Kit 
(QIAGEN, 12162) as per the manufacturer’s protocol. Anion-exchange columns/tips 
were used to In order to purify large quantities of plasmid from a pellet containing 
approximately 9 × 109 – 1.2 × 1010 total cell number (3ml of a culture at 3-4 × 109 
cells/ml). The underlying principle behind his anion-exchange procedure kit is that there 
is a unique stationary phase or resin which is composed of hydrophobic silica beads, 
100µm in particle size, large pore size, coated with diethylaminoethanol (DEAE) which 
is positively charged a the neutral pH of the mobile phase and can therefore retain 
negatively charged macromolecule that pass through (i.e. DNA at pH 7.0). The plasmid 
DNA can then be eluted by stepwise increment of the salt concentration of the mobile 
phase and nucleic acid concentration was quantified using a Nanodrop as described 
below. 
2.11.3 Estimation of nucleic acid concentration via spectrophotometry 
After nucleic acid purification the concentration of each stock was determined using a 
Nanodrop 1000 Spectrophotometer V3.7. Nanodrop sample loading platform has a 
receiving fibre optic cable onto which 1µl of the sample is loaded and a second source 
fibre optic that folds with the sampling arm onto the sample and the receiving fibre. The 
surface tension of the solvent containing the sample (e.g. H2O) is used to hold he 
sample between the small gap generated by the higher and lower measurement 
platforms allowing the light from the xenon flash lamp source to traverse through the 
sample so that a linear charge coupled device (CCD) array on the other side can analyse 
the light that has passed through the sample. The Nanodrop covers a spectrum of 
220nm-750nm which can be used for spectrophotometric measurement of concentrated 
samples containing molecules that show absorbance in this spectral range. Sample type 
DNA-50 was used for DNA quantification and RNA-40 for RNA quantification. A 
blank measurement was taken before sample measurements using the appropriate 
solvent devoid of sample and the pedestals were cleaned with distilled water between 
each measurement. The absorbance spectra were then presented as in Figure 2-6 with 
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readouts for 260:280 and 260:230 ratios. Nucleic acids absorb at 260nm and protein or 
phenol contaminants absorb at 280 therefore this ratio can be used as a measure of 
sample purity. The 260:280 ratio of ~1.8 was considered as pure DNA and ~2.0 as pure 
RNA. A 260:230 ratio is another measure of nucleic acid purity which is normally 
higher than the 260:280 ratio for a given sample (normally 1.8-2.2). Considerably lower 
260:230 ratio suggests carbohydrate or solvent contamination as they both absorb 
strongly at 230nm. 
 
Figure 2-6 Screen shot showing Nanodrop 1000 software presentation of 
absorbance spectra pertaining to a plasmid sample purified by a Miniprep kit. 
2.12 Immunocytochemistry  
Immunocytochemistry can be used to localise antigen of interest with a specific primary 
antibody which is then visualised directly if it is already conjugated to a fluorophore or 
indirectly by a secondary antibody conjugated to a fluorophore. The nucleus is often 
stained with a nucleic acid fluorescent intercalating dye 4',6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI). The samples can then be visualised and assessed by 
fluorescent microscopy. Alternatively confocal microscopy can be used for more high 
resolution imaging and generation of 3 dimentional (3D) images of single cells in high 
resolution for assessing subcellular localisation of antigens. 
2.13 Protein detection by immunofluorescence 
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Fluorescent microscopy relies on the physical phenomenon of fluorescence to localise 
molecules within the cell in situ. Fluorophores or, fluorescent dyes, are molecules that 
can absorb the energy of light (photons) at a particular wavelengths and emit a lower 
amount back to their environment at a different wavelength.  
2.13.1 Immunofluorescence protocol 
Cells were grown on glass coverslips in 6-well plates so that they are 50-70% confluent 
before treatment. At time points of interest following treatment media was aspirated and 
cells were washed with 4°C PBS before being fixed with 100% methanol (slides can be 
stored at -20°C for up to a week). Ethanol was removed and the slides were washed 
with 4°C PBS twice and transfer slides with forceps onto Parafilm M® in a 15cm petri 
dish surrounded by rolled up damp paper towels on the sides. 200µl of blocking reagent 
(2%BSA v/v, 1.5% Triton-X v/v in PBS) was then added to each cover slip and 
incubated for 1 hour before it was aspirated by a micro pipette (Gilson) from the corner 
and 200µl of the primary antibody of interest diluted in blocking reagent also containing 
milk and goat serum (2%BSA v/v, 10% milk w/v, 10% goat serum v/v, 1.5% Triton-X 
v/v in PBS) was added onto the coverslip. WIP1 (F-10) primary antibody was diluted at 
1:500 and the γH2AX (Mouse, 05-636, MERK Millipore) antibody at 1:1000 in 
blocking reagent. Coverslips were incubated at room temperature for 1Hr or at 4°C 
overnight before dipping the coverslip 3 times in 1.5% triton-X-100 v/v in PBS. They 
were then transferred into 6-well plates and wash with 1.5% triton-X-100 v/v in PBS 
another 3×15 min on a platform shaker. Coverslips were then removed and blocking 
buffer containing goat anti-mouse AlexaFluor-488 conjugated antibody (A11001, 
Thermo Fisher scientific) was added and incubated for a further 1 hour incubation, at 
room temperature, in the dark. Alexafluor-488 is a fluorophore that is excited by light at 
495nm and emits 519 which can be detected by the optics in the microscope. 
Immunofluorescence is a technique where antibodies are used to detect specific proteins 
in their anatomical locations. This technique either primary or secondary antibodies that 
are conjugated to fluorophores to detect specific epitopes in situ then a fluorescent or 
confocal microscope is used to examine the localisation of the epitopes within the cell. 
Antibody was removed then the coverslip was washed as above before adding a drop of 
VECTASHIELD® HardSet™ Mounting Medium with DAPI onto the cells and 
mounting the coverslip on a slide approximately 20min before confocal microscopy.  
2.14  Confocal microscopy 
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In a confocal microscope out of focus rays from the fluorophore are filtered out by a set 
of pinholes positioned in the same confocal plane in front of the excitation source and 
the photomultiplier tube. This generates sharper images which allow z-stacking, the 
capture of images at different heights from the base of the sample, which in turn allows 
a 3D reconstruction of the images using the appropriate software.  
Zeiss LSM 700 confocal microscopy system was used to capture images and the z-
stack. The microscope was prepared for imaging using the Zen 2009 software as 
described by the manufacturer. A drop of Immersol (Zeiss, #ISO 8036-1/2) oil was 
placed on the coverslip and the slide was placed into its allocated slot on the microscope 
platform. Laser intensity, master gain, resolution and averaging were kept the same 
within the same experiment. 40× and for z-stacking 63× magnifications were used for 
γH2AX staining and z-stacking respectively. Z-stacking was carried out according to 
the manufacturer’s protocol (with the averaging set at 1). The number of slices taken for 
different z-stack experiment ranged from 30-50. Images taken from different slices were 
presented as a video rather than a 3D image.
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Chapter 3 Exploring the combination treatment of Nutlin-3 and 
inhibitors of DNA repair enzymes in MDM2 inhibitor sensitive and 
resistant cell line pairs
 105 
 
3.1 Introduction 
This chapter describes experiments to explore the role of DNA repair and stress 
response enzymes in determining the sensitivity to MDM2 inhibitors. The strongest 
predictor of response to MDM2 inhibitors is the genetic status of TP53. However, TP53 
wild-type cell lines show a wide range of sensitivity to MDM2 inhibitors suggesting 
that there are more complex mechanisms underlying p53 regulation following its 
activation by MDM2 inhibitors (Saiki, Caenepeel et al. 2015). Deciphering mechanistic 
determinants of sensitivity to MDM2 inhibitors may allow us to stratify tumour types 
more effectively and use optimal combination regimens in TP53 wild-type 
malignancies. 
3.1.1 Use of MDM2 inhibitor resistant clones in investigating determinants of 
MDM2 inhibitor sensitivity 
Mechanisms of drug chemotherapy resistance often involve mutations in the target 
protein or upregulation of pumps such as p-glycoprotein (P-gp) and multi-drug 
resistance protein (MRP-1) that can actively export the drug from the cytoplasm 
(Gottesman, Fojo et al. 2002). However, work carried out by our own group and 
published data show that the primary mechanism of resistance to MDM2 inhibitors is 
through mutational inactivation of TP53 (Aziz, Shen et al. 2011, Michaelis, Rothweiler 
et al. 2011, Jones, Bjorklund et al. 2012). Repeat exposure to MDM2 inhibitors results 
in the selection of TP53 mutant, and otherwise isogenic, MDM2 inhibitor resistant 
clones. However, the origin of these TP53 mutations is unclear. Interestingly, these 
clones have also been reported to show cross-resistance to other genotoxic 
chemotherapeutic agents (Michaelis, Rothweiler et al. 2011, Jones, Bjorklund et al. 
2012). Unique MDM2 inhibitor resistant clones generated in our laboratory are used 
throughout this thesis to investigate the determinants of sensitivity/response to MDM2 
inhibitors and other functional aspects of p53-dependent biological processes.  
3.1.2 Exploring the role of DNA repair enzymes as determinants of response to 
MDM2 inhibitors 
The roles of components of the DNA repair and stress response machinery in 
determining MDM2 inhibitor sensitivity are poorly understood. Sullivan et al., (2012) 
introduced the concept of “synthetic lethality with Nutlin-3 (SLN)”. This was based on 
a genome wide shRNA screen in which a panel of genes was identified, the transient 
knockdown of which, on their own, had little or no effect on cell growth and 
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proliferation while increasing sensitivity of TP53 wild-type cells to Nutlin-3 (Sullivan, 
Padilla-Just et al. 2012). The authors then validated synthetic lethality of two of their 
panel of targets, ATM and MET kinases, by showing that combination of specific ATM 
or MET kinase inhibitors with Nutlin-3 had a synergistic effect in six TP53 wild-type 
cancer cell lines albeit to varying degrees. Given the established role of ATM in post-
translational modification and activation of p53 in response to DNA damage, synergism 
observed by combining an ATM inhibitor and an MDM2 inhibitor raised questions 
about the underlying mechanism. This was proposed initially to be through the role of 
ATM in the pro-survival NFκB signalling cascade (Sullivan, Padilla-Just et al. 2012). 
Later the authors also claimed that the synergy observed was independent of p53 
transcriptional regulation and dependent on ATM’s role in regulation of autophagy 
(Sullivan, Palaniappan et al. 2014). Interestingly the doses of Nutlin-3 used in both 
studies were beyond doses associated with on target non-genotoxic activation of p53 in 
culture (≥10µM) (Sullivan, Padilla-Just et al. 2012, Sullivan, Palaniappan et al. 2014). 
ATM is a member of the PI3KK family and is involved in homologous recombination 
repair (HRR) of double strand breaks (DSB’s). It is well-established that inhibition of 
ATM potentiates the response to DNA damaging agents such as ionising radiation (IR) 
as it results in persistence of lethal DNA DSB lesions (Hickson, Zhao et al. 2004). 
Using high doses of Nutlin-3 in combination with an ATM inhibitor may be 
potentiating the response to Nutlin-3 induced DNA damage rather than an intricate non-
genotoxic mechanism as described by Sullivan et al., (2012 & 2014). Indeed 
phosphorylation of histone H2AXSer139 (γH2AX), a marker of DNA DSB’s, in response 
to >10µM Nutlin-3, has been reported independently (Verma, Rigatti et al. 2010, 
Valentine, Kumar et al. 2011, Rigatti, Verma et al. 2012). These studies assessed 
γH2AX immunofluorescence staining at later time-points following treatment which 
may correspond with DNA-fragmentation due to p53 mediated apoptosis. This suggests 
that the DNA damage observed may be due to off-target effects of Nutlin-3 or a later 
consequences of on-target non-genotoxic activation of p53 through MDM2 inhibition as 
γH2AX staining is also observed during apoptosis (Rogakou, Nieves-Neira et al. 2000). 
Therefore, mechanistic understanding of novel targets involved in sensitising cells to 
non-genotoxic activation of p53 by MDM2 inhibitors requires careful consideration of 
dosage and scheduling. 
3.1.3 Use of small-molecular-weight inhibitors of DNA-repair enzymes in exploring 
determinants of MDM2 inhibitor sensitivity 
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In addition to HRR, repair of DSBs is also achieved through non-homologous end-
joining (NHEJ) which relies on DNA-PKcs another kinase from the PI3KK family. 
Selective inhibition of DNA-PKcs by NU7441, similar to ATM inhibition, also 
potentiates the response to DSB inducing genotoxic agents (Hickson, Zhao et al. 2004, 
Leahy, Golding et al. 2004, Zhao, Thomas et al. 2006). Sullivan et al., (2012) reported 
that pharmacological inhibition of ATM by KU55933 increases sensitivity to Nutlin-3 
in a p53-dependent manner (>10µM). As discussed above this reported increase in 
cellular sensitivity is likely caused by off-target Nutlin-3 induced DNA damage due to 
high doses of this compound reported by Verma et al., (2010), Valentine et al., (2011) 
and  Rigatti et al., (2012) rather than through the intricate mechanisms explained by 
Sullivan et al., (2012 & 2014).  
Given the overlapping roles of ATM and DNA-PKcs in repairing DSBs, it would be 
pertinent to assess whether the selective pharmacological inhibition of ATM or DNA-
PKcs can sensitise cells to mechanistically relevant doses of Nutlin-3 (<10µM). 
Furthermore, inhibition of DNA-PKcs may influence the sensitivity of cells to Nutlin-3 
in the backdrop of DNA damage.  
3.2 Hypotheses 
 Pharmacological inhibition of ATM by KU55933 and DNA-PKcs by NU7441 
sensitises cells to Nutlin-3 in the absence of DNA damage. 
 Inhibition of DNA-PKcs by NU7441 increases cellular sensitivity to MDM2 
inhibitors in the backdrop of DNA damage 
3.3 Specific materials and methods  
3.3.1 MDM2 inhibitor resistant clones and their use  
SJSA-1 and NGP TP53 wild-type parental cell lines and their MDM2 inhibitor resistant 
daughter cell lines SN40R2 and N20R1 respectively had previously been derived in our 
laboratory as described in materials and methods (2.1.2). These resistant cell lines lack 
p53 function due to TP53 mutational inactivation (See 2.1.2) and are routinely used in 
pre-clinical development of in-house MDM2 inhibitors. In this chapter these cell line 
pairs were used to investigate the sensitivity to Nutlin-3 in combination with NU7441, a 
widely used potent selective DNA-PKcs inhibitor, or KU55933, a widely used ATM 
inhibitor. 
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3.3.2 Assessing growth inhibition by SRB assay 
Appropriate densities of cells were seeded in 96-well plates (Corning, UK) 24 hours 
before treatment with 0-50μM Nutlin-3 + 1μM NU7441or 0-10μM NU7441 alone. 
Where IR was added to the treatment a growth inhibition assay 72 hours after 0-6Gy 
dose of IR alone was also carried out in conjunction. Plates where Nutlin-3 + 1μM 
NU7441 were combined, a 1μM NU7441 control was present to enable measurement of 
the effect of NU7441 on the growth inhibition curve of Nutlin-3 + IR. The 
undergraduates’ focus was on combination of 0-50μM Nutlin-3 + 10μM KU55933 and 
0-50μM KU55933 alone no IR was added to the treatment. The final concentration of 
DMSO was kept at 1% in all wells except the media control well. At the end of the 
treatment the cells were fixed stained and analysed as described in materials and 
methods (2.2). GI50 values were calculated as described in (2.3.1). Drug-drug 
combination schedules in this chapter were simultaneous unless otherwise stated. 
Exposure to IR was always 4Hrs following commencement of treatment with 
solvent/drugs unless it is otherwise stated in figure captions. In growth inhibition assays 
with the PARP-1 inhibitor the cells were treated with 0.08-10µM Rucaparib for 1 week 
before SRB assay was carried out. 
3.3.3 Clonogenic assays 
Clonogenic assays for assessing drug sensitivity were carried out as described in 2.4.1. 
Drug-drug combinations where simultaneous and exposure was 48 hours before re-
plating. Cells were always exposed to IR 4Hrs following commencement of Nutlin-3 
treatment in the presence or absence of 1µM NU7441 unless otherwise stated in figure 
captions. Clonogenic assays for assessing IR sensitivity alone were carried out as 
described in 2.4.3. Lethal concentrations at given % survival (e.g. LC50) were 
calculated as described in (2.4). 
3.3.4 Detection of γH2AX by immunofluorescence staining 
Cells were seeded at 3 × 105 cells/well of a 6-well plate onto glass coverslips 24Hrs 
before treatment with Media/DMSO, Nutlin-3 or 2Gy IR. 100% chilled (4°C) methanol 
was used to fix the cells at the time-points stated and in the coverslips stored at -20°C. 
All antibodies, staining protocol and microscopy techniques are explained in general 
materials and methods.   
3.3.4.1 Integrated density quantification 
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The immunofluorescent staining for γH2AX foci in MCF-7 cells was quantified by 
calculating the integrated density (IntD) using Image-Pro Plus software. Areas of >100 
DAPI stained nuclei were measured per treatment. The mean density of pixels 
corresponding to γH2AX (Secondary antibody Alexa Fluor-488) signals within the area 
of each nucleus were also quantified. IntD was then calculated through multiplying the 
area of each DAPI stained nucleus by the total mean density of γH2AX pixels detected 
within. IntD was then normalised to mean density of the background before further 
analysis.  
3.3.5 Statistical analysis 
Three or more independent experiments were carried out to assess statistical 
significance of paired data using paired t-tests on GraphPad Prism 6 Software. 
3.4 Results 
3.4.1 Analysing the cellular and biological response of MDM2 inhibitor resistant 
cell lines to MDM2 inhibitors  
SRB growth inhibition experiments were carried out on NGP and SJSA-1 cells along 
with their resistant daughter cell lines N20R1 and SN40R2 respectively for 72Hrs 
exposure to Nutlin-3 (0.1-50µM). The Nutlin-3 GI50 was ~9-fold higher in N20R1 cells 
compared to the TP53 wild-type parental NGP cells (p = 0.0003). Similarly, Nutlin-3 
GI50 was ~21-fold higher in SN40R2 cells compared to its parental SJSA-1 cell line 
(p=0.0005) (Figure 3-1A). The growth inhibition observed in TP53 mutant daughter cell 
lines at >10µM does not require functional p53 and may therefore be either an off-target 
effect or an MDM2 effect independent of p53 activation. . Clonogenic survival 
following 48Hrs of treatment with Nutlin-3 (1.25-10µM) was then investigated in both 
cell line pairs. SJSA-1 cells were very sensitive to MDM2 inhibitors with an LC50 1.69 
± 0.11 (Mean ± SEM) a marked contrast to their resistant SN40R2 daughter clone with 
an LC50 >10µM (Figure 3-1B). NGP cells were also sensitive to Nutlin-3 with an LC50 
of 3.21 ± 0.21(Mean ± SEM) in contrast to their TP53 mutant daughter clone N20R1. 
Interestingly, there was a 2.8-fold (p = 0.04) difference between LC25 of NGP and 
SJSA-1 cell lines and NGP cells did not reach LC10 within the dose range tested. This 
suggests that a sub-population of NGP cells may undergo reversible cell cycle arrest in 
response to MDM2 inhibitors which does not result in clonogenic cell death. 
3.4.2 Cellular response of the MDM2 inhibitor resistant cell lines to IR  
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Previous work carried out by our group had shown that Nutlin-3 resistant clones used 
here are also cross-resistant to other classes of MDM2 inhibitors such as spiroxindoles 
and isoindolinones (Data not shown but available upon request). It was of interest to 
assess whether the MDM2 inhibitor resistant sub-clones are also equally resistant to 
growth inhibition and loss of clonogenic survival after exposure to IR. NGP cells were 
slightly more sensitive to IR in SRB growth inhibition assays compared to N20R1 cells 
(Figure 3-2A). There was no notable difference in sensitivity to IR treatment between 
SJSA-1 and SN40R2 cells. SRB IR growth inhibition curves appeared to plateau after 
~4Gy IR in both cell line pairs. These observations suggested that SRB growth 
inhibition may not be suitable for detection of dose-dependent cellular response to IR, 
as cells may undergo reversible cell cycle arrest or senescence within the first 72Hrs 
following treatment.  
Interestingly, clonogenic survival assays for both the parental and daughter cell lines 
showed very similar sensitivity to IR (Figure 3-2B). Clonogenic assays were also 
carried out on HCT116+/+ TP53 wild-type and its otherwise isogenic HCT116-/- null cell 
line pairs and these also showed no difference in their sensitivity to IR between the two 
matched isogenic cell lines (Figure 3-2B and C). These data show that clonogenic cell 
death following IR in these cell lines is independent of TP53 genetic status.  
3.4.3 Biochemical p53 activity in MDM2 inhibitor resistant cells in response to IR 
TP53 wild-type parental cell lines and their MDM2 inhibitor resistant TP53 mutant and 
otherwise isogenic sub-clones showed the same sensitivity in response to IR. Therefore, 
the p53 functional status was assessed after exposure to IR in these cell lines. Canonical 
p53 transcriptional target, MDM2, was markedly induced 4Hrs following IR in TP53 
wild-type parental cell lines and not in their TP53 mutant daughter clones (Figure 
3-3A). The p53 induced early apoptotic marker, PUMA, was only detected in NGP cell 
line pair in a p53-dependent manner following IR. This correlated with a marked 
increase in cleaved-caspase-3 48Hrs following IR treatment in NGP cells compared to 
N20R1 cells (Figure 3-3B). Cleaved caspase-3 was not detected in either SJSA-1 or 
HCT116 cell line pairs (Figure 3-3C). Different patterns of PARP-1 cleavage reportedly 
can be markers of different types of cell death (Reviewed in (Chaitanya, Alexander et 
al. 2010)). The Anti-PARP-1 antibody (C2-10) used here showed that PARP-1 is 
cleaved in a caspase-dependent manner in NGP cells following Nutlin-3 producing an 
85kDa fragment (Figure 3-3C). This fragment was not detected in the other cell line 
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pairs. Caspase-independent forms of cell death produce different size fragments and a 
62kDa fragment, which is associated with necrotic cell death, was modestly increased in 
response to IR. Interestingly this fragment was also detected in NGP cells that undergo 
caspase-dependent apoptosis.  
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Figure 3-1 A) SRB Nutlin-3 growth inhibition curves obtained for 72Hrs exposure 
of cell line pairs to Nutlin-3 (0.1-50μM). Bar charts show Nutlin-3 GI50 values 
calculated based on the growth inhibition curves and p-values represent paired t-
tests for n=3 repeats. B) Nutlin-3 clonogenic survival curves after 48Hrs exposure 
to Nutlin-3 (1.25-10µM) for n=3 repeats. GI50: 50% growth inhibitory 
concentration. LC50: Concentration that causes 50% loss of clonogenic survival; 
LC10: Concentration at which there is 10% clonogenic survival.  
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Figure 3-2 A) SRB ionising radiation (IR) growth inhibition curves obtained 72Hrs 
following treatment show that there is little difference in snsitivity between the 
TP53 wild-type parental cell lines and their TP53 mutant otherwise isogenic clones. 
B) There was no difference clonogenic cell survival following IR between the TP53 
wild-type and mutant cell line pairs C) Colony formation in HCT116 cell line pair 
shows that sensitivity to IR is not dependent on the TP53 genetic status.
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Figure 3-3 A) Immunoblots showing the induction of early p53 transcriptional targets in TP53 wild-type and mutant cell line pairs 4Hrs 
following IR. B) Immunoblot showing the extent of caspase-3 cleavage (marker of apoptosis) 48Hrs following IR treatment of the NGP cell 
line pair. C) Cleaved caspase-3 and PARP-1 cleavage could not be detected in SJSA-1 and HCT116 cell line pairs 48Hrs following IR.
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3.4.4 Phosphorylation of histone H2AXSer139 (γH2AX) following Nutlin-3 is a late 
event  
As discussed earlier, three publications had reported γH2AX immunofluorescent 
staining (foci) in the nucleus, a marker of DNA double strand breaks, following 
treatment with Nutlin-3 (Verma, Rigatti et al. 2010, Valentine, Kumar et al. 2011, 
Rigatti, Verma et al. 2012). In all cases the dosage and/or timing had not been 
considered in relation to the mechanism of action of MDM2 inhibitors. We sought to 
investigate the kinetics of the mechanistically relevant doses of Nutlin-3 (0.2-5.0µM) in 
inducing γH2AX staining. Gamma (γ)-H2AX can be detected within the first 30mins 
following IR therefore this was used as a positive control for the immunofluorescent 
staining for this marker (Figure 3-4/See electronic copy for better contrast). Treatment 
of SJSA-1 cells with 5µM Nutlin-3 (~3 × GI50 dose) resulted in no detectable levels of 
γH2AX staining until 24Hrs following treatment, while in contrast distinct γH2AX foci 
were detected 30min following 2Gy IR (Figure 3-4). Pan-nuclear staining was also 
observed in SJSA-1 cells at 24Hrs. Treatment of NGP cells with 5µM Nutlin-3 (~1.7 × 
GI50) also resulted in no γH2AX staining until 24Hrs post-treatment when pan-nuclear 
staining was also observed in fragmented nuclei (Figure 3-4). Higher background is 
observed in NGP cell images due to a higher gain settings on the Alexa Fluor-488 
channel before capturing images in order to increase the sensitivity of the 
photomultiplier tube. Similarly an increment of Nutlin-3 doses (0.2-5.0µM) resulted in 
no increase in γH2AX signal in MCF-7 cells (Nutlin-3 GI50 = 1.8µM, Data not shown). 
Integrated density of pixels was calculated in three independent experiments and paired 
t-tests showed that while IR at 30mins resulted in a statistically significant increase in 
γH2AX staining (p = 0.03) Nutlin-3 does not at any of the mechanistically relevant 
doses used (Figure 3-5). These findings suggest that Nutlin-3 is not damaging DNA at 
doses that are sufficient for activation of p53 followed by apoptosis/growth arrest. 
Therefore, dosage and timing must be considered carefully when investigating markers 
of DNA damage in response to treatment withMDM2 inhibitors. 
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Figure 3-4 5µM Nutlin-3 does not lead to γH2AX staining in SJSA-1 and NGP cells 
until 24Hrs following treatment. Each cell line was also treated with 2Gy IR and 
stained for γH2AX in parallel as positive control for staining.
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Figure 3-5 A) Representative γH2AX immunofluorescence staining of MCF-7 cells 30min after treatment with Nutlin-3 at different doses. IR 
induced γH2AX staining was used as positive control. B) Mean + SEM integrated immunofluorescence signal for three independent 
experiments.
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3.4.5 Pharmacological inhibition of ATM by KU55933 does not sensitise cell lines 
to mechanistically relevant doses of MDM2 inhibitors. 
Work summarised in this section was carried out by supervised undergraduate student 
Mrs Laura Kettlewell. Auto-phosphorylation of ATMSer1981 can be used as a marker of 
ATM activity in cell lines following IR. SJSA-1 cell line pair were pre-treated with 
solvent/10µM KU55933 30min before exposure to 6.3Gy IR. Immunoblots showed that 
ATMSer1981 was phosphorylated 30min following exposure to IR, whereas this 
phosphorylation event was not detected when cells had been pre-treated with 10µM 
KU55933 (Figure 3-6A). This shows that ATM catalytic activity is intact in these cells 
and that it is efficiently inhibited by 10µM KU55933. Single treatment with KU55933 
resulted in similar GI50 values for both cell lines and only slight growth inhibition 
(~10%) was observed at 10µM KU55933 (Figure 2B). The SJSA-1 cell line pair was 
then treated with an increment of Nutlin-3 (0.1-50µM) in the presence or absence (+) 
10µM KU55933 for 72Hrs. Nutlin-3 GI50 for SJSA-1 cells remained unchanged in the 
presence of 10µM KU55933 (Table 3-1). Interestingly, in contrast to the parental cell 
line, the SN40R2 cells were made more sensitive to higher doses of MDM2 inhibitors 
by ATM inhibition as predicted. The Nutlin-3 GI50 was approximately halved in 
SN40R2 cells. 
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Figure 3-6 A) Immunoblot showing the inhibition of IR induced ATMSer1981 
autophosphorylation in the presence of 10µM KU55933. B) KU55933 (0.1-50µM) 
SRB growth inhibition curves after 72Hrs of treatment shows that 10µM KU55933 
causes ~10% growth inhibition in both cell lines regardless of their TP53 genetic 
status.  
 
KU55933 
(Mean + SEM) 
Nutlin-3 
(Mean + SEM) 
Nutlin-3 & 10µM KU55933 
(Mean + SEM) 
SJSA-1 43.08 + 0.86 2.21 + 0.59 2.26 + 0.52 
SN40R2 32.51 + 0.63 34.86 + 2.37 17.43 + 0.68 
Table 3-1 Nutlin-3 (0.1-50µM) SRB growth inhibition in SJSA-1 and SN40R2 cells 
in the presence of 10µM KU55933. SEM and GI50 values are representative of 
three independent experiments (Data obtained from dissertation of Mrs Laura 
Kettlewell). 
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3.4.6 DNA-PKcs is efficiently inhibited by 1µM NU7441  
Extensive previous studies had established that 1µM NU7441 leads to optimal DNA-
PKcs enzymatic inhibition and hence it is the dose used in preclinical studies for 
potentiation of DSB inducing DNA damaging agents (Zhao, Thomas et al. 2006). Auto-
phosphorylation of DNA-PKcsSer2056 (p-DNA-PKSer2056) can be detected following 
exposure to IR and is used as a surrogate marker of DNA-PKcs kinase activity and is 
required for NHEJ (Chen, Chan et al. 2005). Phospho-DNA-PKSer2056 was detected by 
immunoblotting in both TP53 wild-type and mutant cell lines 30mins following 
treatment with 6.3Gy of IR. Importantly, p-DNA-PKSer2056 was markedly diminished 
when cells were pre-treated with 1µM NU7441 30min before irradiation (Figure 3-7). 
These data show that DNA-PKcs is functional in both cell line pairs and that 1µM 
NU7441 can inhibit its catalytic activity efficiently. 
3.4.7 DNA-PKcs inhibition by NU7441 does not affect cellular response to MDM2 
inhibitors in the absence of DNA damage 
It was pertinent to first determine whether 1µM NU7441 results in growth inhibition in 
our cell lines before assessing whether Nutlin-3 sensitivity was altered in its presence. 
NU7441 SRB growth inhibition curves showed that 1µM NU7441 is approximately the 
highest non-growth inhibitory dose of this compound tested (Figure 3-8A and B). 
Interestingly, NU7441 had the same GI50 in our cell line pairs regardless of their TP53 
status. Then in order to assess the role of DNA-PKcs catalytic function in determining 
sensitivity to MDM2 inhibitors we carried out Nutlin-3 growth inhibition assays in the 
presence and absence (+) of 1µM NU7441. Nutlin-3 growth inhibitory curves were not 
affected + 1µM NU7441 (Figure 3-9). 
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Figure 3-7 Immunoblots on lysates from untreated and irradiated cell line pairs in 
the presence or absence of 1µM NU7441. Cells were pre-treated with 1µM NU7441 
for 30min prior to irradiation. DNA-PKcs is functional in both cell lines pairs and 
its autocatalytic activity is inhibited by 1µM NU7441. 
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Figure 3-8 SRB growth inhibition curves obtained after 72Hrs of exposure of cell 
line pairs to NU7441 (0.1-10μM). Sensitivity to NU7441 is independent of the TP53 
genetic status and 1µM NU7441 is the highest non-growth inhibitory dose of DNA-
PKcs inhibitor tested. 
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3.4.8 Biochemical Nutlin-3 mediated p53 response was not affected by 1µM 
NU7441 
Immunoblotting showed that canonical transcriptional targets of p53, p21WAF1 and 
MDM2, were markedly induced at 4Hrs in a Nutlin-3 dose-dependent manner in TP53 
wild-type parental cell lines (Figure 3-10). The induction of these targets were much 
lower or absent in their TP53 mutant and otherwise isogenic clones. Importantly, the 
presence of 1µM NU7441 did not affect their induction notably. Interestingly, there was 
a modest reduction in p53Ser15 phosphorylation which is a known substrate for DNA-
PKcs suggesting that this enzyme may be involved in the phosphorylation of this 
residue following Nutlin-3 treatment. 
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Figure 3-9 A) SRB growth inhibition curves after 72Hrs treatment with Nutlin-3 + 
1µM NU7441. B) Bar charts showing Nutlin-3 GI50 values in the presence and 
absence of 1µM NU7441. P-values were derived from paired t-tests between the 
columns indicated.
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Figure 3-10 Biochemical response of the TP53 wild-type (Green) and mutant (Red) cell line pairs 4Hrs following treatment with Nutlin-3 + 
1µM NU7441. Canonical transcriptional targets of p53 induced by Nutlin-3 such as, MDM2 and p21WAF1 are not affected in the presence of 
1µM NU7441.
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3.4.9 Inhibition of DNA-PKcs potentiates cellular sensitivity to Nutlin-3 in the 
presence of IR in a cell-type-dependent manner 
Cellular sensitivity to Nutlin-3 and its combination with multiples of IR GI50 were 
examined in the presence and absence of 1µM NU7441. The cells were irradiated at 
4Hrs following treatment with Nutlin-3 + 1µM NU7441 so that it coincides with the 
time of maximal Nutlin-3 induced p53 stabilisation. Nutlin-3 growth inhibitory curves 
were generated by normalising out the growth inhibitory effect of DMSO/1µM NU7441 
+ IR for each curve exposed to either 2Gy or 4Gy of IR + NU7441 in order to assess the 
additional growth inhibitory response due to Nutlin-3. The Nutlin-3 growth inhibitory 
curves for NGP cells shifted to the left in the presence of NU7441 in an IR dose-
dependent manner (Figure 3-11A). Moreover, the sigmoidal shape of the growth 
inhibition curve remained the same, indicating that Nutlin-3 dose-dependent growth 
inhibitory effect and change in GI50 values could be determined in spite of normalising 
out the growth inhibitory effect of IR + DMSO or IR + 1μM NU7441 on their 
respective plates. Exposure to IR shifts Nutlin-3 GI50 lower which is enhanced 
significantly in the presence of 1µM NU7441 (4.2-fold at 2Gy and 8.4-fold at 4Gy). 
These observations show that exposure to IR sensitises the cells to the growth inhibitory 
effect of Nutlin-3 and that this is potentiated by DNA-PK inhibition with NU7441.  
For SJSA-1 cells, not only was a shift to the left for Nutlin-3 growth inhibitory curves 
not observed with either IR or IR+NU7441 exposure, but also the Nutlin-3 mean GI50 
increased significantly (~3.5-fold) (Figure 3-12). This suggests that exposure to IR may 
only sensitise cells to Nutlin-3 in a context dependent manner and in some 
circumstances may protect cells from growth inhibition by Nutlin-3.  
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Figure 3-11 A) SRB growth inhibition curves for NGP cells 72 hours after 
treatment with Nutlin-3 + IR + 1µM NU7441. % growth inhibition is calculated 
with respect to either DMSO + IR treated wells or 1µM NU7441 + IR treated wells, 
where NU7441 is present. B) Bar charts showing Nutlin-3 GI50 values calculated 
based on the curves in A. 
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Figure 3-12 A) SRB growth inhibition curves of SJSA-1 cells 72 hours after 
treatment with Nutlin-3 + IR + 1µM NU7441. Growth inhibition is calculated as a 
% of to either DMSO + IR treated wells or 1µM NU7441 + IR treated wells, where 
NU7441 is present. B) Bar charts showing Nutlin-3 GI50 values calculated based 
on the curves in A. 
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3.4.11 NGP cells are sensitive to PARP-1 inhibition by Rucaparib 
As the difference between NGP and SJSA-1 cells may be due to inherent differences in 
DNA repair integrity. We decided to assess whether treatment with the PARP-1 
inhibitor Rucaparib (0.08-10µM), impacts cell growth in any of the cell lines tested. 
Inhibition of PARP-1 is known to be synthetically lethal with defects in homologous 
recombination repair (Helleday 2011). Interestingly, NGP cells were more sensitive to 
growth inhibition by Rucaparib. This may be due to mutations in DNA repair 
components involved in homologous recombination repair, such as the BRCA1/2 genes, 
however this was not investigated further as it was beyond the scope of this project. 
  
 130 
 
 
Figure 3-13 A) Week long SRB Rucaparib growth inhibition curves show that 
NGP cell line pair are more sensitive to PARP-1 inhibition irrespsective of their 
TP53 genetic status compared to the SJSA-1 cell line pair and MCF-7 cells. B) 
Rucaparib GI50 values in each cell line. Mean + SEM represent three independent 
repeats. Rucaparib did not reach its GI50 in SJSA-1 and SN40R2 cells there fore 
the bars represent GI50>10µM. 
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3.4.12 Non-growth inhibitory doses of Nutlin-3 potentiates the response to the 
combination of IR and NU7441  
The maximal non-growth inhibitory dose of 1µM NU7441 inhibits DNA-PKcs 
proficiently and potentiates the response to IR in clonogenic assays (Zhao, Thomas et 
al. 2006). It was of interest to assess whether the highest non-growth inhibitory dose of 
Nutlin-3 (0.2µM) sensitised cells further in response to IR + 1µM NU7441. Cells were 
treated with 0.2µM Nutlin-3 + 1µM NU7441 4Hrs before treatment with either 2Gy or 
4Gy of IR as above. Clonogenic assays were then set up after 48Hrs of exposure, which 
showed that combinations of 0.2µM Nutlin-3 and 1µM NU7441 significantly lowers 
cloning efficiency for NGP but not N20R1 cells (Figure 3-14A). When 0.2µM Nutlin-3 
was present cloning efficiency was 3.1-fold lower (p = 0.03) at 2Gy and 4-fold lower (p 
= 0.02) at 4Gy following treatment with IR + NU7441 (Figure 3-14B). This suggests 
that when DSB repair is compromised Nutlin-3 can further sensitise NGP cell lines to a 
DSB inducing DNA damaging agent. 
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Figure 3-14 A) IR clonogenic survival curves for NGP and N20R1 cells  pre-treated for four hours with 0.2µM Nutlin-3, 1µM NU7441 or their 
combination. Survival is presented as a % of untreated DMSO alone plating efficiency. B) Bar charts for NGP cells showing raw cloning 
efficiencies for each treatment condition. One-tailed paired t-tests were carried out to assess whether the differences between the treatments 
are statistically significant.
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3.5 Discussion 
3.5.1 MDM2 inhibitor resistant cell lines are not cross-resistant to IR 
Our findings are consistent with wild-type TP53 genetic status being the most important 
determinant of response to MDM2 inhibitors. Nutlin-3 sensitivity was markedly 
different in the TP53 mutant and otherwise isogenic MDM2 inhibitor resistant clones in 
both growth inhibition and clonogenic survival assays. Based on growth inhibition 
assays there was no notable difference between NGP and SJSA-1 cells in their 
sensitivity to Nutlin-3. However, SJSA-1 cells were much more sensitive to clonogenic 
cell killing by Nutlin-3 treatment compared to NGP cells. Given that clonogenic 
survival assays are more suitable for distinguishing cell death from reversible cell cycle 
arrest, this suggests that a sub-population of NGP cells undergo reversible cell cycle 
arrest in response to Nutlin-3. Interestingly, there was no difference between parental 
cell lines and their MDM2 inhibitor resistant paired cell lines in their sensitivity to IR in 
both growth inhibition and clonogenic assays. In the three cell line pairs tested wild-
type TP53 genetic status was not necessary for loss of clonogenic survival following IR 
induced DNA damage. Induction of caspase-3 cleavage by IR  observed in NGP cells 
was shown to be p53-dependent as cleaved caspase-3 induction following IR was 
markedly lower in N20R1 cells in which p53 was shown to be mutant and non-
functional. In SJSA-1 and HCT116 cell line pairs however, the cell death mechanism 
did not appear to be caspase-dependent, as not only cleaved caspase-3 could not be 
detected 48Hrs following IR but also there was no evidence of a PARP-1 85kDa 
apoptotic fragment which is cleaved from PARP-1 by other executioner caspases (e.g. 
caspase-7) during apoptosis (Reviewed in (Chaitanya, Alexander et al. 2010). However 
a Cathepsin dependent PARP-1 fragment associated with necrosis was detected, but it 
was not a strong signal and therefore its biological relevance would require further 
investigation. These data overall show that MDM2 inhibitor resistant TP53 mutant 
clones may still be sensitive to DNA damage. Furthermore our observations emphasise 
the important of assessing multiple cellular and biochemical endpoints for investigation 
of the efficacy of treatment regimens and their mechanisms in a preclinical setting.  
3.5.2 Doses of Nutlin-3 associated with on-target mechanism of action 
TP53 mutant and otherwise isogenic MDM2 inhibitor resistant cell lines allow the pre-
clinical determination of doses of MDM2 inhibitors associated with their on target 
activity. Canonical p53 transcriptional targets were not detectably induced at the protein 
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level 4Hrs following either IR or MDM2 inhibitor treatment in the MDM2 inhibitor 
resistant clonal cell lines, in contrast to their TP53 wild-type parental cell lines. This 
shows that the TP53 mutations detected in the resistant clones (SN40R2: Homozygous 
Glu285Lys, N20R1: Heterozygous Pro152Thr and Pro98His) have led to the loss of p53 
transcriptional function following DNA damage. Although Nutlin-3 (0.2-5µM) did not 
detectably induce MDM2 in the resistant cell lines however there was a modest 
induction of p21WAF1 in SN40R2 cells which may be due to p53-independent 
mechanisms (Macleod, Sherry et al. 1995). These findings call into question reports of 
γH2AX immunofluorescence staining following treatment with Nutlin-3 at doses 
>10µM and leads one to suspect that such observations are also due to off-target activity 
of MDM2 inhibitors. This would be consistent with the absence of DNA reactive 
groups in the chemical structure of Nutlin-3. Here we have shown that the on-target 
mechanism of growth inhibition and/or cell death following MDM2 inhibition relies 
solely on the biochemical function of wild-type p53 protein rather than DNA damage. 
We have also showed that γH2AX staining was not detected following mechanistically 
relevant doses of Nutlin-3 within which effective growth inhibition is observed in TP53 
wild-type cell lines. In both parental TP53 wild-type cell lines γH2AX staining was 
undetected until 24Hrs following treatment. Staining at 24 hours was pan-nuclear which 
coincides with the timing of apoptosis during which γH2AX immunofluorescent 
staining has been reported. Gamma-H2AX immunofluorescent staining was not 
assessed in TP53 mutant cell lines. Furthermore reported γH2AX staining in response to 
>10µM doses of Nutlin-3 (Verma, Rigatti et al. 2010, Valentine, Kumar et al. 2011, 
Rigatti, Verma et al. 2012) was not investigated. Data presented here overall emphasises 
the importance of appropriate dosing and scheduling when investigating and 
interpreting combination treatments with targeted agents, particularly MDM2 inhibitors. 
3.5.3 Inhibition of DNA repair enzymes involved in double strand break repair in 
the absence of detectable DNA damage does not potentiate the response to 
MDM2 inhibitors 
Pharmacological inhibition of ATM or DNA-PKcs catalytic activity did not potentiate 
the response to mechanistically relevant doses of single agent Nutlin-3. This is a 
testament to the non-genotoxic mechanism of action of MDM2 inhibitors in inhibiting 
the growth and survival of TP53 wild-type cell lines. Inhibition of these enzymes is 
established to result in potentiation of DSB inducing DNA damaging agents (Hickson, 
Zhao et al. 2004, Leahy, Golding et al. 2004, Zhao, Thomas et al. 2006). Interestingly, 
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the inhibition of ATM or DNA-PKcs combined with Nutlin-3 >10µM appeared to result 
in a slight increase in growth inhibition in TP53 mutant MDM2 inhibitor resistant cell 
lines, although this was not quantified. The data presented in this chapter overall 
strongly suggests that the synthetic lethality with Nutlin-3 observed by Sullivan et al., 
(2012 & 2014) in response to ATM inhibition is likely due to off-target secondary DNA 
damage induced by Nutlin-3 rather than the non-genotoxic mechanisms proposed by the 
authors. 
3.5.4 Inhibition of DNA-PKcs did not alter p53 transcriptional function following 
Nutlin-3 
When cells were treated simultaneously with Nutlin-3 and NU7441 there was no 
difference in the induction of p53 transcriptional targets at 4Hrs. This was consistent 
with DNA-PKcs inhibition not affecting cellular sensitivity to Nutlin-3.  However, there 
was a notable reduction in p53Ser15 phosphorylation in NGP cells when DNA-PK was 
inhibited showing that DNA-PKcs may be involved in this phosphorylation event. 
Phosphorylation of p53 at this residue is widely deemed a marker of DNA damage and 
it was reportedly not detected following Nutlin-1, which was used by the authors to 
claim a non-genotoxic mechanism of action for these compounds (Vassilev, Vu et al. 
2004). Phosphorylation of p53Ser15 following MDM2 inhibitors has been reported since, 
suggesting the possibility that there may be a secondary genotoxic element to the 
mechanism of action of MDM2 inhibitors. However, given the evidence presented 
above, this observation is more likely to be explained by the basal activity of kinases 
and phosphatases targeting this residue following the non-genotoxic unmasking of the 
p53 N-terminus from MDM2 by the MDM2 inhibitor. Overwhelming evidence in the 
literature suggests that this phosphorylation activates p53 (Meek and Anderson 2009). 
Therefore it would be of interest to assess whether non-genotoxic manipulation of the 
p53 phosphorylation status following MDM2 inhibitor treatment affects p53 
biochemical function and consequently cellular sensitivity to MDM2 inhibitors.  
3.5.5 Sensitivity to DNA damage in the presence of Nutlin-3 is context-dependent. 
The Nutlin-3 SRB growth inhibition experiments showed that NGP cells were made 
more sensitive to the effect of Nutlin-3 in the presence of IR in a p53-dependent manner 
which was then enhanced in the presence of NU7441. IR had a small p53-dependent 
protective effect on SJSA-1 cells from growth inhibition by Nutlin-3 + 1µM NU7441. 
These findings suggest that the effect of a DNA damage signal on the sensitivity to 
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Nutlin-3 is context-dependent. NGP cells had a larger sub-population of cells that 
appeared to undergo reversible cell cycle arrest following Nutlin-3 treatment in 
clonogenic assays compared to SJSA-1 cells. The additional growth inhibition observed 
with the NGP cells using SRB assays were then mirrored in NGP cells by clonogenic 
assays. Interestingly, the presence of a non-growth inhibitory dose of Nutlin-3 (0.2µM) 
significantly reduced clonogenic survival following IR only in the presence of the 
DNA-PKcs inhibitor NU7441. This was not observed with TP53 mutant N20R1 cells. 
This shows that MDM2 inhibition increases the sensitivity of NGP cells to IR only 
when DNA-PKcs is functional.  
3.5.6 Summary 
The data presented in this chapter is consistent with wild-type genetic status of TP53 
being the strongest determinant of response to MDM2 inhibitors. There is a difference 
sensitivity to MDM2 inhibitors when comparing matched TP53 wild-type and mutant 
cell lines, however substantial differences in response can also be seen between wild-
type TP53 cell lines, such as when comparing the clonogenic response of SJSA-1 and 
NGP cells. This indicates that there are other determinants of response to MDM2 
inhibitors that although secondary to wild-type TP53 status are nevertheless likely to be 
important in a therapeutic context.  
Given that mutations in the MDM2 inhibitor resistant clones result in loss of 
transcriptional activity of p53, this functional aspect of p53, must also be important in 
determining MDM2 inhibitor sensitivity in TP53 wild-type cell lines. Therefore, 
modulating p53 transcriptional function by influencing its post-translational 
modification through combination treatments should be considered for harnessing the 
full potential of MDM2 inhibitors. Genotoxic agents can be used to activate kinases 
involved in DNA repair such as ATM and DNA-PKcs to increase activating post-
translational signalling to p53, however a non-genotoxic targeted approach would be 
ideal. Indeed p53Ser15 phosphorylation which is important for p53 transcriptional 
transactivation is detectable following non-genotoxic activation of p53 by relevant 
doses of Nutlin-3, albeit to a lesser extent compared to that induced by IR. Therefore, 
non-genotoxic inhibition of phosphatases that lead to an increase in the active 
phosphorylation status of p53 may result in increased sensitivity to MDM2 inhibitors. 
This strategy will be explored in Chapters 4-6.  
 137 
 
Chapter 4 WIP1/PPM1D transient siRNA mediated knockdown 
enhances cellular sensitivity to Nutlin-3
 138 
 
4.1 Introduction 
The human kinome and its role in the regulation of p53 stability and function has been 
extensively investigated in contrast to the phosphatome (Meek and Anderson 2009, 
Donehower 2014). Kinases directly involved in phosphorylation of p53 in response to 
DNA damage promote p53 stability and activity (Appella and Anderson 2001, Meek 
and Anderson 2009). Therefore, inhibiting phosphatases that dephosphorylate the same 
residues might enhance p53 activity following treatment with MDM2 inhibitors. Given 
the importance of PPM1D oncogene product WIP1 phosphatase in homeostatic 
regulation of the p53 network and its cross-talk with stress response pathways (Lowe, 
Cha et al. 2012), the role of this phosphatase in determining sensitivity to MDM2 
inhibitors was investigated. 
4.1.1 The WIP1/PPM1D phosphatase as a modulator of p53 crosstalk with DNA 
damage and stress response pathways  
Wild-type p53-inducible phosphatase-1 or protein phosphatase Mg2+/Mn2+ dependent 
1δ (WIP1/PPM1D) is a member of the PP2C (PPM) family of phosphatases and it has 
been reported to be involved in homeostatic regulation of p53 and its crosstalk with 
stress response (Fuku, Semba et al. 2007, Lu, Ma et al. 2007, Castellino, De Bortoli et 
al. 2008, Lowe, Cha et al. 2012). Italicised ‘PPM1D’ will be used to denote the gene 
and ‘WIP1’ will be used to denote the protein product hereafter. PPM1D is a bona fide 
oncogene which is gained/amplified or overexpressed mostly in TP53 wild-type 
malignancies (Bulavin, Demidov et al. 2002, Ruark, Snape et al. 2013, Zhang, Chen et 
al. 2014). PPM1D-amplification occurs in approximately 11% of primary breast 
tumours, among which TP53 mutations are rare events (Bulavin, Demidov et al. 2002, 
Rauta, Alarmo et al. 2006). Interestingly, PPM1D gain-of-function mutations and TP53 
inactivating mutations are mutually exclusive in brainstem gliomas, which is consistent 
with the role of WIP1 as a negative regulator of p53 tumour suppressor activity (Zhang, 
Chen et al. 2014). Multiple studies have shown that WIP1 knockdown result in growth 
inhibition and loss of survival in cell lines that rely on this phosphatase for negative 
regulation of their wild-type p53 activity (Tan, Lambros et al. 2009, Buss, Read et al. 
2012, Choi, Shi et al. 2012, Zhang, Chen et al. 2014, Zhang, Sun et al. 2014). 
WIP1 is induced in a p53-dependent manner, forming a negative auto-modulatory loop 
by dephosphorylating p53 and other DNA damage and stress signalling components 
involved in activating the p53 network (Figure 1-10) (Fiscella, Zhang et al. 1997, Lu, 
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Ma et al. 2007, Lu, Nguyen et al. 2008, Donehower 2014). Direct and indirect WIP1 
phosphatase activity results in hypophosphorylation of p53, which reduces its stability 
and transcriptional activity, allowing the reversal of cell cycle arrest (Donehower 2014). 
Phosphorylation of p53Ser15 is considered a key event in the sequence of post-
translational modifications of p53 following DNA damage that results in enhanced p53 
stability and activity. Phosphorylated p53Ser15 detected following Nutlin-3 is weaker and 
takes longer to appear compared to that observed after exposure to DNA damaging 
agents (Loughery, Cox et al. 2014). It has been suggested that this low level 
phosphorylation following MDM2 inhibitor treatment is due to the basal activity of 
ATM and ATR, which target that residue on p53 decoupling from MDM2 (Loughery, 
Cox et al. 2014). Since phosphorylated p53Ser15 is also a WIP1 phosphatase substrate, it 
is of interest to investigate whether knockdown of WIP1 expression enhances the 
response to MDM2 inhibitors. 
4.1.2 WIP1 as a determinant of response to MDM2 inhibitors 
In silico modelling of the p53 network and its negative autoregulatory loops has 
highlighted WIP1 as a critical component determining cell fate following p53 activation 
and predicted that a combination of WIP1 inhibition and Nutlin-3 would be synergistic 
by promoting apoptosis (Choi, Shi et al. 2012). In another study combination of WIP1 
inhibition by CCT007093 and MDM2 by Nutlin-3a was shown to be more effective at 
inhibiting growth in a stably transfected PPM1D-overexpressing TP53 wild-type 
medulloblastoma clone of D556 cells (D556-WIP1) and not  a TP53 mutant PPM1D-
overexpressing clone of Daoy cells (Buss, Read et al. 2012). However, the Daoy and 
D556-WIP1cell lines are not an isogenic or closely related TP53 mutant pair in which 
Nutlin-3 mediated p53-dependent cellular endpoints can be compared with confidence. 
The response of D556-WIP1 to Nutlin-3a was also compared to D556 with an empty 
vector (D556-pcDNA3) or the vector overexpressing a phosphatase dead variant of 
WIP1 protein (D556-D314A). Although these clones were deemed to be otherwise 
isogenic to D556-WIP1, the authors did not note that they were insensitive to single 
agent treatment with Nutlin-3a (8µM) (See (Buss, Read et al. 2012) Figure 5D). This 
suggests that these clones are likely TP53 mutant and therefore not appropriate for 
comparing with the on-target activity of Nutlin-3a in the parental cell line (Buss, Read 
et al. 2012). Therefore, more thorough investigation into the role of WIP1 as a 
determinant of response to MDM2 inhibitors is needed. In this chapter TP53 wild-type 
and mutant isogenic pairs that differ in their PPM1D status, including the gain-of-
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function mutation of PPM1D (Kleiblova, Shaltiel et al. 2013) have been used to further 
investigate this question.  
4.1.3 Summary 
Consistent with prior findings, in the previous chapter it was shown that pp53Ser15 is 
detected following treatment with Nutlin-3. Furthermore, this phosphorylation was 
observed over a non-genotoxic dose range of Nutlin-3 which could activate p53 
efficiently and lead to growth inhibition and reduced clonogenic survival. The 
phosphorylation of p53Ser15 reportedly increases p53 transcriptional activity and it is 
considered a “nucleation event” for other activating p53 post-translational modifications 
(Meek and Anderson 2009, Loughery, Cox et al. 2014). Therefore, the modulation of 
this particular post-translational modification event is of particular interest. WIP1 has 
been shown to dephosphorylate p53Ser15 directly and it is also likely to be involved in 
the homeostatic regulation of the p53 network following MDM2 inhibition and re-entry 
from reversible cell cycle arrest (Lu, Nannenga et al. 2005, Donehower 2014). The role 
of WIP1 in homeostatic regulation of Nutlin-3 induced p53 signalling and cell fate 
determination has not been adequately investigated in TP53 wild-type and mutant 
isogenic cell lines pairs with different PPM1D genetic status. In this chapter 
experiments with a panel of TP53 wild-type and mutant cell line pairs with different 
PPM1D genetic status are presented, which critically assess the role of WIP1 in 
determining the cellular and functional response to MDM2 inhibitors.  
4.2 Hypothesis 
 WIP1/PPM1D siRNA mediated knockdown sensitises cells to Nutlin-3 in a p53-
dependent manner.  
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4.3 Specific materials and methods  
4.3.1 Cell lines 
TP53 wild-type and mutant/null otherwise isogenic cell line pairs, differing in their 
PPM1D genetic status, were used in this study to investigate p53-dependent and 
independent processes in differing PPM1D genetic and functional backgrounds (Table 
4-1). The HCT116 and U2OS cell line pairs harboured PPM1D truncating activating 
mutations (Kleiblova, Shaltiel et al. 2013). The U2OS-DN cells constitutively 
overexpress a transfected dominant-negative mutant of p53 (R175H) and have no p53 
functional activity.  
TP53 Wild-type 
parental cell 
lines 
TP53 
mutant/Null 
pair  
Tumour of origin 
PPM1D genetic 
alteration 
SJSA-1 SN40R2 Osteosarcoma 
Wild-type (COSMIC 
(Forbes, Beare et al. 
2015)) 
HCT116+/+ HCT116-/- 
Colorectal 
carcinoma 
c.1344delT/Wt  
(L450X) Gain-of-
function (Kleiblova, 
Shaltiel et al. 2013) 
U2OS U2OS-DN Osteosarcoma 
c.1372C>T/Wt  
(R458X) Gain-of-
function (Kleiblova, 
Shaltiel et al. 2013) 
NGP N20R1 Neuroblastoma 
Copy number gain 
(Richter, Dayaram et 
al. 2015) 
MCF-7  _ 
Breast 
adenocarcinoma 
Amplified 
(Castellino, De 
Bortoli et al. 2008) 
Table 4-1. TP53 Wild-type (Wt) and mutant (Mt)/Null cell line pairs with different 
PPM1D status.  
4.3.2 Monitoring cell morphology, growth and proliferation using IncuCyte 
Zoom® 
IncuCyte Zoom® consists of a microscope gantry which can be placed in a cell 
incubator. With the use of robotics phase contrast images of cells are captured from 
fixed coordinates on the flask, without perturbing the culture, and the data are recorded 
on a networked external controller hard drive for further analysis. Images were 
 142 
 
presented as time-lapse videos for qualitative assessment or in the graphical format by 
analysing cell confluence in all individual images captured over time, using IncuCyte 
Zoom® software package. Data presented in this chapter were acquired by 10 × phase 
contrast microscope time lapse images acquired automatically every 6 hours using 
IncuCyte Zoom® throughout the experiment. Image processing parameters were 
optimised for each cell line before use to account for shape and size (see IncuCyte™ 
ZOOM User Manual) to enable the calculation of percentage confluence over time in 
response to treatment. Each data-point corresponds to an average % confluence 
calculated from 9 images/well of a 24-well plate. 
4.3.2.1 Treatment schedule 
Cell line pairs were seeded in 24-well plates, at the densities stated in Table 4-2, and 
placed on the microscope gantry of IncuCyte Zoom® 16-24 hours before the plates 
were removed again and a scaled down version of the siRNA transfection protocol as 
described in section 2.7.2 was carried out in the appropriate wells. Plates were then 
immediately placed back in IncuCyte 24 hours before addition of either DMSO (1%) or 
5µM Nutlin-3. Nutlin-3/DMSO were added directly to the media in each well so that the 
cells are not perturbed. The plates were placed back in IncuCyte immediately for 
another 120 hours image capture.  High definition images allowed closer observation of 
changes such as those associated with differentiation, cell division, nuclear 
fragmentation and large cellular compartments.   
Cell line pair Densities (Cells/well) 
NGP 6×104 
HCT116 1×104 
SJSA-1 4×104 
Table 4-2 Seeding densities used in 24 well plates for the incucyte experiment. 
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4.3.3 WIP1/PPM1D siRNA mediated knockdown  
For lysate collection and flow cytometry, cells were seeded at 6 × 105 cells/well of a 6-
well plate (Corning) and allowed to adhere for 24hrs (60-70% confluence) before they 
underwent transfection with WIP1/PPM1D siRNA constructs and Lipofectamine 
2000TM transfection reagent (Invitrogen) complex as described in materials and methods 
(2.7). Transfection conditions resulted in marked reduction in confluence and adherence 
of the cells if the media was aspirated to add fresh media containing drug. During 
assessment of cell cycle distribution by flow cytometry, or for lysate preparation, 
solvent/drug was added directly to the media and any floating cells were pooled with 
attached cells before the next step. 
4.3.3.1 The effect of transient knockdown and drug combination treatment on cell 
proliferation and morphology assessed by IncuCyte Zoom® 
For the IncuCyte experiments, siRNA mediated knockdown of WIP1/PPM1D was 
performed in 24-well plates (Corning) for monitoring of cell confluence using different 
starting cell plating densities and WIP1 expression was assessed in parallel to ensure a 
successful WIP1 knockdown. HCT116, SJSA-1 and NGP cell lines and their respective 
TP53 mutant/null pairs were seeded at, 104, 4 × 104 and 6 × 104 cells/well, and allowed 
to adhere for 16-24Hrs and then underwent transfection with WIP1.2 siRNA as 
described earlier (2.7). 24 hours following the transfection, DMSO or stated doses of 
Nutlin-3 were added directly to the media in order not to disturb the cells and then the 
cells were monitored by IncuCyte® for the remainder of the experiment. 
4.3.4 WIP1 targeting siRNA and antibody optimisation  
PPM1D-amplified MCF-7 cells were used to optimise WIP1 antibodies and siRNA 
constructs. Initially two WIP1 antibodies, namely the rabbit polyclonal antibody (H-
300) and the mouse monoclonal WIP1 antibody (F-10) purchased from Santa Cruz 
Biotechnology, were evaluated for western blotting. Both antibodies resulted in up to 4 
distinct bands in MCF-7 cell lysates derived from untreated or irradiated (10Gy, 4Hrs 
time-point) cells. To determine the band corresponding to WIP1 four siRNA constructs 
(WIP1.1-4) were designed to target full-length WIP1 transcript and the alternatively 
spliced but functional shorter isoform (1.15.1) (Figure 4-1). WIP1.1-3 were designed by 
Eurogentec and the sequence for WIP1.4 was obtained from the literature (Fujimoto, 
Onishi et al. 2005). Knockdown of basal WIP1 protein expression was small regardless 
of siRNA dose or time of exposure (Figure 4-2) therefore we decided to assess the 
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ability of our siRNA constructs to suppress WIP1 induction and hence WIP1 
phosphatase activity in response to 10Gy ionising radiation (IR) (Figure 4-3). This 
resulted in 3 out of 4 constructs (WIP1.1, WIP1.2 and WIP1.4) leading to a suppression 
of band intensity detected by the WIP1 antibody at the anticipated molecular weight and 
reduced phosphatase activity as measured by increased pp53Ser15 band intensity 4Hrs 
post 10Gy IR. The bands that were commonly detected by both antibodies and those 
that were consistently diminished in intensity in response to the siRNA were deemed to 
correspond to full length WIP1/PPM1D605 (≈85-90KD) and its shorter isoform 
(WIP1/PPM1D430 ≈65-70KDa) (1.15.1) or other unknown isoforms/potential WIP1 
breakdown products (<60KDa). Bands that were detected by only one antibody and/or 
those that did not change in response to any of the siRNA constructs were considered to 
be non-specific. For example the band detected by WIP1 H-300 at ≈50KDa was 
assumed to be nonspecific. A 25nM concentration of WIP1 siRNA construct 1.2 
(WIP1.2) was chosen for all subsequent knockdown experiments as it lead to the 
longest duration of WIP1 knockdown and reduction in phosphatase activity as measured 
by increased p53Ser15 phosphorylation (Figure 4-3). Also F-10 was chosen as the optimal 
antibody for detection of WIP1. 
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Figure 4-1 Positions and sequences of WIP1 siRNA constructs 1-4 are highlighted 
in yellow over the WIP1 reference sequence obtained from the UCSC genome 
browser. The sequence in dark blue encodes full length WIP1, pale blue letters 
indicate the exon-exon boundaries and the sequence in red outlines the retained 
alternatively spliced exon which leads to a premature stop codon in spite of a 
longer transcript.  
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Figure 4-2 An increment of WIP1.4 siRNA concentration (25nM-100nM), the 
sequence for which had previously been defined and used in the literature, was 
examined to optimise WIP1 protein knockdown conditions at different time-points 
post transfection. WIP1.4 did not result in a notable dose- or time-dependent 
knockdown of basal WIP1 protein levels in MCF-7 cells.  
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Figure 4-3 A) Optimisation of WIP1 antibody and siRNA mediated knockdown in 
MCF-7 cells. Following 24 and 48Hrs of siRNA mediated knockdown conditions, 
MCF-7 cells were treated with 10Gy IR and lysates were collected 4Hrs later for 
western blot analysis. Two antibodies were used to probe for WIP1 (F-10 and H-
300). B) The optical densities (OD) of bands detected by F-10 were measured to 
quantify the extent of WIP1 knockdown and select the most effective siRNA 
construct. C) WIP1 knockdown was expressed as a % of WIP1 OD in the control 
(Cont. siRNA) treated samples and was approximately 60% with the WIP1.2 
construct. SE: Short Film Exposure; LE: Long film exposure; tfxn: transfection 
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4.3.5 Clonogenic survival in response to drug-siRNA combination treatments 
Clonogenic cell survival was investigated in NGP and its daughter cell line N20R1 
cells. The NGP cell line pair were seeded in 6-well plates at 6 × 105 cells/well and 
treated with Control or WIP1.2 siRNA constructs for 24 hours, as described earlier, then 
incubated with multiples of Nutlin-3 LC50 doses for the NGP parental cell line 
(previously calculated to be 1.3μM) for a further 48 hours (See table 6.5)   After Nutlin-
3 treatment cells were harvested, counted with a coulter counter and diluted to two 
densities (1 x 104 cells/ml &1 x 103 cells/ml) in order to seed the appropriate cell 
numbers in 100mm tissue culture dishes (Corning) containing 7.5ml growth media. The 
cell seeding number and Nutlin-3 doses for each well are listed in (Table 4-3). The cells 
were then allowed to form colonies over 2 weeks, after which they were fixed with 
Carnoy’s fixative and stained with 0.4% crystal violate. Visible colonies (>50 cells) 
were counted and expressed as a percentage of colony survival relative to DMSO 
control. 
 DMSO 0.026 µM 0.13µM 0.65µM 1.3µM  
NT 500 1000 1000 1000 1000 
Control 
siRNA 
5000 5000 5000 5000 5000/10000 
WIP1.2 
siRNA 
5000 5000 5000 5000 5000/10000 
Table 4-3 Doses of Nutlin-3 and seeding densities for NGP and N20R1 cell lines in 
100mm dishes. NT: Non transfected 
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4.3.6 FACS analysis of cells treated with MDM2 inhibitor and WIP1 siRNA 
combinations  
FACS analysis was carried out as described in general materials and methods (2.6) to 
analyse cell cycle distribution changes and apoptosis associated with drug induced 
growth arrest and cell death over 72 hours following drug exposure. Cells were seeded 
24 hours before transfection and allowed to adhere. DMSO/Nutlin-3 were added to the 
wells 24 hours following initiation of siRNA transfection in the NGP cell line pair and 
cells were harvested after 48 hours of drug treatment. Drug treatment in siRNA 
knockdown experiments was carried out without aspirating or disturbing the culture in 
order not to lose the floating cell population. Western blots were carried out at least 
once in parallel with the FACS experiment to ensure efficient knockdown of WIP1 and 
silencing of its phosphatase activity had been achieved. Suspension and adherent cells 
in all wells were pooled before being prepared for FACS analysis.  
4.3.7 Statistical analysis 
The significance of differences between mean values was calculated by  comparing the 
mean of 3 or more paired biological repeats using a paired t-test and p-values <0.05 
were considered statistically significant.  
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4.4 Results 
4.4.1 WIP1 basal protein expression and induction by Nutlin-3 among selected cell 
line pairs with varying PPM1D genetic status 
TP53 wild-type and mutant cell line pairs with different PPM1D genetic status (outlined 
in Table 4-1) were assessed for basal WIP1 expression and induction following 
treatment with Nutlin-3. Lysates were obtained from exponentially growing cell lines 
(60-70% confluent cultures) and analysed by western blotting to assess basal WIP1 and 
p53 expression. Basal WIP1 expression was independent of TP53 genetic status as there 
was no difference between the TP53 wild-type cell lines and their respective mutant/null 
daughter lines (Figure 4-4A & B). Both isoforms of WIP1 showed the greatest basal 
protein expression as previously reported for the PPM1D-amplified MCF-7 cells (Li, 
Yang et al. 2002). The NGP cell line pair expressed the second highest level of full-
length WIP1 which was consistent with their PPM1D copy number gain (Richter, 
Dayaram et al. 2015). Also consistent with previous reports HCT116 and U2OS cell 
line pairs harbouring PPM1D/WIP1 L450X and PPM1D/WIP1 R458X variants showed 
intense bands at a lower molecular weight assumed to be associated with lower 
molecular weight WIP1isoforms (Kleiblova, Shaltiel et al. 2013). The SJSA-1 pair 
showed the lowest expression of full-length WIP1, as expected for the only PPM1D 
wild-type cell line pair (cancer.sanger.ac.uk and (Forbes, Beare et al. 2015)).  
The protein products of well-established transcriptional targets of p53 namely WIP1, 
MDM2, p21WAF1 and BAX were analysed by western blotting 4Hrs following treatment 
with DMSO or 5.0µM Nutlin-3 (Figure 4-4). PPM1D-amplified MCF-7 cells showed 
the greatest Nutlin-3 mediated dose-dependent induction of WIP1 compared to NGP 
and SJSA-1 cells (Figure 4-4B to Figure 4-6). WIP1 induction appeared to be very weak 
in response to Nutlin-3 in all cell lines other than MCF-7. Slight WIP1 induction was 
also observed in TP53 mutant/null daughter cell lines, which is consistent with PPM1D 
also showing some degree of transcriptional regulation through p53-independent 
mechanisms (Lowe, Cha et al. 2012) (Figure 4-4B). Nutlin-3 mediated MDM2 and 
p21WAF1 induction were greater in TP53 wild-type cell lines out of each cell line pair, 
apart from NGP and N20R1 cell lines where MDM2 and p21WAF1 induction were not 
detected at this time-point and dose of Nutlin-3 in neither cell line (Figure 4-4B). BAX 
induction was also not detected at this time-point or Nutlin-3 dose in any of the cell 
lines other than MCF-7 cells (Figure 4-4B).  
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Figure 4-4 A) Basal WIP1 expression of TP53 wild-type (green) and mutnat/null 
(Red) cell line pairs. B) Induction of p53 targets, such as WIP1, MDM2, p21WAF1 
and BAX, after 4Hrs 5µM Nutlin-3 treatment (Nut-3). Different duration of 
exposure of the X-ray film to the nitrocellulose membrane corresponding to each 
protein are denoted either as SE: Short exposure or LE: Long exposure. Arrows 
point to the band at the expected molecular weight for that given protein. FL-
WIP1: Full length WIP1; S-WIP1 shorter WIP1 isoform ; T-WIP1: Truncated 
WIP1 isoform.  B was carried out by supervised M.Res student Mrs Liang Zhao.
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Figure 4-5 Dose-dependent response to Nutlin-3 treatment in TP53 wild-type cell lines with different PPM1D status. The anti-WIP1 antibody 
H-300 was used for these blots. SE: Short exposure; LE: Long exposure
 153 
 
4.4.2 Biochemical response to MDM2 inhibition combined with WIP1 transient 
siRNA knockdown  
To assess whether siRNA mediated transient knockdown of PPM1D sensitises TP53 
wild-type cell lines to MDM2 inhibitors, 4 siRNA constructs (WIP1.1-4) were designed 
and optimised to target WIP1 and its shorter isoform as described in 4.3.4. WIP1.2 
siRNA construct was chosen for all subsequent experiments as it resulted in the most 
robust WIP1 knockdown (~50-60%) and increase in pp53Ser15 compared to Cont. siRNA 
(Figure 4-3).  
Nutlin-3 mediated WIP1 induction was decreased in the presence of WIP1.2 siRNA 
compared to non-targeting control (Cont.) siRNA (Figure 4-6). Lanes 1 and 2 are the 
same on both immunoblots presented in Figure 4-6 which allowed for densitometry and 
graphic comparison of relative protein expression in other lanes on the same blot (See 
Figure 4-7). Knockdown of WIP1 resulted in strong enhancement and persistence of 
pp53Ser15 phosphorylation (Figure 4-6 & Figure 4-7). Increased p53Ser15 was concurrent 
with slightly higher intensity p21WAF1 and MDM2 bands but not BAX and PUMA 
(Figure 4-6).  
Phosphorylation of p53Ser46 (pp53Ser46) has previously been reported to be a pro-
apoptotic p53 modification in response to DNA damage (Mayo, Seo et al. 2005) and 
phosphorylation of p53Ser20 (pp53Ser20) is known to be necessary for p53 and MDM2 
dissociation in response to DNA damage (Chehab, Malikzay et al. 1999). Therefore we 
attempted to assess whether these two post-translational modifications are affected by 
Nutlin-3 or WIP1 transient knockdown in the presence of Nutlin-3. Although these 
antibodies were not optimal, comparing lanes 9 and 10 to lanes 3-8 on the blot on the 
left, it appears that transfection conditions result in increased pp53Ser46 and pp53S20 and 
that Nutlin-3 and WIP1 do not appear to play a significant role in these phosphorylation 
events (Figure 4-6). Surprisingly, MDMX was stabilised in response to the combination 
of Nutlin-3 and control siRNA, given that MDMX is not a direct p53 transcriptional 
target. MDMX stabilisation in response to Nutlin-3 was not observed in the presence of 
WIP1 siRNA. This is in line with the previously reported role of WIP1 phosphatase in 
positively influencing MDMX stability by dephosphorylating Ser403 on MDMX 
(Zhang, Lin et al. 2009). Nutlin-3 mediated p53-dependent induction of MDM2 was 
affected modestly in spite of the reported role of WIP1 in regulating MDM2 stability 
(Lu, Ma et al. 2007). However, in this context the reduced stability of MDM2, is most 
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likely masked by its p53-dependent induction by Nutlin-3. 
 
Figure 4-6 The effect of WIP1 siRNA knockdown on p53 post-translational 
modification and its downstream targets over 8 hours in NGP cells. Cells were pre-
treated for 24 hours with control siRNA or WIP1 siRNA and then treated with 
5μM Nutlin-3.  Lysates were collected in parallel at the stated time-points after 
drug treatment and immunoblots carried out simultaneously. Two identical 
controls were loaded onto the first two tracks on each blot as reference points for 
optical density (OD) comparison of bands between blots. WIP1.2 siRNA 
suppresses Nutlin-3 mediated WIP1 induction and increases pp53S15 without 
affecting total p53. LE: Long exposure: SE: Short exposure. 
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Figure 4-7 Densitometry of blots shown in Figure 3-21 where the. OD of each band 
was measured relative to actin and then normalised to 0.5Hr DMSO control (lane 
2) which represents the baseline protein expression on each blot. A) Nutlin-3 
medated WIP1 induction over time is suppressed in the presence of WIP1.2 siRNA 
compared to Cont. siRNA. B) Total p53 induction after 5µM Nutlin-3 in the 
presence of WIP1.2 siRNA was not affected compared to control. C) 
Phosphorylation of p53 on serine 15 (pp53S15) after 5µM Nutlin-3 treatment 
increases in the presence WIP1.2 siRNA compared to control siRNA. Datapoints 
represent one experiment.  
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4.4.3 WIP1 siRNA mediated knockdown increases sensitivity to Nutlin-3 in TP53 
wild-type cell lines 
Monitoring cell morphology and proliferation in response to Nutlin-3 ± Cont./WIP1.2 
siRNA using IncuCyte showed that WIP1 knockdown increases sensitivity to growth 
inhibition by Nutlin-3 in TP53 wild-type cell lines (Figure 4-8 to Figure 4-10) (See 
time-lapse images presentation in enclosed CD). In contrast, none of the TP53 mutant 
null cell lines were made significantly more sensitive to growth inhibition by Nutlin-3 
with WIP1.2 siRNA compared to the control. WIP1 targeting siRNA resulted in slightly 
slower rate of growth for the TP53 wild-type cells NGP, HCT116+/+ and SJSA-1 
compared to control siRNA. Interestingly numerous vacuoles were observed in HCT116 
(Figure 4-12) and SJSA-1 cells (data not shown) under transfection conditions 
compared to non-transfected controls, regardless of their TP53 genetic status. Reduction 
in growth rate was also observed in HCT116-/- and SN40R2 TP53 null and mutant cells 
respectively (Figure 4-8 to Figure 4-10). This suggests that WIP1 knockdown may 
sensitise these cell lines to transfection conditions in a p53-independent manner. Nutlin-
3 resulted in necrotic morphology in HCT116+/+ cells, with compromised membranes 
and fragmented nuclei observed (Figure 4-13).  
Immunoblots carried out on the NGP cell line pair in parallel with the IncuCyte 
experiments showed efficient WIP1 knockdown and an increase in Nutlin-3 mediated 
induction of p53 transcriptional targets p21WAF1 and MDM2 compared to control siRNA 
in the wild-type TP53 NGP cells (Figure 4-11). In spite of p53 stabilisation in the TP53 
mutant N20R1 cells 4Hrs following 5µM Nutlin-3 treatment, MDM2 and p21WAF1 were 
not induced in the TP53 mutant N20R1 cells. Interestingly, p53 Serine 20 
phosphorylation (pp53S20), reported to be indirectly affected by WIP1 through its role in 
deactivating ATM, CHEK1 & 2 dephosphorylation (Shreeram, Demidov et al. , 
Fujimoto, Onishi et al. 2005, Lu, Nannenga et al. 2005, Yoda, Xu et al. 2006, Oliva-
Trastoy, Berthonaud et al. 2007), only increased in TP53 mutant N20R1 cells after 
WIP1 knockdown and Nutlin-3 treatment. Furthermore, in N20R1 cells MDM2 was 
stabilised by the combination of Nutlin-3 + WIP1.2 siRNA compared to Nutlin-3 + 
Cont. siRNA in N20R1 cells (Figure 4-11) although this may be due to the differences 
in loading in the last two lanes. 
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Figure 4-8 Monitoring of (A) NGP and (B) N20R1 cell confluence over time during treatment with WIP1.2 or control (Cont.) siRNA ± 5µM 
Nutlin-3 using IncuCyte. WIP1 siRNA alone reduces confluence over time and markedly increases NGP sensitivity to Nutlin-3 for the NGP 
wild-type TP53 cells. Tfxn: Transfection; Nut-3/DMSO: 5µM Nutlin-3 or 1% (v/v) DMSO  
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Figure 4-9 Monitoring of (A) HCT116+/+ and (B) HCT116-/- cell confluence over time using IncuCyte as described in Figure 3-24. WIP1 siRNA 
alone reduces confluence over time of both cell lines and markedly increases HCT116+/+ sensitivity to Nutlin-3. Tfxn: Transfection; Nut-
3/DMSO: 5µM Nutlin-3 or 1% (v/v) DMSO 
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Figure 4-10 Monitoring of (A) SJSA-1 and (B) SN40R2 cell confluence over time using IncuCyte as described in Figure 3-24. WIP1 siRNA 
alone reduces confluence over time of both cell lines and markedly increases SJSA-1 sensitivity to Nutlin-3. Tfxn: Transfection; Nut-3/DMSO: 
5µM Nutlin-3 or 1% (v/v) DMSO.
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Figure 4-11 WIP1 knockdown Immunoblots carried out in parallel with the 
IncuCyte experiment in NGP cell line pair shows that WIP1 knockdown and 
combination with Nutlin-3 results in an increase in p21WAF1 and MDM2 expression 
in TP53 wild-type NGP cells but it does not affect pp53S20 in contrast to the TP53 
mutant N20R1 cells. Cells were transfected with siRNA 24 Hrs before treatment 
with DMSO/Nutlin-3 and lysates were then collected after 4Hrs of drug 
incubation.  
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Figure 4-12 Transfection conditions result in formation of numerous cytoplasmic 
vacuoles in HCT116 cells by 72 hours.  
 
Figure 4-13 A) Cytoplasmic vacuoles in response to transfection conditions in 
HCT116 cells. B) Loss of membrane integrity in the presence of Nutlin-3 and 
WIP1.2 siRNA.
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4.4.4 WIP1 siRNA transient knockdown decreases clonogenic survival in response 
to Nutlin-3 in a p53-dependent manner 
The NGP and N20R1 cell line pair was transfected with control or WIP1.2 siRNA and 
then treated with multiples of 50% lethal concentration (LC50) of Nutlin-3 (Previously 
obtained LC50=1.3µM) for 48 hours, following which they were re-seeded and allowed 
to form colonies. WIP1.2 siRNA increased the sensitivity of TP53 wild-type NGP cells 
to Nutlin-3 but not the TP53 mutant N20R1 cells. WIP1 knockdown resulted in a 2.7-
fold (p= 0.0004) decrease in the clonogenic survival of NGP cells in response to Nutlin-
3 + WIP1.2 siRNA compared to Nutlin-3 + Cont. siRNA (Figure 4-14). Immunoblotting 
carried out in parallel with the first repeat of the clonogenic assay showed an increase in 
Nutlin-3 induced pp53S15 in the presence of WIP1.2 siRNA compared to control siRNA 
in NGP and to a lesser extent in N20R1 cells (Figure 4-15). In NGP cells this correlated 
with a notable increase in well-established p53 transcriptional target gene products, 
MDM2 and WIP1 but not the pro-apoptotic p53 transcriptional target BAX. In spite of 
similar p53 stabilisation N20R1 cells did not induce WIP1 or BAX in any of the 
treatment conditions but there was a modest induction of MDM2.  
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Figure 4-14 WIP1 siRNA mediated knockdown increases sensitivity to Nutlin-3 in 
clonogenic survival assays in a p53 dependent manner. A & B) NGP cell line pair 
were treated with Cont. siRNA/ WIP1 siRNA and after 24 hours exposed to 
Nutlin-3 (0.03-1.3μM) for 48 hours before being re-plated at different densities 
(500-10000). Cells were left to form colonies, fixed, stained and then colonies 
counted. C) Colony formation assay images of Cont. siRNA + Nutlin-3 and WIP1 
siRNA + Nutlin-3 (0 means DMSO control). Images are representative of the 
biggest difference observed in three independent repeats. Supervised MRes 
student Mrs Liang Zhao assisted with this experimental procedure.  
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Figure 4-15 WIP1 knockdown combined with Nutlin-3 treatment carried out in 
parallel with the clonogenic survival assays showed a marked increase in pp53S15 
compared to control (Cont.) siRNA in NGP cells and to a lesser extent in N20R1 
cells. Cells were transfected with siRNA 24 Hrs before treatment with 
DMSO/Nutlin-3 and lysates were then collected after 4Hrs of drug incubation. 
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4.4.5 WIP1 knockdown enhances Nutlin-3 mediated cell cycle distribution changes 
and increases Sub-G1 apoptotic signals 
The NGP and N20R1 cell line pair was transfected with control siRNA or WIP1.2 
siRNA 24 hours before being treated with 0.5 × and 1 × NGP GI50 doses of Nutlin-3 
and then cell cycle distribution was analysed by flow cytometry. WIP1 siRNA mediated 
knockdown alone (Also treated with 1% DMSO) resulted in no change in cell cycle 
distribution of the NGP cell line pair at 48 hours (Figure 4-16). In spite of the 
observations by IncuCyte and the clonogenic data, WIP1 siRNA results in only a slight 
but statistically significant (paired t-test, p=0.009) increase in Nutlin-3 induced Sub-G1 
apoptotic events in the TP53 wild-type NGP cells and had no effect on the TP53 mutant 
N20R1 daughter cell line (Figure 4-17).  Cell cycle distribution was unaffected by 
Nutlin-3 in the presence or absence of Cont./WIP1.2 siRNA constructs. 
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Figure 4-16 Analysis of cell cycle distribution in response to WIP1 knockdown. In 
NGP or N20R1 cells WIP1 targeting siRNA (WIP1.2) does not affect cell cycle 
distribution at 72 hours and does not cause an increase in Sub-G1 events compared 
to control siRNA (Cont. siRNA). 
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Figure 4-17 In NGP cells combination of WIP1 knockdown and Nutlin-3 treatment 
does not result in changes in cell cycle distribution (A) but it leads to a significant 
increase in Sub-G1 events (B). Paired t-test p-value. Cells were transfected with 
siRNA 24 Hrs before treatment with DMSO/Nutlin-3 and harvested after a further 
48 hours of incubation. 
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Figure 4-18 in N20R1 cells combination of Nutlin-3 and WIP1 knockdown does not 
affect either cell cycle distribution or % of sub-G1 events. Cells were transfected 
with siRNA 24 Hrs before treatment with DMSO/Nutlin-3 and harvested after a 
further 48 hours of incubation. 
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4.4.6 Caspase-independent cell death in HCT116+/+ cells in response to Nutlin-3 
The observation of numerous vacuoles in HCT116+/+ cells under transfection conditions 
(Figure 4-12 and Figure 4-13) and their increase in response to Nutlin-3 and its 
combination with WIP1 knockdown prompted an investigation into the underlying 
mechanism of cell death in this cell line. The pattern of PARP-1 cleavage can be a 
marker of caspase-dependent or independent cell death (Reviewed in (Chaitanya, 
Alexander et al. 2010)). While cleavage of PARP-1 holoenzyme from 114KDa to 
85KDa and 24KDa fragments is associated with caspase-mediated apoptosis, an 
alternative cleavage pattern caused by lysosomal enzymes (e.g. cathepsins), which 
results in a 55KDa PARP-1 fragment, has been associated with necrotic cell death 
(Gobeil, Boucher et al. 2001). PARP-1 cleavage was therefore compared between NGP 
and HCT116+/+ cells to assess whether WIP1siRNA mediated knockdown affects 
PARP-1 cleavage.  
Although WIP1 knockdown had not persisted through 72Hrs following the transfection, 
pp53Ser15 was higher in HCT116+/+ cells treated with Nutlin-3 + WIP1.2 siRNA 
compared to Nutlin-3 + Cont. siRNA; however, it was not detected in NGP cells (Figure 
4-19). Interestingly, pp53Ser15 was associated with higher MDM2 levels in HCT116+/+ 
cells. This is inconsistent with reported role of WIP1 in stabilising MDM2 as knocking 
down WIP1 would destabilise MDM2 (Lu, Ma et al. 2007). However, increased 
transcriptional activity of p53 due to increased pp53Ser15 may be masking this effect. 
The p53 induced pro-apoptotic marker PUMA was induced in response to Nutlin-3, 
although WIP1.2 siRNA did not influence its expression at 48Hrs. A band was detected 
by the PARP-1 C2-10 antibody at ~55KDa in HCT116+/+ Nutlin-3 treated siRNA 
transfected and non-transfected cells (Figure 4-19). The combination of Nutlin-3 and 
WIP1 knockdown resulted in an increase in the 55KDa PARP-1 fragment compared to 
Nutlin-3 + Cont. siRNA. The 55KDa fragment was weak or absent in NGP cells. This 
suggests that the mechanism of Nutlin-3 induced cell death is different between NGP 
and HCT116+/+ cells and that the caspase-3 independent mode of cell death observed in 
HCT116+/+ cells in response to Nutlin-3 is enhanced in the presence of WIP1.2 siRNA.
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Figure 4-19 Comparison of late cell death markers in NGP and HCT116+/+ cells 
after 48 hours treatment with 5µM Nutlin-3 ± Cont./WIP1.2 siRNA. Cleaved 
caspase-3 appears most notably in NGP cells in the presence of Nutlin-3 under 
transfection conditions which correlates with caspase-3 related cleaved PARP-1 
fragment (C-PARP apoptosis = 85KDa). The cleaved caspase-3 signal was very low 
in HCT116+/+ cells and the pattern of PARP-1 cleavage indicated a mode of cell 
death associated with release Cathepsin B and G enzyme activity (C-PARP 
necrosis = 55KDa). Overall WIP1 knockdown appeared to lead to increased 
caspase-3 cleavage or necrosis related PARP-1 cleavage. Western blot carried out 
by supervised student Mrs Liang Zhao.  
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4.5 Discussion 
The range of sensitivity in response to MDM2 inhibitors among TP53 wild-type cell 
lines suggests that factors secondary to the TP53 genetic status may contribute to this 
variability in response. In the previous chapter it was shown that inhibition of members 
of the PI3KK family which are involved in DNA DSB repair did not enhance sensitivity 
to MDM2 inhibitors. The activation of PI3KKs, in response to DNA damage, are 
known to stabilise and activate p53 to promote cell cycle arrest/cell death (Appella and 
Anderson 2001). Phosphatases that target the same residues are also known to 
negatively regulate p53 stability and function to allow recovery from p53 induced cell 
cycle arrest (Donehower 2014). WIP1 is one such phosphatase that negatively regulates 
p53 by dephosphorylating pp53Ser15 and other p53 activating components of the stress 
response which renders them less active (Lu, Ma et al. 2007, Lu, Nguyen et al. 2008). 
Therefore, it was hypothesised that WIP1/PPM1D siRNA mediated knockdown would 
sensitise cells to Nutlin-3 in a p53-dependent manner.  
4.5.1 WIP1 knockdown and antibody optimisation 
With the use of two different anti-WIP1 antibodies and four different WIP1 targeting 
siRNA molecules it was reliably shown which bands correspond to WIP1 in 
immunoblotting experiments. This enabled the assessment of basal WIP1 expression 
and its induction following p53 activation. This also allowed the smaller WIP1 isoform 
to be distinguished from the truncated mutated forms of WIP1 in the HCT116 cell line 
pair and U2OS cell line pair. Basal WIP1 expression and its induction in response to 
Nutlin-3 corresponded to WIP1 copy number, with PPM1D-amplified MCF-7 cells 
showing the highest level of WIP1 induction. Importantly, it was shown that WIP1 
knockdown results in a robust increase in pp53Ser15 following Nutlin-3 treatment in 
NGP cells. Phosphorylated p53Ser15 is a substrate for WIP1 phosphatase activity (Lu, 
Nannenga et al. 2005) which means that pp53Ser15 can be used as a marker of WIP1 
phosphatase activity following Nutlin-3 treatment. Interestingly, WIP1 knockdown and 
corresponding increase in pp53Ser15 correlated with a slight increase in the induction of 
well-established p53 targets, MDM2, p21WAF1 and BAX, by 4Hrs of Nutlin-3 treatment. 
This is consistent with the previously reported role of p53Ser15 phosphorylation in 
enhancing p53Ser15 transcriptional activity (Meek and Anderson 2009, Loughery, Cox et 
al. 2014).  
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4.5.2 WIP1 knockdown increases sensitivity to Nutlin-3  
Consistent with TP53 wild-type genetic status being the strongest predictor of response 
to MDM2 inhibitors, none of the TP53 mutant cells were notably growth inhibited by 
5µM Nutlin-3 when cell proliferation was monitored  by IncuCyte. Cellular sensitivity 
was enhanced in all TP53 wild-type parental cell lines as hypothesised. With the NGP 
and N20R1 cell line pair, WIP1 knockdown alone only resulted in notable growth 
inhibition in NGP and not N20R1 cells. WIP1 knockdown when compared to control 
also resulted in increased sensitivity to loss of clonogenic survival in response to Nutlin-
3 in NGP cells and not the TP53 mutant N20R1 cells. This was consistent with the 
significant increase in Sub-G1 (apoptotic) cell cycle events observed in NGP parental 
cells only following the combination of WIP1 knockdown and Nutlin-3 treatment. This 
in turn is consistent with a significant role in the negative regulation p53 by WIP1 in 
NGP cells following activation of p53 with MDM2 inhibitors. Indeed the reported 
PPM1D copy number gain (Richter, Dayaram et al. 2015) in this cell line may be a 
contributory factor in the observed lower sensitivity to Nutlin-3 in clonogenic assays 
compared to SJSA-1 cells in the previous chapter. 
4.5.2.1 Transfection conditions results in vacuole formation and potential off-
target effects in HCT116 and SJSA-1 
In the SJSA-1 and HCT116 and their otherwise isogenic TP53 mutant and null 
respective pairs, the growth inhibitory effect of WIP1 knockdown did not appear p53-
dependent. Closer assessment of cell morphology, using the time-lapse phase contrast 
images, showed that large vacuoles formed following the initiation of transfection 
regardless of the siRNA molecules. These vacuoles were not observed in NGP cells. 
These may be lipid vacuoles which would normally be catabolised through autophagy. 
WIP1 has been shown to negatively regulate the degradation of these vacuoles by 
autophagy through its inhibition of ATM in macrophages from Ppm1d null mice 
(Le Guezennec, Brichkina et al. 2012). Therefore WIP1 knockdown may increase the 
autophagic degradation of vacuoles while promoting release of lysosomal enzymes such 
as cathepsins followed by autophagic cell death (Uchiyama 2001). Investigation of the 
pattern of PARP-1 cleavage showed that in HCT116+/+ cells the mode of cell death 
likely involved lysosomal proteases of the cathepsin family. Moreover, the smaller 
fragment of PARP-1 associated with necrosis was increased when Nutlin-3 and WIP1 
silencing siRNA were combined compared to Nutlin-3 and cont. siRNA.   
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4.5.3 Summary 
It was shown in this chapter that WIP1 siRNA mediated knockdown robustly influences 
the post-translational modification of p53 and increases sensitivity to Nutlin-3 in TP53 
wild-type cell lines. This increased sensitivity to Nutlin-3 was further examined and 
confirmed using clonogenic assays and flow cytometry in one cell line pair. 
Importantly, closer examination of cell line morphology, using IncuCyte time-lapse 
images, brought to light a potential caveat in the use of transfection reagents (cationic 
liposome formulations) for siRNA delivery in target validation or combination 
treatment studies. Large vacuoles were observed in two of the cell line pairs (HCT116 
and SJSA-1 cells) independent of the siRNA sequence or treatment with Nutlin-3. 
Therefore, the effect of WIP1 knockdown on sensitivity to Nutlin-3 in these cell lines 
must be interpreted with these potential off-target effects in mind. Despite these 
potential caveats the data overall suggest that reduced WIP1 phosphatase activity 
increases sensitivity to MDM2 inhibitors. In the following chapter the role of WIP1 in 
determining the sensitivity to MDM2 inhibitors is further  assessed using a recently 
developed highly selective allosteric WIP1 inhibitor, GSK2830371 (Gilmartin, Faitg et 
al. 2014).
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Chapter 5 Selective chemical inhibition of WIP1/PPM1D by 
GSK2830371 potentiates cellular response to MDM2-p53 binding 
antagonists
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5.1 Introduction 
In the previous chapter WIP1 transient siRNA knockdown was used to investigate the 
role of this phosphatase in the response to Nutlin-3. WIP1 transient siRNA knockdown 
was shown to enhance sensitivity to Nutlin-3 in a p53-dependent manner. In this chapter 
the investigation of this hypothesis was extended to simultaneous selective 
pharmacological inhibition of WIP1 and MDM2. Recently a potent and highly selective 
allosteric inhibitor of WIP1 phosphatase has been developed (Gilmartin, Faitg et al. 
2014), which is used throughout this chapter to investigate the role of WIP1 in p53 
signalling and determining the response to MDM2 inhibitors.  
5.1.1 Selective WIP1 inhibition by GSK2830371  
Despite the importance of phosphatases in key cellular processes their selective 
inhibition has proven challenging. This may be due to the structural similarities between 
catalytic sites of phosphatases of different families and their complex relationship with 
multiple regulatory subunits (McConnell and Wadzinski 2009). Interestingly, WIP1 is a 
member of the PPM family of Ser/Thr phosphatases, which function as monomers 
(McConnell and Wadzinski 2009), and may theoretically be less complex to target and 
investigate biochemically. Given the identification of the role of PPM1D as an 
oncogene multiple approaches have been used to discover and develop selective and 
potent WIP1 inhibitors with varying degrees of success (Rayter, Elliott et al. 2007, 
Hayashi, Tanoue et al. 2011, Yagi, Chuman et al. 2012, Gilmartin, Faitg et al. 2014). 
Recently, a highly selective allosteric WIP1 inhibitor, namely GSK2830371, has been 
reported to both degrade WIP1 protein and potently inhibit its catalytic activity by 
binding to a structurally unique flap-subdomain on WIP1, proximal to its catalytic site 
(Gilmartin, Faitg et al. 2014). Two different high throughput screens were carried out to 
identify the ideal pharmacophore for selective WIP1 inhibition, 1) a high throughput 
biochemical screen measuring the hydrolysis of fluorescent diphosphate (FDP) by 
truncated WIP1 (amino acids 2-420); and 2) a high affinity binding assay based on 
DNA-encoded small-molecule library (DEL) to full length WIP1. In DEL a library of 
compounds are each labelled with a unique DNA sequence and are incubated in a one 
pot reaction with the target as the stationary phase. The unbound compounds are 
washed off and the bound compounds are identified by high throughput DNA 
sequencing. Both screens identified a group of structurally similar compounds, termed 
capped amino acids due to their amino acid-like cores, which inhibited WIP1 
biochemical activity and bound to it with great affinity in vitro (Gilmartin, Faitg et al. 
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2014). These candidate compounds were shown to have cell free assay inhibitory 
activity against established WIP1 substrates, phospho-p38-MAPK14 (T180) and 
pp53Ser15 with half maximal inhibitory concentrations (IC50) of <20nM. The optimal 
compound, GSK2830371 (WIP1 IC50 = 6nM), was tested for its ability to inhibit 20 
other human phosphatases, showing that none of the other phosphatases could be 
inhibited by up to 30,000nM concentration in vitro.  
5.1.2 Activity in cell culture and in vivo  
GSK2830371 was reported to show growth inhibitory activity against TP53 wild-type 
cell lines, out of a large panel, using metabolic activity as an end-point for growth 
(CellTiter-Glo, measuring ATP levels) (Gilmartin, Faitg et al. 2014). No growth 
inhibitory activity was observed in TP53 mutant cell lines regardless of PPM1D status. 
However, there was a range of sensitivity to GSK2830371 (~270-fold range in GI50) 
within the TP53 wild-type cell lines, with cell lines of haematological lineage showing 
the greatest sensitivity. This suggests that TP53 wild-type is necessary but not sufficient 
for response to GSK2830371. This compound also showed in vivo inhibitory activity 
against DoHH2 (B-cell lymphoma) xenograft tumours in mice at 150mg/kg (thrice 
daily).  
5.1.3 Allosteric inhibition and WIP1 degradation 
Competition assays showed that these compounds do not bind to the active site of WIP1 
(Gilmartin, Faitg et al. 2014). Photoaffinity labelling and ESI-LC/MS/MS sequencing 
techniques were then used to show that these series of compounds bind between P219-
P295 which is characterised as a flap-subdomain unique to WIP1. Interestingly, the 
authors showed that treatment with GSK2830371 (Figure 5-1) resulted in marked 
degradation of WIP1 protein in cultured cell lines. The combination of GSK2830371 
and MG132 was reported to result in reversal of this effect suggesting that this process 
is dependent on proteasomal mediated degradation. Interestingly, site-directed 
mutagenesis of a well-established WIP1 ubiquitination residue, K238A, also diminished 
the degradation of WIP1 in response to GSK2830371 compared to wild-type WIP1 
suggesting that this process is ubiquitin-mediated. 
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Figure 5-1 Chemical structure of the allosteric WIP1 inhibitor GSK2830371 as 
described by Gilmartin et al., (2014). Image was obtained from 
http://www.selleckchem.com/ 
5.1.4 Summary 
GSK2830371 is a highly selective low molecular weight inhibitor of WIP1 with 
promising cellular and in vivo activity. This compound also reportedly promotes 
ubiquitin mediated degradation of WIP1. In the only other study to date published on 
GSK2830371, which was carried out by the same group, it was shown that this 
compound is effective against TP53 wild-type neuroblastoma cell lines with a wide 
range of sensitivity between them (Richter, Dayaram et al. 2015). Beyond its potential 
for clinical use as a single agent, GSK2830371 is a useful tool compound for 
investigating the role of WIP1, including potential modulation of the response to 
MDM2 inhibitors. Therefore TP53 wild-type and mutant cell line pairs differing in their 
PPM1D genetic status are used in investigations described in this chapter to assess 
whether chemical inhibition of WIP1 affects cellular sensitivity to MDM2 inhibitors. 
Furthermore, the impact of GSK2830371 on p53 biochemical signalling, cell cycle 
regulation and cell killing are described to provide mechanistic insight. 
5.2 Hypothesis 
Pharmacological inhibition of WIP1 by GSK2830371 can sensitise cells to MDM2 
inhibitors in a p53-dependent manner.  
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5.3 Specific materials and methods  
5.3.1 Cell lines 
Cell lines used and their relevant information are outlined in 4.3.1. Additionally ovarian 
cancer cell lines used by supervised MRes student, Mrs Rachael Mason and relevant 
information are outlined in (Table 5-1). 
Cell line TP53 status 
PPM1D status and 
additional information 
A2780 Wild-type 
PPM1D Wild-type 
CP70 Mutant 
PPM1D Wild-type, 
Cisplatin resistant sub-
clone of A2780 
CP70-MLH1 c. Mutant 
PPM1D status unknown 
CP70 with MLH1 
corrected 
IGROV1 Wild-type 
PPM1D Wild-type 
OAW42 Wild-type 
PPM1D Wild-type 
PA-1 
Wild-type 
(Polymorphic/silent 
p.P316P) 
PPM1D truncating 
mutation (p.A457fs*8) 
(Forbes, Beare et al. 2015) 
Table 5-1 Table outlining Ovarian cancer cell lines used by Mrs Rachael Mason 
and additional relevant information obtained from the literature and catalogue of 
Somatic Mutations in Cancer (COSMIC) database. 
5.3.2 Assessing growth inhibition by SRB assay 
Cell lines were seeded at densities ensuring approximately ≥ 3 × population doubling 
times over the 7 day DMSO/drug exposure and that they were in their exponential 
growth phase before treatment initiation. Due to the rapid population doubling of the 
HCT116 cell line pair, 72Hrs drug exposure was also carried out using the same 
density. At the end of the treatment the cells were fixed stained and analysed as 
described in materials and methods (2.2). The drug combination schedule in this chapter 
was simultaneous unless otherwise stated. Solvent concentration was kept at 1% DMSO 
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which is a non-growth inhibitory concentration in these cell lines. GI50 values were 
determined by fitting a Lowess/Spline curve to the data-points and interpolating the X-
coordinate from Y at 50% on the curve.  
5.3.3 Measuring synergy in drug combination treatments 
Synergy experiments summarised in 5.5.8 were carried out by Ms Rachael Mason, an 
MRes student under the supervision of Ms Maryam Zanjirband and the author of this 
thesis. Ovarian cancer cells lines described in Table 5-1 were seeded in 96-well plates 
24Hrs before being treated with 1:1 ratio combinations of doses for each compound and 
fixed and stained as above after 72Hrs. Mean SRB optical density of cells fixed 24Hrs 
post-seeding (Day 0) was subtracted from SRB optical density from all wells prior to all 
calculations. The combination index (CI) values were produced by median dose-effect 
analysis using CalcuSyn v2 (Biosoft, Cambridge, UK) software as described in 2.3.2.  
5.3.4 Treatment of cells before FACS analysis 
FACS analysis was carried out as described in general materials and methods (2.6) to 
analyse cell cycle distribution changes and apoptosis associated with drug induced 
growth arrest and cell death over 72 hours following drug exposure. Cells were seeded 
24Hrs before treatment with media/solvent/drug(s) and were harvested every 24 hours 
for analysis of cell cycle distribution by propidium iodide (PI) staining and FACS 
analysis. Suspension and adherent cells in all wells were pooled before being prepared 
for FACS analysis as described in (2.6).  
5.3.5 Quantification of Caspase-3/7 catalytic activity 
The Caspase-Glo® 3/7 assay system from Promega was used as described in Materials 
and Methods (2.8). Cells were seeded at densities stated in materials and methods and 
allowed to adhere for 24 hours  before being treated with 1% DMSO, 2.5µM 
GSK2830371 and multiples of Nutlin-3 GI50 ± 2.5µM GSK2830371. Caspase-3/7 
activity mediated luminescence was then measured 24 and 48 hours following drug 
treatment and absolute luminescence values of the DMSO/drug treated samples were 
normalised to media control values in order to assess their effect on Caspase-3/7 
catalytic activity at that given time-point.  
5.3.6 Continuous exposure cloning efficiency experiments 
Continuous exposure cloning efficiency experiments were carried out in HCT116+/+ 
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cells as caspase 3/7 activity could not be detected in this cell line. Cells were seeded in 
100mm dishes (corning) and left for 24 hours to adhere. They were then treated as 
outlined in the table and left to form colonies over 12 days. Visible colonies (>50 cells) 
were counted and plotted as absolute cloning efficiency values. 
Treatment Media DMSO GSK2830371 
(2.5µM) 
Nutlin-3 
(4.5µM) 
Combination 
Cells/dish 250 250 250 4000 4000 
Table 5-2 Number of cells seeded per 100mm dish for assessing cloning efficiency 
in response to the stated treatments. 
5.3.7 Statistical analysis 
The significance of differences between mean values was obtained by  comparing the 
mean of 3 or more paired biological repeats using a paired t-test and p-values <0.05 
were considered statistically significant.  
5.4 Results 
5.5 Sensitivity to single agent GSK2830371 in cell TP53 wild-type and mutant cell 
line pairs differing in PPM1D genetic status  
The novel and selective WIP1 inhibitor GSK2830371 was used to assess the role of 
WIP1 in the growth and proliferation of TP53 wild-type and mutant/null cell line pairs 
differing in their PPM1D genetic status. SRB Growth inhibition assays were performed 
with 0.08-10µM GSK2830371 (WIP1i) as described in paragraph 3.3.2. MCF-7 cells 
were the only cell line sensitive to treatment with single agent GSK2830371, with a 
mean GI50 value of 2.65µM ± 0.54 (Mean ± SEM) (Figure 5-2). All the other cell lines 
had GSK2830371 GI50 values >10µM irrespective of their PPM1D or TP53 genetic 
status and basal protein expression. Interestingly, the SRB growth inhibition curve for 
GSK2830371 in MCF-7 cells plateaued at doses in the range 2.5µM-10µM suggesting 
that a subpopulation of MCF-7 cells is resistant to growth inhibition following maximal 
inhibition of WIP1 catalytic activity. 
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Figure 5-2 Week-long (168hrs) dose-dependent growth inhibition in response to the WIP1 inhibitor GSK2830371 in MCF-7 cells and the four 
TP53 wild-type (Green) and mutant (Red) cell line pairs. MCF-7 cells are the most sensitive cell line to GSK2830371 as a single agent.
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5.5.1 GSK2830371 potentiates the response to MDM2 inhibitors Nutlin-3 and 
RG7388 in a p53-dependent manner 
The highest non-growth inhibitory dose of GSK2830371 (2.5µM), which corresponded 
approximately to the MCF-7 GI50, was combined with Nutlin-3/RG7388 to assess the 
effect of WIP1 inhibition on the response to MDM2 inhibitors. GSK2830371 at 2.5µM 
concentration potentiated the response to Nutlin-3 and RG7388 in a p53-dependent 
manner in cell lines that are not sensitive to growth inhibition by that dose of 
GSK2830371 alone (Figure 5-3). TP53 wild-type parental cell lines HCT116, NGP and 
SJSA-1 showed a 2.4-fold (p=0.007), 2.1-fold (p=0.039) and 1.3-fold (p =0.017) 
decrease in their Nutlin-3 GI50 values respectively in the presence of GSK2830371 at 
2.5μM. In contrast the Nutlin-3 GI50 did not change in their TP53 null/mutant matched 
pairs: HCT116p53 -/-, N20R1 and SN40R2. Interestingly, pertinent to the possibility of 
gaining a potential improvement in the MDM2 inhibitor therapeutic index in the clinic, 
the same dose of GSK2830371 resulted in a much greater potentiation of RG7388 in 
TP53 wild-type cell lines with either PPM1D gain-of-function or copy number gain. 
NGP 5.8-fold (p=0.049), U2OS 5.3-fold (p=0.039) and HCT116+/+ 4.8-fold (p=0.018) 
compared to PPM1D wild-type SJSA-1 cells 1.4-fold (p=0.020). None of the TP53 
mutant/null isogenic daughter cell lines were growth inhibited by RG7388 + 2.5µM 
GSK2830371. 
Despite the significant potentiation of RG7388, U2OS TP53 Wt cells showed a trend 
towards potentiation of Nutlin-3 in combination with GSK2830371 at 2.5µM as the 
Nutlin-3 GI50 was reduced by 3.2-fold, however this was borderline not statistically 
significant (p=0.08). U2OS-DN cells were not sensitive to either treatment. Interestingly 
the growth inhibition curve for HCT116+/+ cells in response to Nutlin-3/RG7388 ± 
GSK2830371 plateaued at approximately 30-45%. This was most likely caused by the 
combination of a resistant sub-populaiton and relatively rapid doubling time (≈24Hrs) 
for this cell line, which meant that the resistant subpopulation would have grown back 
considerably by the end of the experiment. When the same seeding density of 
HCT116+/+ cell was used in a 72 hour growth inhibition, a 2.4-fold (p=0.01) and 2.7-
fold (p=0.008) reduction in Nutlin-3 and RG7388 GI50 was observed respectively 
(Figure 5-4); moreover the subpopulation of resistant cells was reduced. This suggests 
that  there is a resistant subpopulation of HCT116+/+ cells which may recover if in 
response to this combination treatment.
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Figure 5-3 Non-growth inhibitory doses of GSK2830371 (WIP1i) potentiated the 
response of TP53 wild-type cell lines to MDM2 inhibitors. A-H) SRB growth 
inhibition assays were performed on cell lines described in 5.3.2 with stated doses 
of Nutlin-3/RG7388 in the presence or absence of 2.5µM GSK283037. 
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Figure 5-4 Non-growth inhibitory dose of 2.5µM GSK2830371 (WIP1i) potentiated 
the response of HCT116+/+ cells to Nutlin-3 and RG7388 to a lesser extent over 72 
hours. A & B) SRB growth inhibition assays performed on HCT116+/+ cells with 
the stated doses of Nutlin-3/RG7388 in the presence or absence of 2.5µM 
GSK283037. 
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5.5.2 Biochemical response to single agent GSK2830371 in MCF-7 cells 
Single agent growth inhibitory activity of the WIP1 inhibitor GSK2830371 in MCF-7 
cells was associated with its ability to stabilise p53, increase p53 phosphorylation on 
Ser15 (pp53Ser15), and induce p21WAF1 as a single agent at approximately the MCF-7 
GI50 dose (2.5µM) of GSK2830371 (Figure 5-5 A & B). In Figure 5-5B p38 inhibitor 
did not appear to notably impact response to GSK2830371 so it was not further 
investigated but the p21WAF1 signal is more obvious in this blot. This suggests that 
growth inhibition in MCF-7 cells is likely through p53 stabilisation and its induction of 
p21WAF1. There was a marked reduction in total WIP1 expression following 2.5µM 
GSK2830371 which is consistent with the reports that this compound promotes the 
degradation of WIP1 (Gilmartin, Faitg et al. 2014). There was an accompanying notable 
reduction in MDM2 expression in MCF-7 cells following GSK2830371 treatment, 
which is consistent with the reported role of WIP1 in increasing MDM2 stability (Lee, 
Kim et al. 2007). 
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Figure 5-5 A & B) Biochemical response of MCF-7 cells to 2.5µM GSK2830371 
(~GI50) and its impact on p53 transcriptional activity and post-translational 
modification over time. GSK2830371 results in time-dependent degradation of 
WIP1, stabilisation of p53, increased p53Ser15 and induction of p21WAF1. 
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5.5.3 Biochemical response to single agent GSK2830371 treatment and its 
combination with Nutlin-3 in NGP cells 
WIP1 inhibition by 2.5µM GSK2830371 resulted in a marked reduction in WIP1 
protein expression in NGP cells which persisted through to 24Hrs following treatment 
(Figure 5-6A). However, stabilisation of p53, its phosphorylation at Ser15 and induction 
of p53 transcriptional targets such as MDM2, p21WAF1 and BAX was not detected in 
response to single treatment with GSK2830371 (Figure 5-6A & B). Well-established 
p53 transcriptional targets, notably MDM2 and WIP1, were induced following 
treatment with 3µM Nutlin-3 (Figure 5-6A & B). Where Nutlin-3 and GSK2830371 
were combined, Nutlin-3 mediated WIP1 induction appeared to be offset by 
GSK2830371 mediated degradation. Phosphorylated p53Ser15 was observed most 
strongly in the combined presence of the WIP1 inhibitor with Nutlin-3 and was 
associated with the detection of cleaved caspase-3 at 24hrs.   
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Figure 5-6 A) Biochemical response of NGP cells to the stated doses of Nutlin-3, 
GSK2830371 and their combinations at 4Hrs and 24Hrs. In contrast to the single 
treatment with each agent, phosphorylated p53Ser15 (pp53Ser15) is most prominently 
detected in response to the combination treatment and it is associated with p53 
stabilisation over the time course and cleaved caspase-3 at 24Hrs. B) Immunoblot 
showing the biochemical response to single agent GSK2830371 and its combination 
with 3µM Nutlin-3 over time. Treatment with 2.5µM GSK2830371 alone results in 
degradation of WIP1 but does not induce p53 transcriptional targets.  
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5.5.4 WIP1 inhibition by GSK2830371 potentiates caspase-3/7 activation by 
Nutlin-3 in NGP and SJSA-1 cell lines 
Caspase 3/7 catalytic activity was measured following treatment with multiples of 
Nutlin-3 GI50 + GSK2830371 (2.5µM) in order to quantify and compare the amount of 
caspase-3/7 activation as a measure of apoptosis between these regimens.  
NGP cells and SJSA-1 cells showed a dose-dependent increase in their caspase-3/7 
activity in response to multiples of their Nutlin-3 GI50 values (0.5 × and 1 × GI50) at 
24 and 48 hours respectively (Figure 5-7). However, caspase 3/7 activity could not be 
detected in these cell lines following 2.5µM GSK2830371 alone. In NGP cells, 24 hour 
combination treatment with 0.5 × and 1 × Nutlin-3 GI50 + 2.5µM GSK2830371 
resulted in a 3.2-fold (p=0.005) and 4.1-fold (p=0.02) increase in caspase-3/7 activity 
respectively compared to Nutlin-3 alone at either dose (Figure 5-7A). In NGP cells 48 
hour treatment with Nutlin-3 GI50 resulted in a 1.8-fold increase (p=0.002) in caspase-
3/7 catalytic activity which was then increased by 3.1-fold (p=0.01) in the presence of 
2.5µM GSK2830371. Treatment of the NGP derived Nutlin-3 resistant, TP53 mutant 
daughter cell line (N20R1 cells), with Nutlin-3 alone or in combination with WIP1 
inhibitor treatment for 48 hours, did not result in detectable increase in caspase-3/7 
catalytic activity. 
In SJSA-1 cells caspase-3/7 activity response was not detected until 48 hours after 
treatment with 0.5 × and 1 × Nutlin-3 GI50 (Figure 5-7B). The presence of 2.5µM 
GSK2830371 resulted in a 2-fold (p=0.04) increase in caspase-3/7 activity compared to 
the effect of the GI50 dose of Nutlin-3 alone in SJSA-1 cells (Figure 5-7B). Treatment 
of the SJSA-1 derived Nutlin-3 resistant, TP53 mutant daughter cell line (SN40R2 
cells), with Nutlin-3 alone or in combination with WIP1 inhibitor treatment for 48 
hours, did not result in detectable increase in caspase-3/7 catalytic activity. 
 
An increase in caspase-3/7 catalytic activity was not detected in MCF-7 and HCT116+/+ 
cell lines following treatment with multiples of Nutlin-3 GI50 and/or 2.5µM 
GSK2830371 at 24 and 48 hours (Data shown in the methods section). These results 
were consistent with previous reports that MCF-7 cells do not express caspase-3 and 
that they undergo apoptosis through caspase-3 independent mechanisms (Oberhammer, 
Wilson et al. 1993, Jänicke, Sprengart et al. 1998, Eck-Enriquez, Kiefer et al. 2000). 
Also HCT116+/+ cells reportedly do not undergo apoptosis in response to MDM2 
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inhibitors (Huang, Deo et al. 2009). 
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Figure 5-7 WIP1 inhibitor GSK2830371 (WIP1i) potentiates the Nutlin-3 mediated caspase-3/7 activity in TP53 Wild-type parental cell lines 
and not their TP53 mutant Nutlin-3 resistant daughter cells. A) NGP cells were treated with 0.5 × and 1 × their approximate Nutlin-3 GI50 
(1.5µM and 3.0µM respectively) ± 2.5µM GSK2830371 for 24 hours and Caspase-3/7 catalytic activity was quantified. B) Caspase-3/7 activity 
in response to 48 hour treatment with Nutlin-3 GI50 (3.0µM) + 2.5µM GSK2830371 was measured in NGP cells showing that the combination 
treatment results in a significant increase in caspase-3/7 signal. SJSA-1 cells were treated with 0.5 × and 1 × their approximate Nutlin-3 GI50 
(0.75µM and 1.5µM respectively) ± 2.5µM GSK2830371 for 48 hours and Caspase-3/7 catalytic activity was quantified. There was no caspase-
3/7 catalytic activity in neither of the Nutlin-3 resistant cell lines (red bars) derived from NGP and SJSA-1 (green bars). P-values represent 
paired t-test. *: p<0.05; **: p<0.005.
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Figure 5-8 Induction of caspase-3/7 activity was not detected in HCT116+/+ and 
MCF-7 cells 48 hours following treatment with Nutlin-3 ± 2.5µM GSK2830371 
(WIP1i). A) HCT116+/+ cells treated with 0.5 × and 1 × their Nutlin-3 GI50 (4.5µM 
and 9.0µM respectively) ± 2.5µM GSK2830371 for 48 hours and Caspase-3/7 
catalytic activity was quantified. B) MCF-7 cells were treated with 0.5 × and 1 × 
their approximate Nutlin-3 GI50 (1.5µM and 3.0µM respectively) ± 2.5µM 
GSK2830371 for 48 hours and Caspase-3/7 catalytic activity was quantified.  
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5.5.5 Potentiation of MDM2 inhibitors by GSK2830371 in HCT116+/+ cells is due to 
increase in p53 mediated cell cycle arrest.  
Because neither caspase-3/7 activity nor cleaved caspase-3 were detected in HCT116+/+ 
cells in response to any of the treatments, continuous exposure cloning efficiency 
experiments were carried out to assess any potential reduction in survival by other 
mechanisms. There was no reduction in the cloning efficiency of HCT116+/+ cells in 
response to 2.5µM GSK2830371 alone in spite of the activating PPM1DL450X 
mutation (Figure 5-9A). However, there was a significant decrease in clonogenic 
survival of this cell line following Nutlin-3 at 0.5 × GI50 dose compared to DMSO or 
WIP1 inhibitor treatment alone (p=0.02). Remarkably the combination of Nutlin-3 and 
GSK2830371 resulted in 89-fold reduction in cloning efficiency of HCT116+/+ cells 
(p=0.008). 
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Figure 5-9 A) Continuous treatment clonogenic efficiency experiment in 
HCT116+/+ cell lines in response to 4.5µM Nutlin-3 (0.5 × GI50) ± 2.5µM 
GSK2830371 (WIP1i). B) Colony formation following 10 days of treatment. Images 
representative of the biggest difference observed between single and combination 
treatment among the three independent repeats. P-value t-test. 
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5.5.6 Biochemical response of HCT116+/+ cells in response to GSK2830371 and its 
combination with MDM2 inhibitors  
Interestingly, the combination of 3.0µM Nutlin-3 and 2.5µM GSK2830371 resulted in a 
marked increase in p21WAF1 induction compared to each drug alone 4Hrs following 
treatment (Figure 5-10). Of additional interest, the truncated gain-of-function 
(PPM1DL450X gene product) protein was also degraded following GSK2830371. 
 
Figure 5-10 Biochemical response of HCT116+/+ cells to 3µM Nutlin-3, 2.5µM 
GSK2830371, or their combination after 4Hrs treatment.  
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5.5.7 Analysis of cell cycle distribution by FACS following pharmacological 
inhibition of MDM2, WIP1 or their combination 
In all cell lines, 2.5µM GSK2830371 alone did not significantly affect cell cycle 
distribution throughout 72 hours of treatment (Figure 5-11). Changes in cell cycle 
distribution after exposure to Nutlin-3 + 2.5µM GSK2830371 were cell line-dependent. 
In SJSA-1 and NGP cell lines, 24 hours exposure to Nutlin-3 resulted in an increase in 
the proportion of cells in G1/G0 phases of the cell cycle. In SJSA-1 cells this effect of 
Nutlin-3 remained unchanged in the following 48 hours treatment with Nutlin-3 + 
GSK2830371. However, in NGP cells the relative proportion of cells in G2/M and S-
phase increased over the following 48 hours when Nutlin-3 and the WIP1 inhibitor were 
combined compared to Nutlin-3 alone. In HCT116+/+ cells Nutlin-3 resulted in an 
increase in the proportion of cells in G1/G0 and G2/M phases at 24 hours, which 
persisted to the 72 hours treatment time point (Figure 5-11) Cell cycle distribution was 
not affected in HCT116-/- cells regardless of the treatment condition, suggesting that 
the changes in cell cycle distribution observed in HCT116+/+ cells are p53-dependent 
(Figure 5-11).  
In response to the combination treatment compared to Nutlin-3 alone, the increase in 
SubG1 FACS signal after exposure to Nutlin-3 was significantly augmented in the 
presence of 2.5µM GSK2830371 (WIP1i) in both SJSA-1 and NGP cell lines (Figure 
5B and Supplementary figure S4B). This is in keeping with the increased cleaved 
caspase-3/7 activity in NGP and SJSA-1 cells (Figure 5-12). Sub-G1 signals were not 
significantly changed in HCT116+/+cells throughout the 72 hours of Nutlin-3 ± 
GSK2830371 treatment (Figure 5-12). 
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Figure 5-11 Analysis of cell cycle distribution of TP53 wild-type cells treated with 
stated doses of Nutlin-3 (GI50 or 0.5 × GI50 dose), GSK2830371 (WIP1i), or 
combination over 72 hours. Sub-G1 events were gated out in this analysis.
 198 
 
 
Figure 5-12 Representative cell cycle distribution histograms for NGP and SJSA-1 
cells indicating the increase in the proportion of Sub-G1events in response to 72 
hours of treatment with GSK2830371 (WIP1i), Nutlin-3 and their combination. P-
values are from paired t-test. 
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Figure 5-13 3D representation of analysis of cell cycle distribution histograms following treatment with multiples of Nutlin-3 GI50 dose ± 
2.5µM GSK2830371 (WIP1i). Histograms correspond to one biological repeat representative of grouped bar charts in Figure 3-21.
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5.5.8 GSK2830371 synergises with MDM2 inhibitors in TP53 wild-type ovarian 
cancer cell lines 
Mosaic PPM1D-truncating activating mutations have been reported to predispose 
individuals to breast and ovarian carcinoma (Ruark, Snape et al. 2013). PPM1D copy 
number gain is also associated with poor overall survival in ovarian carcinoma and has 
been shown to be a potential therapeutic target (Tan, Lambros et al. 2009). A panel of 
ovarian cell lines differing in their TP53 genetic status was used to assess their 
functional and cellular response to GSK2830371 and its combination with MDM2 
inhibitors. Relevant results summarised here were produced by Ms Rachael Mason, 
under the co-supervision of Mrs Maryam Zanjirband and the author of this thesis. 
Mono-treatment with GSK2830371 resulted in different degrees of growth inhibition in 
TP53 wild-type ovarian cancer cell lines with a 50% growth inhibitory concentration 
(1.88 ± 0.67) only being achieved in PA-1 cells within the dose range tested (0.09-
12µM) (Figure 5-14A). Interestingly this was the only cell line with a PPM1D-
truncating activating mutation (c.1370delC, p.A457fs*8). All TP53 wild-type cell lines 
were responsive to both Nutlin-3 and RG7388 in contrast to the two TP53 mutant cell 
lines (Figure 5-14B and C). 4 hour treatment with incremental GSK2830371 doses 
resulted in marked p53 stabilisation and increased p53Ser15 phosphorylation in PA-1 
cells (Figure 5-14D). This occurred to a lesser extent in the other TP53 wild-type cell 
lines which were less sensitive to GSK2830371 (Figure 5-14D). Moreover, in all cell 
lines WIP1 protein was degraded at 4 hours after GSK2830371 exposure.  
Combination of multiples of different growth inhibitory doses of GSK2830371 with 
multiples of MDM2 inhibitor GI50 doses resulted in more than additive or synergistic 
response in all TP53 wild-type cell lines as measured by combination index (CI) values 
(Figure 5-15A & B) (Chou and Talalay 1984). Synergism was more pronounced at 
lower doses (Figure 5-15B). 
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Figure 5-14 A) 72Hrs GSK2830371 SRB growth inhibition in a panel of TP53 wild-type (wt-green) and mutant (mut-red) ovarian cancer cell 
lines. B & C) Cellular sensitivity to MDM2 inhibitors Nutlin-3 and RG7388. D)  Immunoblots showing the biochemical response to 
GSK2830371 after 4 hours. PA1 cells harbouring a PPM1D-truncating activating mutation (c.1370delC) show the most p53 activation 
following treatment with GSK2830371. 
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Figure 5-15 A) Table in aid of interpretation of combination index (CI) values. B) CI values calculated based on 3 independent repeats if 
72Hrs growth inhibition experiments combining MDM2 inhibitors Nutlin-3/RG7388 and GSK2830371 at 1:1 ratio of doses with known 
effects. MDM2 inhibitors are shown to synergise with GSK2830371 at lower doses. 
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5.6 Discussion 
MDM2 inhibitors are small targeted anti-tumour agents in pre-clinical and clinical 
development. Multiple pharmaceutical companies have compounds in late stage 
development and early phase clinical trials, hoping to establish the best in class clinical 
candidate, with Roche Pharmaceuticals presently leading the race (Ray-Coquard, Blay 
et al. 2012, Ding, Zhang et al. 2013, Zhao, Liu et al. 2013, Zhao, Aguilar et al. 2015). 
Preclinical and clinical data show that there is a heterogeneity in sensitivity to MDM2 
inhibitors, even within and between, cell lines and tumours with a TP53 wild-type 
genetic background (Ray-Coquard, Blay et al. 2012, Saiki, Caenepeel et al. 2015). 
Addressing this heterogeneity is in part also limited by on-target MDM2 inhibitor dose-
limiting toxicity in a subpopulation of patients causing neutropenia and 
thrombocytopenia (Ray-Coquard, Blay et al. 2012, Iancu-Rubin, Mosoyan et al. 2014). 
Therefore research into determinants of sensitivity to MDM2 inhibitors is an important 
step in optimising their clinical use to provide a non-genotoxic alternative for wild-type 
TP53 cancers or tumours with mixed population of TP53 wild-type and mutant cells. 
This would allow for the design of effective combination treatment regimens which 
involve non-genotoxic agents capable of synergy with or potentiation of MDM2 
inhibitors in a tumour-specific manner. This is provided that the second target is 
important for the survival of the tumour cells when p53 is activated by an MDM2 
inhibitor and not important for the survival of the healthy cells in response to the same 
treatment. A lower dose of a chemotherapeutic agent might then be used to eliminate 
any remaining subpopulations of TP53 mutant cells minimising unpleasant and 
sometimes irreversible off-target toxicities, particularly with genotoxic agents, while 
improving survival and quality of life.  
5.6.1 WIP1 as a target for non-genotoxic activation of p53  
The prevalence of PPM1D oncogenic activation, copy number gain or amplification in 
TP53 wild-type malignancies is indicative of its role in negative regulation of p53 
function (Saito-Ohara, Imoto et al. 2003, Rauta, Alarmo et al. 2006, Zhang, Chen et al. 
2014, Richter, Dayaram et al. 2015). Multiple studies have now shown that silencing of 
WIP1 mRNA expression or pharmacological inhibition of its phosphatase activity can 
be anti-proliferative in cell lines that are dependent on WIP1 for negative regulation of 
wild-type TP53 (Parssinen, Alarmo et al. 2008, Tan, Lambros et al. 2009, Gilmartin, 
Faitg et al. 2014, Richter, Dayaram et al. 2015). However, these data suggest TP53 
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wild-type status is necessary but not sufficient for ex-vivo growth inhibitory or apoptotic 
response to WIP1 inhibition (Gilmartin, Faitg et al. 2014). The same premise likely 
holds true in-vivo (Gilmartin, Faitg et al. 2014). Importantly, among responding cell 
lines there is a wide range of sensitivity to WIP1 inhibition by the most selective 
commercially available WIP1 inhibitor GSK2830371 (Gilmartin, Faitg et al. 2014, 
Richter, Dayaram et al. 2015). The exceptional selectivity of GSK2830371, owed to its 
targeting of a distinct allosteric site on WIP1, makes this compound a unique 
pharmacological tool for studying WIP1 chemical biology. 
In our selected panel of TP53 wild-type and mutant isogenic cell line pairs, with 
different PPM1D genetic status, GSK2830371 did not have single agent growth 
inhibitory activity within the mechanistically relevant dose range. However, MCF-7 
cells treated in parallel with these isogenic pairs were responsive and therefore acted as 
a positive control for single agent activity of GSK2830371 in culture. Importantly, the 
response to single agent GSK2830371 correlated with WIP1 degradation, p53 
stabilisation and Ser15 phosphorylation, followed by p21WAF1 induction. This was also 
consistent with single agent sensitivity to GSK2830371 in the ovarian panel of cell lines 
where the extent of growth inhibition concurred with WIP1 degradation, p53 stability 
and phosphorylation at Ser15 and p21WAF1 induction. Notably, the most GSK2830371 
sensitive ovarian cancer cell line, PA-1, harboured a truncating mutation in WIP1 which 
is consistent with the role of activated WIP1 in regulation of p53 function. While WIP1 
was also degraded by GSK2830371 in TP53 wild-type HCT116+/+ and NGP cell lines, 
p53 stabilisation, p53Ser15 phosphorylation and p21WAF1 induction were not observed in 
response to GSK2830371. This correlated with no single agent GSK2830371 growth 
inhibitory activity in these cell lines. Therefore WIP1 inhibition/degradation by 
GSK2830371 does not impact the growth of the cell unless that cell relies on WIP1 for 
negative regulation of p53 function. Furthermore, the absence of p53 activation 
following GSK2830371 treatment shows that p53 dissociation from MDM2 is not 
dependent on WIP1 phosphatase activity in HCT116+/+ and NGP cell lines. This 
strongly supports the notion that p53 activation is necessary for ex-vivo growth 
inhibitory response to WIP1 inhibition by GSK2830371.  
5.6.2 The role of WIP1 in determining sensitivity to MDM2 inhibitors 
WIP1 chemical inhibition or transient knockdown consistently resulted in increased 
sensitivity to MDM2 inhibitors in all the TP53 wild-type parental cell lines of the pairs 
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tested, while not affecting the sensitivity of their TP53 mutant daughter cells. 
Potentiation/synergy occurred most notably in cell lines with PPM1D activating 
mutations or increased expression. This correlated with an increase in apoptotic 
endpoints as measured by caspase-3/7 activity, reduced clonogenic survival and 
increased Sub-G1 cell cycle signals. Interestingly, combination of MDM2 inhibitors in 
ovarian cancer cell lines that were sensitive to single agent GSK2830371 also resulted 
in synergy. An alternative form of PARP-1 cleavage associated with cathepsin mediated 
cell death (which was not seen with the chemical inhibitor) was also observed in 
response to transfection conditions and Nutlin-3 and was intensified by WIP1 siRNA 
knockdown (Chapter 4.4.6). The potentiation/synergy and increased apoptotic end-
points were also associated with an increased p53Ser15 phosphorylation. 
5.6.3 Role of WIP1 in cell cycle regulation following MDM2 inhibition 
Nutlin-3 mediated changes in cell cycle distribution were all enhanced in the presence 
of a dose of GSK2830371 which on its own did not affect cell cycle distribution. The 
observed increase in Sub-G1 FACS analysis signals following combination treatment of 
NGP and SJSA-1 cell lines with WIP1 and MDM2 inhibitors is consistent with 
potentiation of apoptosis and growth inhibition in these cell line. In NGP cells transient 
knockdown of WIP1 also resulted in an increased sensitivity to MDM2 inhibitors as 
measured by Sub-G1 signal in FACS analysis (See 4.4.5). This was not observed in 
N20R1 cells suggesting that the change in cell cycle distribution in response to the 
combination treatment is p53dependent.  
Chemical inhibition by GSK2830371 or WIP1 knockdown did not influence Nutlin-3 
mediated changes in cell cycle distribution in NGP cells However, in HCT116+/+ cells 
WIP1 inhibition enhanced the Nutlin-3 mediated increase in the proportion of cells in 
G2/M phase of the cell cycle whereas in HCT116-/- cells no changes to cell cycle 
distribution were observed. This success that the additional cell cycle changes observed 
in response to the combination treatment are p53-dependent. A notable increase in 
p21WAF1 protein induction, as detected by western blotting, 4 hours after treatment the 
combination of Nutlin-3 and GSK2830371, preceded the increased proportion of cells 
in G2/M in HCT116+/+ cells. This is consistent with the importance of p21WAF1 negative 
regulation of cell cycle progression (Eldeiry, Harper et al. 1994, Deng, Zhang et al. 
1995, Bunz, Dutriaux et al. 1998). Kleiblova et al., (Kleiblova, Shaltiel et al. 2013) had 
previously shown that transient knockdown of truncated PPM1D increases G1 
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checkpoint arrest in response to ionising radiation (IR). Interestingly, in our study, 
WIP1 inhibition and depletion by GSK2830371 in HCT116+/+ cells harbouring a 
PPM1D/WIP1 L450X truncation mutation resulted in an increase in the proportion of 
cells in G2/M in a p53-dependent manner following p53 activation by Nutlin-3, while 
this did not occur in NGP and SJSA-1 cell lines that do not have gain-of-function 
mutations. Lindqvist A. et al., 2009 (Lindqvist, de Bruijn et al. 2009) also reported that 
WIP1 knockdown ablates the competence of cellular p53-dependent G2 checkpoint 
recovery following cellular stress, although the authors were not aware of the gain-of-
function PPM1D/WIP1 R458X mutation in U2OS cells used in their study, as it had not 
yet been reported. These findings suggest that the increase in the proportion of cells in 
G2 observed in HCT116+/+ cells treated with the combination of MDM2 and WIP1 
inhibitor is likely due to inhibition of PPM1D/WIP1 L450X which would otherwise be 
negatively regulating p53 transcriptional activity in these cell lines. 
5.6.4 Potential role for p53Ser15 phosphorylation in enhancing p53 activity 
The phosphorylation status of p53Ser15 following treatment with MDM2 inhibitors has 
been reported to be due to basal activity of kinases, like ATM and ATR ( and most 
likely other members of the PI3KK family), that are normally involved in 
phosphorylation of this residue in response to cellular stress such as DNA damage 
(Meek and Anderson 2009, Loughery, Cox et al. 2014). Phosphorylated p53Ser15 is also 
directly dephosphorylated by WIP1 and protein phosphatase 1α (PP1A) (Haneda, 
Kojima et al. 2004, Lu, Nannenga et al. 2005). Phosphorylation of this residue has been 
implicated in increased p53 transcriptional activity and recruitment of key 
transcriptional co-factors, such as p300/CBP, which are required for chromatin 
remodelling at the sites of p53 regulated promoters and acetylation of p53 C-terminus 
on residues that would otherwise be ubiquitylated by MDM2 (Loughery, Cox et al. 
2014, Meek 2015). We showed that although MDM2 or WIP1 inhibition alone do not 
result in strong p53Ser15 phosphorylation in HCT116+/+ and NGP cell lines, p53Ser15 is 
markedly increased when these agents are combined. Therefore, in these cell lines, the 
level of p53Ser15 phosphorylation can be used as a marker of WIP1 activity only if 
p53Ser15 is not masked by MDM2. Also consistent with this model was the observation 
that WIP1 knockdown alone does not impact pp53Ser15 phosphorylation in NGP cells at 
8 hours, whereas in the presence of Nutlin-3, pp53Ser15 significantly increases. It is 
likely that the phosphorylation status of p53Ser15 is in a dynamic equilibrium that is 
catalysed by kinases and phosphatases for which this residue is a substrate. This is the 
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likely reason for an increase in Ser15 phosphorylation following increased kinase 
activity (e.g. in response to DNA damage) or decreased phosphatase activity (e.g. in 
response to WIP1 inhibition). 
5.6.5 Summary 
Wild-type TP53 genetic status is the most important determinant of response to MDM2 
inhibitors, while being necessary but not sufficient for growth inhibitory response to 
WIP1 inhibition by GSK2830371. Following their promising clinical outcomes so far in 
early phase clinical trials, MDM2 inhibitors will be explored in combination with other 
anticancer agents to optimise their therapeutic potential. Combination regimens of non-
genotoxic agents which could minimise genotoxic stress to healthy tissue are a much 
preferred strategy. Here we have shown that specific pharmacological inhibition of 
WIP1 combined with MDM2 inhibitors is a promising therapeutic strategy in TP53 
wild-type tumours that show increased WIP1 function, and that phosphorylated p53Ser15  
and PPM1D genotype are of potential mechanistic importance and can be predictive 
biomarkers for response to this combination treatment. In the next chapter global gene 
expression is following treatment with RG7388 in the presence or absence of 
GSK2830371 is analysed and the mechanistic role of p53Ser15 in transcriptional 
transactivation of p53 is explored. 
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Chapter 6 Phosphorylation of p53S15 is of mechanistic importance in 
GSK2830371 mediated potentiation of response to MDM2 
inhibitors
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6.1 Introduction 
Hotspot TP53 mutations found in malignancies overall, affect residues functionally 
necessary for p53 DNA binding to its consensus sequence (Raycroft, Wu et al. 1990, 
Cho, Gorina et al. 1994, Hainaut and Hollstein 2000). This strongly suggests that p53 
transcription factor function is very important for its role as a tumour suppressor 
(Levine, Momand et al. 1991). In order for wild-type p53 to become transcriptionally 
active it must dissociate from its key negative regulators MDM2 and MDMX that mask 
the p53 transcriptional transactivation domain (Chen, Marechal et al. 1993, Oliner, 
Pietenpol et al. 1993, Haines, Landers et al. 1994, Lin, Chen et al. 1994, Marine, Dyer 
et al. 2007). In response to many types of stress, such as DNA damage or oncogenic 
stress, p53 and its regulatory binding partners undergo a complex array of post-
translational modifications (PTM’s) which prevent their interaction (Appella and 
Anderson 2001, Kruse and Gu 2009, Meek and Anderson 2009, Meek and Hupp 2010). 
MDM2 inhibitors can potentially bypass these PTM’s and activate p53 transcriptional 
function in the absence of DNA damage. Phosphorylation of p53Ser15 which is arguably 
“a critical focal point” for p53 function following cellular stress (Meek and Anderson 
2009), has different intensity and kinetics in response to MDM2 inhibitors compared 
with response to DNA damage (Loughery, Cox et al. 2014). In the previous chapter we 
showed that p53Ser15 phosphorylation increased markedly in response to the combination 
of MDM2 inhibitors and GSK2830371 in contrast to the same dose of each drug alone. 
This correlated with potentiation of growth inhibition and an increase in apoptotic 
response in TP53 wild-type cell lines, but not in their TP53 mutant daughter cells which 
lack p53 transcriptional activity. These observations suggest that the potentiation of 
MDM2 inhibitors is likely through p53-dependent transcriptional mechanisms. 
Therefore we aimed to assess whether the difference in apoptotic response correlated 
with a difference in gene expression between single MDM2 inhibitor treatment and its 
combination with WIP1 inhibition. 
6.1.1 Phosphorylation of p53Ser15 after MDM2 inhibition 
Regulation of p53 stability, subcellular localisation and transcription factor function is 
primarily post-translational through modification by enzymes involved in cellular stress 
response. The complex array of p53 PTM’s has been reviewed extensively by multiple 
authors (Meek 1999, Appella and Anderson 2001, Kruse and Gu 2009, Meek and 
Anderson 2009). Phosphorylation of p53Ser15 is broadly considered a marker of 
genotoxic stress as it is catalysed by the PI3KK family of kinases, such as ATM, ATR 
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and DNA-PK, which are activated in response to DNA damage. However, this 
phosphorylation also occurs in response to oncogenic stress and depleted energy levels 
by AMPK (AMP-activated kinase) (Jones, Plas et al. 2005). Absence of p53Ser15 
phosphorylation, 20 hours following 6µM Nutlin-1, in comparison to genotoxic agents 
such as etoposide (1µM) and doxorubicin (10µM), was presented as evidence of the 
non-genotoxic mechanism of p53 activation by MDM2 inhibitors (Vassilev, Vu et al. 
2004). However, since then many other groups have reported phosphorylation of 
p53Ser15 (pp53Ser15) following treatment with Nutlin-3 the most potent MDM2 inhibitor 
reported in the original publication by Vassilev et al., (2004). Treatment with Nutlin-3 
racemic mixture (or Nutlin-3a the purified active enantiomer) has been shown to result 
in pp53Ser15 and in some publications this was reported to correlate with an increase in 
markers of DNA damage marker γH2AX (Phosphorylation of Histone 
H2AXSer139)(Verma, Rigatti et al. 2010, Valentine, Kumar et al. 2011, Rigatti, Verma et 
al. 2012). Although in chapter 3 it was discussed that this may be due to off-target 
effects of MDM2 inhibitors.  
In a recent publication by Loughery et al., however pp53Ser15 was assessed at a 
mechanistically relevant time-point (6 hours post-treatment) with a range of doses of 
Nutlin-3a compared to other genotoxic activators of p53 such as IR, UV and etoposide 
in HCT116 and U2OS cell lines (Loughery, Cox et al. 2014). It was shown that 
phosphorylation of p53Ser15 is more intense in response to DNA damaging agents and 
that this PTM did not correlate with levels of total p53 stabilisation. Interestingly, it was 
also shown that the basal activities of ATM and ATR may be in part responsible for 
phosphorylation of this residue in response to Nutlin-3a. Inhibitors of ATM KU55933 
(10µM) and ATR by VE821 (10µM) alone did not change 10µM Nutlin-3a mediated 
pp53Ser15, whereas their combination decreased this phosphorylation notably. The effect 
of single treatment or combination treatment with each of the kinase inhibitors on 
inhibition of pp53Ser15 was much more marked in response to 50µM etoposide than in 
response to Nutlin-3a (Loughery, Cox et al. 2014). These observations were consistent 
with the hypotheses outlined in Chapter 5 (5.6.4) of a dynamic equilibrium of kinases 
and phosphatases regulating p53Ser15 phosphorylation status. It is important to note that 
the abundance of the common substrate of both groups of enzymes (unmasked p53Ser15) 
appears to also be a factor in the amount of the product (pp53Ser15) observed. The 
substrate is made more available by inhibition of MDM2 from masking p53 N-terminus 
and therefore the product gradually accumulates in the absence of DNA damaging 
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agents. This is likely the reason for observed p53Ser15 phosphorylation in response to 
MDM2 inhibitors in the absence of any credible evidence for DNA damage (Loughery, 
Cox et al. 2014). Importantly, our results in chapter 5 showed that this balance can be 
tilted in favour of p53 activating kinases by inhibition of WIP1. Loughery et al., (2014) 
also showed that pp53Ser15 was associated with increased transcriptional transactivation 
from p53 regulated promoters. Therefore, the correlation of pp53Ser15 with increased 
apoptotic end-points may be due to an increase in transcriptional transactivation. 
6.1.2 The role of p53Ser15 phosphorylation in regulation of p53 transcriptional 
activity 
Initial studies to identify the function of various conserved domains of p53 were carried 
out during the early 1990’s which distinguished an acidic N-terminus transactivation, 
DNA binding, and an oligomerisation domains (Reviewed in chapter 1). Hybrid studies 
in yeast showed that there are two sub-domains within the N-terminal transactivation 
domain (TAD) of p53 which span across amino acids 1-40 (TAD1) and 40-83 (TAD2) 
(Candau, Scolnick et al. 1997). By that time, it had already been shown that MDM2 
inhibits p53 TAD interaction with components of the basal transcription machinery like 
TATA box binding protein (Truant, Xiao et al. 1993) and key transcriptional 
coactivators CBP/p300, TAFII60, TAFII40 and TAFII31 (Lu and Levine 1995, Thut, 
Chen et al. 1995, Lambert, Kashanchi et al. 1998, Dumaz and Meek 1999, Meek and 
Anderson 2009). Therefore it was important to find out which PTM’s are key to the 
decoupling of p53 from its principal negative regulator MDM2. Due to the proximity of 
p53 residues Ser15, Thr18 and Ser20 to the three key p53 amino acids (Phe19, Try23 
and Leu26) essential for MDM2 binding (Böttger, Böttger et al. 1997), it was suspected 
that phosphorylation of one or more of these residues would result in p53 dissociation 
from MDM2. Initially it was suggested that DNA damage induced p53Ser15 
phosphorylation was critical for dissociation of p53 from MDM2 (Shieh, Ikeda et al. 
1997). Independent publications in 1999 however, found that phosphorylation of 
p53Ser15 was dispensable for dissociation from MDM2 (Dumaz and Meek 1999) in 
contrast to phosphorylation of Ser20 and Thr18 (Chehab, Malikzay et al. 1999, Ferreon, 
Lee et al. 2009, Teufel, Bycroft et al. 2009). The functional significance of 
phosphorylation of individual p53 serine residues was investigated by their individual or 
combined site-directed mutagenesis to alanine residues which could no longer be 
phosphorylated. Alternatively mimicking a phosphorylation by mutating that same 
residue to aspartate which is negatively charged. Dumaz and Meek (1999) generated a 
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hybrid reporter system by fusing the DNA binding domain of the yeast GAL4 
transcription factor with either wild-type p53 residues 1-42 (TAD1) or TAD1 with 
single or double mutations in putative phosphorylation sites (Dumaz and Meek 1999). 
Plasmids carrying the fusion constructs were then co-transfected with a GAL4 regulated 
reporter construct either into Trp53 null MEFs or COS-7 cells which have no p53 
activity due to SV40 large T antigen expression. Only p53S15A and p53S15A/S37A resulted 
in significant reductions of the reporter signal which suggests that p53Ser15 is important 
for transcriptional transactivation function carried out by this domain of p53. Moreover, 
p53S15D rescued the transactivation function of the fusion protein. Importantly, reporter 
signal was diminished in a dose-dependent manner when constructs expressing wild-
type and mutant p53 were co-transfected with different doses of a plasmid that 
expressed MDM2 suggesting that the mutations in these residues did not impact the 
MDM2-p53 interaction. Full-length p53S15A or p53S15D co-transfection with a reporter 
under the regulation of MDM2 or CDKN1A (p21WAF1) promoters in MEFTrp53-/- also 
resulted in decreased expression in p53S15A  compared to wild-type p53 which was 
reversed by p53S15D (Dumaz and Meek 1999). These data strongly suggests that p53Ser15 
phosphorylation enhances p53 transcriptional activity. Subsequent studies published by 
the same group and others have supported this notion and suggested potential 
mechanisms for this enhanced p53 activity (Lambert, Kashanchi et al. 1998, Teufel, 
Bycroft et al. 2009, Loughery, Cox et al. 2014). 
6.1.2.1 The role of p53 N-terminal phosphorylation events as studied in transgenic 
mice 
In line with these findings, knock-in mice homozygous for Trp53S18A (equivalent of 
human TP53S15A) did not show impairment in IR induced stabilisation of p53 in their 
thymocytes (Chao, Hergenhahn et al. 2003). This suggests that dissociation from 
MDM2 is not solely regulated by p53S18 phosphorylation in mice. However, there was a 
difference between wild-type and mutant Trp53 knock-in mice in their IR induced 
Trp53-mediated transcription and apoptosis in certain physiological contexts (Borges, 
Chao et al. 2004). Using murine Affymetrix gene chip system the authors showed that 
Trp53S18A homozygous thymocytes had reduced Trp53 target gene expression 8 hours 
after exposure to IR (5Gy) compared to Trp53 wild-type mice. This reduced expression 
was promoter specific and correlated with histone acetylation consistent with earlier 
findings that p53Ser15 phosphorylation is important for recruitment of co-activators 
(Such as CBP/p300) to certain promoters (Lambert, Kashanchi et al. 1998). Crucially, a 
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more recent study has shown that Trp53S18A knock-in mice are prone to late-onset 
malignancies such as lymphomas and that B cells derived from these mice show 
deficiencies in induction of Puma protein and apoptosis following 8Gy ionising 
radiation and in turn apoptosis compared to Trp53 wild-type cells (Armata, Garlick et 
al. 2007). Surprisingly knock-in mice with Trp53Ser23 (equivalent of human TP53Ser20) 
showed no difference in Trp53 induced transcription, apoptosis or Trp53 stabilisation 
following UV induced DNA damage (Wu, Earle et al. 2002). However, knock-in mice 
with Trp53S18A/S23A double mutation, showed significant aberrations in p53 stabilisation 
and apoptotic response following DNA damage (Chao, Herr et al. 2006).  
It has therefore been shown that p53Ser15 is functionally significant in cell fate 
determination in a context-dependent manner and that it most likely exerts its effect 
through modulating p53 transcriptional transactivation from p53-regulated promoters. 
Given that WIP1 and MDM2 inhibitor combination markedly increases p53Ser15 
phosphorylation in the absence of any detectable DNA damage, it is important to assess 
whether this also impacts p53 transcriptional activity. 
6.2 Hypothesis 
 Potentiation of MDM2 inhibitors is due to increased transcription from p53 
regulated promoters because of the non-genotoxic phosphorylation of p53Ser15 
following MDM2 and WIP1 inhibition  
6.3 Specific materials and methods 
6.3.1 Cell lines 
Cell lines used and their growth conditions are outlined in general materials and 
methods in 2.1.1. DD7 and DR4 cells were seeded at 1 × 104 cells/well and SRB growth 
inhibition assays were carried out as described in 2.2 and 5.3.2. Growth curves for DD7 
and DR4 cell lines can be seen Figure 6-1.  
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Figure 6-1 Growth curves of DD7 and DR4 cells stably transfected with p53 
luciferase reporter and internal control.  
6.3.1.1 Treatment schedules and lysate collection before western blotting 
Kinase inhibitors were always added 30min before treatment with IR. All other drug 
combinations were administered simultaneously unless otherwise stated. Lysates were 
collected at time-points stated in captions and western blotting carried out as described 
in 2.9. 
6.3.2 Reporter gene analysis  
TP53 wild-type and mutant glioblastoma cell lines stably transfected with p53 
responsive reporter are described in 2.1.1. Cells were also seeded at 1 × 104 cells/well of 
a white-well 96-well plates (Greiner Bio-one, #GN-VW-655083) 48Hrs before 
treatment with multiples of DD7 Nutlin-3 GI50 (~1.5µM) in the presence or absence of 
2.5µM GSK2830371. The dual-Glo luciferase assay system (Promega, #: E2920) was 
used to quantify Firefly and Renilla luciferase enzymatic activity in sequence as 
described in the manufacturer’s protocol. The final volume of media containing drug 
however was kept at 50µl and the ratios of reagents were kept the same to reduce costs. 
The incubation time after the addition of each Luciferase reagent was 30min. A micro-
well luminometer (FLUOstar Omega Reader, BMG Labtech) was used to measure 
luminescence/well. Raw Firefly luciferase activity value/well was then normalised to 
Renilla activity in that well before further data analysis. 
6.3.3 RNA extraction for microarray gene expression profiling and qRT-PCR 
validation 
NGP cells were seeded at 6 × 106 cells/well of a 6-well plate 24 hours before treatment 
and RNA was harvested 4 hours following treatment with either DMSO (0.5%), 75nM 
RG7388 + 2.5µM GSK280371. In order to isolate high quality RNA molecules for 
individual or global gene expression analysis QIAGEN RNeasy Plus Mini Kit was used, 
which comprises two different silica columns per sample processed. The first column 
allows the isolation and disposal of genomic double stranded DNA and the second the 
isolation >200mer RNA molecules excluding irrelevant ubiquitous RNA molecules 
such as 5.8S rRNA, 5S rRNA, and tRNAs which together comprise 15-20% of cellular 
RNA content. Prior to RNA extraction, highly denaturing guanidine–
thyocyanatecontaining lysis buffer is used to lyse the cells which prevents RNA 
degradation by RNases and then the genomic DNA is isolated using a gDNA column 
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which allows the retention of genomic DNA in a high salt concentration buffer in the 
stationary phase and the column is then disposed of. RNA is isolated from the eluent by 
passing it through a specialised silica-gel column at high salinity and gradual decrement 
of salinity and centrifugation steps elute the RNA while disposing of other contaminants 
like proteins and solvents. RNA concentration was quantified using the Nanodrop as 
described in materials and methods. 
6.3.4 RNA quality analysis 
Concentration and quality (RNA integrity numbers) of mRNA were determined using  
Agilent RNA 6000 nano kit on an Agilent 2100 Bioanalyser ensuring RNA integrity 
number (RIN) >9 in all samples before gene expression analysis. A 16-well chip 
interconnected with microcapillaries was loaded with a sieving polymer and a 
fluorescent intercalating nucleotide dye and then the 12 RNA samples (diluted 1:3) 
along with a RNA 6000 ladder (a size reference point) were loaded in separate wells. 
16-independent electrodes then enter the wells (1/well) and an electric current is applied 
throughout the polymer filled capillaries interconnecting the wells with charged 
molecules migrating through the capillaries at a rate proportional to their size. The 
smaller molecules migrate faster through the polymer and cross the path of a laser 
which excites the dye molecules intercalated with RNA molecules resulting in their 
fluorescence. An electropherogram is then digitally generated (y-axis: fluorescent units 
(FU) v x-axis: size relative to ladder fragments) by the 2100 Expert software (Figure 
6-2). Fluorescence units are proportional to the amount of dye intercalated in RNA 
molecules. A smaller marker is also run with each sample to use as a control for 
potential shifts between the different samples run on each chip. When RNA has not 
been degraded ubiquitously expressed and stable 28S and 18S ribosomal RNA (rRNA) 
components that are normally detected as two distinct peaks have a ~2:1 ratio in FU 
peak intensity. Human 28S rRNA is 5034 bases long as compared to 18S rRNA which 
is 1870 bases long producing a theoretical ratio of 2.69. RNA integrity was traditionally 
calculated based on 28S:18S ratio with optical densities obtained running samples on a 
denaturing agarose gel (alkaline conditions) followed by densitometry. Aligent expert 
software uses an algorithm that uses the whole of the electropherogram trace generated 
to calculate an RIN value from a smaller amount of initial RNA and it offers 
standardisation of the equipment and reagents. It is also important to note that this 
procedure is not under denaturing conditions. RIN values range from 1-10 with values 
above 7-8 being acceptable for most applications (Schroeder, Mueller et al. 2006).
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Figure 6-2 Aligent Bioanalyzer electropherogram trace and gel representation (on the right). RNA concentration and RIN value are calculated 
and presented. The ratio of 28S:18S rRNA molecules are calculated based on the area under each curve. Peaks associated with other rRNA or 
tRNA molecules has been arrowed in addition to the control molecule.
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6.3.5 Global gene expression analysis by Illumina HumanHT-12 v4.0 Expression 
BeadChip array 
Expression levels of multiple genes can be simultaneously quantified through the use of 
DNA microarray technology. Early experiments involved spot fixing fragments of 
cDNA, genomic DNA or plasmid libraries, often with known sequences, onto porous 
material such as nylon, and then hybridising radioactive labelled cDNA from sample of 
interest onto the membrane (Lockhart and Winzeler 2000). Bound material could then 
be detected by radiography allowing the identification and quantification by 
densitometry of genes that are expressed in that sample. In 1995 however, it was shown 
the nucleic acid probes can be secured on glass 96-well plates and that the hybridising 
material can be fluorescently labelled instead (Schena, Shalon et al. 1995). It was also 
suggested that robotic printing can be used to fix a high density of nucleic acid probes 
onto solid substrates and enable simultaneous measurement of thousands of genes. This 
lead to a revolution in gene expression analysis which continues to date resulting in 
generation of various platforms enabling the analysis of global gene expression 
(Bumgarner 2013). Illumina BeadChip expression arrays are a variation of DNA 
microarray technology developed in 2004 (Kuhn, Baker et al. 2004). Messenger RNA is 
first converted to cDNA by in vitro reverse transcription using oligo-dT primers that 
will only bind to messenger RNA poly-A tails and synthesise cDNA from mRNA. 
Complementary RNA (cRNA) is then generated from cDNA by in vitro transcription 
and biotin is incorporated to the cRNA. Labelled cRNA from each samples is then 
directly hybridised to each BeadChip array on the planar silica slides which house 3µm 
silica beads with protruding 50mer DNA probes complementary to specific cRNA 
molecules (Figure 6-3 A cartoon explaining the inner workings and specifications of 
Illimina-HumanHT-12-v4.0 BeadChip expression arrays.). 47’000 transcripts can be 
detected with high degree of redundancy per probe (30/probe). Unbound cRNA 
molecules are washed-off and Streptavidin-Cy3 is then used to detect those bound to 
specific probes. The BeadChip arrays can then be scanned using a HiScan, iScan or 
Bead Array Reader to quantify and record the fluorescence signal intensity from each 
position on the array. 
6.3.5.1 Experimental design and sample preparation 
Details of the experimental design are outlined in Figure 6-4. Good quality total cellular 
RNA (RIN~10) was adjusted to 25ng/µl by dilution in distilled water and packaged with 
dry ice before being sent to AROS Applied Biotechnology for gene expression analysis. 
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Illimina-HumanHT-12-v4.0 BeadChip arrays were used for gene expression analysis as 
described above. 
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Figure 6-3 A cartoon explaining the inner workings and specifications of Illimina-HumanHT-12-v4.0 BeadChip expression arrays. 
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Figure 6-4 Experimental design and RNA extraction for use in microarray gene expression analysis. Total protein was also extracted as 
explained in (2.9.2) from replica samples in parallel.
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6.3.5.2 . Uploading data and statistical analysis 
Each treated sample was given a sample name before statistical analysis was carried out 
by Dr Sirintra Nakjang in our bioinformatics support group. A copy of the sample sheet 
containing grouping and Sentrix positions are shown in (Table 6-1). Microarray data 
was processed using an R Bioconductor package lumi  (Du, Kibbe et al. 2008). For 
sample names and their respective treatments see Table 6-1. Probe intensity values were 
transformed using variance stabilising transformation implemented in the lumi package 
before data normalisation. The robust spline normalization method was used as a 
normalization method. Poor quality probes (detection threshold < 0.01), and probes that 
are not detected at all in the remaining arrays were removed. Differential expression 
analysis was performed using R Bioconductor package limma (Ritchie, Phipson et al. 
2015). Benjamini-Hotchberg method was applied when correcting for multiple 
hypothesis testing. 
6.3.5.3 Array quality control  
The following controls were also carried out by Dr Sirintra Nakjang. The spread of the 
standard deviation of ranked mean signal intensities detected for each probe across the 
12 arrays showed that the higher the mean signal intensity the greater the standard 
deviation (Figure 6-5). This modest increase in standard deviation observed with some 
probes with mean signal intensity >35000 was deemed acceptable as most probes fell 
<35000 mean signal intensity. Signal intensity box plots for each sample showed that all 
samples have around the same median signal intensity and the spread of the sample 
signal intensities are the same (Figure 6-6A). Density plot of sample intensities showed 
that the spread of signal intensity is the same between all 12 samples (Figure 6-6B). The 
raw average signal intensity data can be used to assess sample-dependent and -
independent built in controls via the Illumina Genome Studio Software (Figure 6-7). 
Sample-dependent controls include 1) Negative controls: Negative control are probes 
with random sequence that should not detect any of the labelled cRNA molecules, 2) 
Noise controls: Shows the standard deviation of the negative control probes (Figure 
6-7A), 3) Housekeeping controls: Shows the average signal caused by the expression of 
housekeeping genes that can be detected by the array, 4) All genes controls: Shows the 
average signal of all genes on the array (Figure 6-7B). Sample-independent controls 
include 1) Hybridisation controls: This control assesses whether the signal from Cy3 
labelled oligonucleotides spiked into the hybridisation reaction correlates with their 
concentration (Figure 6-7C), 2) Low stringency control: The signal comparison between 
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two Cy3 labelled controls spiked into the hybridisation reaction that have 2 mismatches 
to their respective probes (Figure 6-7D), 3) Biotin controls: These are biotin labelled 
oligonucleotides that spiked into the hybridisation reaction that bind to specific probes 
and their successful secondary staining with Streptavidin-Cy3 conjugate demonstrates 
successful secondary staining (Figure 6-7E).  
Sample Name Treatment Group  Sentrix positions 
K1.1 DMSO a 3999538022_A 
K2.1 75nM RG7388 a 3999538022_B 
K3.1 75nM RG7388 + 2.5µM 
GSK2830371 
a 3999538022_C 
K1.2 DMSO b 3999538022_D 
K2.2 75nM RG7388 b 3999538022_E 
K3.2 75nM RG7388 + 2.5µM 
GSK2830371 
b 3999538022_F 
K1.3 DMSO c 3999538022_G 
K2.3 75nM RG7388 c 3999538022_H 
K3.3 75nM RG7388 + 2.5µM 
GSK2830371 
c 3999538022_I 
K1.4 DMSO d 3999538022_J 
K2.4 75nM RG7388 d 3999538022_K 
K3.4 75nM RG7388 + 2.5µM 
GSK2830371 
d 3999538022_L 
Table 6-1 Table shows sample names, their treatment and groups (Independent 
repeats). Sentrix positions are related to the position of each planar silica slide 
exposed to a sample.
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Figure 6-5 Ranked mean signal intensity per probe and standard deviation 
between samples show that standard deviation does not correlate positively with 
mean signal intensity 
 
Figure 6-6 A) Boxplot of median signal intensities of arrays show that median 
signal intensity and the spread of the data are similar among arrays. B) Density 
plot of intensity of all arrays shows that the spread of signal intensity is the same 
among samples.
  
 
2
2
4 
 
Figure 6-7 A-E) Summary of controls from 12 arrays/samples as suggested by Illumina. Sample –dependent and independent 
controls (explained in 6.3.5.3) show no signs of experimental errors or inconsistencies. In D mm2: Mismatch; pm: Perfect match 
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6.3.5.4 Conclusion of array experimental controls 
There were no indications of failed samples and excessive background. Hybridisation 
and stringency controls were also satisfactory. 
6.3.5.5 Pathway analysis 
Because differentially expressed genes just below the statistical significance cut-off 
after Benjamini-Hotchberg correction for multiple testing were mostly p53 target genes 
we decided to upload the data of  the top genes with the lowest p-values ( cut-off α = 
0.001) into the Ingenuity Pathway Analysis (IPA) software package (Ingenuity 
Systems). The IPA calculates P-values based on the number of significantly 
differentially expressed genes that map to a specific biological function or pathway in 
comparison to the IPA knowledge base (Reference set). Fisher’s exact test is then used 
to assess the following null hypothesis: The proportion of genes mapping to a function 
or pathway in our set of significant genes is similar to the proportion that map in the 
reference set. If the proportions were similar, then no biological effect was presumed.  
6.3.6 Site-directed mutagenesis of cDNA in plasmids 
Plasmid vector used in this study, pcDNA3.1 (+/-) 5428/5427bp, had been purchased 
from Invitrogen (# V790-20 and V795-20) and full-length human TP53 complementary 
DNA (cDNA) was cloned into this backbone by Dr Xiaohong Lu prior to my arrival 
(Figure 6-8). This vector will be referred to as Wtp53 henceforth. Wtp53 was 
subsequently used in a site-directed mutagenesis procedure to generate full-length TP53 
cDNA sequences with two different mutations in codon 15 encoding p53 
Serine15Alanine (S15A) and p53 Serine15Aspartate (S15D) mutants. Site-directed 
mutagenesis is a procedure through which a target DNA molecule can be mutated on 
specific sites so that the role of those sites in manifesting the phenotype associated with 
the target DNA can be investigated. Forward and reverse primers were designed so that 
they form Watson-Crick pairing with 5 codons upstream and downstream of the codon 
of interest which was modified with the mismatch that would encode either Alanine or 
aspartate. Primer sequences are provided in Table 6-2 were used to PCR amplify the 
Wtp53 vector under the conditions stated in (Table 6-3 and Table 6-4). PfuTurbo DNA 
polymerase (Aligent technologies, # 600254) is a proprietary enhanced recombinant 
version of Pfu DNA polymerase which shows higher replication fidelity and it is more 
thermostable. PfuTurbo shows an error rate 6-fold lower than that of Taq DNA 
polymerase (1.3 × 10-6 V 8 × 10-6). A 30µl aliquot of each PCR reaction was then 
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incubated for 1 hour at 37°C with 1µl if the restriction endonuclease enzyme Dpn1 (Life 
Technologies, ER1702) which will degrade the methylated Wtp53 vector replicated by 
the host bacterium. The unmethylated PCR products were then used in transformation 
experiments as described above and DNA was extracted from 4 transformed bacterial 
colonies followed by Sanger sequencing (DBS genomics, Durham university) allowing 
the identification of mutant vectors. Mutation of Serine 15 to Alanine prevents the 
phosphorylation of this residue. A mutation to the negatively charged amino acid 
Aspartate at the same site had been reported to mimic a phosphorylated residue 
(pp53S15). This site directed mutagenesis protocol was obtained and adapted from 
Gozani lab protocols (Gozani). 
6.3.7 Transient overexpression of p53 in TP53 null mammalian cells 
HCT116-/- cells were seeded at 6 × 105 cells/well of a 6-well plate 24Hrs before 
transient transfection with plasmid-lipofectamine complex. Transient transfection was 
carried out as explained in 2.7.2 with the minor modification so that the ratio of vector 
(µg):lipofectamine used for complex formation was 1:2.5. Lysates were collected at 
different time-points following transfection and immunoblotting was carried out to 
assess the biochemical effects of overexpression of different doses of both wild-type 
and mutant p53. 
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Figure 6-8 The map of pcDNA3.1 plasmid as presented in its online user manual 
(Invitrogen #: V790-20 and V795-20). The full-length p53 cDNA sequence was 
cloned downstream of the Cytomegalovirus (CMV) promoter. This plasmid was 
used in site-directed mutagenesis studies of p53 and for overexpression of p53 in 
HCT116-/- cells. 
  
 228 
 
Primer name Primer sequence 5’-3’ 
Forward-p53S15A GTCGAGCCCCCTCTGGCTCAGGAAACATTTTCA 
Reverse-p53S15A TGAAAATGTTTCCTGAGCCAGAGGGGGCTCGAC 
Forward-p53S15D GTCGAGCCCCCTCTGGACCAGGAAACATTTTCA 
Reverse-p53S15D TGAAAATGTTTCCTGGTCCAGAGGGGGCTCGAC 
Table 6-2 Primers used in site-directed mutagenesis experiments. Codons modified 
are denoted in red text. 
Constituent Volume/amount 
ddH2O  33.5μl  
10X PfuTurbo Reaction mix  5μl  
2.5mM dNTP  2μl  
DMSO 2.5µl  
Forward Primer (10µM stock) 2μl  
Reverse Primer (10µM stock) 2μl  
Template DNA (2pg-200ng) 2µl  
PfuTurbo DNA Polymerase (final concentration 
1U/50µl reaction) 
1µl  
Total volume  50µl 
Table 6-3 Constituents of the PCR reaction for site-directed mutagenesis. 
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Steps  Name Temperature (°C) Duration (Sec) 
1 Template melting 95 120 
2 Template melting 95 20 
3 Primer annealing 55 30 
4 Elongation 68 600* PfuTurbo 
(1min/kb) 
5 Repeated cycles Repeat steps 2-4 for 19 cycles 
6 Elongation 68 600 
7 Storage 4 ∞ 
Table 6-4 Thermal cycling during the site-directed mutagenesis PCR experiment. 
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6.4 Results 
6.4.1 Comparison between Nutlin-3 and ionising radiation induced p53Ser15 
phosphorylation 
The absence of p53Ser15 phosphorylation was used as evidence for the non-genotoxic 
mechanism of action of MDM2 inhibitors in the initial publication by Vassilev et al., 
where the Nutlin class of small molecular weight inhibitors of MDM2 were first 
reported (Vassilev, Vu et al. 2004). However, since then there have been multiple 
independent reports of p53Ser15 phosphorylation including consistent observations in our 
own laboratory. Given that Nulin-3 does not possess any obvious chemical properties 
that are associated with genotoxic compounds we investigated the differences between 
ionising radiation (IR) and Nutlin-3 induced p53Ser15 phosphorylation. NGP cells treated 
with 10Gy IR showed rapid and maximal p53Ser15 phosphorylation which was 
disproportional in signal intensity to p53 stabilisation following IR exposure (Compare 
lane 1 to lanes 3-8 on Figure 6-9A) whereas in response to 5µM Nutlin-3 this 
phosphorylation event was more gradual and proportional to total p53 stabilisation 
(Compare lane 1 to lanes 3-8 on Figure 6-9B). The direct p53 transcriptional target 
MDM2 was induced in response to Nutlin-3 and IR. It is important to note that while in 
this experiment the dose of IR is ~5 × GI50 compared to the dose of Nutlin-3 which is 
~1.7 × GI50, 4Gy IR which is around ~2 × GI50 also result in a very intense and more 
immediate p53Ser15 phosphorylation (Figure 6-11).  
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Figure 6-9 Kinetics of p53Ser15 phosphorylation in NGP cells following either 10Gy 
IR (A) or 5µM Nutlin-3 (B). The first and the last lanes on each blot can be used as 
positive control for p53Ser15 and comparators for band intensity on each blot.  
6.4.2 Phosphorylation of p53Ser15 after Nutlin-3 is not exclusive to class of MDM2 
inhibitors or cell type 
We sought to assess whether p53Ser15 phosphorylation in response to MDM2 inhibitors 
is cell type or drug class specific. Immunoblots were used to investigate pp53Ser15 levels 
in NGP and SJSA-1 cell lines 4Hrs following MDM2 inhibitors of spiroxindole (MI63) 
and isoindolinone classes (NCL-20135, structure unpublished) along with another more 
potent cis-imidazoline clinical compound RG7112. All classes of MDM2 inhibitors 
showed increased pp53Ser15 in both cell lines suggesting that there is no class or cell line 
specific effect with regards to this PTM. Moreover, all MDM2 inhibitors increased the 
transcription of p53 targets MDM2 and p21WAF1.
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Figure 6-10 Phosphorylation of p53Ser15 4Hrs following treatment with MDM2 inhibitors is neither class nor cell type specific. Different classes 
of MDM2 inhibitors all cause an increase in p53Ser15 phosphorylation in both NGP and SJSA-1 cell lines.  Supervised  undergraduate student 
Mr Alex Smith assisted with this experiment.
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6.4.3 Phosphorylation of p53 following Nutlin-3 is due to the basal activity of 
PI3KK 
In order to assess whether the p53Ser15 phosphorylation is due to the activity of the same 
kinases that phosphorylate p53 in response to DNA damage (PI3KKs) we tested the 
effect of specific and broad spectrum kinase inhibitors on pp53Ser15 levels 4Hrs 
following 5µM Nutlin-3 and 30min post 4Gy IR in the TP53 Wild-type NGP cell line 
and its otherwise isogenic TP53 mutant daughter cell line N20R1. NU7441 at 1µM 
resulted in no change in IR induced p53Ser15 phosphorylation while Wortmannin at 1µM 
inhibited this phosphorylation modestly. 10µM KU55933 however resulted in marked 
inhibition of p53Ser15 phosphorylation as predicted by the reported importance of ATM 
in targeting this residue in response to IR. The combination of ATM and DNA-PK 
inhibition also resulted in the same outcome although NU7441 likely did not contribute 
to the inhibition of this phosphorylation event. In stark contrast the most robust 
inhibition of p53Ser15 phosphorylation in response to 5µM Nutlin-3 was achieved by the 
combination of NU7441 and KU55933 followed by the broad spectrum PI3K inhibitor 
Wortmannin. Single treatment with either NU7441 or KU55933 did not affect Nutlin-3 
mediated p53Ser-15 phosphorylation. Not long following this observation; Loughery et 
al., (2014) (Loughery, Cox et al. 2014) reported that the combination of ATR and ATM 
inhibition have a similar effect on p53Ser15 phosphorylation following Nutlin-3. This is 
consistent with the model that the basal activities of multiple kinases targeting this 
residue are likely responsible for this phosphorylation event (Loughery, Cox et al. 
2014). Interestingly reduced p53Ser15 phosphorylation in the presence of the relevant 
kinase inhibitors coincided with diminished p53 mediated MDM2 induction (Figure 
6-12). All these processes were independent of TP53 genetic status with both wild-type 
and mutant cell lines undergoing phosphorylation which could be inhibited by ATM 
inhibition alone in the case of IR and modestly by the combination of ATM and DNA-
PKcs inhibition.
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Figure 6-11 IR induced phosphorylation of p53Ser15 is dependent on ATM catalytic activity. NGP and their otherwise isogenic TP53 mutant 
daughter cell line N20R1 were pre-treated for 30min with the stated doses of kinase inhibitors and then exposed to IR 30 min before lysate 
extraction. KU: ATM inhibitor KU55933; NU: DNA-PK inhibitor NU7441; WMN: Broad spectrum PI3K inhibitor Wortmannin.  
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Figure 6-12 Phosphorylation of p53Ser15 following MDM2 inhibitors is dependent on both ATM and DNA-PK kinase activity. Individual 
specific kinase inhibitors NU7441 (DNA-PK) and KU55933 (ATM) did not reduce p53Ser15 phosphorylation as effectively as their combination. 
Cells were treated simultaneously with doses of Nutlin-3 or stated kinase inhibitor(s) 4Hrs prior to lysate collection. KU: ATM inhibitor 
KU55933; NU: DNA-PK inhibitor NU7441; WMN: Broad spectrum PI3K inhibitor Wortmannin.
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6.4.4 Pharmacological elevation of p53Ser15 phosphorylation in the absence of DNA 
damage concurs with induction of a larger subset of genes regulated by p53-
driven promoters 
As was shown in Chapter 5, the combination of non-genotoxic doses of MDM2 
inhibitors and GSK2830371 increases p53Ser15 phosphorylation markedly in cell lines 
where neither drug on their own detectably influence this residue. This phosphorylation 
event coincided with increased growth inhibition and cell death endpoints only when 
p53 was transcriptionally functional. Given the reported role of p53Ser15 phosphorylation 
in enhancing p53 interaction with transcriptional coactivator such as p300/CBP 
(Jenkins, Durell et al. 2012), it was of interest to assess whether the subset of early 
genes activated by p53 differed in response to the combination regimen compared to 
RG7388 treatment alone. This may be an important underlying mechanism for the 
observed potentiation in response to the combination treatment  
Maximal p53 target protein induction in NGP cells by treatment with MDM2 inhibitors 
was reached at 6-8Hrs (Figure 6-9) so we predicted that transcripts would precede this 
by at least 2Hrs. Therefore we assessed global changes in gene expression at 4Hrs 
treatment in NGP cells which showed the greatest potentiation in response to the 
combination treatment (5.8-fold, Section 5.5.1). Induction of early p53 target genes 
were of particular interest given that the appearance of transcripts at later time-points 
may not be directly regulated by p53.  
NGP cells were treated with 0.5% DMSO, 75nM RG7388 (~GI50) + 2.5µM 
GSK2830371 for 4Hrs before RNA and protein extraction in parallel. The number of 
statistically significant transcripts induced 4Hrs after 75nM RG7388 were 9 (after 
Benjamini-Hotchberg correction for multiple testing), all of which were known p53 
transcriptional targets (Table 6-5, Table 6-6 and Figure 6-13). The subset of statistically 
significant p53 transcriptional target genes induced by RG7388 however increased from 
9 to 24 when WIP1 was inhibited. There was an increase in both pro-apoptotic and pro-
arrest genes in the combination treatment. Western blotting on lysates isolated from 
cells treated in parallel to the samples used for expression array analysis showed that 
this increase in differential expression correlates with p53Ser15 phosphorylation in the 
absence of any changes to total p53 levels (Figure 6-14). Furthermore all the 
statistically significant changes in p53 transcriptional targets show positive increase in 
transcript level and transcription suppression was not detected. This is also translated to 
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the protein level as p21WAF1 induction was subtly increased in two out of three repeats 
analysed by western blotting and MDM2 in one out of three repeats.   
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(A) RG7388 V DMSO 
Gene Symbol log2 (Fold-
change) 
Adjusted 
p-value 
OR Function summary 
CDKN1A 2.07 0.002 3.95 Pro-arrest 
PHLDA3 1.58 0.002 3.94 Pro-apoptotic 
SESN1 1.12 0.018 2.57 ↓ROS 
BTG2 0.84 0.002 3.80 Pro-arrest 
AEN 0.83 0.026 2.31 Pro-apoptotic/Exonuclease 
activity 
TP53INP1 0.77 0.001 4.42 Pro-apoptotic 
RGMA 0.66 0.018 2.63 Inhibitor of neurite outgrowth 
C12orf5 0.59 0.016 2.85 ↓ROS 
FAM212B 0.52 0.017 2.74 Poorly understood 
Table 6-5 Genes induced following treatment of NGP cells with 75nM RG7388 
(GI50). OR: Odds Ratio; ROS: Reactive oxygen species 
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(B) RG7388 + WIP1i V DMSO 
Gene Symbol log2 (Fold-
change) 
Adjusted 
p-value 
OR Function summary 
BTG2 1.31 0.0001 6.77 Pro-arrest 
TP53INP1 0.95 0.0001 6.76 Pro-apoptotic 
CDKN1A 2.67 0.0002 6.35 Pro-arrest 
PHLDA3 1.93 0.0002 6.15 Pro-apoptotic 
FAM212B 0.88 0.0002 6.09 Poorly understood 
RGMA 0.96 0.0009 5.38 Inhibitor of neurite outgrowth 
C12orf5 0.77 0.0012 5.17 ↓ROS 
SESN1 1.46 0.0019 4.84 ↓ROS 
SESN2 0.58 0.0027 4.58 ↓ROS 
ACTA2 0.71 0.0028 4.51 Structural/Motility 
XPC 0.66 0.0041 4.22 DNA Repair 
Nucleotide excision repair 
ZNF79 0.43 0.0062 3.91 Poorly understood 
AEN 0.85 0.0147 3.27 Pro-apoptotic/Exonuclease activity 
LOC101927383 0.63 0.0151 3.21 Long non-coding RNA 
FAM212B 0.32 0.0178 3.04 Poorly understood 
TNFRSF10B 0.52 0.0210 2.87 Pro-apoptotic 
PIDD1 0.37 0.0368 2.41 Pro-apoptotic 
TRIAP1 0.66 0.0389 2.33 Anti-apoptotic 
ARC 0.38 0.0420 2.23 Structural 
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DDB2 0.29 0.0429 2.17 DNA Repair 
Nucleotide excision repair 
MDM2 0.51 0.0434 2.10 Pro-survival 
TOB1 0.53 0.0434 2.09 Pro-arrest 
BLOC1S2 0.31 0.0454 1.97 lysosome-related organelles/Neurite 
formation 
GADD45A 0.74 0.0454 1.97 Pro-arrest 
ZMAT3 0.59 0.0454 1.96 Pro-arrest/-apoptotic 
Table 6-6 A larger subset of p53 transcriptional targets are induced by a 
combination of 75nM RG7388 and 2.5µM GSK2830371. OR: Odds ratio; ROS: 
Reactive oxygen species. This table is a continuation of the table on the previous 
page.
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Figure 6-13 Volcano plot showing the top 50 differentially expressed genes between DMSO and the two treatment conditions. A larger subset 
of p53 target genes are differentially expressed in response to the combination of RG7388 and GSK2830371 at compared RG7388 single 
treatment at 4Hrs. Y-axis shows –log10 adjusted p-value (Benjamini-Hotchberg Corrected) and the x-axis shows log2 fold-change.
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Figure 6-14 Immunoblot shows treatment with the combination of RG7388 and 
GSK2830371 compared to RG7388 alone results in an increase in p53Ser15 
phosphorylation pp53Ser15 at 4Hrs which correlates with an increase in p53 
transcriptional targets p21WAF1 and MDM2. 
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6.4.5 Pathway analysis of gene expression 
Upon closer inspection genes just below the significance level, as ranked by raw p-value 
after correction for multiple testing, were mostly p53 transcriptional targets. This is 
unlikely to be coincidental given the total number of probes detected (~18000). 
Benjamini-Hotchberg or Bonferroni methods used in correction for multiple testing in 
the context of microarray data for gene expression changes have been suggested to be 
too conservative. This is because the hypotheses tested are not wholly independent as 
the genes involved are generally altered in a mutually dependent groups by the same 
transcription factor (Perneger 1998, Bender and Lange 1999). Given our knowledge of 
the mechanism of action of MDM2 inhibitors and the p53 network and its 
transcriptional targets, we know that independence of all the tested variables is not a 
justifiable assumption. We wanted to assess whether other pathways are activated that 
are just below the statistical significance level after correction for multiple testing.  
The number of statistically significant genes in both treatment conditions exceeded 
1000 when p-values from paired t-tests were examined without correction for multiple 
testing if significance level (α) <0.05. In order to detect biologically relevant changes, 
reduce the computational load and increase confidence levels, α < 0.001 was used as the 
cut-off point prior to selection of genes for pathway analysis using Ingenuity Pathway 
Analysis (IPA) software package system. This analysis confirmed that most genes in the 
p-value range <0.001, before correction for multiple testing, were involved in p53 
signalling. This was the case with respect to both treatment conditions (RG7388 p=3.19 
× 10-9 and RG7388 + GSK2830371 p=7.78 × 10-10). IPA calculates the p-values for 
pathway analysis as described in 6.3.5.5. Transcripts which are considered as canonical 
p53 targets are highlighted using IPA pathway designer (Figure 6-15 and Figure 6-16). 
Canonical p53 pro-apoptotic transcriptional targets PUMA and PIDD1 were induced 
only WIP1 was inhibited suggesting altered promoter selectivity in the presence of 
WIP1 inhibition. Although these results must be further investigated at mRNA and 
protein level at various time-points after treatment.
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Figure 6-15 Canonical p53 transcriptional targets induced in response to treatment with 75nM RG7388 and their involvement in 
cellular processes (p=3.19 × 10-9). Nodes filled grey are not induced in response to RG7388 single treatment. 
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Figure 6-16 Canonical p53 transcriptional targets induced in response to treatment with 75nM RG7388 + 2.5µM GSK2830371 and 
their involvement in cellular processes as identified by IPA reference data set (p=7.78 × 10-10). PIDD1 and PUMA are induced in 
the presence of WIP1 inhibition.
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6.4.5.1 qRT-PCR validation of the array data 
Differentially expressed genes of interest among those listed in Table 6-6A & B which 
were implicated in important biological processes were selected for validation by qRT-
PCR using cDNA generated from the same samples used for microarray analysis. 
CDKN1A (p21WAF1) and BTG2 were among the genes validated which were involved in 
inhibition of cell cycle progression (Eldeiry, Tokino et al. 1993, Rouault, Falette et al. 
1996). TP53INP1 and PHLDA3 also validated are pro-apoptotic p53 transcriptional 
target genes (Okamura, Arakawa et al. 2001, Kawase, Ohki et al. 2009). The increased 
basal expression of XPC, a gene involved in nucleotide excision repair, was also 
investigated as it is one member elevated in a gene expression signature associated with 
an increased sensitivity to MDM2 inhibitors RG7112 and RG7388 both pre-clinically 
and clinically in acute lymphoblastic leukaemia (ALL) (Zhong, Chen et al. 2015). 
CDKN1A and BTG2 both showed increased fold-change in expression in response to 
single treatment with RG7388 and were elevated significantly when WIP1 inhibitor was 
additionally present (Figure 6-17). Consistent with an increase in apoptosis in response 
to the combination treatment compared to single MDM2 inhibitor in NGP cells there 
was a significant increase in the expression of TP53INP1 in response to RG7388 which 
was also significantly elevated in the presence of GSK2830371 (WIP1i). Although the 
expression of PHLDA3 was not significantly different between RG7388 single 
treatment and in the background of WIP1 inhibition there was a trend towards increased 
expression in the combination treatment as the p-value decreased by a decimal point. 
MDM2 was also differentially induced in the presence of the GSK2830371 compared to 
RG7388 alone. XPC expression was not differ in expression comparing the single 
treatment to combination treatment using qRT-PCR. These transcriptional changes 
likely contribute to the potentiation MDM2 inhibitors in NGP cells in the presence of 
GSK2830371 and are likely caused by an increase in p53Ser15 phosphorylation 
(Loughery, Cox et al. 2014). 
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Figure 6-17 Quantitative real-time PCR carried out to assess the validity of 
microarray data. Data represent mean ± standard error of mean (SEM) relative 
quantities of four independent repeats where GAPDH was used as endogenous 
control and DMSO as the calibrator for each independent repeat with the formula 
2-ΔΔCT. P-values calculated by paired t-test; *: p<0.05; **: p<0.005; ***: p<0.0005 
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6.4.6 p53-dependent reporter gene expression was induced by Nutlin-3 but showed 
no further change with the addition of GSK2830371 (WIP1i) 
The combination of MDM2 and WIP1 inhibition at mechanistically relevant doses was 
shown to increase p53Ser15 transcription in the absence of any DNA damaging agents. 
We sought to assess p53 transcriptional activity from a p53 consensus sequence 
regulated luciferase reporter system stably transfected in TP53 wild-type and mutant 
glioblastoma cell lines following multiples of Nutlin-3 GI50 + 2.5µM GSK2830371. No 
reporter activity was observed in response to 2.5µM GSK2830371. However, there was 
dose-dependent increase in reporter activity 24Hrs following Nutlin-3 multiples of GI50 
dose in the DD7 (TP53 Wild-type) cells but not in DR4 cells (TP53 Mutant). This 
reporter activity was not enhanced in the presence of the WIP1 inhibitor. The 24Hrs 
time-point was chosen because earlier time-points did not produce a Nutlin-3 dose-
dependent reporter signal. We aimed to assess whether GSK2830371 can sensitise cells 
to Nutlin-3. SRB growth inhibition assays were carried out as described in Chapter 5 
which showed that GSK2830371 modestly (1.7-Fold, p=0.005) potentiated the response 
of DD7 cells to Nutlin-3 in the presence of 2.5µM GSK2830371 (Figure 6-18). 
Interestingly, WIP1 inhibitor on its own resulted in growth inhibition in the TP53 
mutant DR4 cell lines. These findings overall suggest that p53 transcriptional activity 
may not be important for the potentiation of MDM2 inhibitors by GSK2830371 in these 
cell lines.   
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Figure 6-18 A) Firefly luciferase reporter enzyme activity 24Hrs following 1 × and 
2 × Nutlin-3 DD7 GI50. B) SRB Growth inhibition of stably transfected 
glioblastoma cell lines in the presence and absence of 2.5µM GSK2830371. 
Potentiation of the TP53 wild-type cell lines is modest. Wt: Wild-type; Mut: 
Mutant 
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6.4.7 Mutations of p53Ser15 modulate the levels of p53 induced transcriptional 
targets  
Previous reports in the literature have shown that p53Ser15 phosphorylation, while not 
necessary for the dissociation of p53 from MDM2, enhances transcription from p53-
driven promoters (Dumaz and Meek 1999, Loughery, Cox et al. 2014). Residue Serine 
15 was mutated to alanine (p53S15A) to prevent phosphorylation at that site. Also 
separately we mutated this to aspartate (p53S15D) known to mimic a phosphate group. 
We then ectopically expressed these mutants of p53 to assess their impact on p53 
transcriptional activity compared to wild-type p53 overexpression. Site-directed 
mutagenesis was carried out on full-length wild-type p53 cDNA as described in 6.3.6 
and Sanger sequencing data showed that the mutagenesis had been successful (Figure 
6-19). Concentrations of plasmids were transfected in order to make the data more 
comparable to approximate physiological levels of p53 under these experimental 
conditions. Western blots (Figure 6-20) showed that p53S15A or p53S15D cannot be 
detected by a phospho-p53S15 (pp53Ser15) antibody confirming that these mutants cannot 
be phosphorylated on that residue. Also interestingly consistent with previous findings, 
p53 transcriptional activity as measured by MDM2 and p21WAF1 expression, is subtly 
higher either when p53Ser15 can be phosphorylated or when the phosphorylation is 
mimicked by an aspartate residue (p53S15D) (Figure 6-20). The observations are 
consistent with earlier findings that p53Ser15 plays a role in transcriptional activity from 
p53 regulated promoters (Loughery, Cox et al. 2014). Images obtained from cells 
transfected with these vectors show that there are more floating cells in wells 
transfected with wild-type p53 and p53S15D compared to p53S15A (Figure 6-21) which 
warrants further investigation into the expression of early and late apoptotic markers. 
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Figure 6-19 Chromatogram traces from the Sanger sequencing experiment before 
and after site-directed mutagenesis of full-length p53 plasmid.
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Figure 6-20 Phosphorylation of p53 influences expression of p53 transcriptional targets MDM2 and p21WAF1 at the protein level. A) 
Immunoblot showing TP53 Null HCT116 cells (HCT116-/-) transfected with 4.0µg of either wild-type (Wtp53) or mutant p53 (p53S15A or 
p53S15D) expression plasmids 12Hrs before lysate extraction and western blotting. B)  Immunoblot of HCT116-/- cells transfected with lower 
amounts of p53 overexpressing plasmids with lysate collection at two different time-points. HCT116+/+ cells were used as a positive control in 
B. Tfxn: transfection; Conc.: Concentration  
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Figure 6-21 Apoptotic morphology of HCT116-/- cells 24Hrs following overexpression of wild-type p53 (Wtp53) compared to p53S15A or 
p53S15D.  Apoptotic/floating cells were more numerous in 
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6.5 Discussion 
Activation of p53, in response to cellular stress, depends on a complex array of post-
translational modifications (PTM’s) that lead to the dissociation of p53 from MDM2, 
and both release and activate its transcriptional function. DNA damage induced p53 
PTM’s have been extensively investigated in contrast to those induced by MDM2 
inhibitors. Phosphorylation of p53Ser15 following treatment with MDM2 inhibitors has 
been observed by various groups including ours. Our data show that pp53Ser15 
accumulation is slow and proportional to p53 stabilisation following MDM2 inhibitors 
compared to its immediate and intense appearance after DNA damage with IR. These 
observations are consistent with an earlier model that MDM2 inhibitors result in 
exposure of p53Ser15 to the basal activity of kinases and phosphatases that target this 
residue. In the previous chapter we showed that WIP1 inhibition tilts this balance 
towards the kinases that target this residue and markedly increases MDM2 inhibitor 
induced pp53Ser15. This was shown to correlate with potentiation of MDM2 inhibitors. 
In this evidence was presented to support the hypothesis that this potentiation is due to 
increased p53 transcriptional activity caused by increased p53Ser15 phosphorylation. This 
demonstrates that sensitivity to MDM2 inhibitors can be increased by 
pharmacologically modulating p53 transcriptional activity through influencing its post-
translational modification. 
6.5.1 Phosphorylation of p53Ser15 in the absence of DNA damage 
Phosphorylation of p53Ser15 has also been used as a surrogate marker for DNA damage 
in the literature. However, this model presumes kinases that respond immediately 
following their activation by DNA damaging agents. Our observations suggest that 
while this model may hold true in response to the seemingly all or none activity of 
ATM kinase in phosphorylation of p53Ser15 after IR, it cannot explain the slow increase 
in pp53Ser15 following treatment with MDM2 inhibitors. Phosphorylation of p53Ser15 
after MDM2 inhibitors is less intense more gradual and independent of MDM2 inhibitor 
class and cell type. Inhibition of ATM by KU55933 resulted in a marked reduction in 
p53Ser15 phosphorylation after IR in contrast to the relative lack of effect with DNA-PK 
inhibition (NU7441) or broad spectrum PI3K inhibition (Wortmannin). Inhibition of 
ATM or DNA-PK kinases alone did not influence pp53Ser15 following Nutlin-3, whereas 
their combination resulted in a notable reduction in Nutlin-3 mediated pp53Ser15. 
Wortmannin also reduced p53Ser15 phosphorylation following Nutlin-3 treatment. The 
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above observation suggest that it is likely the basal activity of multiple kinases are 
involved in targeting this residue and their effect is only apparent when p53 is released 
from MDM2. Interestingly, in Chapter 5 we showed that single agent treatment with 
MDM2 or WIP1 inhibitors did not influence pp53Ser15 in contrast to their combination 
which resulted in a marked increase in pp53Ser15. This showed that p53Ser15 
phosphorylation status, after MDM2 inhibitor treatment is mostly down-regulated by 
WIP1 phosphatase and makes this a prime target for potentiating the effect of MDM2 
inhibitors via its effect on p53 function and cell fate.  
6.5.2 Increasing MDM2 inhibitor induced pp53Ser15 coincides with enhanced p53 
transcriptional activity 
Phosphorylation of p53Ser15 is considered a “nucleation event” which can initiate 
subsequent post-translational modifications important in modulation of p53 
transcriptional function and its interaction with MDM2 (Sakaguchi, Saito et al. 2000, 
Meek and Anderson 2009). Phosphorylation of p53Ser15 after MDM2 inhibition was 
markedly increased in response to the selective WIP1 inhibitor GSK2830371 or siRNA 
mediated WIP1 knockdown. This pp53Ser15 increase concurred with increased 
sensitivity to MDM2 inhibitors only in p53 wild-type cell lines in which p53 is 
transcriptionally active. Protein levels of p53 transcriptional targets MDM2 and 
p21WAF1, as measured by immunoblotting, were only slightly affected by the WIP1 
inhibition. Array based differential gene expression analysis showed that more p53 
transcriptional target genes were significantly upregulated in the presence of the 
selective WIP1 inhibitor GSK2830371 than with RG7388 alone. This correlation 
suggests that WIP1 inhibitor mediated potentiation of MDM2 inhibitors in NGP cells is 
caused by an increase in transcription from p53 regulated promoters. Interestingly, most 
genes that were differentially induced in the presence of the WIP1 inhibitor have been 
implicated in pro-apoptotic signalling. Validation by qRT-PCR confirmed that the 
expression of CDKN1A, BTG2 and MDM2 were increased in response to RG7388 and 
enhanced in the presence of GSK2830371. These were consistent with the subtle 
changes observed at the protein level in response to the combination of MDM2 and 
WIP1 inhibition in Chapter 5. Expression of other genes such as TNFRSF10B, AEN and 
XPC as measured by qRT-PCR were also increased in response to RG7388 + 
GSK2830371. Although these genes showed a pattern towards enhanced transcriptional 
induction in the presence of GSK2830371 it would be difficult to assume biological 
relevance purely based on the changes detected by the qRT-PCR and the array at this 
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dose and time point alone. As it was noted in chapter 1 p53 transcriptional target genes 
have different kinetics of induction following p53 activation. This has been attributed to 
differences between p53 response elements at gene promoters and different efficiency 
of pre-initiation complex formation among target gene promoters (Espinosa, Verdun et 
al. 2003, Morachis, Murawsky et al. 2010). Therefore, interpretation of differential 
expression of p53 target genes detected by the array may require further mechanistic 
investigations following different doses and time-points of the combination treatment.  
6.5.2.1 Induction of p53 targets and kinetics of PTM’s 
Modifications of other p53 residues important for p53 function such as acetylation of C-
terminal residues K320 and K382 and phosphorylation of Ser9, Thr18 and Ser20 have 
also been reported to require p53Ser15 phosphorylation (Sakaguchi, Herrera et al. 1998, 
Sakaguchi, Saito et al. 2000, Saito, Goodarzi et al. 2002, Saito, Yamaguchi et al. 2003). 
These modifications may impact MDM2-p53 interaction or p53 transcriptional function 
at later time points than 4Hrs following p53 activation. There were many other p53 
transcriptional targets that were just below the significance threshold p-value after 
correction for multiple testing. This was shown by pathway analysis for the top 50 
differentially expressed genes (raw p-value <0.001) between both treatment conditions. 
The efficient induction of these genes may require special barcodes of p53 PTM’s that 
occur in sequence to p53Ser15 and recruit other co-factors. Therefore analysis of gene 
expression following >4Hrs combination of MDM2 and WIP1 inhibitors may be 
informative about the role of pp53Ser15 in differential induction of these genes and in 
turn in cell fate determination. The dose of RG7388 used in this experiment was 
equivalent to the GI50 value for this compound in NGP cells, in which the greatest 
potentiation of MDM2 inhibitors was observed. Due to the differences between 
densities in the growth inhibition setting (~20%) and those used for RNA preparation 
(~50-60%) at the time of treatment however, a higher dose of MDM2 inhibitors may be 
better representative of any differential expression of p53 transcriptional targets. 
6.5.2.2 Luciferase reporter gene expression in response to the combination of 
MDM2 and WIP1 inhibitors. 
DD7 and DR4 cells stably transfected with p53 reporter gene construct were derived 
from DBTRG and T98G respectively, neither of which have been reported to show 
differences in WIP1 expression or PPM1D mutations. The growth inhibition of the 
TP53 wild-type clone (DD7) to Nutlin-3 was potentiated in the presence of 2.5µM 
GSK2830371. The sensitivity of the TP53 mutant clone did not change in the presence 
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of GSK2830371. Interestingly, 2.5µM GSK2830371 resulted in modest growth 
inhibition in the TP53 mutant cell line which suggests a p53-independent mechanisms 
of action for this compound. However, this may be because both cell lines are grown 
under selection conditions which may make cells more sensitive to WIP1 inhibition 
through a p53 independent mechanism. This may result in p53-independent mechanisms 
of growth inhibition. Treatment with 1× and 2× Nutlin-3 GI50 doses resulted in a dose-
dependent increase in luciferase activity in the TP53 wild-type clone (DD7) and not the 
mutant (DR4). However the addition of 2.5µM GSK2830371 did not enhance this 
activity. This may suggest that the potentiation of the Nutlin-3 growth inhibitory 
response in DD7 cells does not rely on an increase in p53 transcriptional activity. 
Unfortunately because of time limitations pp53Ser15 following MDM2 and WIP1 
inhibitor combination was not investigated in these cell lines to confirm the increased 
phosphorylation. 
6.5.3 Transient expression of p53 containing mutations in p53Ser15 
Expression of wild-type p53 and its comparison with p53S15A and p53S15D variants 
generated by site-directed mutagenesis showed that the phosphorylation of this residue 
is important for transcriptional regulation from p53 driven promoters. The phospho-
mimic aspartate residue on Ser15 consistently resulted in a notable increase in p53 
transcriptional targets MDM2 and p21WAF1 when compared to non-phosphorylated 
alanine at the same residue. Interestingly all three p53 expression constructs resulted in 
apoptotic morphology 24Hrs following transfection. There appeared to be fewer cells 
with apoptotic morphology in response to p53S15A overexpression as compared to p53 
wild-type and p53S15D overexpression. However this remains a qualitative impression at 
present and has not been quantified or biochemically assessed yet.  
6.5.4 Summary 
The overall evidence presented in Chapters 6 and 7 strongly supports the notion that 
phosphorylation of p53Ser15 is not only a reliable biomarker for on target activity of the 
combination treatment but it is also mechanistically important for p53 transcriptional 
activity. The evidence also supports the model of dynamic regulation of the 
phosphorylation status of p53Ser15 following MDM2 inhibitors. This model is 
summarised in (Figure 6-22). These findings provide a rationale for the combination of 
MDM2 and WIP1 inhibitors, particularly in TP53 wild-type malignancies with 
increased PPM1D expression or gain-of-function. One such malignancy which is 
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mostly TP53 wild-type at diagnosis and shows increased PPM1D mRNA expression is 
neuroblastoma (Saito-Ohara, Imoto et al. 2003, Carr-Wilkinson, O'Toole et al. 2010). 
WIP1 is considered a potential therapeutic target in neuroblastoma and increased 
expression of its mRNA is a marker of poor progression (Richter, Dayaram et al. 2015). 
In the following chapter PPM1D expression and its relationship to clinical and 
pathological information will be further investigated in neuroblastoma.  
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Figure 6-22 The working model explaining the underlying mechanism of 
regulation of p53Ser15 phosphorylation status and its contribution to potentiation of 
MDM2 inhibitors by the WIP1 inhibitor GSK2830371.
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Chapter 7 The expression of PPM1D mRNA and WIP1 protein in 
neuroblastoma: relationship to pathology and survival
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7.1 Introduction 
In the previous chapters we showed that selective WIP1 inhibition results in 
potentiation of response to MDM2 inhibitors and related this to an increase in p53 
transcriptional activity. This potentiation was most notable in TP53 wild-type cell lines 
with increased WIP1 expression or gain-of-function mutations. Therefore, tumours with 
increased WIP1 expression or phosphatase activity would be ideal subgroups for use of 
WIP1 and MDM2 inhibitor combinations. Increased PPM1D mRNA expression has 
been reported to be associated with poor prognosis in neuroblastoma (Saito-Ohara, 
Imoto et al. 2003, Richter, Dayaram et al. 2015). However, the association between 
WIP1 protein expression and overall survival has not been investigated in this 
malignancy to date. In this chapter publically available online gene expression datasets 
are firstly investigated to assess the relative PPM1D mRNA expression in human 
malignancies and any correlation with overall survival, focusing on neuroblastoma. 
WIP1 immunohistochemical (IHC) staining is then investigated in an independent 
cohort of neuroblastoma tumour samples to analyse any correlation with clinical and 
pathological variables.  
7.1.1 PPM1D/WIP1 expression as a marker of prognosis in human malignancies 
Increased PPM1D mRNA expression was first reported to predict poorer survival in 
neuroblastoma (Saito-Ohara, Imoto et al. 2003). This was prompted by frequent gain of 
the distal region of chromosome 17q (17q21-17qter) which had been associated with 
poorer overall survival in neuroblastoma (Bown, Cotterill et al. 1999). Saito et al., 
(2003) aimed to identify which gene(s) at this locus was the most likely target for the 
chromosomal gain. Comparative genomic hybridisation experiments showed that 
PPM1D lies within the minimal common region gained among 25 neuroblastoma cell 
lines (Saito-Ohara, Imoto et al. 2003). This region included 15 genes, among which 7, 
including PPM1D, showed an increase in mRNA expression due to regional copy 
number gain. Primary neuroblastoma samples were then investigated by qRT-PCR for 
any association between mRNA expression of these 7 genes and overall survival. 
Survival analysis (Log-rank tests) showed that above median PPM1D mRNA 
expression was associated with poorer overall survival in this malignancy (Saito-Ohara, 
Imoto et al. 2003). Interestingly, the prognostic significance was not independent of 
MYCN-amplification, which is established as the strongest cytogenetic marker of poor 
overall survival in neuroblastoma (Brodeur, Seeger et al. 1984, Seeger, Brodeur et al. 
1985, Seeger, Wada et al. 1988). Another publication from the same group using similar 
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techniques showed that the 17q21-24 region, which includes PPM1D, is gained in clear 
cell ovarian carcinoma (Hirasawa, Saito-Ohara et al. 2003). This copy number gain also 
resulted in increased PPM1D mRNA expression and correlated with poorer overall 
survival in this malignancy. Interestingly, the mRNA expression of Amyloid Beta 
Precursor Protein (Cytoplasmic Tail) Binding Protein 2 (APPBP2) which is the first 
gene upstream of PPM1D was also shown to increase and correlate with poorer overall 
survival. Therefore, caution must be observed when interpreting genes affected in 
cytogenetic abnormalities as prognostic markers as it is difficult to distinguish driver 
genes from passenger genes. Driver genes are genes the products of which play a key 
mechanistic role in cancer development and progression and that are therefore more 
likely to be positively selected. Passenger genes however do not play a significant 
mechanistic role in cancer development; but are frequently positively selected along 
with key driver genes due to their close physical proximity. 
Rauta et al., (2006) showed that PPM1D-amplification was associated with an ERBB2 
positive subgroup of breast cancers which confers a poorer prognosis. Although it was 
shown that PPM1D-amplification results in an increased mRNA expression, WIP1 
protein level was not assessed (Rauta, Alarmo et al. 2006). Analysis of WIP1 protein 
expression in gastric carcinoma showed that approximately 75% of these tumours had 
intense IHC staining for WIP1 and that this correlated with tumour size; however no 
survival analysis was carried out (Fuku, Semba et al. 2007). In a more recent 
independent study investigating WIP1 expression in 800 gastric cancer samples 
however, high WIP1 IHC staining was correlated with various adverse clinical 
outcomes including poor overall survival (Ma, Zhang et al. 2014).  Lung 
adenocarcinoma was the first malignancy in which WIP1 protein expression was linked 
to poorer clinical and pathological  end-points, such as shorter survival after surgery, 
increased proliferation marker (Ki-67) and increased invasion to the pulmonary vein 
(Satoh, Maniwa et al. 2011). Interestingly, increased WIP1 expression also correlated to 
increased γH2AX staining in these samples, which is contrary to the reported role of 
WIP1 in dephosphorylating γH2AX (Cha, Lowe et al. 2010). This suggests that WIP1 
may have been induced in response to DNA double strand breaks following genotoxic 
stress in these tumours.  
Another study on glioma samples compared to healthy brain tissue showed that 
increased PPM1D mRNA expression correlated with increased WIP1 protein 
expression, as measured by western blotting and immunohistochemistry, (Liang, Guo et 
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al. 2012). Survival analysis then showed that increased WIP1 IHC staining correlated 
with poorer overall survival. The authors showed through immunofluorescence that 
WIP1 expression is both nuclear and cytoplasmic before attempting IHC staining. 
Interestingly, PPM1D activating truncating mutations, such as those in HCT116 and 
U2OS cells, are also frequent in brainstem gliomas (Zhang, Chen et al. 2014). In two 
studies carried out by the same group, WIP1 IHC staining was also shown to be a 
marker of poor prognosis in colorectal cancer and hepatocellular carcinoma (Li, Zhang 
et al. 2013, Li, Zhang et al. 2013). Elevated WIP1 IHC staining compared to healthy 
prostate tissue has also been correlated to poorer overall survival after radical 
prostectomy (Peng, He et al. 2014). Most recently, WIP1 protein expression analysis by 
IHC staining is reported to be of prognostic significance in kidney carcinoma, non-small 
cell lung cancer and nasopharyngeal carcinoma (Sun, Wang et al. 2015, Sun, Zhang et 
al. 2015, Yang, Gao et al. 2015).  
7.1.2 Summary 
These findings strongly support the notion that PPM1D mRNA and WIP1 protein 
expression are of prognostic relevance in various malignancies. In keeping with the 
findings by Saito-Ohara et al., (2003), data-mining was also used in a more recent study 
to show that increased PPM1D mRNA expression is a marker of poor prognosis in 
neuroblastoma (Richter, Dayaram et al. 2015). However, the prognostic significance of 
WIP1 protein expression in neuroblastoma tumours has not yet been investigated.  
7.2 Hypothesis  
 Elevated WIP1 immunohistochemical staining is an independent marker of poor 
prognosis in neuroblastoma 
7.3 Specific materials and methods 
7.3.1 Online resources 
Large deposits of biomedical data collected by independent research groups are 
deposited on the World Wide Web and are publically available for mining and use in 
research. These databases include gene expression data on cell lines and tumour 
samples. Analysis of PPM1D mRNA expression in cell lines was carried out by mining 
the Broad Institute Database (Massachusetts Institute of Technology and Harvard). The 
R2 genetic analysis and visualisation platform of the Academic Medical Centre in 
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Amsterdam was then used to mine data across various malignancies. The R2: 
MegaSampler online tool was used for assessing PPM1D mRNA expression across 99 
different tumour datasets from various malignancies. The highest PPM1D expressing 
dataset with publically available clinical and pathological data namely ‘Tumour 
Neuroblastoma public - Versteeg - 88 - MAS5.0 - u133p2’ was used for survival 
analysis. Kaplan Meier survival analysis and Log-rank test were performed with the 
categorisation cut-off set at median or varied using the scanner facility. The scanner will 
test all possible cut-off points and report the most significantly different expression cut-
off statistics including a Bonferroni-corrected p-value to correct for multiple testing. 
The plots were also analysed according to MYCN amplified and non-amplified sub-
categories. 
7.3.2 Use immunocytochemistry to determine WIP1 antibody specificity 
PPM1D-amplified MCF-7 cells were seeded and grown onto sterile glass slides and 
allowed to reach 50-60% confluence. Cells were then exposed to DMSO, 5µM Nutlin-3, 
2.5µM GSK2830371 or their combination 4Hrs before being fixed and prepared for 
immunocytochemistry as explained in (2.12). Anti-WIP1 (F-10) antibody was diluted 
1:200 in blocking reagent. Only blocking reagent was added to the no primary antibody 
control followed by the incubation with the secondary antibody. Exposure to 2.5µM 
GSK2830371 resulted in a marked reduction of WIP1 fluorescent signal (Alexa fluor 
488 secondary (AF-488) secondary antibody) as expected from the ability of this drug 
to markedly degrade WIP1 protein (Figure 7-1). Also WIP1 signal was increased in 
response to Nutlin-3 and in its combination with GSK2830371 the reduction in WIP1 
signal was reversed by Nutlin-3. Finally there was no WIP1 staining in the absence of 
the WIP1 primary antibody (Figure 7-2). The fluorescent signal was therefore 
attributable solely to WIP1 staining.  
7.3.2.1 Confocal microscopy z-stack and WIP1 sub-cellular localisation 
Confocal microscopy as described in materials and methods was used to assess WIP1 
staining and localisation. A z-stack image capture was carried out with image capture 
from 20-50 slices from which a video of a series of images traversing through confocal 
planes of the cell were generated and a 3D image constructed (Please see electronic 
copies of PowerPoint slides accompanying this thesis for these images).  It was 
observed that the fluorescence signal from the secondary antibody (AF-488) that 
detected F-10 was both nuclear and cytoplasmic regardless of PPM1D genetic status.  
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Figure 7-1 Confocal microscopy images of MCF-7 cells treated with DMSO, 5µM 
Nutlin-3, 2.5µM GSK2830371 or their combination for 4Hrs. GSK2830371 results 
in a dramatic reduction in both cytoplasmic and nuclear WIP1 signal intensity 
(AF-488 channel) which is restored modestly when it is combined with Nutlin-3. 
Nutlin-3 increases WIP1 signal intensity, most likely due to p53 dependent 
induction of WIP1. 
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Figure 7-2 Gain on both DAPI and AF488 channels was increased to assess the no 
primary control. There was no WIP1 staining detected at high detector gain in the 
absence the WIP1 primary antibody showing that the secondary antibody does not 
bind to other non-specific antigens 
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7.3.3 Immunohistochemistry  
Surgical resections or biopsies of tumour tissue can be examined by 
immunohistochemistry to explore the expression and subcellular localisation of antigens 
of interest with specific antibodies (Schacht and Kern 2015). 
7.3.3.1 Sample preparation 
The resected tissue region is fixed in 10% neutral buffered formalin, dehydrated through 
a series of ascending ethanol concentration (70%-100%), cleared in several changes of 
xylene and then infiltrated with paraffin wax. This tissue is embedded in paraffin wax 
blocks to prevent putrification. These are termed formalin fixed paraffin embedded 
(FFPE) blocks (Taylor and Burns 1974) and this procedure was carried out by Dr 
Jennifer Jackson. The blocks were then used for slide preparation. 
7.3.3.2 Slide preparation from paraffin embedded formalin fixed blocks 
Blocks were placed at -20°C for 20min and kept chilled on ice, covered with a thin layer 
of 70% ethanol in order to make sectioning easier. A microtome  tissue sectioning 
device was then used to cut the paraffin block into 1µm slices which were then spread 
on the surface of 45°C water (just below wax paraffin melting temperature). A glass 
slide was then used to fish-out the tissue section and the wax paraffin was allowed to 
fully solidify onto the slide at room temperature. 
7.3.3.3 Antigen retrieval 
Although formalin fixing preserves the morphological features of the proteins it leads to 
the formation of methylene bridges between proteins which reduce antigenicity 
(Schacht and Kern 2015). Antigenicity is the ability of an antigen to be detected by an 
antibody raised against it through acquired immunity. Enzymes or heat can be used to 
unmask antigens in a process called antigen retrieval. Heat antigen retrieval was used. 
Therefore, Slides were dewaxed in xylene, hydrated through graded ethanol (100%-70% 
(v/v)) and rinsed in tap water before antigen retrieval by submerging them into Tris-
EDTA buffer (Table 7-1) and heating them in a decloaker/pressure cooker. The 
temperature is raised slowly to 130°C and then kept there for 30sec after which it is 
dropped rapidly. The slides are then exposed to 3% (v/v) hydrogen peroxide for 10 min 
and rinsed in tap water. This leads to the unmasking of antigens before staining with the 
primary antibody. 
7.3.3.4 Antibody application and visualisation 
Anti-WIP1 F-10 was diluted in TBS/T as stated in figure legends. A hydrophobic 
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marker was used to draw around the tissue to prevent spillage of the diluted antibody 
solution. Slides were incubated with the antibody at room temperature for 60min then 
rinsed in TBST before using the X-cell-Plus horseradish peroxidase (HRP) detection kit 
(Menapath, #MP-XCPDAB-U100) to visualise primary antibody-antigen binding. A 
universal probe that detects mouse primary antibody fragment crystallisable (Fc) region 
is used to bind to the primary antibody (30min incubation) and excess probe is washed 
in TBST before the HRP-polymer is incubated with the sample (30min). HRP-polymer 
binds to the universal probe and by extension amplifies the signal from the primary 
antibody. Unbound polymer is washed off and 3, 3 diaminobenzidine (DAB) 
chromogen is applied to the samples for 10 min and rinsed in tap water. DAB 
precipitates a brown formazan stain in the presence of HRP. Slides were then washed 
with tap water (5min) and then counter stained in Gills No. 2 haematoxylin (Sigma, #: 
GHS216) for 5secs before being rinsed once in tap water and once in Scott’s tap water 
(Table 7-1) for 30secs. Samples were then dehydrated through graded ethanol and 
cleared in xylene as before. Coverslips were then mounted using DPX mounting media 
(Thermo scientific) and left to dry overnight. 
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Buffer  Constituents and concentration 
Tris-EDTA Tris base (10mM) 
EDTA (1.3mM) 
Tween-20 0.05% (v/v) 
pH 9.0 
Scotts tap-water 41.7mM Sodium hydrogen carbonate  
0.17mM Magnesium sulphate 
A few crystals of Thymol 
Table 7-1 Buffers ad their constituents 
7.3.4 Neuroblastoma tissue microarrays 
Tissue microarrays (TMA’s) allow the simultaneous staining and analysis of many 
representative tumour core biopsies on one slide. Neuroblastoma TMA’s were provided 
by Great Ormond’s Street Hospital (In collaboration with Dr Ximena Montano). We 
were blinded to clinical and pathological data before assigning scores of WIP1 
expression to each core. These samples included 71 anonymised core biopsies of 
neuroblastoma tumours with survival data, of which 67 had information on metastasis 
and MYCN cytogenetic status, 61 with information on stage (I-IV no IVs), 50 on 
chromosome 1p status, 39 on 17q status and 33 on 11q status.   
7.3.5 WIP1 immunohistochemical staining and antibody optimisation 
Because we only acquired one replicate of each neuroblastoma TMA, we could not 
justify the direct use of these samples in antibody optimisation. Therefore we had to 
optimise the conditions for IHC staining of WIP1 before attempting to stain these 
samples. For optimisation of WIP1 antibody we assessed the staining of the F-10 
antibody in a two different samples before staining the neuroblastoma TMA’s. 1) FFPE 
mouse NGP and N20R1 xenografts (kindly provided by Dr Lindi Chen). 2) TMA’s of 
ovarian origin which were intended for use in an independent project (kindly provided 
by Mrs Maryam Zanjirband). We found optimal antibody dilution to be 1:500 as it 
resulted in differential staining between tumour and stroma in ovarian tissue (Figure 7-3 
& Figure 7-4).  The buffer chosen for antigen retrieval was Tris-EDTA.
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Figure 7-3 WIP1 IHC staining of xenografts arisen from NGP and N20R1 cell line pair. F-10 antibody dilution used here was 1:50 as 
recommended in the datasheet by the vendor. 
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Figure 7-4 WIP1 IHC staining in ovarian TMA’s at two different dilutions.  1:500 dilution is more specific at staining tumour tissue and nuclei 
compared to connective tissue.
 273 
 
 
7.3.5.1 Slide scanning and H-score calculation 
Imaging of slides and scoring were carried out using an automated digital scanner 
Aperio ScanScope® CS (Aperio Technologies, Bristol, UK) and SpectrumTM image 
management software. Given that the core origins were not known and they were 
morphologically heterogeneous, an algorithm was used for calculating WIP1 nuclear 
stain intensity and proportion of staining in the field selected. Cytoplasmic staining was 
weak and therefore not used in scoring. The algorithm calculated the % of cells that 
showed no staining, weak staining, intermediate and strong staining. A modified H-
score was used, which was the product of intensity (No staining = 0, weak = 1, 
intermediate = 2 and strong = 3) and percentage positive (1-14% = 1, 15-24% = 2, 25-
39% = 3, 40-59% = 4, 60-79% = 5 and 80-100% = 6). There was a wide range of H-
scores corresponding to WIP1 protein expression in different neuroblastoma cores on 
each array (Figure 7-5).  
7.3.6 Statistical analysis 
7.3.6.1 Receiver operating characteristic (ROC) curve 
When using a continuous variable in a diagnostic/prognostic test the distribution of true 
positive (TP) and true negative (TN) cases for that measurement overlap (Figure 7-6A). 
The cut-off chosen for the continuous variable between normal and abnormal will 
determine the proportion of false positive (FP) and false negative (FN) 
diagnoses/prognoses. Receiver operating characteristic (ROC) curve analysis is used to 
determine optimal cut-off points for continuous variables intended for use in diagnostic 
tests. When a given cut-off is chosen the ratio of abnormal detected by the test to the 
total abnormal cases present is termed sensitivity. The ratio of normal cases detected by 
the test to total normal cases is termed specificity. A ROC curve can be generated by 
plotting the % Sensitivity against 1 - % Specificity at different cut-off points. An ideal 
diagnostic/prognostic cut-off for a continuous variable would have high specificity at 
low sensitivity and a large area under the curve as shown in Figure 7-6B. Although this 
could differ based on which is more important for that given endpoint and whether the 
cost: benefit ratio of choosing a cut-off with lower specificity or sensitivity is 
acceptable.  
This approach was applied to WIP1 expression. WIP1 H-scores from our cohort were 
split into two groups of overall survival (Group 1: alive and Group 2: dead). ROC curve 
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analysis was then carried out in GraphPad Prism 6 software to assess which WIP1 H-
score cut-off would result the most specificity while retaining optimal sensitivity.  
7.3.6.2 The log-rank test and Kaplan Meier survival curves 
The Log-rank test is a nonparametric hypothesis test used to compare the survival 
distributions of two groups (Bland and Altman 2004). The assumptions of this test are 
that 1) Missing data (censoring) are unrelated to prognosis, 2) Subjects have the same 
probability of survival regardless of their order and time of diagnosis 3) The time to 
event is accurate. Data were divided into two groups based on discrete or continuous 
variable of interest being investigated and their overall survival in months from 
diagnosis to death (endpoint). GraphPad prism 6 was then used to carry out a log-rank 
test and generate a Kaplan Meier plot to determine whether a given group had a poorer 
outcome. Hazard ratios which are a measure of the rate of death in each group based on 
the slopes of the survival curves were also derived. 
7.3.6.3 Contingency tables and Fisher’s exact test  
To assess whether there was any correlation between other clinicopathological events 
and WIP1 H-score (High or low) we used contingency tables and Fisher’s exact test.  
7.3.6.4 Normality test 
Normality tests were carried out using GraphPad Prism 6 software to assess how far the 
distribution of a given variable deviates from Gaussian distribution.
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Figure 7-5 Range of WIP1 IHC staining and their corresponding H-scores.  
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Figure 7-6 A) Overlapping distributions of hypothetical test results for a given continuous variable. B) Hypothetical representation of the 
ROC curve for an ideal test and the optimal cut off point (green point). TN: True Negative; TP: True Positive; FN: False Negative; FP: False 
Positive; AUC: Area Under the Curve. 
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7.4 Results 
7.4.1 Data-mining shows that neuroblastoma cell lines have the highest average 
PPM1D mRNA expression  
Publicly available Cancer Cell Line Encyclopaedia (CCLE) from the Broad Institute 
(MIT and Harvard) online cell line database was mined in order to compare PPM1D 
mRNA expression between cell lines of different tumour origin. The data showed that 
PPM1D copy number positively correlates with mRNA expression although the 
relationship is not close (Figure 7-7). Importantly cell lines of neuroblastoma and 
medulloblstoma origins had the highest average mRNA expression compared with other 
malignancies (Figure 7-8). The panel of cell lines includes PPM1D-amplified cell lines 
reported by Natrajan et al., (2009) including MCF-7 cells used for 
immunocytochemistry earlier (Figure 7-1). These findings are consistent with the 
reports in the literature of PPM1D gain and its higher expression in these malignancies 
(Saito-Ohara, Imoto et al. 2003, Castellino, De Bortoli et al. 2008, Richter, Dayaram et 
al. 2015). This is also consistent with the sensitivity of neuroblastoma cell lines to WIP1 
inhibition by GSK2830371 (Richter, Dayaram et al. 2015).  
7.4.2 Increased PPM1D mRNA expression in Neuroblastoma is a marker of poor 
prognosis 
We assessed PPM1D mRNA expression across 99 different datasets derived from 
various malignancies on the R2: MegaSampler from the AMC. The only malignancy 
with relatively high PPM1D mRNA expression, for which clinicopathological data was 
publically available, was the Versteeg neuroblastoma database. We explored PPM1D 
mRNA expression in this dataset using the R2: Genomics Analysis and Visualisation 
Platform. The data show an 8-fold range of PPM1D mRNA expression in the 88 
neuroblastoma tumour samples (Figure 7-9). Given that MYCN amplification is a well-
established cytogenetic marker of poor prognosis in neuroblastoma used clinically for 
risk group treatment stratification (Brodeur, Seeger et al. 1984, Seeger, Brodeur et al. 
1985, Seeger, Wada et al. 1988), we assessed the correlation between MYCN and 
PPM1D mRNA expression. The correlation between MYCN and PPM1D expression 
was weak (R = 0.343, p = 0.001) in this dataset (Figure 7-10). Using Kaplan Meier 
Scanner Pro we found that above median expression of PPM1D mRNA is significantly 
associated with poor prognosis (p=0.02) (Figure 7-11). A similar plot was 
independently published by Richter et al., (2015) using the same online platform. 
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Although the authors had suggested that PPM1D mRNA correlated with survival (p = 
0.005 before correction), the adjusted p-value reported was 0.364, which is not 
significant. Importantly, MYCN-amplification was not considered in their analysis. 
PPM1D mRNA expression was not of prognostic significance if MYCN-amplified 
(MNA) and non-amplified (MNnA) subgroups of tumours were analysed separately 
with the cut-off set at median expression (p=0.091 and p=0.712 respectively) (Figure 
7-12A and B). If the cut-off was set to scan, as done by Ricther et al., 2015, then the 
PPM1D expression prognostic significance would also not be independent of MYCN 
status (MNnA, p=0.06  and MNA p=0.712, plots not shown). These findings suggest 
that when the threshold of PPM1D mRNA expression is set at median PPM1D is of 
prognostic relevance however, this is not independent of MYCN-amplification status. 
This is consistent with the findings of Saito-Ohara et al., (2003) who had investigated 
PPM1D mRNA expression in an independent cohort of neuroblastoma tumour samples.
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Figure 7-7 Relationship of PPM1D mRNA to DNA copy number in cell lines. R-Pearson = 0.474 
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Figure 7-8 Box and whiskers plot mine from the Broad Institute database for PPM1D mRNA expression among cancer cell lines of different 
tissue origin. 
  
 
 
2
8
1 
 
Figure 7-9 Range of PPM1D mRNA expression in neuroblastoma tumours.  Age at diagnosis: Red ≤ 18 months old, Green ≥ 18 months old; 
Alive: Green = alive Red = dead; Histology: Red = Neuroblastoma; INSS stage:  Green = stages 1 or 2, Amber = stage 3, Red = stage 4, Blue = 
stage 4s. 
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Figure 7-10 Correlation between MYCN and PPM1D expression. Age at diagnosis: Red ≤ 18 months old, Green ≥ 18 months old; Alive: Green 
= alive Red = dead; Histology: Red = Neuroblastoma; INSS stage:  Green = stages 1 or 2, Amber = stage 3, Red = stage 4, Blue = stage 4s. 
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Figure 7-11 Above median PPM1D mRNA expression is associated with poorer 
overall survival in the Versteeg neuroblastoma dataset. 
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Figure 7-12 PPM1D mRNA prognostic significance is not independent of MYCN 
amplification. 
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7.4.3 The relationship between WIP1 IHC staining and patient survival in a panel 
of neuroblastoma tumour samples 
To assess whether the WIP1 protein expression is also of prognostic significance in 
neuroblastoma we assessed WIP1 IHC staining in a panel neuroblastoma tumour 
samples in the form of a series of TMA’s. This was a cohort of 71 neuroblastoma core 
biopsies with provided survival data and different combinations of clinicopathological 
information (7.3.4). We first assessed the prognostic significance of established 
clinicopathological markers in neuroblastoma to examine the validity of the cohort and 
associated clinicopathological variables. In this cohort metastasis (p = 0.0001, Hazard 
ratio (HR) = 14.88) and advanced stage disease (p = 0.003), as determined by the 
International Neuroblastoma Staging System (INSS), both significantly correlated with 
poor overall survival (Figure 7-13A and B). Similarly, established cytogenetic 
prognostic biomarkers such as MYCN amplification (p = 0.0001, HR = 6) (Brodeur, 
Seeger et al. 1984, Seeger, Brodeur et al. 1985) or 11q deletion (p = 0.005, HR=5.3) 
correlated with poor overall survival in this cohort and dataset (Figure 7-14A and B). 
Other reportedly significant poor prognostic cytogenetic markers such as 1p deletion (p 
= 0.3) (Caron, vanSluis et al. 1996) and 17q gain (p = 0.5) (Bown, Cotterill et al. 1999) 
were not of prognostic significance in this cohort (Figure 7-15A and B). Given that 
PPM1D is reportedly the most commonly gained gene when 17q is gained in 
neuroblastoma cell lines (Saito-Ohara, Imoto et al. 2003) it was surprising to find that 
there is no difference between WIP1 H-score in tumours with and without 17q gain (p = 
0.239) (Figure 7-15C). Although normality tests showed that the H-scores associated 
with 17q gain are not normally distributed which suggests that WIP1 protein 
expression/regulation is affected by 17q gain. 
A ROC curve analysis showed that the median would be a reasonable cut-off point with 
optimal sensitivity and specificity (Figure 7-17A). The shape of the ROC curve 
suggested that WIP1 H-score is not a reliable prognostic marker. A log-rank test carried 
out on survival and WIP1 H-score in this cohort showed that high and low WIP1 protein 
expression defined by a median value cut-off was not significantly related to survival in 
our cohort of  neuroblastoma patients (0.26) (Figure 7-17B). Further analysis of the 
established prognostic markers through contingency tables and Fisher’s exact test 
showed that there was no difference in WIP1 H-score between clinicopathological sub-
groups (Table 7-2).  
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Figure 7-13 Metastasis and advanced INSS stage disease are significantly 
associated with of poor survival in our cohort of neuroblastoma patients. 
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Figure 7-14 Tumour MYCN-amplification and 11q deletion are significantly 
associated with poor survival in our neuroblastoma patient cohort. Log-rank test 
and patient survival according to tumour MYCN-amplification (A) and 11q 
deletion status (B). 
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Figure 7-15 Tumour 17q gain and 1p deletion were not significantly predictive of 
overall survival in our neuroblastoma patient cohort. Log-rank test and patient 
survival according to tumour 17q gain (A) and 1p deletion status (B). C) There is 
no statistical difference between mean WIP1 H-score in tumours with and without 
17q gain (Unpaired t-test p = 0.239). 
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Figure 7-16 The three normality tests used to assess whether H-scores belonging to 
each subgroup of follow a Gaussian distribution. H-scores associated with the 17q 
gain subgroup are not normally distributed. 
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Figure 7-17 A) ROC curve of WIP1 H-scores as a prognostic test.  B) Log-rank test 
and Kaplan Meier plot of WIP1 H-Scores < 7.5 and H-scores > 7.5 groups show 
that WIP1 protein expression was not significantly related to survival in our 
cohort of neuroblastoma patients. 
  
  
292 
 
 
WIP1 Protein expression (H Score) 
 
Variables n H-Score < 7.5 H-Score > 7.5 p-value 
Stage  
I-II 15 7 8 0.33 
III-IV 46 28 18 
MYCN status  
MNA 10 6 4 0.88 
MNnA 40 25 15 
11q status  
11q del  5 3 2 0.68 
No 11q del 28 14 14 
17q status  
17q gain 15 10 5 0.16 
No 17q gain  23 10 13 
1p status  
1p del 7 4 3 0.96 
No 1p del 43 25 18 
Table 7-2 Contingency tables generated to assess any association between other 
prognostic markers and above and below median WIP1 H-score. The p-values in 
the last column were determined by Fisher’s exact test.  
7.5 Discussion 
High PPM1D mRNA expression has been reported to be a marker of poor prognosis in 
neuroblastoma (Saito-Ohara, Imoto et al. 2003, Richter, Dayaram et al. 2015). Our data-
mining shows that although above median value PPM1D expression is significantly 
associated with poor survival, when MNA and MNnA samples are assessed as separate 
groups, there is no significant correlation between elevated PPM1D mRNA and poorer 
overall survival. This suggests that the role of WIP1 phosphatase activity in 
neuroblastoma is likely subtle and could be influenced by MYCN function. This could 
also suggest that other genes gained on the distal end of the chromosome 17 may be 
more reliable markers of prognosis, in contrast to reports by Saito-Ohara et al., (2003). 
However, in contrast to reports in the literature (Bown, Cotterill et al. 1999),  the gain of 
17q21-17qter was not a significant prognostic marker in our current cohort.  
Liang et al., (2012) had used immunofluorescence microscopy to show that WIP1 
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staining is both nuclear and cytoplasmic; however they had not tested the specificity of 
their antibody. During our antibody validation process we assessed specificity of the 
Anti-WIP1 antibody (F-10) by degrading WIP1 using GSK2830371 and then using 
immunofluorescence microscopy to assess whether the WIP1 signal had dropped. This 
showed that the antibody is specific for our target antigen and that WIP1 is both nuclear 
and cytoplasmic. The same antibody was then optimised for IHC staining of 
neuroblastoma core biopsies on a TMA, which showed that WIP1 IHC staining was not 
significantly related to overall survival and hence is unlikely to be a useful prognostic 
biomarker for neuroblastoma. The WIP1 H-score was not different in 17q21-17qter gain 
group of tumours or any other groups for which we had clinicopathological data. 
However, WIP1 H-score was shown to not be normally distributed in the 17q gain 
subgroup suggesting that this event results in tighter regulation of WIP1 protein 
expression. It would be of interest to investigate the 17q breakpoint and how it may 
impact regulation of WIP1 expression.  
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Chapter 8 General discussion 
8.1 Mechanistically relevant dose range and scheduling of MDM2 inhibitors in 
pre-clinical evaluation 
An overwhelming body of evidence in the literature and the data presented in this thesis 
have shown that the strongest determinant of response to MDM2 inhibitors is wild-type 
TP53 genetic status. Indeed MDM2 inhibitor resistant sub-clones developed in our 
laboratory, through continuous exposure to an increment of Nutlin-3, and resistant sub-
clones reported by others, all possess TP53 inactivating mutations (Aziz, Shen et al. 
2011, Michaelis, Rothweiler et al. 2011, Jones, Bjorklund et al. 2012). This suggests 
that TP53, but not MDM2, is under strong negative selection in a context where MDM2 
inhibition is lethal. This is in stark contrast to the most common mechanism of acquired 
resistance observed in response to other targeted agents, such as tyrosine kinase 
inhibitors, which is mostly caused by the emergence of de novo mutations in genes that 
encode the target protein (point mutations in epidermal growth factor receptor in 
Gefitinib resistance) (Chen and Fu 2011). Notably, there have been no reports of de 
novo MDM2 mutations in MDM2 inhibitor resistant sub-clones to date. It could be 
argued that mutations in MDM2 that alter its hydrophobic binding pocket structure in a 
way that it can no longer accommodate an MDM2 inhibitor, would equally no longer 
house the p53 N-terminus and would be negatively selected in a p53-dependent manner. 
These observations reinforce the notion that MDM2 is the most important regulator of 
p53 stability and function and the primary mechanism through which MDM2 inhibition 
can result in cell cycle arrest and/or cell death is through activation of wild-type p53 
signalling. Therefore, what distinguishes on-target from off-target activity of MDM2 
inhibitors in cell lines, is likely the dose range that induces minimal to maximal p53-
dependent growth inhibition or cell death. The upper limit of this dose range coincides 
with the lowest growth inhibitory or lethal dose of the same MDM2 inhibitor in a TP53 
mutant otherwise isogenic setting as shown in chapter 3 using the MDM2 inhibitor 
resistant clones. This could approximate the mechanistically relevant on-target dose 
range of MDM2 inhibitors in a given cell line. The importance of establishing this range 
must be considered when investigating whether MDM2 inhibitors cause direct DNA 
damage. The importance of timing discussed in Chapter 3 must also not be overlooked. 
The appearance of the DNA DSB marker, γH2AX, detectable by immunofluorescent 
staining, 24 hours following a mechanistically relevant dose of Nutlin-3 (5µM) in TP53 
wild-type cell lines (See Chapter 3), may be attributed to DNA fragmentation during 
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apoptosis observed in NGP and SJSA-1 cells which was evident from significant 
increase in caspase-3/7 activity and significant loss of clonogenic survival (Rogakou, 
Nieves-Neira et al. 2000). The comparison of the rapid detection of γH2AX 
immunofluorescent staining 30min following a dose of IR and the long delay in the case 
of Nutlin-3 supports this interpretation.  
8.2 DNA repair enzymes as potential co-determinants of response to MDM2 
inhibitors 
Data presented in chapter 3 of this thesis focuses on the role of two members of the 
PI3KK family, ATM and DNA-PKcs, in determining or modulating the response to 
Nutlin-3. This investigation was prompted by a report suggesting that inhibition of 
ATM and Nutlin-3 results in synthetic lethality in TP53 wild-type cell lines in culture 
(Sullivan, Padilla-Just et al. 2012). MDM2-p53 binding antagonists such as Nutlin-3 
were optimised to activate wild-type p53 signalling through non-genotoxic inhibition of 
the p53-MDM2 protein-protein binding interaction (Vassilev, Vu et al. 2004). ATM 
kinase activity is associated with activation of p53 signalling by DNA damage, which 
meant that these results were counterintuitive (Canman, Lim et al. 1998, Appella and 
Anderson 2001). Given that Sullivan et al., 2012 had used doses of Nutlin-3 (10µM, 
20µM and 30µM) that had independently been reported to induce DNA DSBs (Verma, 
Rigatti et al. 2010, Valentine, Kumar et al. 2011, Rigatti, Verma et al. 2012), the 
synergy reported was suspected to be due to potentiation of the consequences of DSBs 
by MDM2 inhibitors rather than the intricate mechanism explained by the authors. It is 
well established that the inhibition of ATM kinase activity to potentiate the response of 
cells to DNA DSB inducing anticancer agents (Hickson, Zhao et al. 2004). Therefore, 
the potential for synergy between ATM and MDM2 inhibitors was tested at lower 
mechanistically relevant doses of Nutlin-3 that are related to the non-genotoxic 
activation of p53 by MDM2 inhibitors.   
Combined inhibition of ATM (10µM KU55933) and Nutlin-3 doses <10µM did not 
enhance the Nutlin-3 sensitivity of TP53 wild-type or mutant cells. However, TP53 
mutant cell were made slightly more sensitive to >10µM doses of Nutlin-3 which would 
be consistent with the potentiation of cellular sensitivity to indirect DNA damage by 
ATM inhibition. Selective chemical inhibition of DNA-PKcs also did not result in 
increased sensitivity to Nutlin-3 over the dose range used. These findings suggested that 
ATM or DNA-PKcs alone do not determine sensitivity to MDM2 inhibitors as single 
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agents. However, the role of DNA-PKcs was pronounced in determining the response to 
combinations of Nutlin-3 and IR in a cell type dependent manner. IR protected SJSA-1 
TP53 wild-type osteosarcoma cells against Nutlin-3 regardless of DNA-PKcs inhibition. 
However, IR sensitised TP53 wild-type NGP neuroblastoma cells, not their TP53 
mutant N20R1 daughter cell line, to Nutlin-3 and DNA-PKcs inhibition potentiated this 
effect significantly. Potentiation of IR by NU7441 in NGP TP53 wild-type cells was 
then shown to be significantly enhanced by a non-cytotoxic dose of Nutlin-3 (0.2µM) in 
clonogenic assays. Whether or not the IR induced protection of SJSA-1 cells, against 
growth inhibition by Nutlin-3, would also translate to clonogenic survival was not 
investigated.  
NGP cells are MYCN-amplified. It has been reported that MYCN-amplification, which is 
a frequently detected cytogenetic abnormality in advanced stage neuroblastoma and a 
marker of poor prognosis, impairs DNA DSB repair (Karlsson, Deb-Basu et al. 2003). 
This may be the underlying reason for the difference between the sensitivity of SJSA-1 
cells and NGP cells to the combination treatments tested in the presence of IR. Indeed 
inhibition of PARP-1 using Rucaparib in NGP cell line pair resulted in growth 
inhibition in a p53-independent manner in contrast to the SJSA-1 cell line pair which 
were resistant to PARP-1 inhibition. Rucaparib potentiates cellular response to DSB 
inducing DNA damaging agents (Znojek, Willmore et al. 2014) which would be 
consistent with the consequences of defective DNA DSB repair in the MYCN-amplified 
NGP and N20R1 neuroblastoma cell line pair. A recent study also showed that 
increased MYCN expression increases cellular sensitivity to DNA-PKcs knockdown or 
its chemical inhibition by NU7441 (Zhou, Patel et al. 2014). Although our data did not 
show any notable difference between the sensitivity of SJSA-1 and NGP cells to 
NU7441 single agent treatment, it showed that inhibition of DNA-PKcs in NGP cells 
potentiated the cellular response to Nutlin-3 and IR whereas it did not impact on SJSA-
1 sensitivity in response to the combination. Another possible explanation for difference 
in response between SJSA-1 and NGP cells may be that p53 induced G1 arrest is intact 
in SJSA-1 cells whereas it is defective in NGP cells (chapters 5), so SJSA-1 cells may 
be protected in response to DNA damage. It has been previously reported that MYCN 
amplification is associated with defects in p21WAF1 induction and IR induced G1 arrest 
in neuroblastoma cell lines including NGP cells (Tweddle, Malcolm et al. 2001). 
Further investigation into the role of MYCN expression in the observed potentiation of 
response to Nutlin-3 and IR are merited on these ground.  
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In the experiments described in chapter 3 of this thesis the cells were treated with a 
combination of Nutlin-3 + NU7441 for 4Hrs before exposure to IR, so that at the time 
of IR exposure p53 expression was maximal. Given the reported role of MDM2 in p53-
independent inhibition of homologous recombination repair through its interaction with 
NBS1 (Bouska and Eischen 2009, Carrillo, Hicks et al. 2015), a component of the MRN 
complex, this schedule would have provided enough time for accumulation of MDM2 
and its inhibition of DNA repair. Considering the results observed in NGP cells in 
isolation one would consider this hypothesis to hold true. However, their TP53 mutant 
otherwise isogenic daughter cell line N20R1 was not made more sensitive by any of the 
combination treatments in the presence of Nutlin-3, which suggests that the increased 
sensitivity observed in NGP cells is p53-dependent. As the IR sensitivity of NGP and 
N20R1 cells was the same regardless of their TP53 status the addition of a non-
cytotoxic dose of Nutlin-3 further potentiated the effect of IR + NU7441 only in the 
TP53 wild-type NGP parental cells. Also it could be expected that any p53-independent 
DNA repair inhibitory effects of Nutlin-3, which is reportedly mediated through MDM2 
inhibition of NBS1, would be particularly pronounced in SJSA-1 cells which are 
MDM2 amplified and in which MDM2 induction following Nutlin-3 is very strong. 
However, in SJSA-1 DNA damage did not influence the sensitivity to Nutlin-3 even 
when DNA-PKcs was inhibited. Although this should be further investigated in 
clonogenic assays, based on the preliminary data presented in this thesis the impact of 
Nutlin-3 mediated p53 independent DNA repair inhibition does not seem to lead to a 
dramatic increase in sensitivity to IR in SJSA-1 cells. Also, if MDM2 inhibitors were to 
potentiate the response to DNA damage in a p53-independent manner then the Nutlin-3 
mediated growth inhibition of both of the TP53 mutant SN40R2 and N20R1 cells would 
have also been enhanced in the presence of IR. However, this was not the case. 
These results are overall consistent with the non-genotoxic mechanism of action of 
Nutlin-3 as the chemical inhibition of key enzymes involved in homologous 
recombination repair (ATM), non-homologous end joining (DNA-PKcs) and base 
excision repair (PARP-1) could not influence sensitivity to the MDM2 inhibitor in the 
absence of additional DNA damage by IR. This also casts doubt over the reported p53-
independent role of MDM2 inhibitors in inhibition of HRR. However, combination 
treatment with DNA-PKcs inhibition suggested that loss of DNA DSB repair integrity is 
important in determining the response to combination treatment of Nutlin-3 with IR. 
Finally, the efficacy of combination of Nutlin-3 with IR is context-dependent and 
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probably requires careful consideration of dosing and scheduling. More comprehensive 
pre-clinical investigation is required to avoid any potential antagonism in antitumour 
effects between the compounds.  
8.3 WIP1 phosphatase activity as a determinant of cellular response to MDM2 
inhibitors 
Although MDM2-amplified or overexpressing TP53 wild-type cell lines have been 
reported to be among the more sensitive to growth inhibition by MDM2 inhibitors 
(Saiki, Caenepeel et al. 2015, Zhong, Chen et al. 2015), many other TP53 wild-type cell 
lines that do not share this genetic alteration are also sensitive to MDM2 inhibitors. For 
example, the Wellcome Trust Sanger Institute drug sensitivity data cited earlier, 
highlighted a number of other predictors of sensitivity to MDM2 inhibitors such as 
MYCN-amplification which has also been verified independently to increase sensitivity 
to MDM2 inhibitors in spite of wild-type MDM2 genetic status (Gamble, Kees et al. 
2012). The range of sensitivity to MDM2 inhibitors in TP53 wild-type cell lines, and 
their limited anti-tumour efficacy in clinical trials, reflects a need for the identification 
other mechanisms that determine cell fate following the activation of p53 signalling. 
These mechanisms, some of which were introduced in chapter 1 (Section 1.16.6) are 
very complex and context-dependent; however combination treatments are already 
being considered, hence there is a need to investigate the mechanisms and optimise the 
use of MDM2 inhibitors. The ideal combination regimen would preferably rely on other 
non-genotoxic targeted agents that show tumour specific synthetic lethality with MDM2 
inhibitors in order to increase tumour sensitivity and selectivity. Such agents may target 
proteins directly involved in regulation of p53 stability and/or function (such as MDMX 
(Graves, Thompson et al. 2012)) or parallel pathways, the inhibition of which results in 
increased sensitivity of cancer cells to MDM2 inhibitors (Such as PI3K or MAPK 
pathways (Saiki, Caenepeel et al. 2014)). Alternatively, these combinations may 
increase cellular sensitivity to other conventional DNA damaging anticancer agents as 
described above.  
In chapters 4 and 5 of this thesis it was shown that knockdown or inhibition of the WIP1 
phosphatase can potentiate the cellular growth inhibitory and apoptotic response to 
MDM2 inhibitors of TP53 wild-type cells, particularly in those with increased PPM1D 
expression or gain-of-function. Transient knockdown of WIP1 resulted in sensitisation 
of the three TP53 wild-type cell lines NGP, SJSA-1 and HCT116 cells to MDM2 
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inhibition. Interestingly, WIP1 knockdown also resulted in modest p53-dependent 
growth inhibition in the NGP cell line pair but not in the SJSA-1 or HCT116 cell line 
pairs. Monitoring the morphology of the cell lines in which WIP1 knockdown resulted 
in p53-independent growth inhibition suggested that transfection conditions may be 
causing additional stress that can potentially confound the findings. Large cytoplasmic 
vacuoles were observed under transfection conditions in HCT116 and SJSA-1 cell line 
pairs. Increased growth inhibition in TP53 mutant SN40R2 and HCT116-/- cell lines in 
the presence of WIP1 siRNA can be explained if these vacuoles are signs of autophagy 
as WIP1 knockdown may promote autophagic cell death involving inhibition of ATM 
(Le Guezennec, Brichkina et al. 2012). Further investigation of this mechanism was 
beyond the scope of this project. The NGP cell line pair, in which these morphological 
signs of stress were not observed, were used in the subsequent flow cytometry and 
clonogenic experiments combining Nutlin-3 and WIP1 siRNA knockdown. These 
experiments also showed that NGP TP53 wild-type cells were significantly more 
sensitive to Nutlin-3 when WIP1 expression was knocked down.  
The commercial availability of a highly selective allosteric WIP1 inhibitor, 
GSK2830371, allowed the investigation of the growth inhibitory efficacy of combining 
MDM2 and WIP1 inhibition (See chapter 5). Initially the sensitivity to WIP1 inhibitor 
as a single agent was tested showing that none of the four isogenically matched TP53 
wild-type and mutant pairs were sensitive to growth inhibition by GSK2830371 in the 
dose range used by the original authors, regardless of their PPM1D status. The efficacy 
of the compound was tested in parallel with a PPM1D-amplified TP53 wild-type cell 
line, MCF-7, which had been reported to be sensitive to growth inhibition by 
GSK2830371. Single agent treatment with this compound in MCF-7 cells was 
confirmed to result in growth inhibition which was associated with degradation of WIP1 
protein and its isoform in addition to p53 stabilisation and p21WAF1 induction. The 
GSK2830371 growth inhibitory curve for MCF-7 cells plateaued after reaching the 
GI50 dose for this compound in this cell line (2.5µM). This led to the assumption that 
there is a resistant sub-population that is likely unaffected by maximal WIP1 inhibition 
as the dose range covered (0.08-10µM). Since GSK2830371 has an in vitro IC50 of 
6nM in cell-free assays, this compound is likely to be in excess at 2.5µM in culture. 
Incidentally, 2.5µM GSK2830371 was the highest non-growth inhibitory dose in all of 
the other cell lines which meant that maximal inhibition of WIP1 does not impact the 
growth of these cell lines. However, because of the established role of WIP1 in 
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homeostatic regulation of p53 signalling it was pertinent to assess its role in determining 
the response to MDM2 inhibitors. 2.5µM GSK2830371 simultaneously combined with 
the relevant dose ranges of Nutlin-3 caused significant potentiation of the cellular 
growth inhibitory response in a p53-dependent manner. This was more pronounced in 
cell lines with either elevated PPM1D expression or gain-of-function mutations. 
Assessment of cell death endpoints showed that WIP1 inhibition by GSK2830371 
resulted in significant and marked increase in either biochemical markers of cell death 
and loss of clonogenic survival. When 2.5µM GSK2830371 was combined with the 
more potent and selective clinical candidate MDM2 inhibitor, RG7388, pronounced 
potentiation of the response to the MDM2 inhibitor was also observed in TP53 wild-
type cell lines with elevated PPM1D expression or gain-of-function.  
8.4 Phosphorylation of p53 and altered p53-dependent transcription in the 
potentiation of MDM2-p53 binding antagonists by WIP1 inhibition   
The most interesting observation was that p53Ser15 phosphorylation (pp53Ser15), which is 
a well-established substrate for WIP1, was only enhanced notably in response to the 
combination of WIP1 and MDM2 inhibition, whereas each compound alone did not 
impact its levels in cell line pairs that were unaffected by 2.5µM GSK2830371. It has 
been reported that increased Ser15 phosphorylation results in increased acetylation of 
p53 C-terminal residues, by p300, which are also ubiquitinated by MDM2. Therefore it 
was predicted that the increase in pp53Ser15 would result in reduced p53 degradation (Li, 
Luo et al. 2002). This would be consistent with the increased sensitivity in response to 
the combination treatment. However, it could also be said that an increase in pp53Ser15 
may be proportional to an increase in total p53 and that the inhibition of WIP1 
phosphatase activity has little to do with the increase in pp53Ser15 observed. The increase 
in pp53Ser15 in response to the combination however was not due to enhance p53 
stabilisation in combination treatment, as the band intensity for total p53 in western 
blots was the same in MDM2 inhibitor treated cells in the presence and absence of 
WIP1 inhibition. This is consistent with the most recent in vivo data from knock-in mice 
that are with substitutions in the cluster of C-terminal lysins residues on p53 normally 
ubiquitinated by Mdm2. Substitution of K367, K369, K370, K378, K379, K383 and/or 
K384 residues to R, which cannot be ubiquitinated, resulted in no difference in p53 
stability (Feng, Lin et al. 2005, Krummel, Lee et al. 2005). Furthermore addition of 
Nutlin resulted in stabilisation of p53 in these mice which suggests that MDM2 is still 
important for p53 proteasomal degradation in these mice. This suggests that other 
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MDM2 ubiquitinated p53 K residues may be important for p53 degradation. This is also 
consistent with a basal equilibrium between the phosphatases and kinases that target the 
p53Ser15 residue, which following p53-MDM2 decoupling by MDM2 inhibitors is tilted 
in favour of the basal activity of p53 activating kinases such as the PI3KKs. Given the 
importance of this post-translational modification in transcriptional transactivation of 
p53 it was hypothesised that the reason for potentiation observed may be due to the 
modulation or enhancement of p53 transcriptional activity promoting pro-apoptotic 
signalling. Global gene expression analysis was carried out in NGP cells, for which the 
most pronounced potentiation was observed, 4Hrs following treatment with 75nM 
RG7388 + 2.5µM GSK2830371, to assess which genes, if any, are differentially 
induced by p53 between the two treatments. The 75nM dose of RG7388 chosen was 
based on the GI50 for RG7388 in NGP SRB growth inhibition assays at which the 
greatest potentiation was observed. Protein levels of the canonical transcriptional targets 
of p53 are induced maximally at approximately 6-8Hrs following commencement of 
treatment with MDM2 inhibitors, which meant that altered p53-dependent 
transcriptional changes would be evident at 4Hrs if the p53-dependent induction of 
these proteins is at the transcriptional level. As hypothesised, the findings showed that 
the expression of p53 transcriptional target genes induced by RG7388 was enhanced 
when WIP1 was inhibited by GSK2830371. In addition to an increase in the transcript 
levels of genes induced by RG7388 alone, a larger subset of genes were significantly 
induced in response to the combination which was consistent with hypothesised 
enhanced p53 transcriptional activity. It is well understood that p53 transcriptional 
targets have different kinetics of induction following p53 activation in a context-
dependent manner (see 1.16.6). Therefore, further investigation of the kinetics of these 
transcriptional target genes in response to the combination treatment and their biological 
significance may provide more distinct answers as to which mechanisms of cell death 
rather are activated in response to the combination treatment. 
Interestingly, pathway analysis of all the genes that were differentially expressed in 
response to both treatment conditions identified activation of p53 signalling. This attests 
to the p53 mediated mechanism of action of MDM2 inhibitors regardless of WIP1 
inhibition. These data are also consistent with the previous reports of Trp53 knock-in 
transgenic mouse models in which S18A or S23A mutations were introduced in serine 
residues homologous to human Ser15 and Ser20. Trp53/p53 is still stabilised efficiently 
in response to IR in Trp53S18A homozygous knock-in transgenic mice, which means that 
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the phosphorylation of this residue is dispensable for Trp53 dissociation from Mdm2 in 
mice following DNA damage. However, the induction of known Trp53 transcriptional 
targets 8Hrs following IR was different in Trp53S18A homozygous transgenic mouse 
thymocytes compared to those derived from wild-type mice (Table 8-1). In spite of the 
differences between p53 activating stimulus (IR vs RG7388), species and tissue types, 
the pattern of differential expression of the human homologues of Trp53 transcriptional 
target genes, CDKN1A (p21WAF1) and MDM2, bear similarities to the differential 
expression seen in the present study when comparing RG7388 + 2.5µM GSK2830371. 
The Trp53S18A mutation was reported to result in diminished mRNA expression from 
the Cdkn1a locus (p21Waf1) whereas it did not impact significantly on Mdm2 expression 
(Chao et al., (2003)). In the presently reported study, the presence of GSK2830371 
resulted in a marked increase in pp53Ser15 following RG7388 treatment, which then 
correlated with a 50% increase in CDKN1A (p21WAF1) mRNA and a 7% increase in 
MDM2 mRNA induction. This implies that the increased pp53Ser15 in combination 
treatment may be playing a role in promoter specific induction of p53 transcriptional 
target genes following non-genotoxic stabilisation of p53 by MDM2 inhibitors. 
However, further investigation of these subsets of genes at various time-points 
following the combination treatment regimens may be required for a more complete 
description of the time course of changes in the mRNA levels of the differentially 
expressed subset of genes. Furthermore, the preliminary findings in this thesis with the 
p53 overexpressing constructs with S15A and S15D mutations transfected into HCT116 
p53 null cells are consistent with these findings and are supported by those reported by 
Loughery et al., (2014), but require further validation.. 
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 Folds of induction in thymocytes after IR 
Genes Wild type Trp53 Trp53S18A 
 Expt. 1 Expt. 2 Average Expt. 1 Expt. 2 Average 
p21 12 15 13.5 2.8 6 4.4 
Mdm2 1.7 1.5 1.6 1.5 2.5 2 
14-3-3σ 6.2 6 6.1 1.9 2.1 2 
TNF-α 4.7 8 6.4 0.7 1.2 0.95 
C/EBP 14 11.5 12.75 2.2 1.3 1.75 
SNK 16 7.5 11.75 3.4 3.3 3.3 
Calcyclin 18 14 16 0.5 0.8 0.7 
Perp 8.5 4.5 6.5 3 1 2 
Apaf1 4 2 3 3 3.5 3.25 
Bax 4 4.5 4.25 5 6 5.5 
BLK 1 2 1.5 2 4 3 
Wig-1 6 4 5 6.5 8 7.25 
Pig8 3.5 2.5 3 2.7 3.2 2.95 
Table 8-1 Differential Trp53 target gene expression between Trp53 wild-type and 
Trp53S18A knock-in transgenic mouse thymocytes, 8Hrs following 5Gy IR, show 
that Trp53 induced transcription of its canonical targets are diminished in a 
promoter specific manner when Trp53 Ser18 is mutated to Ala and cannot be 
phosphorylated. The cells highlighted in amber showed greater than 2-fold 
reduction in mRNA expression as measured by a murine Affymetrix array. The 
table is reproduced in modified form from Chao et al., (2003). 
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The p53 regulated luciferase reporter assay used as a different endpoint for measuring 
the transcriptional transactivation activity of p53, showed a dose-dependent increase in 
reporter signal 24Hrs following treatment with Nutlin-3. This increase in response was 
not observed in the TP53 mutant cell line stably transfected with the same reporter, 
suggesting that the Nutlin-3 mediated induction of this reporter is p53-dependent. 
Modest potentiation of growth inhibition (1.7-fold reduction in GI50) was observed in 
the TP53 wild-type DD7 cells. However WIP1 inhibition by GSK2830371 did not 
enhance the Nutlin-3 mediated p53-dependent induction of the reporter in this context. 
This may indicate that the potentiation observed is due to transcriptional independent 
mechanisms of action. However, the reporter assay was not fully optimised as the dose 
dependent Nutlin-3 mediated reporter response could not be optimised at earlier time 
points because the signal was saturated at both doses used (Data not shown). Also the 
levels of p53Ser15 phosphorylation were not examined in response to the combination 
treatment in neither of the cell lines; therefore it cannot be assessed whether or not 
pp53Ser15 was enhanced in these cell lines in response to the combination treatment. 
Although these findings suggest that changes in the effect of WIP1 inhibitor on 
modulation of p53 mediated transcription may be context-dependent, further 
optimisation of this reporter system is necessary to increase the assay sensitivity for 
detection of modulations of p53 transcriptional activity.  
As it was discussed in chapter 1, p53 transcriptional transactivation can be considered 
the key to p53 mediated cell fate determination between reversible cell cycle arrest, 
senescence and apoptosis. However, more recent studies have explored the potentially 
important role of other less well-characterised p53 transcriptional targets which are 
involved in metabolic processes. For example radiosensitive tissue or MEFs derived 
from transgenic knock-in mice homozygous for Trp53K117R, K161R, K162R, which cannot be 
acetylated on those residues, do not undergo cell cycle arrest, senescence or apoptosis in 
response to IR because they cannot induce key p53 transcriptional targets involved in 
these processes (Li, Kon et al. 2012). Interestingly, the early onset tumour formation 
observed in Trp53 null mice is not observed in these mice. The authors ascribe this to 
the fact that p53K117R, K161R, K162R can still induce other transcriptional targets of p53 that 
are involved in metabolic processes. This is consistent with other findings showing 
efficient p53 mediated tumour suppression in transgenic mouse models that lack p21, 
Puma and Noxa (Valente, Gray et al. 2013). Therefore, investigating other p53 
regulated mechanisms which are deemed important in tumour suppression, such as 
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metabolic control, may be of interest when investigating the combination treatment 
proposed in this thesis. 
8.5 Assessing the role of WIP1 protein expression as a prognostic factor in 
neuroblastoma 
Elevated PPM1D mRNA expression had been reported to be a potential marker of poor 
prognosis in neuroblastoma and WIP1 is reportedly a potential target for the treatment 
of TP53 wild-type neuroblastoma (Saito-Ohara, Imoto et al. 2003, Richter, Dayaram et 
al. 2015). Richter et al., (2015) analysed the sensitivity of a large panel of 
neuroblastoma cell lines to GSK2830371 and showed that only TP53 wild-type cell 
lines responded to this compound, albeit with a wide range of sensitivity as measured by 
GI50 values. This is consistent with findings by Gilmartin et al., (2014) showing that 
the response to GSK2830371 is p53-dependent. Overall these reports indicate that 
WIP1 phosphatase activity plays an important role in the negative regulation of p53 
signalling in neuroblastoma and may confer a poorer overall survival when highly 
expressed. However, WIP1 protein levels have not been investigated in neuroblastoma 
to date. Our findings in chapter 7 show that although elevated PPM1D mRNA, as 
reported by others, may be a predictor of poorer outcome, WIP1 expression as measured 
by immunohistochemistry was not found to have prognostic significance in this study.  
It is important to note that observations in chapter 7 do not nullify the potential 
usefulness of the WIP1 inhibitor (GSK2830371) in sensitising TP53 wild-type 
neuroblastoma tumours to MDM2 inhibitors. The lack of prognostic relevance of WIP1 
should not be misinterpreted as lack of mechanistic relevance in response to this 
combination regimen. The preclinical data presented in the previous chapters strongly 
support the notion that WIP1 inhibitors markedly potentiate MDM2 inhibitor response 
in the least GSK2830371 sensitive TP53 wild-type neuroblastoma cell line with 
PPM1D copy number gain (Richter, Dayaram et al. 2015). However, there are other 
more subtle issues brought to attention in chapter 7 that must be considered before use 
of this combination regimen in a clinical setting. Cancer Cell Line Encyclopaedia 
(CCLE) and Amsterdam Medical Centre (AMC) data showed that cell lines or primary 
samples of haematological malignancies also had high PPM1D mRNA expression. 
Notably, Gilmartin et al., (2014) reported that sensitivity to the selective WIP1 
inhibitor, GSK2830371, was greatest in cell lines of the haematological lineage. This 
may mean that targeting WIP1 has the potential to cause toxicity to healthy cells of the 
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haematological lineage. This is not desirable for the combination treatment with WIP1 
and MDM2 inhibitors as the dose limiting toxicities observed in MDM2 inhibitors are 
to tissues of haematological lineage and may be exacerbated in response to combination 
treatment. However, the sensitivity of healthy cells of haematological lineage in 
response to MDM2 and WIP1 inhibitors has not been investigated yet. This may be 
made possible by investigating the colony formation ability of healthy donor bone 
marrow cells in culture following single agent and combination treatments with WIP1 
and MDM2 inhibitors. 
8.6 MDM2 inhibitor resistant clones show the same sensitivity to IR 
Although it is not the central line of inquiry in this thesis, it is very important to note 
that contrary to previous reports (Michaelis, Rothweiler et al. 2011, Jones, Bjorklund et 
al. 2012), MDM2 inhibitor resistant clones generated in our lab showed the exact same 
sensitivity to IR in clonogenic assays as their wild-type TP53 parental cell line 
counterparts. This suggests that not all MDM2 inhibitor resistant TP53 mutant sub-
clones show cross-resistance to IR and perhaps other DNA damaging agents. 
Interestingly, the drug sensitivity data on the Sanger database shows that the TP53 
genetic status is not a strong determinant of response for DNA damaging agents or other 
targeted agents (Figure 8-1). This suggests that TP53 genetic status is not a universal 
determinant of response to IR. This is consistent with previous findings that suggest IR 
induced cell death is only dependent on TP53 genetic status in certain radiation 
sensitive rapidly proliferating tissue (MacCallum et al., 1996) (Komarova et al., 1997). 
The importance of these observations must not be underestimated as they could have far 
reaching implications in devising first line cancer management strategies using MDM2 
inhibitors in TP53 wild-type tumours. The knowledge of radio- or chemo-sensitivity of 
MDM2 inhibitor resistant clone could be used in the following hypothetical clinical 
strategy to optimise the use of MDM2 inhibitors. An MDM2 inhibitor could induce 
apoptosis in a population of the TP53 wild-type cells in the tumour within the first 24-
48 hours, based on data from our work and other published pre-clinical data. Of course 
this will differ depending on tumour origin and the concentration achieved throughout 
the malignant tissue by oral or systemic administration. This process selects for TP53 
mutant cells in the tumour but it is very likely that it will also select for cells that have 
undergone p53-dependent reversible cell cycle arrest. The TP53 mutant sub-population 
will still be sensitive to genotoxic agents and a lower dose can potentially be used to 
eliminate them. However, the scheduling must be considered carefully. If the genotoxic 
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agent was delivered concomitantly with the MDM2 inhibitor then the sub-population 
that had undergone reversible cell cycle arrest will be refractory to DNA damage. 
(Pawlik and Keyomarsi 2004). Therefore MDM2 inhibitors must be allowed to clear 
before the genotoxic agent is administered to eliminate the remaining MDM2 inhibitor 
insensitive TP53 wild-type cells. Although, it must be noted that due to the range of 
sensitivity of TP53 wild-type cell lines and tumours reported, optimal efficacy of 
MDM2 inhibitor single agent as first line treatment is highly unlikely for majority of 
solid tumours. However, a synergistic combination of MDM2 inhibitors with other non-
genotoxic targeted agents (e.g. a WIP1 inhibitor) can potentially eliminate a larger 
proportion of the TP53 wild-type cells within a tumour population. Furthermore, this 
may be achieved with considerably lower doses of both compounds avoiding toxicity 
caused by off-target or on-target activity. The non-genotoxic compounds can then be 
allowed to clear for the same reasons mentioned earlier and a round of less aggressive 
genotoxic treatment could be used to eliminate the combination treatment resistant 
subpopulation of cells remaining (Figure 8-2). There are many tumour types that are 
mostly TP53 wild-type at diagnosis and many of them have interestingly been reported 
to also show PPM1D increased expression or gain-of function mutations. This approach 
could potentially provide an ideal model to optimise dosage in the aim to minimise both 
damage to healthy tissue and the likelihood of chemotherapy induced secondary cancers 
in malignancies that are TP53 wild-type at diagnosis. However, this simplistic model 
does not take into account the multitude of other variables that influence tumour 
response to systemic treatment such as drug pharmacokinetics, tumour blood and 
oxygen supply and potential roles for the ancillary tumour components described by 
Hanhan and Weinberg (2000). These known and some yet to be discovered variables 
will determine the ultimate anti-tumour efficacy of MDM2 inhibitors or their 
combination with other targeted and/or DNA damaging anticancer agents.
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Figure 8-1 The volcano plot shows that the TP53 genetic status is a far better determinant of response to Nutlin-3a (P-value = 1.26e-54) 
than it is for DNA damaging agents or other targeted agents. Y-axis: The p-value from multivariate ANOVA of drug gene interaction 
on an inverted log10 scale. X-axis: Magnitude of the effect that genetic events have on the GI50 of the drug in cell lines. The size of the 
circle indicates the number of genetic events corresponding to the analysis for a given gene or a drug. Figure obtained from 
(http://www.cancerrxgene.org/). 
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Figure 8-2 The diagram outlines the proposed ideal model for the use of MDM2 inhibitors in combination with other non-genotoxic and 
genotoxic agents. The main underlying assumption is that TP53 mutant MDM2 inhibitor resistant cells remain sensitive to DNA damaging 
agents. See chapter 3 for data in support of this assumption. This strategy has the potential to reduce healthy tissue toxicities and the 
likelihood of secondary cancers. 
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8.7 Achieving the full potential of MDM2-p53 binding antagonists in anti-cancer 
therapy 
Approximately 50% of human malignancies diagnosed overall are reported to have 
wild-type TP53 genetic status however, it has been suggested that, in a proportion of 
these tumours, p53 signalling is inactivated through other means, such as the 
overexpression of MDM2 in sarcomas (Momand, Zambetti et al. 1992, Oliner, Kinzler 
et al. 1992, Momand, Jung et al. 1998, Kruse and Gu 2009). In spite of the many layers 
of post-translational regulation of p53 signalling making it very complex to predict cell 
fate following p53 activating treatment regimens, such modes of regulation can be 
exploited to harness the full p53 tumour suppressor potential in a more selective 
manner. MDM2-p53 binding antagonists have proven successful in stabilising and 
activating wild-type p53 signalling, albeit to varying degrees, pre-clinically and 
clinically. In anticipation/reaction to a wide range of sensitivity to MDM2 inhibitors in 
pre-clinical and clinical settings, determinants of sensitivity to MDM2 inhibitors have 
been investigated and the potential need for better tumour stratification and combination 
strategies are rapidly being explored (Saiki, Caenepeel et al. 2014, Saiki, Caenepeel et 
al. 2015, Zhong, Chen et al. 2015). These studies report to have identified candidate 
target pathways for efficacious combination treatments with MDM2 inhibitors, or to 
have deciphered optimal gene expression signatures which predict cell sensitivity to 
MDM2 inhibitors. Indeed these are positive steps toward overcoming the present 
challenges faced in clinical use of MDM2 inhibitors, such as limited anti-tumour 
efficacy and dose limiting haematological toxicities. In this thesis it has been shown that 
successful pre-clinical identification of such predictors of response to MDM2 inhibitors, 
or optimal combination regimens, depends on careful considerations of dosage, 
scheduling and translationally valid proposals of patient stratification. Furthermore one 
such strategy has been proposed with sufficient evidence to initiate in vivo preclinical 
studies combining MDM2 and WIP1 inhibition. 
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Small Molecule Therapeutics
Chemical Inhibition of Wild-Type p53-Induced
Phosphatase 1 (WIP1/PPM1D) by GSK2830371
Potentiates the Sensitivity to MDM2 Inhibitors in a
p53-Dependent Manner
Arman Esfandiari1, Thomas A. Hawthorne1, Sirintra Nakjang1,2, and John Lunec1
Abstract
Sensitivity to MDM2 inhibitors is widely different among
responsive TP53 wild-type cell lines and tumors. Understand-
ing the determinants of MDM2 inhibitor sensitivity is pertinent
for their optimal clinical application. Wild-type p53-inducible
phosphatase-1 (WIP1) encoded by PPM1D, is activated,
gained/amplified in a range of TP53 wild-type malignancies,
and is involved in p53 stress response homeostasis. We inves-
tigated cellular growth/proliferation of TP53 wild-type and
matched mutant/null cell line pairs, differing in PPM1D genetic
status, in response to Nutlin-3/RG7388  a highly selective
WIP1 inhibitor, GSK2830371. We also assessed the effects of
GSK2830371 on MDM2 inhibitor-induced p53Ser15 phosphor-
ylation, p53-mediated global transcriptional activity, and apo-
ptosis. The investigated cell line pairs were relatively insensitive
to single-agent GSK2830371. However, a non–growth-inhibi-
tory dose of GSK2830371 markedly potentiated the response to
MDM2 inhibitors in TP53 wild-type cell lines, most notably in
those harboring PPM1D-activating mutations or copy number
gain (up to 5.8-fold decrease in GI50). Potentiation also cor-
related with significant increase in MDM2 inhibitor–induced
cell death endpoints that were preceded by a marked increase
in a WIP1 negatively regulated substrate, phosphorylated
p53Ser15, known to increase p53 transcriptional activity. Micro-
array-based gene expression analysis showed that the combi-
nation treatment increases the subset of early RG7388-induced
p53 transcriptional target genes. These findings demonstrate
that potent and selective WIP1 inhibition potentiates the
response to MDM2 inhibitors in TP53 wild-type cells, partic-
ularly those with PPM1D activation or gain, while highlighting
the mechanistic importance of p53Ser15 and its potential use as
a biomarker for response to this combination regimen. Mol
Cancer Ther; 15(3); 379–91. 2016 AACR.
Introduction
Mutational inactivation of the p53 tumor suppressor protein,
encoded by the TP53 gene, occurs in approximately 50% of
malignancies overall (1, 2). Nongenotoxic activation of p53 in
the remaining TP53 wild-type malignancies has attracted atten-
tion as a therapeutic strategy (3–5). In unstressed cells, p53 is
rapidly turned over by binding to one of its transcriptional target
gene products, MDM2, which inhibits p53-mediated transcrip-
tion, promotes p53 ubiquitin-mediated nuclear export and its
proteasomal degradation (3). Cellular stress can activate effector
molecules (e.g., DNA-PK, ATM, and ATR) that posttranslation-
ally modify MDM2 and or p53, leading to their dissociation
followed by p53-mediated reversible cell-cycle arrest, senescence,
or programmed cell death (6). Proof-of-concept that pharmaco-
logic inhibition of theMDM2-p53 interaction by smallmolecular
weight MDM2 inhibitors can be successfully used for nongeno-
toxic activation of p53 has been established in preclinical and
clinical settings with encouraging antitumor activity (4, 7).
Although, it is firmly established that the most important deter-
minant of response toMDM2 inhibitors is wild-type TP53 genetic
status (Supplementary Fig. S1A and ref. 8), multiple independent
studies using various classes of MDM2 inhibitors, and drug
sensitivity data generated by the Sanger Institute, have shown
that there is awide range of sensitivity toMDM2 inhibitors among
TP53 wild-type cell lines [Supplementary Fig. S1B (8–10)]. These
highlight that the determinants of sensitivity toMDM2 inhibitors
in aTP53wild-type background are poorly understood. The use of
combination regimens and patient stratification strategies are
therefore being investigated to optimize tumor-specific response
in TP53 wild-type malignancies (11–13).
Another strategy for nongenotoxic activation of p53 currently
in preclinical development is inhibition of wild-type p53-induc-
ible phosphatase-1 (WIP1/PPM1D), which is involved in homeo-
static regulation of p53 function and stability following cellular
stress (14–16). PPM1D is a bona fide oncogene that is activated,
gained, or amplified mostly in TP53 wild-type malignancies
(17–19). Notably, PPM1D gain-of-function mutations (activa-
tion) and TP53-inactivating mutations are mutually exclusive in
brainstemgliomas, consistentwith the role ofWIP1 (PPM1D gene
product) in negative regulation of p53 (18). Following cellular
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stress, p53 transcriptionally induces WIP1, which forms a
negative automodulatory loop with the p53 network by depho-
sphorylating p53 and other signaling components involved in
p53 posttranslational regulation (15). In spite of selectivity and
bioavailability challenges associated with pharmacological tar-
geting of phosphatases (20), recently a highly selective alloste-
ric WIP1 inhibitor, GSK2830371, which targets the unique flap-
subdomain on WIP1 was identified and characterized (16).
Although, the response to GSK2830371 was contingent on
wild-type TP53, some TP53 wild-type cell lines did not respond
in the dose range associated with on-target activity (16). In a
subsequent publication that highlighted WIP1 as a potential
target in neuroblastoma, GSK2830371 was shown to effectively
inhibit the growth of TP53 wild-type cell lines with PPM1D
copy number gain. However, there was greater than 52-fold
range in sensitivity, with NGP cells (PPM1D copy number gain)
showing no response at all within the dose range tested (10
mmol/L cutoff; ref. 21).
MDM2 blocks the p53 transactivation domain by interacting
with three key p53 amino acids (Phe19, Tyr23, and Leu26) that
are proximal to a WIP1 substrate, phosphorylated p53Ser15
(pp53Ser15) (22, 23). Unlike the strong influence of p53Ser20
phosphorylation on binding to MDM2, the phosphorylation of
p53Ser15 has been reported to either have no or a modest effect on
binding of p53 toMDM2 (24, 25), it has nevertheless been shown
to contribute to increased p53 proapoptotic transcriptional trans-
activation activity (25–27). After MDM2 inhibitor–mediated dis-
sociation of p53 from MDM2, pp53Ser15 is generated by the basal
unstimulated activity of effector kinases that normally phosphor-
ylate p53Ser15 following genotoxic stress (26). This suggests that a
dynamic equilibrium exists between kinases and phosphatases in
regulating pp53Ser15 following MDM2 inhibitor–induced p53
stabilization, which can be tilted in favor of the p53-activating
kinases by inhibiting WIP1. Therefore, in this study, we have
investigated whether a selective WIP1 inhibitor GSK2830371 can
potentiate the response to MDM2 inhibitors Nutlin-3 and
RG7388 in a panel of cell line pairs differing in their TP53 and
PPM1D genetic status. Our findings show that a nongrowth–
inhibitory dose of GSK2830371 can substantially increase sensi-
tivity to MDM2 inhibitors in TP53 wild-type cell lines, particularly
in those with PPM1D copy number gain or gain-of-function
mutation. Furthermore, global gene expression analysis showed
that RG7388 in the presence of GSK2830371 induces additional
early p53 transcriptional target genes involved in apoptosis in
TP53 wild-type cell lines that are not responsive to the WIP1
inhibitor alone. We propose that the combination of WIP1 and
MDM2 inhibitors can selectively accentuate the sensitivity to
MDM2 inhibitors in TP53 wild-type tumors with increased
WIP1 expression or activity, with elevated pp53Ser15 as a potential
mechanistic biomarker for response to this combination.
Materials and Methods
Cell lines and growth conditions
All cell lines used were obtained from Northern Institute for
Cancer Research cell line bank that only includes cell lines that
have been authenticated using short tandem repeatDNAprofiling
(LGC Standards). Postauthentication passages were limited to 30
for experimental procedures (<6 months) before replacing with
lower passage number stocks. Cell line pairs used and their TP53
and PPM1D genetic status are described in Table 1. MCF-7 cells
were used as a positive control for WIP1 protein expression and
response to the WIP1 inhibitor GSK2830371. The S_N40R2
(SN40R2) and N_N20R1 (N20R1) cell lines were TP53 mutant,
otherwise isogenic, Nutlin-3–resistant clones derived from SJSA-1
osteosarcoma and NGP neuroblastoma cells, respectively, and
have been cited in preclinical studies of MDM2 inhibitors (28;
see Table 1 for mutation details). U2OS-DN cells overexpress
the R175H variant of p53 that is reported to have a dominant
negative effect (29).
Growth inhibition assay
Cells were seeded in 96-well plates 24 hours before treatment.
Cells were then fixed with Carnoy fixative and Sulforhodamine B
assay was carried out as described in ref. 30. A spectrophotometer
(Bio-Rad Model 680) was used for densitometry at 570 nm.
Immunoblotting
Western blotting was carried out as described in ref. 31. Anti-
bodies used were MDM2 (Ab-1) 1:300 (Cat No.: OP46-100UG,
Merck Millipore), MDMX (Cat No.: A300287A-2 Bethyl Labora-
tories), WIP1 (F-10) 1:200 (Cat No.: sc-376257, Santa Cruz
Biotechnology), p53 1:500 (Cat No.: NCL-L-p53-DO7, Leica
Microsystems Ltd.), phospho-p53Ser-15 1:1,000 (Cat No.: 9284
Cell Signaling Technology), p21WAF1 1:100 (Cat No.: OP64,
Calbiochem), BAX 1:1,000 (Cat No.: 2772S, Cell Signaling Tech-
nology), cleaved caspase-3 1:1,000 (CatNo.: 9664S,NewEngland
Biolabs Ltd.), and actin 1:3,000 (Cat No.: A4700, Sigma-Aldrich).
Secondary goat anti-mouse/rabbit horseradish peroxidase–con-
jugated antibodies (Cat No.: P0447/P0448, Dako) were used at
1:1,000. All antibodies were diluted in 5% milk/1  TBS-tween
(w/v). Proteins were visualized using enhanced chemilumines-
cence (GE Healthcare Life Sciences) and x-ray film (Fujifilm).
Densitometry was carried out using ImageJ software.
Denaturing immunoprecipitation
Treated cellswere lysed [50mmol/L Tris, 150mmol/LNaCl, 0.2
mmol/L Na3VO4, 1% NP40 v/v, 1 mmol/L phenylmethylsulfo-
nylfluoride, Roche cOmplete protease inhibitor tablet, 1 mmol/L
dithiothreitol (DTT), 2% SDS] then aliquots were conserved as
input. Nondenaturing (no SDS) lysis buffer was used to dilute the
Table 1. TP53 wild-type and mutant/null cell line pairs with different PPM1D genetic status
TP53 wild-type parental cell lines TP53-mutant/null daughter lines Tumor of origin PPM1D genetic alteration (citation)
SJSA-1 SN40R2 (E285K) Osteosarcoma Wild-type (51)
HCT116þ/þ HCT116/(Null) Colorectal carcinoma c.1344delT/Wt (L450X) gain-of-function (39)
U2OS U2OS-DN (R175H) Osteosarcoma c.1372C>T/Wt (R458X) gain-of-function (39)
NGP N20R1 (P152T and P98H) Neuroblastoma Copy number gain (21)
MCF-7 — Breast adenocarcinoma Amplified (38)
NOTE: PPM1D status of SJSA-1 cells were obtained from sanger.ac.uk (51). TP53-mutant daughter cell lines of NGP and SJSA-1 cell lines were derived as described in
Materials and Methods.
Abbreviations: Mt, mutant; Wt, wild-type.
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remainder of the lysates (<0.1% SDS). A total of 1 to 2 mg of rabbit
antiubiquitin antibody (Cat No.: FL-76, Santa Cruz Biotechnol-
ogy) or rabbit IgG control (Cat No.: X0903, Dako) was added to
each appropriate vessel and incubated overnight at 4C. Sephar-
ose beads (Cat No.: 17-0618-01, GEHealthcare) were then added
and incubated for a further 4 hours at 4C. Beadswerewashedfirst
with0.5mol/LKCl thenwith0.1mol/LKCl, then treated as lysates
in the immunoblotting protocol above.
Caspase-3/7 assay
A total of 2  104 cells/well (60%–70% confluence) were
seeded in white 96-well plates (CELLSTAR, Greiner Bio-One
international) and treated after 24 hours. Caspase-3/7 enzymatic
activities were quantified by adding a 1:1 ratio of CaspaseGlo 3/7
reagent (Promega) to growthmedia 30minutes beforemeasuring
the luminescence signal using a FLUOstar Omega plate reader
(BMG Labtech) and all values were expressed as a ratio of signal
relative to solvent control.
Expression array
NGP cells were seeded at 6 105 cells per well of a 6-well plate
and treatedwith eitherDMSOor75nmol/Lof RG7388 (GI50)
2.5 mmol/L GSK2830371 for 4 hours before RNA extraction using
RNeasy Plus Mini Kit (Qiagen). Concentration and quality of
mRNA were determined using Agilent RNA 6000 nano kit on an
Agilent 2100 Bioanalyzer (RNA integrity numbers > 9). RNA
samples were sent to AROS Applied Biotechnology (Aarhus,
Denmark) for gene expression analysis using Illumina Beadchip
expression arrays (HumanHT-12v4.0). Array data processing,
background correction, normalization, and quality control checks
were performed using the R package "Lumi" (bioconductor.org).
Probe intensity values were converted to variance stabilized data.
Robust spline normalization was used as an array normalization
method. Poor-quality probes (detection threshold < 0.01), and
probes that are not detected at all in the remaining arrays were
removed prior to downstream analysis. The remaining probe
normalized intensity values (18,634) were used in the differential
expression analysis. The data discussed in this article have been
deposited in NCBI's Gene Expression Omnibus (GEO; ref. 32)
and are accessible through GEO Series accession number
GSE75197 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE75197).
RNA extraction and qRT-PCR
Complementary DNA was generated using the Promega
Reverse Transcription System (A3500, Promega) as described by
the manufacturer. qRT-PCR was carried out using SYBR green RT-
PCR master mix (Life Technologies) as per the manufacturer's
guidelines and the following primers (50-30): CDKN1A [forward
(F)-TGTCCGTCAGAACCCATGC, reverse (R)-AAAGTCGAAGT-
TCCATCGCTC), TP53INP1 (F-TCTTGAGTGCTTGGCTGATACA,
R-GGTGGGGTGATAAACCAGCTC), BTG2 (F-CCTGTGGGTG-
GACCCCTAT, R-GGCCTCCTCGTACAAGACG), MDM2 (F-CAG-
TAGCAGTGAATCTACAGGGA, R- CTGATCCAACCAATCACCT-
GAAT) and GAPDH (F-CAATGACCCCTTCATTGACC, R-GATC-
TCGCTCCTGGAAGAT)]. A total of 50ng/mL of the cDNA samples
per 10 mL final reaction volume, with the standard cycling para-
meters (stage 1: 50C for 2minutes, stage 2: 95C for 10minutes,
then 40 cycles of 95C for 15 seconds, and 60C for 1 minute),
were set and carried out on an ABI 7900HT sequence detection
system. Data were presented asmean SEM relative quantities of
four independent repeats whereGAPDHwas used as endogenous
control and DMSO used as the calibrator for each independent
repeatwith the formula 2DDCt. Analysiswas carried out using SDS
2.2 software (Applied Biosystems).
Site-directed mutagenesis and p53 overexpression
The plasmid vector used in this study was pcDNA3.1 (þ/; Life
Technologies, Cat No. V790-20 and V795-20) and full-length
human TP53 cDNA cloned into this backbone. The Gozani
laboratory protocol for site-directed mutagenesis (33) was used
to generate the p53Ser15mutants. Primers used: p53S15A (F-GTCG-
AGCCCCCTCTGGCTCAGGAAACATTTTCA, R- TGAAAATGTT-
TCCTGAGCCAGAGGGGGCTCGAC) and p53S15D (F- GTCGA-
GCCCCCTCTGGACCAGGAAACATTTTCA, R-TGAAAATGTTTC-
CTGGTCCAGAGGGGGCTCGAC). HCT116/ cells were trans-
fected with Lipofectamine 2000 and plasmid DNA 12 hours
before lysates were collected at different time intervals.
Flow cytometry
After treatment, floating and adhered cells were pooled and
incubated in propidium iodide solution [150 mmol/L propidium
iodide (Calbiochem), 1.46 mmol/L DNase free-RNase A (Sigma),
3.88 mmol/L sodium citrate (Sigma), and 0.3% Triton-X 100
(Sigma)] for 10 minutes at 25C and then FACS was carried out
using a FACSCalibur (BD Biosciences)]. CellQuest software was
used to establish cell-cycle distribution and gated histograms.
Statistical analysis
Statistical tests were carried out in GraphPad Prism 6 software
and all P values represent two-tailed paired t tests of three ormore
independent repeats unless otherwise stated. For microarray
differential expression analysis, R-statistical software was used.
Microarray datawas processed using R Bioconductor package lumi
(34) Probes intensity values were transformed using variance
stabilizing transformation implemented in the lumi package
before data normalization. The robust spline normalization was
used as a normalization method. Poor quality probes (detection
threshold < 0.01), and probes that were not detected at all in the
remaining arrays were removed. Differential expression analysis
was performed using R Bioconductor package limma (35).
Results
GSK2830371 potentiates the response to MDM2 inhibitors
Nutlin-3 and RG7388 in a p53-dependent manner
Growth inhibition assays were carried out on a panel of TP53
wild-type andmutant/null cell line pairs differing in their PPM1D
genetic status, to assess their sensitivity to the selective allosteric
WIP1 inhibitor GSK2830371 and its ability in turn to sensitize
cells toMDM2 inhibitors (Fig. 1A).GSK2830371-sensitiveMCF-7
cells were used as a positive control for the growth-inhibitory
activity and biochemical effect of this compound. GSK2830371
had a 50%growth inhibitory concentration (GI50) of 2.65mmol/L
 0.54 (SEM) in MCF-7 cells. The growth inhibition curve for
GSK2830371 plateaued in MCF-7 cells at doses 2.5 to 10 mmol/L
suggesting that a subpopulation of MCF-7 cells are resistant to
growth inhibition and apoptosis in response to maximal WIP1
inhibition (Fig. 1A). All other cell line pairs were not sensitive to
growth inhibition by GSK2830371 alone, with GI50 > 10 mmol/L
irrespective of their PPM1D or TP53 genetic status (Fig. 1A).
Basal expression of WIP1 across the panel of cell line pairs was
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Figure 1.
A, the effect on growth of a panel of p53 wild-type (green) andmutant/null (maroon) cell line pairs with different PPM1D genetic status to 0.08–10 mmol/L GSK2830371
exposure for 168 hours, using Sulforhodamine B growth inhibition assays. B, basal expression of WIP1 and p53 in cell lines (SE, short film exposure; LE, long
exposure). C, the sensitivity of a panel of p53 Wt (green) and mutant/null (maroon) cell line pairs with different PPM1D genetic status to 0.08–10 mmol/L Nutlin-3
and 0.008–1 mmol/L RG7388 in 168 hours Sulforhodamine B growth inhibition assays in the presence and absence of the highest nongrowth inhibitory dose of
GSK2830371 (2.5 mmol/L). The U2OS cell line pair was treatedwith MDM2 inhibitors 1.25 mmol/L GSK2830371. FL-WIP1, full-lengthWIP1; S-WIP1,WIP1 shorter isoform;
S-WIP1, the shortest band detected by the F-10 antibody; T-WIP1, truncatedWIP1mutants;WIP1i, GSK2830371;WIP1 L450X in HCT116 cells orWIP1 R458X in U2OS cells.
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assessed by immunoblotting with an antibody that detects WIP1
(FL-WIP1), its previously described shorter isoform (S-WIP1;
ref. 36), and the two WIP1 gain-of-function mutant proteins in
HCT116 and U2OS cell line pairs (Fig. 1B). Transient knock-
down of WIP1 using four different anti-PPM1D siRNA con-
structs resulted in a reduction in the intensity of all the bands
detected by the WIP1 antibody (F-10), which suggests that all of
the bands detected in these conditions correspond to WIP1
(Supplementary Fig. S2A). This includes a further WIP1 isoform
detected by F-10 (55 kDa), which is referred to here as
S-WIP1. PPM1D-amplified MCF-7 cells (37) showed the high-
est basal expression of WIP1 and its isoforms, consistent with
their sensitivity to GSK2830371 single treatment (Fig. 1B; see
ref. 38). NGP cells, with PPM1D copy number gain (21), and its
otherwise isogenic TP53-mutant daughter cell line, N20R1,
were insensitive to <10 mmol/L GSK2830371 despite showing
the second highest expression of full-length WIP1 after MCF-7
cells. The SJSA-1 and SN40R2 TP53 wild-type and mutant pair,
with wild-type PPM1D, showed the least WIP1 protein expres-
sion among all cell line pairs in the panel. Shorter bands
corresponding to the previously reported truncated and acti-
vating WIP1-mutant proteins WIP1 L450X and WIP1 R458X
were detected in lysates derived from HCT116 and U2OS cell
line pairs, respectively (Fig. 1B; ref. 39).
Because of the role of WIP1 in homeostatic feedback regulation
of the p53 network, we aimed to assess whether GSK2830371
(WIP1i) can potentiate the response to MDM2 inhibitors. Treat-
ment with a combination of the highest nongrowth-inhibitory
dose of GSK2830371 (2.5 mmol/L), potentiated the response to
MDM2 inhibitors Nutlin-3 and RG7388 in a p53-dependent
manner in cell lines that were not sensitive to growth inhibition
by GSK2830371 alone (Fig. 1C). TP53wild-type parental cell lines
HCT116þ/þ, NGP, and SJSA-1 showed a 2.4-fold (P¼ 0.007), 2.1-
fold (P¼ 0.039), and 1.3-fold (P¼ 0.017) decrease, respectively, in
their Nutlin-3 GI50 values in the presence of 2.5 mmol/L
GSK2830371. In contrast, Nutlin-3 GI50 did not change for
theirTP53 null/mutant matched pairs HCT116/, N20R1, and
SN40R2. However, pertinent to the widening of RG7388 thera-
peutic index in the clinic, the samedoseofGSK2830371 resulted in
amuch greater potentiation of RG7388 in TP53wild-type cell lines
with either PPM1D gain-of-function or copy number gain: NGP
5.8-fold (P ¼ 0.049) and HCT116þ/þ 4.8-fold (P ¼ 0.018) com-
pared with PPM1D wild-type SJSA-1 cells 1.4-fold (P ¼ 0.020; Fig.
1C). U2OS TP53 wild-type cells showed a similar trend toward
potentiation ofNutlin-3 in combinationwithGSK2830371 at 1.25
mmol/L as Nutlin-3 GI50 was reduced by 3.2-fold (P ¼ 0.08);
however, the same dose of theWIP1 inhibitor resulted in a 5.3-fold
(P ¼ 0.039) decrease in RG7388 GI50. None of the TP53-mutant
daughter cell lines showed increased sensitivity to RG7388 in the
presence of the WIP1 inhibitor. Interestingly, the combination of
Nutlin-3 or RG7388 with 2.5 mmol/L GSK2830371 also augment-
ed the growth inhibitory effect in MCF-7 cells compared with
each drug alone. Therefore, the most marked fold change in
sensitivity to both MDM2 inhibitors was observed in TP53 wild-
type cell lines that have increased WIP1 expression or activity.
Inhibition of WIP1 catalytic activity by GSK2830371 is
separable from its induction of ubiquitin-mediated WIP1
degradation
Treatment of MCF-7 cells with 2.5 mmol/L GSK2830371
resulted inmarked time-dependent degradation of both isoforms
ofWIP1 over 8 hours, which correlatedwith p53 stabilization and
pp53Ser15 consistent with previous reports by Gilmartin and
colleagues, (Fig. 2A; ref. 16). Quantification of WIP1 signal
intensity is presented in Supplementary Fig. S2B.
To test the effect of the GSK2830371 inhibitor on WIP1
phosphatase activity separate from degradation of WIP1, its
effect on the phosphorylation of p53Ser15 30 minutes following
exposure of MCF7 cells to ionizing radiation was assessed.
GSK2830371 was seen to inhibit pp53Ser15 dephosphorylation
at a timepointwhen theWIP1protein expressionhadnot yet been
affected by this compound (compare pp53Ser15 on the last two
tracks in Fig. 2B). These data show that inhibition of the catalytic
activity of WIP1 by GSK2830371 is separable from its ubiquitin-
mediated degradation.
It was noteworthy that GSK2830371 also lead to the degra-
dation of truncated WIP1 mutants within 4 hours (Fig. 2C). We
carried out a denaturing immunoprecipitation experiment
probing for all ubiquitinated species in HCT116þ/þ cells trea-
ted with the proteasome inhibitor MG132 and either
GSK2830371 alone or in combination with Nutlin-3, to assess
whether wild-type WIP1 and WIP1 L450X are both degraded by
ubiquitin-mediated processes (Fig. 2C). The anti-ubiquitin
antibody (Ub-Ab) migrated to a similar molecular weight as
full-length WIP1 and it was detected by the goat anti-mouse
antibody (Fig. 2D, last lane Ub-Ab Control); therefore, the
ubiquitination of full-length WIP1 could not be determined.
However, ubiquitinated WIP1 L450X was observed to be
increased by GSK2830371 (Fig. 2D). Interestingly, this ubiqui-
tination event was also reduced in the presence of Nutlin-3.
Increased ubiquitination of p53 in the presence of MG132 þ
GSK2830371 was reversed by Nutlin-3 as expected because
inhibiting MDM2-p53 interaction prevents MDM2-mediated
p53-ubiquitination.
GSK2830371 significantly increases MDM2 inhibitor–
mediated apoptosis and reduces clonogenic cell survival in
TP53 wild-type cell lines
The combination of GSK2830371 and multiples of Nutlin-3
GI50 dose resulted in a marked increase in caspase-3/7 activity in
both NGP and SJSA-1 cells compared with treatment with either
drug alone (Fig. 3A and B). For NGP cells, 24-hour treatment with
2.5 mmol/L GSK2830371 did not lead to detectable caspase-3/7
activity, whereasNutlin-3 at 0.5 and 1GI50 resulted in a dose-
dependent increase in caspase-3/7 signal, which was significantly
enhanced (4-fold P¼ 0.005 and3-fold P¼ 0.02, respectively)
in the presence of 2.5 mmol/L GSK2830371 (Fig. 3A). No
increased caspase-3/7 activity was observed in SJSA-1 cells after
24 hours of exposure to 2.5mmol/LGSK2830371 alone orNutlin-
3 2.5 mmol/L GSK2830371 (data not shown). Similarly in both
cell line pairs, 48 hours treatment with 2.5 mmol/L GSK2830371
alone resulted in no increased caspase-3/7 activity, whereas its
presence significantly increased response to Nutlin-3 (2.7-fold
P¼ 0.01 in NGP,2-fold P¼ 0.04 in SJSA-1) in a p53-dependent
manner (Fig. 3B).
Caspase-3/7 activity could not be detected in HCT116þ/þ and
for up to 48 hours following treatment (data not shown), so
continuous exposure cloning efficiency experiments were carried
out as described in Fig. 3C (see caption) to assess clonogenic cell
survival. There was no reduction in clonogenic efficiency in the
presence of the GSK2830371 alone in comparison with untreated
controls. Cloning efficiency of HCT116þ/þ cells in the presence of
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0.5  Nutlin-3 GI50 significantly decreased (P ¼ 0.008) when
GSK2830371 was present at 2.5 mmol/L (Fig. 3C).
In NGP cells, pp53Ser15 was not affected by the GI50 dose of
Nutlin-3 or 2.5 mmol/L GSK2830371 alone, whereas in combi-
nation there was a marked increase in pp53Ser15 at 4 hours that
persisted through to 24 hours and correlated with the detection
of cleaved caspase-3 (Fig. 3D and E). GSK2830371 alone resulted
in modest p53 stabilization in NGP cells, after 24-hour treat-
ment, which did not result in detectable induction of p53 direct
transcriptional targets p21WAF1 and MDM2 (Fig. 3E). Interest-
ingly, monotreatment with the same dose of GSK2830371 in
MCF-7 cells was sufficient for WIP1 degradation, p53 stabiliza-
tion and increase pp53Ser15 in contrast to NGP cells (Fig. 2A
vs. Fig. 3E). Consistently,WIP1was also degraded inNGP cells in
the presence of the WIP1 inhibitor (track 3 vs. track 1 in Fig. 3D)
even when WIP1 was induced by Nutlin-3 (track 4 vs. track 2
in Fig. 3D). The lack of a p53 response of NGP cells to 2.5 mmol/L
GSK2830371 may explain their insensitivtiy to GSK2830371
monotreatment compared with MCF-7 cells. Also, the addition
of 2.5 mmol/L GSK283037 did not affect MDM2 induction by
Nutlin-3 (Fig. 3D). This suggests that the reported role ofWIP1 in
downregulation of MDM2 (14) may be counterbalanced by the
p53-dependent transcriptional induction of MDM2 in the pres-
ence of Nutlin-3. There was a reduction in MDMX expression 24
hours after combination treatment compared with Nutlin-3
treatment alone (Fig. 3D). Given that MDMX increased expres-
sion has been proposed to contribute to reduced sensitivity to
MDM2 inhibitors (40), it is likely that the role of WIP1 in
negative regulation of MDMX stability (41) may be a factor in
its ability to potentiate MDM2 inhibitors in MDMX-overexpres-
sing NGP cells. There was no change in the expression of the p53
proapoptotic transcriptional target BAX at 4 and 24 hours
following combination treatment compared with Nutlin-3 or
WIP1 inhibitor monotreatments (Fig. 3D). This suggests that
BAX is likely not involved in potentiation of Nutlin-3 by the
WIP1 inhibitors.
Figure 2.
A, GSK2830371 (2.5 mmol/L) treatment of MCF-7 cells over 8 hours shows WIP1 degradation over time, p53 stabilization, and Phospho-p53Ser15 (pp53Ser15)
accumulation. B, p53Ser15 phosphorylation in MCF-7 cells 30minutes after 2 Gy ionizing radiation in the presence or absence of 2.5 mmol/L. GSK2831371 inhibitsWIP1
catalytic activity independent of WIP1 protein levels. C, 4-hour treatment with 2.5 mmol/L GSK2830371 results in degradation of full-length and truncated
WIP1 in HCT116þ/þ and U2OS cells. D, lysates obtained from HCT116þ/þ cells treated with 20 mmol/L proteasome inhibitor MG132 and 2.5 mmol/L GSK2830371 3.0
mmol/L Nutlin-3 overnight underwent immunoprecipitation with anti-ubiquitin antibody (Ub-Ab) and the precipitates probed for WIP1 and p53 by western
blot analysis. Input samples (left panel) are western blots of total lysate before IP for comparison with the IP results on the righthand panel. An aliquot of
MG132-treated lysate was precipitated with rabbit IgG instead of Ub-Ab as a negative control. Ub-Ab, anti-ubiquitin antibody; WIP1i, GSK2830371; WIP1 (Wt),
wild-type WIP1; WIP1 L450X, truncated WIP1.
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Figure 3.
A, dose-dependent increase in caspase 3/7 activity of NGP cells after 24 hours treatment with Nutlin-3 (Nut-3 GI50  3.0 mmol/L) alone or in combination
with 2.5 mmol/L GSK2830371. B, increase in caspase-3/7 activity in NGP and SJSA-1 cells and their TP53-mutant daughter cell lines 48 hours after treatment with
Nutlin-3  2.5 mmol/L GSK2830371. C, reduction in clonogenic efficiency of HCT116þ/þ cells following exposure to 0.5  GI50 concentration of Nutlin-3 in the
presence of 2.5 mmol/L GSK2830371 comparedwith either inhibitor alone over 10 days. D, immunoblot of NGP cells showing Nutlin-3–dependent phosphorylation of
p53 at Ser15 is markedly enhanced by GSK2830371 at 4- and 24-hour exposure and leads to increased caspase-3 cleavage at 48 hours. E, time-course of NGP
response to 3.0 mmol/L Nutlin-3 (GI50)  2.5 mmol/L GSK2830371 over 24 hours. WIP1i, GSK2830371;  , P  0.05; , P  0.005.
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GSK2830371 increases RG7388-induced p53-dependent
transcription of growth inhibitory and proapoptotic genes
Phosphorylation of p53Ser15 has been reported to increase
p53-mediated transcriptional transactivation but not to be
necessary for dissociation of p53 from MDM2 in response to
DNA damage (24, 26). Also, reports in the literature have
suggested that p53 posttranslational modifications can behave
as variable barcodes and induce transcription of alternate sets
of p53 target genes that could lead to different cell fates after
p53 activation (42). As the greatest potentiation of MDM2
inhibitors by GSK2830371 was observed in NGP cells (5.8-
fold), we assessed whether the subset of early genes activated in
response to RG7388 in this cell line differed in the presence of
2.5 mmol/L GSK2830371, which produced a marked increase in
pp53Ser15. Peak p53 transcriptional target expression (e.g.,
p21WAF1 and MDM2) as detected by western blotting is reached
by 6 to 8 hours after treatment (Fig. 3E). Because later changes
in transcription may be secondary effects and not directly p53-
dependent, we assessed changes in global gene expression 4
hours following RG7388 (GI50  75 nmol/L)  2.5 mmol/L
GSK2830371 using the Illumina BeadChip expression array
platform. A testament to the specificity of RG7388 in exclu-
sively activating p53, 4 hours of exposure to a GI50 dose of
RG7388 led to significantly increased mRNA expression of only
9 genes, all of which were known p53 transcriptional targets
(Fig. 4A). The top 41 genes just below the statistical significance
cut-off point (P > 0.05 after correction for multiple testing)
were also mostly genes that are well established to be direct p53
transcriptional targets. Interestingly, in the presence of 2.5
mmol/L GSK2830371, the subset of statistically significant
RG7388-mediated transcriptional changes increased from 9 to
24 genes, indicating that inhibition of WIP1 results in a sig-
nificant increase of additional p53-mediated transcriptional
activity at this early time point (Fig. 4B; for a list of genes refer
to Supplementary Tables S1A and S1B).
To validate the results of the array, we assessed the expression of
the top three genes with the highest odds ratio difference between
single and combination treatments [CDKN1A (p21WAF1),
TP53INP1, and BTG2] and one of the genes that was exclusively
induced in the combination treatment (MDM2) by qRT-PCR
using the same mRNA samples used in the expression array
experiment (Fig. 4C). Consistent with the array data, all the genes
tested showed significant increase in their mRNA expression in
combination treatment compared with the RG7388 alone (Fig.
4C). TP53INP1/P53DINP1 is a known proapoptotic p53 tran-
scriptional target gene, the overexpression or induction of which
following cellular stress has been associated with increased p53-
mediated apoptosis (43). Among the 16 additional p53-regulated
target genes induced exclusively in response to the combination
treatment were TNF super family member 10B (TNFRSF10B) and
p53-induced death domain protein 1 (PIDD1), two genes critical
for extrinsic and intrinsic proapoptotic pathways, respectively
(44–47). Interestingly, despite neither of the agents being geno-
toxic, one of the other genes that showeddifferential expression in
response to the combination treatment was the DNA base exci-
sion repair gene xeroderma pigmentosum complementation
group C (XPC), the increased basal expression of which has been
reported to correlate with increased sensitivity to MDM2 inhibi-
tors in a large panel ofTP53wild-type cell lines andpredict a better
clinical response to RG7112 and RG7388 in acute myeloid
leukaemia patients (13).
The increase in the subset of genes expressed correlated with
a marked increase in the proportion of pp53Ser15 to total p53 in
immunoblots of lysates prepared in parallel to the mRNA
samples used in the expression array experiment (Fig. 4D and
see Supplementary Fig. S3A). These data suggest that the
underlying mechanism for the observed potentiation of
MDM2 inhibitors in combination with WIP1 phosphatase
inhibition may be contributed to by the increased p53Ser15
phosphorylation that enhances p53-dependent proapoptotic
gene transcription.
In line with this hypothesis, increased pp53Ser15 phosphoryla-
tion in HCT116þ/þ following combination treatment resulted in
an increase in the p21WAF1 product of the CDKN1A gene in
comparison with monotreatment with either drug (Fig. 4E). To
confirm earlierfindings showing that phosphorylation of p53Ser15
increases p53-mediated transcription in HCT116 cells, we over-
expressed wild-type (Wt) p53, mutant p53S15A, or p53S15D in
HCT116/ cells and assessed p53-mediated expression of
p21WAF1 protein encoded by the CDKN1A gene, which had
showed the biggest fold change in expression on the array fol-
lowing the combination treatment in NGP cells. Consistent with
previous findings (24, 26), Wt p53 and phospho-mimetic
p53S15Dmutant constructs increased p53-mediated expression of
p21WAF1 and MDM2 following transfection compared with the
p53S15A mutant, which could not be phosphorylated on that
residue (Fig. 4F). See Supplementary Fig. S3B and S3C for repeat
and densitometry data.
The effect of combined MDM2 and WIP1 inhibition on cell-
cycle distribution
Given that WIP1 inhibition potentiated the growth inhibitory
and apoptotic response of TP53 wild-type cell lines to MDM2
inhibitors, and the highest fold increase in transcriptionwas of the
CDKN1A (p21WAF1) cyclin-dependent kinase inhibitor gene, we
investigated changes in cell-cycle distribution following this com-
bination treatment. In all cell lines, 2.5 mmol/L GSK2830371
alone did not significantly affect cell-cycle distribution through-
out 72 hours of treatment (Fig. 5A and Supplementary Fig. S4).
Changes in cell-cycle distribution after exposure toNutlin-3 2.5
mmol/L GSK2830371 were cell line-dependent. In SJSA-1 and
NGP cell lines, 24 hours exposure to Nutlin-3 resulted in an
increase in theproportionof cells inG1–G0phases of the cell cycle.
In SJSA-1 cells, this effect of Nutlin-3 remained unchanged in the
following 48 hours treatment with Nutlin-3  GSK2830371.
However, in NGP cells, the relative proportion of cells in
G2–M and S-phase increased over the following 48 hours when
Nutlin-3 and the WIP1 inhibitor were combined compared with
Nutlin-3 alone. In HCT116þ/þ cells, Nutlin-3 resulted in an
increase in the proportion of cells in G0–G1 and G2–M phases
at 24 hours, which persisted to the 72 hours treatment time point
(Fig. 5A), consistent with the increase in CDKN1A (p21WAF1)
expression in response to the combination treatment (Fig. 4E).
Cell-cycle distribution was not affected in HCT116/ cells
regardless of the treatment condition, suggesting that the changes
in cell-cycle distribution observed in HCT116þ/þ cells are p53-
dependent (Fig. 5A).
Sub-G1 changes
In response to the combination treatment compared with
Nutlin-3 alone, the increase in sub-G1 FACS signal after exposure
to Nutlin-3 was significantly augmented in the presence of
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2.5 mmol/L GSK2830371 (WIP1i) in both SJSA-1 and NGP cell
lines (Fig. 5B and Supplementary Fig. S4B). This is in keepingwith
the increased cleaved caspase-3/7 activity in NGP and SJSA-1 cells
(Fig. 3A and B). Sub-G1 signals were not significantly changed in
HCT116þ/þcells throughout the 72 hours of Nutlin-3 
GSK2830371 treatment (Fig. 5B).
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Figure 5.
A, time-course of cell-cycle distribution changes over 72 hours of treatment using FACS analysis. B, percent of sub-G1 signals for NGP, SJSA-1, HCT116
þ/þ, and
HCT116/ cells in response to the stated treatments at 72 hours. WIP1i, GSK2830371.
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Discussion
Although mutant TP53 status is a dominant mechanism of
resistance to MDM2-p53 binding antagonists, there is neverthe-
less a clinically relevant wide range of sensitivity to MDM2
inhibitors among TP53 wild-type cancer cell lines. Importantly,
this variation of response is not exclusive to one class of MDM2
inhibitors and is clearly seen in panels of cell lines with validated
wild-type TP53 status. Amgen has recently reported a wide range
of sensitivity to their MDM2 inhibitor AMGMDS3 among their
carefully curated panel of TP53wild-type and functional cell lines
showing a 500-fold GI50 difference between the least to most
sensitive (8). These observations suggest that there are a diverse set
of underlying genetic variables that determine cell fate following a
dose of activated/stabilized p53. Here we have shown a non-
growth-inhibitory dose of the selective orally bioavailable allo-
steric WIP1 phosphatase inhibitor, GSK2830371, can modulate
the phosphorylation state of p53 and potentiate both the growth
inhibitory and apoptotic response to MDM2 inhibitors in TP53
wild-type cell lines, especially those with increased WIP1 expres-
sion or activity. MDM2 inhibitor potentiation was at its greatest
when the cell line harbored either PPM1D copy number gain/
elevated expression or gain-of-function truncating mutations,
thus providing a rationale for specific combination treatment
targeting of tumors with this genotype.
The argument in support of p53Ser15 phosphorylation increas-
ing p53-mediated transcription (24, 26, 27) is compelling and
consistent with our findings. In contrast to what was originally
reported by Vassilev and colleagues, in 2004, phosphorylation of
p53 following treatment with MDM2 inhibitors is observed;
however, it is not as intense and immediate compared with
p53Ser15 phosphorylation following DNA damaging agents of
equivalent growth-inhibitory dose (7, 26). As shown by Loughery
and colleagues, the basal activity of kinases involved in phos-
phorylation of p53Ser15 (e.g., ATM and ATR) in response to DNA
damage are also likely responsible for, or contribute to, this
posttranslational modification in response to MDM2 inhibitors
(26). Our findings have shown that, in the presence of a selective
WIP1 inhibitor, the minimal phosphorylation of p53Ser15 in
response to MDM2 inhibitors is markedly accentuated, which
correlates with potentiation of apoptotic and growth-inhibitory
response toMDM2 inhibitors in TP53wild-type cells, particularly
in those with high WIP1 expression or activity. This was also
associated with significantly increased transcript levels from an
increased number of immediate p53 transcriptional target genes
as compared with those induced by single-agent RG7388.
Increased p53Ser15 phosphorylation in response to the combina-
tion treatment also resulted in increased p21WAF1 and MDM2
protein expression. Consistent with the reported role of p53Ser15
phosphorylation in increasing transcriptional activity of p53, we
also confirmed that mutation of this residue influenced expres-
sion of p21WAF1 and MDM2 proteins. Thus, our current working
model includes evidence for the role of enhanced p53 transcrip-
tional activity in response to the combination of MDM2 inhibi-
tors and GSK2830371 (Fig. 6). It is likely, however, that direct
and/or indirect WIP1-mediated posttranslational modifications
that effect the stability and function of stress response proteins
and their cross-talk with the p53 network (as reviewed in ref. 15)
may also contribute to MDM2 inhibitor potentiation in the
presence of GSK2830371. Regardless of this, our data strongly
suggest that increased pp53Ser15 can be considered a surrogate
marker of p53 dissociation from MDM2 in response to single-
agent GSK2830371 treatment or its combination with MDM2
inhibitors, as thismodification coincides with p53 transcriptional
activation that precedes the subsequent enhanced p53-mediated
growth inhibitory or apoptotic response to each of these
treatments.
Nutlin-3–mediated changes in cell-cycle distribution were all
enhanced in the presence of a dose of GSK2830371 that on its
owndid not affect cell-cycle distribution. The observed increase in
sub-G1 FACS analysis signalswith combination treatment ofNGP
cells is consistent with potentiation of apoptosis and growth
inhibition in this cell line. Enhancement of Nutlin-3–mediated
Figure 6.
Proposed model for potentiation of
cellular response to MDM2 inhibitors by
the selective allosteric WIP1 inhibitor
GSK2830371. After activation of p53 by
MDM2 inhibitors, p53Ser15 is unmasked
and therefore available as a substrate
for the basal level activity of multiple
kinases and phosphatases normally
involved in posttranslational
modification of this residue in response
to cellular stress. In normal homeostatic
control, phosphorylation of p53Ser15 is
kept in check by an equilibrium
between the kinase and phosphatase
activities. Inhibition of WIP1 by
GSK2830371 tilts this balance in favor of
the activating kinases, which in turn
increases p53 transcriptional activity
and is enhanced in combination with
MDM2 inhibitors. Dashed lines indicate
direct p53 transcriptional upregulation
of the corresponding genes for MDM2
and WIP1.
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G1:S and G2:S ratios in the presence of GSK2830371 are also
consistent with the increased CDKN1A (p21WAF1) expression
observed at both transcript and protein levels and its importance
in negative regulation of cell-cycle progression (48, 49). Kleiblova
and colleagues, (39) had previously shown that transient knock-
down of truncated PPM1D increases G1 checkpoint in response to
ionizing radiation. Interestingly, in our current study, WIP1
inhibition and depletion by GSK2830371 in HCT116þ/þ cells
harboring a PPM1D L450X truncation mutation also resulted in
an increase in p53-dependent G1 arrest following p53 activation
by Nutlin-3, whereas this did not occur in NGP and SJSA-1 cell
lines that do not have PPM1D gain-of-functionmutations. Lindq-
vist and colleagues (50) also reported that WIP1 knockdown
ablates the competence of cellular p53-dependent G2 checkpoint
recovery following cellular stress, although the authors were not
aware of the gain-of-function WIP1 R458X mutation in U2OS
cells used in their study, as it had not yet been reported. These
findings suggest that the increase in G2:S ratio observed in
HCT116þ/þ cells treated with the combination of MDM2 inhi-
bitors and GSK2830371 is likely due to inhibition of WIP1
L450X that would otherwise be negatively regulating p53 tran-
scriptional activity in these cell lines. Of note, we have also shown
that GSK2830371 increases the ubiquitin-mediated degradation
of truncated WIP1 as postulated by Gilmartin and colleagues,
(16). Interestingly, this increase in the ubiquitination of truncated
WIP1 was reversed by inhibition of MDM2, which suggests that
MDM2 is directly or indirectly involved in WIP1 ubiquitination
following GSK2830371.
Wild-type TP53 genetic status is the most important determi-
nant of response to MDM2 inhibitors, while being necessary but
not sufficient for growth inhibitory response to WIP1 inhibition
by GSK2830371. Following their promising clinical outcomes so
far, MDM2 inhibitors will be explored in combination with other
anticancer agents to optimize their therapeutic potential. Com-
bination regimens of these nongenotoxic agents could minimize
DNA damage to healthy tissue that does not express altered forms
of PPM1D. Here we have shown that specific pharmacologic
inhibition of WIP1 combined with MDM2 inhibitors is a prom-
ising therapeutic strategy in TP53 wild-type tumors that show
increased WIP1 function, and that pp53Ser15 and PPM1D geno-
type are important both mechanistically and as predictive bio-
markers for response to this combination treatment.
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